Method of detecting and/or identifying adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby

ABSTRACT

A method for detecting and isolating AAV sequences in a sample of DNA obtained from tissue or cells is provided. The invention further provides AAV sequences identified by this method, and vectors constructed using these sequences.

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This is a non-provisional of U.S. provisional patent applicationNo. 60/386,675, filed Jun. 5, 2002, U.S. provisional patent applicationNo. 60/377,066, filed May 1, 2002; U.S. provisional patent applicationNo. 60/341,117, filed Dec. 17, 2001, and U.S. provisional patentapplication No. 60/350,607, filed Nov. 13, 2001.

BACKGROUND OF THE INVENTION

[0002] Adeno-associated virus (AAV), a member of the Parvovirus family,is a small nonenveloped, icosahedral virus with single-stranded linearDNA genomes of 4.7 kilobases (kb) to 6 kb. AAV is assigned to the genus,Dependovirus, because the virus was discovered as a contaminant inpurified adenovirus stocks. AAV's life cycle includes a latent phase atwhich AAV genomes, after infection, are site specifically integratedinto host chromosomes and an infectious phase in which, following eitheradenovirus or herpes simplex virus infection, the integrated genomes aresubsequently rescued, replicated, and packaged into infectious viruses.The properties of non-pathogenicity, broad host range of infectivity,including non-dividing cells, and potential site-specific chromosomalintegration make AAV an attractive tool for gene transfer.

[0003] Recent studies suggest that AAV vectors may be the preferredvehicle for gene therapy. To date, there have been 6 different serotypesof AAVs isolated from human or non-human primates (NHP) and wellcharacterized. Among them, human serotype 2 is the first AAV that wasdeveloped as a gene transfer vector; it has been widely used forefficient gene transfer experiments in different target tissues andanimal models. Clinical trials of the experimental application of AAV2based vectors to some human disease models are in progress, and includesuch diseases as cystic fibrosis and hemophilia B.

[0004] What are desirable are AAV-based constructs for gene delivery.

SUMMARY OF THE INVENTION

[0005] In one aspect, the invention provides a novel method of detectingand identifying AAV sequences from cellular DNAs of various human andnon-human primate (NHP) tissues using bioinformatics analysis, PCR basedgene amplification and cloning technology, based on the nature oflatency and integration of AAVs in the absence of helper virusco-infection.

[0006] In another aspect, the invention provides method of isolatingnovel AAV sequences detected using the above described method of theinvention. The invention further comprises methods of generating vectorsbased upon these novel AAV serotypes, for serology and gene transferstudies solely based on availability of capsid gene sequences andstructure of rep/cap gene junctions.

[0007] In still another aspect, the invention provides a novel methodfor performing studies of serology, epidemiology, biodistribution andmode of transmission, using reagents according to the invention, whichinclude generic sets of primers/probes and quantitative real time PCR.

[0008] In yet another aspect, the invention provides a method ofisolating complete and infectious genomes of novel AAV serotypes fromcellular DNA of different origins using RACE and other moleculartechniques.

[0009] In a further aspect, the invention provides a method of rescuingnovel serotypes of AAV genomes from human and NHP cell lines usingadenovirus helpers of different origins.

[0010] In still a further aspect, the invention provides novel AAVserotypes, vectors containing same, and methods of using same.

[0011] These and other aspects of the invention will be readily apparentfrom the following detailed description of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

[0012] FIGS. 1A through 1AAAR provide an alignment of the nucleic acidsequences encoding at least the cap proteins for the AAV serotypes. Thefull-length sequences including the ITRs, the rep region, and the capsidregion are provided for novel AAV serotype 7 [SEQ ID NO:1], and forpreviously published AAV1 [SEQ IN NO:6], AAV2 [SEQ ID NO:7]; and AAV3[SEQ ID NO:8]. Novel AAV serotypes AAV8 [SEQ ID NO:4] and AAV9 [SEQ IDNO:5] are the subject of co-filed applications. The other novel clonesof the invention provided in this alignment include: 42-2 [SEQ ID NO:9],42-8 [SEQ ID NO:27], 42-15 [SEQ ID NO:28], 42-5b [SEQ ID NO: 29], 42-1b[SEQ ID NO:30]; 42-13 [SEQ ID NO: 31], 42-3a [SEQ ID NO: 32], 42-4 [SEQID NO:33], 42-5a [SEQ ID NO: 34], 42-10 [SEQ ID NO:35], 42-3b [SEQ IDNO: 36], 42-11 [SEQ ID NO: 37], 42-6b [SEQ ID NO:38], 43-1 [SEQ ID NO:39], 43-5 [SEQ ID NO: 40], 43-12 [SEQ ID NO:41], 43-20 [SEQ ID NO:42],43-21 [SEQ ID NO: 43], 43-23 [SEQ ID NO:44], 43-25 [SEQ ID NO: 45], 44.1[SEQ ID NO:47], 44.5 [SEQ ID NO:47], 223.10 [SEQ ID NO:48], 223.2 [SEQID NO:49], 223.4 [SEQ ID NO:50], 223.5 [SEQ ID NO: 51], 223.6 [SEQ IDNO: 52], 223.7 [SEQ ID NO: 53], A3.4 [SEQ ID NO: 54], A3.5 [SEQ IDNO:55], A3.7 [SEQ ID NO: 56], A3.3 [SEQ ID NO:57], 42.12 [SEQ ID NO:58], 44.2 [SEQ ID NO: 59]. The nucleotide sequences ofthe signatureregions of AAV10 [SEQ ID NO: 117], AAV11 [SEQ ID NO: 118] and AAV12 [SEQID NO:119] are provided in this figure. Critical landmarks in thestructures of AAV genomes are shown. Gaps are demonstrated by dots. The3′ ITR of AAV1 [SEQ ID NO:6] is shown in the same configuration as inthe published sequences. TRS represents terminal resolution site. Noticethat AAV7 is the only AAV reported that uses GTG as the initiation codonfor VP3.

[0013]FIGS. 2A through 2F are an alignment of the amino acid sequencesof the proteins of the vp1 capsid proteins of previously published AAVserotypes 1 [SEQ ID NO:64], AAV2 [SEQ ID NO:70], AAV3 [SEQ ID NO: 71],AAV4 [SEQ ID NO:63], AAV5 [SEQ ID NO:114], and AAV6 [SEQ ID NO:65] andnovel AAV sequences of the invention, including: C1 [SEQ ID NO:60], C2[SEQ ID NO:61], C5 [SEQ ID NO:62], A3-3 [SEQ ID NO:66], A3-7 [SEQ IDNO:67], A3-4 [SEQ ID NO:68], A3-5 [SEQ ID NO: 69], 3.3b [SEQ ID NO: 62],223.4 [SEQ ID NO: 73], 223-5 [SEQ ID NO:74], 223-10 [SEQ ID NO:75],223-2 [SEQ ID NO:76], 223-7 [SEQ ID NO: 77], 223-6 [SEQ ID NO: 78], 44-1[SEQ ID NO: 79], 44-5 [SEQ ID NO:80], 44-2 [SEQ ID NO:81], 42-15 [SEQ IDNO: 84], 42-8 [SEQ ID NO: 85], 42-13 [SEQ ID NO:86], 42-3A [SEQ IDNO:87], 42-4 [SEQ ID NO:88], 42-5A [SEQ ID NO:89], 42-1B [SEQ ID NO:90],42-5B [SEQ ID NO:91], 43-1 [SEQ ID NO: 92], 43-12 [SEQ ID NO: 93], 43-5[SEQ ID NO:94], 43-21 [SEQ ID NO:96], 43-25 [SEQ ID NO: 97], 43-20 [SEQID NO:99], 24.1 [SEQ ID NO: 101], 42.2 [SEQ ID NO:102], 7.2 [SEQ ID NO:103], 27.3 [SEQ ID NO: 104], 16.3 [SEQ ID NO: 105], 42.10 [SEQ ID NO:106], 42-3B [SEQ ID NO: 107], 42-11 [SEQ ID NO: 108], F1 [SEQ ID NO:109], F5 [SEQ ID NO: 110], F3 [SEQ ID NO:111], 42-6B [SEQ ID NO: 112],42-12 [SEQ ID NO: 113]. Novel serotypes AAV8 [SEQ ID NO:95] and AAV9[SEQ ID NO:100] are the subject of co-filed patent applications.

[0014]FIGS. 3A through 3C provide the amino acid sequences of the AAV7rep proteins [SEQ ID NO:3].

DETAILED DESCRIPTION OF THE INVENTION

[0015] In the present invention, the inventors have found a method whichtakes advantage of the ability of adeno-associated virus (AAV) topenetrate the nucleus, and, in the absence of a helper virusco-infection, to integrate into cellular DNA and establish a latentinfection. This method utilizes a polymerase chain reaction (PCR)-basedstrategy for detection, identification and/or isolation of sequences ofAAVs from DNAs from tissues of human and non-human primate origin aswell as from other sources. Advantageously, this method is also suitablefor detection, identification and/or isolation of other integrated viraland non-viral sequences, as described below.

[0016] The invention further provides nucleic acid sequences identifiedaccording to the methods of the invention. One such adeno-associatedvirus is of a novel serotype, termed herein serotype 7 (AAV7). Othernovel adeno-associated virus serotypes provided herein include AAV10,AAV11, and AAV12. Still other novel AAV serotypes identified accordingto the methods of the invention are provided in the presentspecification. See, Figures and Sequence Listing, which is incorporatedby reference.

[0017] Also provided are fragments of these AAV sequences. Amongparticularly desirable AAV fragments are the cap proteins, including thevp1, vp2, vp3, the hypervariable regions, the rep proteins, includingrep 78, rep 68, rep 52, and rep 40, and the sequences encoding theseproteins. Each of these fragments may be readily utilized in a varietyof vector systems and host cells. Such fragments may be used alone, incombination with other AAV sequences or fragments, or in combinationwith elements from other AAV or non-AAV viral sequences. In oneparticularly desirable embodiment, a vector contains the AAV cap and/orrep sequences of the invention.

[0018] As described herein, alignments are performed using any of avariety of publicly or commercially available Multiple SequenceAlignment Programs, such as “Clustal W”, accessible through Web Serverson the internet. Alternatively, Vector NTI utilities are also used.There are also a number of algorithms known in the art which can be usedto measure nucleotide sequence identity, including those contained inthe programs described above. As another example, polynucleotidesequences can be compared using Fasta, a program in GCG Version 6.1.Fasta provides alignments and percent sequence identity of the regionsof the best overlap between the query and search sequences. Forinstance, percent sequence identity between nucleic acid sequences canbe determined using Fasta with its default parameters (a word size of 6and the NOPAM factor for the scoring matrix) as provided in GCG Version6.1, herein incorporated by reference. Similar programs are availablefor amino acid sequences, e.g., the “Clustal X” program. Generally, anyof these programs are used at default settings, although one of skill inthe art can alter these settings as needed. Alternatively, one of skillin the art can utilize another algorithm or computer program whichprovides at least the level of identity or alignment as that provided bythe referenced algorithms and programs.

[0019] The term “substantial homology” or “substantial similarity,” whenreferring to a nucleic acid, or fragment thereof, indicates that, whenoptimally aligned with appropriate nucleotide insertions or deletionswith another nucleic acid (or its complementary strand), there isnucleotide sequence identity in at least about 95 to 99% of the alignedsequences. Preferably, the homology is over full-length sequence, or anopen reading frame thereof, or another suitable fragment which is atleast 15 nucleotides in length. Examples of suitable fragments aredescribed herein.

[0020] The term “substantial homology” or “substantial similarity,” whenreferring to amino acids or fragments thereof, indicates that, whenoptimally aligned with appropriate amino acid insertions or deletionswith another amino acid, there is amino acid sequence identity in atleast about 95 to 99% of the aligned sequences. Preferably, the homologyis over full-length sequence, or a protein thereof, e.g., a cap protein,a rep protein, or a fragment thereof which is at least 8 amino acids, ormore desirably, at least 15 amino acids in length. Examples of suitablefragments are described herein.

[0021] By the term “highly conserved” is meant at least 80% identity,preferably at least 90% identity, and more preferably, over 97%identity. Identity is readily determined by one of skill in the art byresort to algorithms and computer programs known by those of skill inthe art.

[0022] The term “percent sequence identity” or “identical” in thecontext of nucleic acid sequences refers to the residues in the twosequences which are the same when aligned for maximum correspondence.The length of sequence identity comparison may be over the full-lengthof the genome, the full-length of a gene coding sequence, or a fragmentof at least about 500 to 5000 nucleotides, is desired. However, identityamong smaller fragments, e.g. of at least about nine nucleotides,usually at least about 20 to 24 nucleotides, at least about 28 to 32nucleotides, at least about 36 or more nucleotides, may also be desired.Similarly, “percent sequence identity” may be readily determined foramino acid sequences, over the full-length of a protein, or a fragmentthereof. Suitably, a fragment is at least about 8 amino acids in length,and may be up to about 700 amino acids. Examples of suitable fragmentsare described herein.

[0023] The AAV sequences and fragments thereof are useful in productionof rAAV, and are also useful as antisense delivery vectors, gene therapyvectors, or vaccine vectors. The invention further provides nucleic acidmolecules, gene delivery vectors, and host cells which contain the AAVsequences of the invention.

[0024] As described herein, the vectors of the invention containing theAAV capsid proteins of the invention are particularly well suited foruse in applications in which the neutralizing antibodies diminish theeffectiveness of other AAV serotype based vectors, as well as otherviral vectors. The rAAV vectors of the invention are particularlyadvantageous in rAAV readministration and repeat gene therapy.

[0025] These and other embodiments and advantages of the invention aredescribed in more detail below. As used throughout this specificationand the claims, the terms “comprising” and “including” and theirvariants are inclusive of other components, elements, integers, stepsand the like. Conversely, the term “consisting” and its variants isexclusive of other components, elements, integers, steps and the like.

[0026] I. Methods of the Invention

[0027] A. Detection of Sequences Via Molecular Cloning

[0028] In one aspect, the invention provides a method of detectingand/or identifying target nucleic acid sequences in a sample. Thismethod is particularly well suited for detection of viral sequenceswhich are integrated into the chromosome of a cell, e.g.,adeno-associated viruses (AAV) and retroviruses, among others. Thespecification makes reference to AAV, which is exemplified herein.However, based on this information, one of skill in the art may readilyperform the methods of the invention on retroviruses [e.g., felineleukemia virus (FeLV), HTLVI and HTLVII], and lentivirinae [e.g., humanimmunodeficiency virus (HIV), simian immunodeficiency virus (SIV),feline immunodeficiency virus (FIV), equine infectious anemia virus, andspumavirinal)], among others. Further, the method of the invention mayalso be used for detection of other viral and non-viral sequences,whether integrated or non-integrated into the genome of the host cell.

[0029] As used herein, a sample is any source containing nucleic acids,e.g., tissue, tissue culture, cells, cell culture, and biological fluidsincluding, without limitation, urine and blood. These nucleic acidsequences may be DNA or RNA from plasmids, natural DNA or RNA from anysource, including bacteria, yeast, viruses, and higher organisms such asplants or animals. DNA or RNA is extracted from the sample by a varietyof techniques known to those of skill in the art, such as thosedescribed by Sambrook, Molecular Cloning: A Laboratory Manual (New York:Cold Spring Harbor Laboratory). The origin of the sample and the methodby which the nucleic acids are obtained for application of the method ofthe invention is not a limitation of the present invention. Optionally,the method of the invention can be performed directly on the source ofDNA, or on nucleic acids obtained (e.g., extracted) from a source.

[0030] The method of the invention involves subjecting a samplecontaining DNA to amplification via polymerase chain reaction (PCR)using a first set of primers specific for a first region ofdouble-stranded nucleic acid sequences, thereby obtaining amplifiedsequences.

[0031] As used herein, each of the “regions” is predetermined based uponthe alignment of the nucleic acid sequences of at least two serotypes(e.g., AAV) or strains (e.g., lentiviruses), and wherein each of saidregions is composed of sequences having a 5′ end which is highlyconserved, a middle which is preferably, but necessarily, variable, anda 3′ end which is highly conserved, each of these being conserved orvariable relative to the sequences of the at least two aligned AAVserotypes. Preferably, the 5′ and/or 3′ end is highly conserved over atleast about 9, and more preferably, at least 18 base pairs (bp).However, one or both of the sequences at the 5′ or 3′ end may beconserved over more than 18 bp, more than 25 bp, more than 30 bp, ormore than 50 bp at the 5′ end. With respect to the variable region,there is no requirement for conserved sequences, these sequences may berelatively conserved, or may have less than 90, 80, or 70% identityamong the aligned serotypes or strains.

[0032] Each of the regions may span about 100 bp to about 10 kilobasepairs in length. However, it is particularly desirable that one of theregions is a “signature region”, i.e., a region which is sufficientlyunique to positively identify the amplified sequence as being from thetarget source. For example, in one embodiment, the first region is about250 bp in length, and is sufficiently unique among known AAV sequences,that it positively identifies the amplified region as being of AAVorigin. Further, the variable sequences within this region aresufficiently unique that can be used to identify the serotype from whichthe amplified sequences originate. Once amplified (and therebydetected), the sequences can be identified by performing conventionalrestriction digestion and comparison to restriction digestion patternsfor this region in any of AAV1, AAV2, AAV3, AAV4, AAV5, or AAV6, or thatof AAV7, AAV10, AAV11, AAV12, or any of the other novel serotypesidentified by the invention, which is predetermined and provided by thepresent invention.

[0033] Given the guidance provided herein, one of skill in the art canreadily identify such regions among other integrated viruses to permitready detection and identification of these sequences. Thereafter, anoptimal set of generic primers located within the highly conserved endscan be designed and tested for efficient amplification of the selectedregion from samples. This aspect of the invention is readily adapted toa diagnostic kit for detecting the presence of the target sequence(e.g., AAV) and for identifying the AAV serotype, using standards whichinclude the restriction patterns for the AAV serotypes described hereinor isolated using the techniques described herein. For example, quickidentification or molecular serotyping of PCR products can beaccomplished by digesting the PCR products and comparing restrictionpatterns.

[0034] Thus, in one embodiment, the “signature region” for AAV spansabout bp 2800 to about 3200 of AAV 1 [SEQ ID NO:6], and correspondingbase pairs in AAV 2, AAV3, AAV4, AAV5, and AAV6. More desirably, theregion is about 250 bp, located within bp 2886 to about 3143 bp of AAV 1[SEQ ID NO:6], and corresponding base pairs in AAV 2 [SEQ ID NO:7], AAV3[SEQ ID NO8], and other AAV serotypes. See, FIG. 1. To permit rapiddetection of AAV in the sample, primers which specifically amplify thissignature region are utilized. However, the present invention is notlimited to the exact sequences identified herein for the AAV signatureregion, as one of skill in the art may readily alter this region toencompass a shorter fragment, or a larger fragment of this signatureregion.

[0035] The PCR primers are generated using techniques known to those ofskill in the art. Each of the PCR primer sets is composed of a 5′ primerand a 3′ primer. See, e.g., Sambrook et al, cited herein. The term“primer” refers to an oligonucleotide which acts as a point ofinitiation of synthesis when placed under conditions in which synthesisof a primer extension product which is complementary to a nucleic acidstrand is induced. The primer is preferably single stranded. However, ifa double stranded primer is utilized, it is treated to separate itsstrands before being used to prepare extension products. The primers maybe about 15 to 25 or more nucleotides, and preferably at least 18nucleotides. However, for certain applications shorter nucleotides,e.g., 7 to 15 nucleotides are utilized.

[0036] The primers are selected to be sufficiently complementary to thedifferent strands of each specific sequence to be amplified to hybridizewith their respective strands. Therefore, the primer sequence need notreflect the exact sequence of the region being amplified. For example, anon-complementary nucleotide fragment may be attached to the 5′ end ofthe primer, with the remainder of the primer sequence being completelycomplementary to the strand. Alternatively, non-complementary bases orlonger sequences can be interspersed into the primer, provided that theprimer sequence has sufficient complementarity with the sequence of thestrand to be amplified to hybridize therewith and form a template forsynthesis of the extension product of the other primer.

[0037] The PCR primers for the signature region according to theinvention are based upon the highly conserved sequences of two or morealigned sequences (e.g., two or more AAV serotypes). The primers canaccommodate less than exact identity among the two or more aligned AAVserotypes at the 5′ end or in the middle. However, the sequences at the3′ end of the primers correspond to a region of two or more aligned AAVserotypes in which there is exact identity over at least five,preferably, over at least nine base pairs, and more preferably, over atleast 18 base pairs at the 3′ end of the primers. Thus, the 3′ end ofthe primers is composed of sequences with 100% identity to the alignedsequences over at least five nucleotides. However, one can optionallyutilize one, two, or more degenerate nucleotides at the 3′ end of theprimer.

[0038] For example, the primer set for the signature region of AAV wasdesigned based upon a unique region within the AAV capsid, as follows.The 5′ primer was based upon nt 2867-2891 of AAV2 [SEQ ID NO:7],5′-GGTAATTCCTCCGGAAATTGGCATT3′. See, FIG. 1. The 3′ primer was designedbased upon nt 3096-3122 of AAV2 [SEQ ID NO:7],5′-GACTCATCAACAACAACTGGGGATTC-3′. However, one of skill in the art mayhave readily designed the primer set based upon the correspondingregions of AAV 1, AAV3, AAV4, AAV5, AAV6, or based upon the informationprovided herein, AAV7, AAV10, AAV11, AAV12, or another novel AAV of theinvention. In addition, still other primer sets can be readily designedto amplify this signature region, using techniques known to those ofskill in the art.

[0039] B. Isolation of Target Sequences

[0040] As described herein, the present invention provides a firstprimer set which specifically amplifies the signature region of thetarget sequence, e.g., an AAV serotype, in order to permit detection ofthe target. In a situation in which further sequences are desired, e.g.,if a novel AAV serotype is identified, the signature region may beextended. Thus, the invention may further utilize one or more additionalprimer sets.

[0041] Suitably, these primer sets are designed to include either the 5′or 3′ primer of the first primer set and a second primer unique to theprimer set, such that the primer set amplifies a region 5′ or 3′ to thesignature region which anneals to either the 5′ end or the 3′ end of thesignature region. For example, a first primer set is composed of a 5′primer, P1 and a 3′ primer P2 to amplify the signature region. In orderto extend the signature region on its 3′ end, a second primer set iscomposed of primer P1 and a 3′ primer P4, which amplifies the signatureregion and contiguous sequences downstream of the signature region. Inorder to extend the signature region on its 5′ end, a third primer setis composed of a 5′ primer, P5, and primer P2, such that the signatureregion and contiguous sequences upstream of the signature region areamplified. These extension steps are repeated (or performed at the sametime), as needed or desired. Thereafter, the products results from theseamplification steps are fused using conventional steps to produce anisolated sequence of the desired length.

[0042] The second and third primer sets are designed, as with the primerset for the signature region, to amplify a region having highlyconserved sequences among the aligned sequences. Reference herein to theterm “second” or “third” primer set is for each of discussion only, andwithout regard to the order in which these primers are added to thereaction mixture, or used for amplification. The region amplified by thesecond primer set is selected so that upon amplification it anneals atits 5′ end to the 3′ end of the signature region. Similarly, the regionamplified by the third primer set is selected so that upon amplificationit anneals at its 3′ end anneals to the 5′ end of the signature region.Additional primer sets can be designed such that the regions which theyamplify anneal to the either the 5′ end or the 3′ end of the extensionproducts formed by the second or third primer sets, or by subsequentprimer sets.

[0043] For example, where AAV is the target sequence, a first set ofprimers (P1 and P2) are used to amplify the signature region from thesample. In one desirable embodiment, this signature region is locatedwithin the AAV capsid. A second set of primers (P1 and P4) is used toextend the 3′ end of the signature region to a location in the AAVsequence which is just before the AAV 3′ ITR, i.e., providing anextension product containing the entire 3′ end of the AAV capsid whenusing the signature region as an anchor. In one embodiment, the P4primer corresponds to nt 4435 to 4462 of AAV2 [SEQ ID NO:7], andcorresponding sequences in the other AAV serotypes. This results inamplification of a region of about 1.6 kb, which contains the 0.25 kbsignature region. A third set of primers (P3 and P2) is used to extendthe 5′ end of signature region to a location in the AAV sequences whichis in the 3′ end of the rep genes, i.e., providing an extension productcontaining the entire 5′ end of the AAV capsid when using the signatureregion as an anchor. In one embodiment, the P3 primer corresponds to nt1384 to 1409 of AAV2 [SEQ ID NO:7], and corresponding sequences in theother AAV serotypes. This results in amplification of a region of about1.7 kb, which contains the 0.25 kb signature region. Optionally, afourth set of primers are used to further extend the extension productcontaining the entire 5′ end of the AAV capsid to also include the repsequences. In one embodiment, the primer designated P5 corresponds to nt108 to 133 of AAV2 [SEQ ID NO:7], and corresponding sequences in theother AAV serotypes and is used in conjunction with the P2 primer.

[0044] Following completion of the desired number of extension steps,the various extension products are fused, making use of the signatureregion as an anchor or marker, to construct an intact sequence. In theexample provided herein, AAV sequences containing, at a minimum, anintact AAV cap gene are obtained. Larger sequences may be obtained,depending upon the number of extension steps performed.

[0045] Suitably, the extension products are assembled into an intact AAVsequence using methods known to those of skill in the art. For example,the extension products may be digested with DraIII, which cleaves at theDraIII site located within the signature region, to provide restrictionfragments which are re-ligated to provide products containing (at aminimum) an intact AAV cap gene. However, other suitable techniques forassembling the extension products into an intact sequence may beutilized. See, generally, Sambrook et al, cited herein.

[0046] As an alternative to the multiple extension steps describedabove, another embodiment of the invention provides for directamplification of a 3.1 kb fragment which allows isolation of full-lengthcap sequences. To directly amplify a 3.1 kb full-length cap fragmentfrom NHP tissue and blood DNAs, two other highly conserved regions wereidentified in AAV genomes for use in PCR amplification of largefragments. A primer within a conserved region located in the middle ofthe rep gene is utilized (AV1ns: 5′ GCTGCGTCAACTGGACCAATGAGAAC 3′, nt ofSEQ ID NO:6) in combination with the 3′ primer located in anotherconserved region downstream of the Cap gene (AV2cas: 5′CGCAGAGACCAAAGTTCAACTGAAACGA 3′, SEQ ID NO: 7) for amplification of AAVsequences including the full-length AAV cap. Typically, followingamplification, the products are cloned and sequence analysis isperformed with an accuracy of ≧99.9%. Using this method, the inventorshave isolated at least 50 capsid clones which have subsequently beencharacterized. Among them, 37 clones were derived from Rhesus macaquetissues (rh.1-rh.37), 6 clones from cynomologous macaques (cy.1-cy.6), 2clones from Baboons (bb.1 and bb.2) and 5 clones from Chimps(ch.1-ch.5). These clones are identified elsewhere in the specification,together with the species of animal from which they were identified andthe tissues in that animal these novel sequences have been located.

[0047] C. Alternative Method for Isolating Novel AAV

[0048] In another aspect, the invention provides an alternative methodfor isolating novel AAV from a cell. This method involves infecting thecell with a vector which provides helper functions to the AAV; isolatinginfectious clones containing AAV; sequencing the isolated AAV; andcomparing the sequences of the isolated AAV to known AAV serotypes,whereby differences in the sequences of the isolated AAV and known AAVserotypes indicates the presence of a novel AAV.

[0049] In one embodiment, the vector providing helper functions providesessential adenovirus functions, including, e.g., E1a, E1b, E2a, E4ORF6.In one embodiment, the helper functions are provided by an adenovirus.The adenovirus may be a wild-type adenovirus, and may be of human ornon-human origin, preferably non-human primate (NHP) origin. The DNAsequences of a number of adenovirus types are available from Genbank,including type Ad5 [Genbank Accession No. M73260]. The adenovirussequences may be obtained from any known adenovirus serotype, such asserotypes 2, 3, 4, 7, 12 and 40, and further including any of thepresently identified human types [see, e.g., Horwitz, cited above].Similarly adenoviruses known to infect non-human animals (e.g.,chimpanzees) may also be employed in the vector constructs of thisinvention. See, e.g., U.S. Pat. No. 6,083,716. In addition to wild-typeadenoviruses, recombinant viruses or non-viral vectors (e.g., plasmids,episomes, etc.) carrying the necessary helper functions may be utilized.Such recombinant viruses are known in the art and may be preparedaccording to published techniques. See, e.g., U.S. Pat. No. 5,871,982and U.S. Pat. No. 6,251,677, which describe a hybrid Ad/AAV virus. Theselection of the adenovirus type is not anticipated to limit thefollowing invention. A variety of adenovirus strains are available fromthe American Type Culture Collection, Manassas, Va., or available byrequest from a variety of commercial and institutional sources. Further,the sequences of many such strains are available from a variety ofdatabases including, e.g., PubMed and GenBank.

[0050] In another alternative, infectious AAV may be isolated usinggenome walking technology (Siebert et al., 1995, Nucleic Acid Research,23:1087-1088, Friezner-Degen et al., 1986, J. Biol. Chem. 261:6972-6985,BD Biosciences Clontech, Palo Alto, Calif.). Genome walking isparticularly well suited for identifying and isolating the sequencesadjacent to the novel sequences identified according to the method ofthe invention. For example, this technique may be useful for isolatinginverted terminal repeat (ITRs) of the novel AAV serotype, based uponthe novel AAV capsid and/or rep sequences identified using the methodsof the invention. This technique is also useful for isolating sequencesadjacent to other AAV and non-AAV sequences identified and isolatedaccording to the present invention. See, Examples 3 and 4.

[0051] The methods of the invention may be readily used for a variety ofepidemiology studies, studies of biodistribution, monitoring of genetherapy via AAV vectors and vector derived from other integratedviruses. Thus, the methods are well suited for use in pre-packaged kitsfor use by clinicians, researchers, and epidemiologists.

[0052] II. Diagnostic Kit

[0053] In another aspect, the invention provides a diagnostic kit fordetecting the presence of a known or unknown adeno-associated virus(AAV) in a sample. Such a kit may contain a first set of 5′ and 3′ PCRprimers specific for a signature region of the AAV nucleic acidsequence. Alternatively, or additionally, such a kit can contain a firstset of 5′ and 3′ PCR primers specific for the 3.1 kb fragment whichincludes the full-length AAV capsid nucleic acid sequence identifiedherein (e.g., the AV1ns and AV2cas primers.) Optionally, a kit of theinvention may further contain two or more additional sets of 5′ and 3′primers, as described herein, and/or PCR probes. These primers andprobes are used according to the present invention amplify signatureregions of each AAV serotype, e.g., using quantitative PCR.

[0054] The invention further provides a kit useful for identifying anAAV serotype detected according to the method of the invention and/orfor distinguishing novel AAV from known AAV. Such a kit may furtherinclude one or more restriction enzymes, standards for AAV serotypesproviding their “signature restriction enzyme digestions analyses”,and/or other means for determining the serotype of the AAV detected.

[0055] In addition, kits of the invention may include, instructions, anegative and/or positive control, containers, diluents and buffers forthe sample, indicator charts for signature comparisons, disposablegloves, decontamination instructions, applicator sticks or containers,and sample preparator cups, as well as any desired reagents, includingmedia, wash reagents and concentration reagents. Such reagents may bereadily selected from among the reagents described herein, and fromamong conventional concentration reagents. In one desirable embodiment,the wash reagent is an isotonic saline solution which has been bufferedto physiologic pH, such as phosphate buffered saline (PBS); the elutionreagent is PBS containing 0.4 M NaCl, and the concentration reagents anddevices. For example, one of skill in the art will recognize thatreagents such as polyethylene glycol (PEG), or NH₄SO₄ may be useful, orthat devices such as filter devices. For example, a filter device with a100 K membrane would concentrate rAAV.

[0056] The kits provided by the present invention are useful forperforming the methods described herein, and for study ofbiodistribution, epidemiology, mode of transmission of novel AAVserotypes in human and NHPs.

[0057] Thus, the methods and kits of the invention permit detection,identification, and isolation of target viral sequences, particularlyintegrated viral sequences. The methods and kits are particularly wellsuited for use in detection, identification and isolation of AAVsequences, which may include novel AAV serotypes.

[0058] In one notable example, the method of the invention facilitatedanalysis of cloned AAV sequences by the inventors, which revealedheterogeneity of proviral sequences between cloned fragments fromdifferent animals, all of which were distinct from the known six AAVserotypes, with the majority of the variation localized to hypervariableregions of the capsid protein. Surprising divergence of AAV sequenceswas noted in clones isolated from single tissue sources, such as lymphnode, from an individual rhesus monkey. This heterogeneity is bestexplained by apparent evolution of AAV sequence within individualanimals due, in part, to extensive homologous recombination between alimited number of co-infecting parenteral viruses. These studies suggestsequence evolution of widely disseminated virus during the course of anatural AAV infection that presumably leads to the formation of swarmsof quasispecies which differ from one another in the array of capsidhypervariable regions. This is the first example of rapid molecularevolution of a DNA virus in a way that formerly was thought to berestricted to RNA viruses.

[0059] Sequences of several novel AAV serotypes identified by the methodof the invention and characterization of these serotypes is provided.

[0060] III. Novel AAV Serotypes

[0061] A. Nucleic Acid Sequences

[0062] Nucleic acid sequences of novel AAV serotypes identified by themethods of the invention are provided. See, SEQ ID NO:1, 9-59, and117-120, which are incorporated by reference herein. See also, FIG. 1and the sequence listing.

[0063] For novel serotype AAV7, the full-length sequences, including theAAV 5′ ITRs, capsid, rep, and AAV 3′ ITRs are provided in SEQ ID NO:1.

[0064] For other novel AAV serotypes of the invention, the approximately3.1 kb fragment isolated according to the method of the invention isprovided. This fragment contains sequences encoding full-length capsidprotein and all or part of the sequences encoding the rep protein. Thesesequences include the clones identified below.

[0065] For still other novel AAV serotypes, the signature regionencoding the capsid protein is provided. For example, the AAV10 nucleicacid sequences of the invention include those illustrated in FIG. 1[See, SEQ ID NO:117, which spans 255 bases]. The AAV11 nucleic acidsequences of the invention include the DNA sequences illustrated in FIG.1 [See, SEQ ID NO:118 which spans 258 bases]. The AAV12 nucleic acidsequences of the invention include the DNA sequences illustrated in FIG.1 [See, SEQ ID NO:119, which consists of 255 bases]. Using themethodology described above, further AAV10, AAV11 and AAV12 sequencescan be readily identified and used for a variety of purposes, includingthose described for AAV7 and the other novel serotypes herein.

[0066]FIG. 1 provides the non-human primate (NHP) AAV nucleic acidsequences of the invention in an alignment with the previously publishedAAV serotypes, AAV 1 [SEQ ID NO:6], AAV2 [SEQ ID NO:7], and AAV3 [SEQ IDNO:8]. These novel NHP sequences include those provided in the followingTable 1, which are identified by clone number: TABLE 1 AAV Cap CloneSource SEQ ID NO Sequence Number Species Tissue (DNA) Rh.1 Clone 9Rhesus Heart 5 (AAV9) Rh.2 Clone 43.1 Rhesus MLN 39 Rh.3 Clone 43.5Rhesus MLN 40 Rh.4 Clone 43.12 Rhesus MLN 41 Rh.5 Clone 43.20 Rhesus MLN42 Rh.6 Clone 43.21 Rhesus MLN 43 Rh.7 Clone 43.23 Rhesus MLN 44 Rh.8Clone 43.25 Rhesus MLN 45 Rh.9 Clone 44.1 Rhesus Liver 46 Rh.10 Clone44.2 Rhesus Liver 59 Rh.11 Clone 44.5 Rhesus Liver 47 Rh.12 Clone RhesusMLN 30 42.1B Rh.13 42.2 Rhesus MLN 9 Rh.14 Clone Rhesus MLN 32 42.3ARh.15 Clone Rhesus MLN 36 42.3B Rh.16 Clone 42.4 Rhesus MLN 33 Rh.17Clone Rhesus MLN 34 42.5A Rh.18 Clone Rhesus MLN 29 42.5B Rh.19 CloneRhesus MLN 38 42.6B Rh.20 Clone 42.8 Rhesus MLN 27 Rh.21 Clone 42.10Rhesus MLN 35 Rh.22 Clone 42.11 Rhesus MLN 37 Rh.23 Clone 42.12 RhesusMLN 58 Rh.24 Clone 42.13 Rhesus MLN 31 Rh.25 Clone 42.15 Rhesus MLN 28Rh.26 Clone 223.2 Rhesus Liver 49 Rh.27 Clone 223.4 Rhesus Liver 50Rh.28 Clone 223.5 Rhesus Liver 51 Rh.29 Clone 223.6 Rhesus Liver 52Rh.30 Clone 223.7 Rhesus Liver 53 Rh.31 Clone Rhesus Liver 48 223.10Rh.32 Clone C1 Rhesus Spleen, Duo, 19 Kid & Liver Rh.33 Clone C3 Rhesus20 Rh.34 Clone C5 Rhesus 21 Rh.35 Clone F1 Rhesus Liver 22 Rh.36 CloneF3 Rhesus 23 Rh.37 Clone F5 Rhesus 24 Cy.1 Clone 1.3 Cyno Blood 14 Cy.2Clone Cyno Blood 15 13.3B Cy.3 Clone 24.1 Cyno Blood 16 Cy.4 Clone 27.3Cyno Blood 17 Cy.5 Clone 7.2 Cyno Blood 18 Cy.6 Clone 16.3 Cyno Blood 10bb.1 Clone 29.3 Baboon Blood 11 bb.2 Clone 29.5 Baboon Blood 13 Ch.1Clone A3.3 Chimp Blood 57 Ch.2 Clone A3.4 Chimp Blood 54 Ch.3 Clone A3.5Chimp Blood 55 Ch.4 Clone A3.7 Chimp Blood 56

[0067] A novel NHP clone was made by splicing capsids fragments of twochimp adenoviruses into an AAV2 rep construct. This new clone, A3.1, isalso termed Ch.5 [SEQ ID NO:20]. Additionally, the present inventionincludes two human AAV sequences, termed H6 [SEQ ID NO:25] and H2 [SEQID NO:26].

[0068] The AAV nucleic acid sequences of the invention further encompassthe strand which is complementary to the strands provided in thesequences provided in FIG. 1 and the Sequence Listing [SEQ ID NO:1,9-59, 117-120], nucleic acid sequences, as well as the RNA and cDNAsequences corresponding to the sequences provided in FIG. 1 and theSequence Listing [SEQ ID NO:1, 9-59, 117-120], and their complementarystrands. Also included in the nucleic acid sequences of the inventionare natural variants and engineered modifications of the sequences ofFIG. 1 and the Sequence Listing [SEQ ID NO:1, 9-59, 117-120], and theircomplementary strands. Such modifications include, for example, labelswhich are known in the art, methylation, and substitution of one or moreof the naturally occurring nucleotides with a degenerate nucleotide.

[0069] Further included in this invention are nucleic acid sequenceswhich are greater than 85%, preferably at least about 90%, morepreferably at least about 95%, and most preferably at least about 98 to99% identical or homologous to the sequences of the invention, includingFIG. 1 and the Sequence Listing [SEQ ID NO:1, 9-59, 117-120]. Theseterms are as defined herein.

[0070] Also included within the invention are fragments of the novel AAVsequences identified by the method described herein. Suitable fragmentsare at least 15 nucleotides in length, and encompass functionalfragments, i.e., fragments which are of biological interest. In oneembodiment, these fragments are fragments of the novel sequences of FIG.1 and the Sequence Listing [SEQ ID NO:1, 9-59, 117-120], theircomplementary strands, cDNA and RNA complementary thereto.

[0071] Examples of suitable fragments are provided with respect to thelocation of these fragments on AAV1, AAV2, or AAV7. However, using thealignment provided herein (obtained using the Clustal W program atdefault settings), or similar techniques for generating an alignmentwith other novel serotypes of the invention, one of skill in the art canreadily identify the precise nucleotide start and stop codons fordesired fragments.

[0072] Examples of suitable fragments include the sequences encoding thethree variable proteins (vp) of the AAV capsid which are alternativesplice variants: vp1 [e.g., nt 825 to 3049 of AAV7, SEQ ID NO:1]; vp2[e.g., nt 1234-3049 of AAV7, SEQ ID NO: 1]; and vp 3 [e.g., nt 1434-3049of AAV7, SEQ ID NO:1]. It is notable that AAV7 has an unusual GTG startcodon. With the exception of a few house-keeping genes, such a startcodon has not previously been reported in DNA viruses. The start codonsfor vp1, vp2 and vp3 for other AAV serotypes have been believed to besuch that they permit the cellular mechanism of the host cell in whichthey reside to produce vp1, vp2 and vp3 in a ratio of 10%:10%:80%,respectively, in order to permit efficient assembly of the virion.However, the AAV7 virion has been found to assemble efficiently evenwith this rare GTG start codon. Thus, the inventors anticipate this itis desirable to alter the start codon of the vp3 of other AAV serotypesto contain this rare GTG start codon, in order to improve packagingefficiency, to alter the virion structure and/or to alter location ofepitopes (e.g., neutralizing antibody epitopes) of other AAV serotypes.The start codons may be altered using conventional techniques including,e.g., site directed mutagenesis. Thus, the present invention encompassesaltered AAV virions of any selected serotype, composed of a vp 3, and/oroptionally, vp 1 and/or vp2 having start codons altered to GTG.

[0073] Other suitable fragments of AAV, include a fragment containingthe start codon for the AAV capsid protein [e.g., nt 468 to 3090 ofAAV7, SEQ ID NO:1, nt 725 to 3090 of AAV7, SEQ ID NO:1, andcorresponding regions of the other AAV serotypes]. Still other fragmentsof AAV7 and the other novel AAV serotypes identified using the methodsdescribed herein include those encoding the rep proteins, including rep78 [e.g., initiation codon 334 of FIG. 1 for AAV7], rep 68 [initiationcodon nt 334 of FIG. 1 for AAV7], rep 52 [initiation codon 1006 of FIG.1 for AAV7], and rep 40 [initiation codon 1006 of FIG. 1 for AAV7] Otherfragments of interest may include the AAV 5′ inverted terminal repeatsITRs, [nt 1 to 107 of FIG. 1 for AAV7]; the AAV 3′ ITRs [nt 4704 to 4721of FIG. 1 for AAV7], P19 sequences, AAV P40 sequences, the rep bindingsite, and the terminal resolute site (TRS). Still other suitablefragments will be readily apparent to those of skill in the art. Thecorresponding regions in the other novel serotypes of the invention canbe readily determined by reference to FIG. 1, or by utilizingconventional alignment techniques with the sequences provided herein.

[0074] In addition to including the nucleic acid sequences provided inthe figures and Sequence Listing, the present invention includes nucleicacid molecules and sequences which are designed to express the aminoacid sequences, proteins and peptides of the AAV serotypes of theinvention. Thus, the invention includes nucleic acid sequences whichencode the following novel AAV amino acid sequences: C1 [SEQ ID NO:60],C2 [SEQ ID NO:61], C5 [SEQ ID NO:62], A3-3 [SEQ ID NO:66], A3-7 [SEQ IDNO:67], A3-4 [SEQ ID NO:68], A3-5 [SEQ ID NO: 69], 3.3b [SEQ ID NO: 62],223.4 [SEQ ID NO: 73], 223-5 [SEQ ID NO:74], 223-10 [SEQ ID NO:75],223-2 [SEQ ID NO:76], 223-7 [SEQ ID NO: 77], 223-6 [SEQ ID NO: 78], 44-1[SEQ ID NO: 79], 44-5 [SEQ ID NO:80], 44-2 [SEQ ID NO:81], 42-15 [SEQ IDNO: 84], 42-8 [SEQ ID NO: 85], 42-13 [SEQ ID NO:86], 42-3A [SEQ IDNO:87], 42-4 [SEQ ID NO:88], 42-5A [SEQ ID NO:89], 42-1B [SEQ ID NO:90],42-5B [SEQ ID NO:91], 43-1 [SEQ ID NO: 92], 43-12 [SEQ ID NO: 93], 43-5[SEQ ID NO:94], 43-21 [SEQ ID NO:96], 43-25 [SEQ ID NO: 97], 43-20 [SEQID NO:99], 24.1 [SEQ ID NO: 101], 42.2 [SEQ ID NO:102], 7.2 [SEQ ID NO:103], 27.3 [SEQ ID NO: 104], 16.3 [SEQ ID NO: 105], 42.10 [SEQ ID NO:106], 42-3B [SEQ ID NO: 107], 42-11 [SEQ ID NO: 108], F1 [SEQ ID NO:109], F5 [SEQ ID NO: 110], F3 [SEQ ID NO:111], 42-6B [SEQ ID NO: 112],and/or 42-12 [SEQ ID NO: 113], and artificial AAV serotypes generatedusing these sequences and/or unique fragments thereof.

[0075] As used herein, artificial AAV serotypes include, withoutlimitation, AAV with a non-naturally occurring capsid protein. Such anartificial capsid may be generated by any suitable technique, using anovel AAV sequence of the invention (e.g., a fragment of a vp1 capsidprotein) in combination with heterologous sequences which may beobtained from another AAV serotype (known or novel), non-contiguousportions of the same AAV serotype, from a non-AAV viral source, or froma non-viral source. An artificial AAV serotype may be, withoutlimitation, a chimeric AAV capsid, a recombinant AAV capsid, or a“humanized” AAV capsid.

[0076] B. AAV Amino Acid Sequences, Proteins and Peptides

[0077] The invention provides proteins and fragments thereof which areencoded by the nucleic acid sequences of the novel AAV serotypesidentified herein, including, e.g., AAV7 [nt 825 to 3049 of AAV7, SEQ IDNO: 1] the other novel serotypes provided herein. Thus, the capsidproteins of the novel serotypes of the invention, including: H6 [SEQ IDNO: 25], H2 [SEQ ID NO: 26], 42-2 [SEQ ID NO:9], 42-8 [SEQ ID NO:27],42-15 [SEQ ID NO:28], 42-5b [SEQ ID NO: 29], 42-1b [SEQ ID NO:30]; 42-13[SEQ ID NO: 31], 42-3a [SEQ ID NO: 32], 42-4 [SEQ ID NO:33], 42-5a [SEQID NO: 34], 42-10 [SEQ ID NO:35], 42-3b [SEQ ID NO: 36], 42-11 [SEQ IDNO: 37], 42-6b [SEQ ID NO:38], 43-1 [SEQ ID NO: 39], 43-5 [SEQ ID NO:40], 43-12 [SEQ ID NO:41], 43-20 [SEQ ID NO:42], 43-21 [SEQ ID NO: 43],43-23 [SEQ ID NO:44], 43-25 [SEQ ID NO: 45], 44.1 [SEQ ID NO:47], 44.5[SEQ ID NO:47], 223.10 [SEQ ID NO:48], 223.2 [SEQ ID NO:49], 223.4 [SEQID NO:50], 223.5 [SEQ ID NO: 51], 223.6 [SEQ ID NO: 52], 223.7 [SEQ IDNO: 53], A3.4 [SEQ ID NO: 54], A3.5 [SEQ ID NO:55], A3.7 [SEQ ID NO:56], A3.3 [SEQ ID NO:57]42.12 [SEQ ID NO: 58], and 44.2 [SEQ ID NO: 59],can be readily generated using conventional techniques from the openreading frames provided for the above-listed clones.

[0078] The invention further encompasses AAV serotypes generated usingsequences of the novel AAV serotypes of the invention, which aregenerated using synthetic, recombinant or other techniques known tothose of skill in the art. The invention is not limited to novel AAVamino acid sequences, peptides and proteins expressed from the novel AAVnucleic acid sequences of the invention and encompasses amino acidsequences, peptides and proteins generated by other methods known in theart, including, e.g., by chemical synthesis, by other synthetictechniques, or by other methods. For example, the sequences of any of C1[SEQ ID NO:60], C2 [SEQ ID NO:61], C5 [SEQ ID NO:62], A3-3 [SEQ IDNO:66], A3-7 [SEQ ID NO:67], A3-4 [SEQ ID NO:68], A3-5 [SEQ ID NO: 69],3.3b [SEQ ID NO: 62], 223.4 [SEQ ID NO: 73], 223-5 [SEQ ID NO:74],223-10 [SEQ ID NO:75], 223-2 [SEQ ID NO:76], 223-7 [SEQ ID NO: 77],223-6 [SEQ ID NO: 78], 44-1 [SEQ ID NO: 79], 44-5 [SEQ ID NO:80], 44-2[SEQ ID NO:81], 42-15 [SEQ ID NO: 84], 42-8 [SEQ ID NO: 85], 42-13 [SEQID NO:86], 42-3A [SEQ ID NO:87], 42-4 [SEQ ID NO:88], 42-5A [SEQ IDNO:89], 42-1B [SEQ ID NO:90], 42-5B [SEQ ID NO:91], 43-1 [SEQ ID NO:92], 43-12 [SEQ ID NO: 93], 43-5 [SEQ ID NO:94], 43-21 [SEQ ID NO:96],43-25 [SEQ ID NO: 97], 43-20 [SEQ ID NO:99], 24.1 [SEQ ID NO: 101], 42.2[SEQ ID NO:102], 7.2 [SEQ ID NO: 103], 27.3 [SEQ ID NO: 104], 16.3 [SEQID NO: 105], 42.10 [SEQ ID NO: 106], 42-3B [SEQ ID NO: 107], 42-11 [SEQID NO: 108], F1 [SEQ ID NO: 109], F5 [SEQ ID NO: 110], F3 [SEQ ID NO:111], 42-6B [SEQ ID NO: 112], and/or 42-12 [SEQ ID NO: 113] by bereadily generated using a variety of techniques.

[0079] Suitable production techniques are well known to those of skillin the art. See, e.g., Sambrook et al, Molecular Cloning: A LaboratoryManual, Cold Spring Harbor Press (Cold Spring Harbor, N.Y.).Alternatively, peptides can also be synthesized by the well known solidphase peptide synthesis methods (Merrifield, J. Am. Chem. Soc., 85:2149(1962); Stewart and Young, Solid Phase Peptide Synthesis (Freeman, SanFrancisco, 1969) pp. 27-62). These and other suitable production methodsare within the knowledge of those of skill in the art and are not alimitation of the present invention.

[0080] Particularly desirable proteins include the AAV capsid proteins,which are encoded by the nucleotide sequences identified above. Thesequences of many of the capsid proteins of the invention are providedin an alignment in FIG. 2 and/or in the Sequence Listing, SEQ ID NO: 2and 60 to 115, which is incorporated by reference herein. The AAV capsidis composed of three proteins, vp1, vp2 and vp3, which are alternativesplice variants. The full-length sequence provided in these figures isthat of vp1. Based on the numbering of the AAV7 capsid [SEQ ID NO:2],the sequences of vp2 span amino acid 138-737 of AAV7 and the sequencesof vp3 span amino acids 203-737 of AAV7. With this information, one ofskill in the art can readily determine the location of the vp2 and vp3proteins for the other novel serotypes of the invention.

[0081] Other desirable proteins and fragments of the capsid proteininclude the constant and variable regions, located between hypervariableregions (HPV) and the sequences of the HPV regions themselves. Analgorithm developed to determine areas of sequence divergence in AAV2has yielded 12 hypervariable regions (HVR) of which 5 overlap or arepart of the four previously described variable regions. [Chiorini et al,J. Virol, 73:1309-19 (1999); Rutledge et al, J. Virol., 72:309-319]Using this algorithm and/or the alignment techniques described herein,the HVR of the novel AAV serotypes are determined. For example, withrespect to the number of the AAV2 vp1 [SEQ ID NO:70], the HVR arelocated as follows: HVR1, aa 146-152; HVR2, aa 182-186; HVR3, aa262-264; HVR4, aa 381-383; HVR5, aa 450-474; HVR6, aa 490-495; HVR7,aa500-504; HVR8, aa 514-522; HVR9, aa 534-555; HVR10, aa 581-594; HVR11,aa 658-667; and HVR12, aa 705-719. Utilizing an alignment prepared inaccordance with conventional methods and the novel sequences providedherein [See, e.g., FIG. 2], one can readily determine the location ofthe HVR in the novel AAV serotypes of the invention. For example,utilizing FIG. 2, one can readily determine that for AAV7 [SEQ ID NO:2].HVR1 is located at aa 146-152; HVR2 is located at 182-187; HVR3 islocated at aa 263-266, HVR4 is located at aa 383-385, HVR5 is located ataa 451-475; HVR6 is located at aa 491-496 of AAV7; HVR7 is located at aa501-505; HVR8 is located at aa 513-521; HVR9 is located at 533-554;HVR10 is located at aa 583-596; HVR11 is located at aa 660-669; HVR12 islocated at aa 707-721. Using the information provided herein, the HVRsfor the other novel serotypes of the invention can be readilydetermined.

[0082] In addition, within the capsid, amino acid cassettes of identityhave been identified. These cassettes are of particular interest, asthey are useful in constructing artificial serotypes, e.g., by replacinga HVR1 cassette of a selected serotype with an HVR1 cassette of anotherserotype. Certain of these cassettes of identity are noted in FIG. 2.See, FIG. 2, providing the Clustal X alignment, which has a ruler isdisplayed below the sequences, starting at 1 for the first residueposition. The line above the ruler is used to mark strongly conservedpositions. Three characters (*, : , .) are used. “*” indicates positionswhich have a single, fully conserved residue. “:” indicates that a“strong” group is fully conserved “.” Indicates that a “weaker” group isfully conserved. These are all the positively scoring groups that occurin the Gonnet Pam250 matrix. The strong groups are defined as a strongscore >0.5 and the weak groups are defined as weak score <0.5.

[0083] Additionally, examples of other suitable fragments of AAV capsidsinclude, with respect to the numbering of AAV2 [SEQ ID NO:70], aa 24-42,aa 25-28; aa 81-85; aa133-165; aa 134-165; aa 137-143; aa 154-156; aa194-208; aa 261-274; aa 262-274; aa 171-173; aa 413-417; aa 449-478; aa494-525; aa 534-571; aa 581-601; aa 660-671; aa 709-723. Still otherdesirable fragments include, for example, in AAV7, amino acids 1 to 184of SEQ ID NO:2, amino acids 199 to 259; amino acids 274 to 446; aminoacids 603 to 659; amino acids 670 to 706; amino acids 724 to 736; aa 185to 198; aa 260 to 273; aa447 to 477; aa495 to 602; aa660 to 669; andaa707 to 723. Still other desirable regions, based on the numbering ofAAV7 [SEQ ID NO:2], are selected from among the group consisting of aa185 to 198; aa 260 to 273; aa447 to 477;aa495 to 602; aa660 to 669; andaa707 to 723. Using the alignment provided herein performed using theClustal X program at default settings, or using other commercially orpublicly available alignment programs at default settings, one of skillin the art can readily determine corresponding fragments of the novelAAV capsids of the invention.

[0084] Other desirable proteins are the AAV rep proteins [aa 1 to 623 ofSEQ ID NO:3 for AAV7] and functional fragments thereof, including, e.g.,aa 1 to 171, aa 172 to 372, aa 373 to 444, aa 445 to 623 of SEQ ID NO:3,among others. Suitably, such fragments are at least 8 amino acids inlength. See, FIG. 3. Comparable regions can be identified in theproteins of the other novel AAV of the invention, using the techniquesdescribed herein and those which are known in the art. In addition,fragments of other desired lengths may be readily utilized. Suchfragments may be produced recombinantly or by other suitable means,e.g., chemical synthesis.

[0085] The sequences, proteins, and fragments of the invention may beproduced by any suitable means, including recombinant production,chemical synthesis, or other synthetic means. Such production methodsare within the knowledge of those of skill in the art and are not alimitation of the present invention.

[0086] IV. Production of rAAV with Novel AAV Capsids

[0087] The invention encompasses novel, wild-type AAV serotypesidentified by the invention, the sequences of which wild-type AAVserotypes are free of DNA and/or cellular material with these virusesare associated in nature. In another aspect, the present inventionprovides molecules which utilize the novel AAV sequences of theinvention, including fragments thereof, for production of moleculesuseful in delivery of a heterologous gene or other nucleic acidsequences to a target cell.

[0088] The molecules of the invention which contain sequences of a novelAAV serotype of the invention include any genetic element (vector) whichmay be delivered to a host cell, e.g., naked DNA, a plasmid, phage,transposon, cosmid, episome, a protein in a non-viral delivery vehicle(e.g., a lipid-based carrier), virus, etc. which transfer the sequencescarried thereon. The selected vector may be delivered by any suitablemethod, including transfection, electroporation, liposome delivery,membrane fusion techniques, high velocity DNA-coated pellets, viralinfection and protoplast fusion. The methods used to construct anyembodiment of this invention are known to those with skill in nucleicacid manipulation and include genetic engineering, recombinantengineering, and synthetic techniques. See, e.g., Sambrook et al,Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, ColdSpring Harbor, N.Y.

[0089] In one embodiment, the vectors of the invention contain sequencesencoding a novel AAV capsid of the invention (e.g., AAV7 capsid, AAV44-2 (rh.10), an AAV10 capsid, an AAV11 capsid, an AAV12 capsid), or afragment of one or more of these AAV capsids. Alternatively, the vectorsmay contain the capsid protein, or a fragment thereof, itself.

[0090] Optionally, vectors of the invention may contain sequencesencoding AAV rep proteins. Such rep sequences may be from the same AAVserotype which is providing the cap sequences. Alternatively, thepresent invention provides vectors in which the rep sequences are froman AAV serotype which differs from that which is providing the capsequences. In one embodiment, the rep and cap sequences are expressedfrom separate sources (e.g., separate vectors, or a host cell and avector). In another embodiment, these rep sequences are expressed fromthe same source as the cap sequences. In this embodiment, the repsequences may be fused in frame to cap sequences of a different AAVserotype to form a chimeric AAV vector. Optionally, the vectors of theinvention further contain a minigene comprising a selected transgenewhich is flanked by AAV 5′ ITR and AAV 3′ ITR.

[0091] Thus, in one embodiment, the vectors described herein containnucleic acid sequences encoding an intact AAV capsid which may be from asingle AAV serotype (e.g., AAV7 or another novel AAV). Alternatively,these vectors contain sequences encoding artificial capsids whichcontain one or more fragments of the AAV7 (or another novel AAV) capsidfused to heterologous AAV or non-AAV capsid proteins (or fragmentsthereof). These artificial capsid proteins are selected fromnon-contiguous portions of the AAV7 (or another novel AAV) capsid orfrom capsids of other AAV serotypes. For example, it may be desirable tomodify the coding regions of one or more of the AAV vp1, e.g., in one ormore of the hypervariable regions (i.e., HPV1-12), or vp2, and/or vp3.In another example, it may be desirable to alter the start codon of thevp3 protein to GTG. These modifications may be to increase expression,yield, and/or to improve purification in the selected expressionsystems, or for another desired purpose (e.g., to change tropism oralter neutralizing antibody epitopes).

[0092] The vectors described herein, e.g., a plasmid, are useful for avariety of purposes, but are particularly well suited for use inproduction of a rAAV containing a capsid comprising AAV sequences or afragment thereof. These vectors, including rAAV, their elements,construction, and uses are described in detail herein.

[0093] In one aspect, the invention provides a method of generating arecombinant adeno-associated virus (AAV) having an AAV serotype 7 (oranother novel AAV) capsid, or a portion thereof. Such a method involvesculturing a host cell which contains a nucleic acid sequence encoding anadeno-associated virus (AAV) serotype 7 (or another novel AAV) capsidprotein, or fragment thereof, as defined herein; a functional rep gene;a minigene composed of, at a minimum, AAV inverted terminal repeats(ITRs) and a transgene; and sufficient helper functions to permitpackaging of the minigene into the AAV7 (or another novel AAV) capsidprotein.

[0094] The components required to be cultured in the host cell topackage an AAV minigene in an AAV capsid may be provided to the hostcell in trans. Alternatively, any one or more of the required components(e.g., minigene, rep sequences, cap sequences, and/or helper functions)may be provided by a stable host cell which has been engineered tocontain one or more of the required components using methods known tothose of skill in the art. Most suitably, such a stable host cell willcontain the required component(s) under the control of an induciblepromoter. However, the required component(s) may be under the control ofa constitutive promoter. Examples of suitable inducible and constitutivepromoters are provided herein, in the discussion of regulatory elementssuitable for use with the transgene. In still another alternative, aselected stable host cell may contain selected component(s) under thecontrol of a constitutive promoter and other selected component(s) underthe control of one or more inducible promoters. For example, a stablehost cell may be generated which is derived from 293 cells (whichcontain E1 helper functions under the control of a constitutivepromoter), but which contains the rep and/or cap proteins under thecontrol of inducible promoters. Still other stable host cells may begenerated by one of skill in the art.

[0095] The minigene, rep sequences, cap sequences, and helper functionsrequired for producing the rAAV of the invention may be delivered to thepackaging host cell in the form of any genetic element which transferthe sequences carried thereon. The selected genetic element may bedelivered by any suitable method, including those described herein. Themethods used to construct any embodiment of this invention are known tothose with skill in nucleic acid manipulation and include geneticengineering, recombinant engineering, and synthetic techniques. See,e.g., Sambrook et al, Molecular Cloning: A Laboratory Manual, ColdSpring Harbor Press, Cold Spring Harbor, N.Y. Similarly, methods ofgenerating rAAV virions are well known and the selection of a suitablemethod is not a limitation on the present invention. See, e.g., K.Fisher et al, J. Virol., 70:520-532 (1993) and U.S. Pat. No. 5,478,745.

[0096] A. The Minigene

[0097] The minigene is composed of, at a minimum, a transgene and itsregulatory sequences, and 5′ and 3′ AAV inverted terminal repeats(ITRs). It is this minigene which is packaged into a capsid protein anddelivered to a selected host cell.

[0098] 1. The Transgene

[0099] The transgene is a nucleic acid sequence, heterologous to thevector sequences flanking the transgene, which encodes a polypeptide,protein, or other product, of interest. The nucleic acid coding sequenceis operatively linked to regulatory components in a manner which permitstransgene transcription, translation, and/or expression in a host cell.

[0100] The composition of the transgene sequence will depend upon theuse to which the resulting vector will be put. For example, one type oftransgene sequence includes a reporter sequence, which upon expressionproduces a detectable signal. Such reporter sequences include, withoutlimitation, DNA sequences encoding β-lactamase, β-galactosidase (LacZ),alkaline phosphatase, thymidine kinase, green fluorescent protein (GFP),chloramphenicol acetyltransferase (CAT), luciferase, membrane boundproteins including, for example, CD2, CD4, CD8, the influenzahemagglutinin protein, and others well known in the art, to which highaffinity antibodies directed thereto exist or can be produced byconventional means, and fusion proteins comprising a membrane boundprotein appropriately fused to an antigen tag domain from, among others,hemagglutinin or Myc.

[0101] These coding sequences, when associated with regulatory elementswhich drive their expression, provide signals detectable by conventionalmeans, including enzymatic, radiographic, colorimetric, fluorescence orother spectrographic assays, fluorescent activating cell sorting assaysand immunological assays, including enzyme linked immunosorbent assay(ELISA), radioimmunoassay (RIA) and immunohistochemistry. For example,where the marker sequence is the LacZ gene, the presence of the vectorcarrying the signal is detected by assays for beta-galactosidaseactivity. Where the transgene is green fluorescent protein orluciferase, the vector carrying the signal may be measured visually bycolor or light production in a luminometer.

[0102] However, desirably, the transgene is a non-marker sequenceencoding a product which is useful in biology and medicine, such asproteins, peptides, RNA, enzymes, or catalytic RNAs. Desirable RNAmolecules include tRNA, dsRNA, ribosomal RNA, catalytic RNAs, andantisense RNAs. One example of a useful RNA sequence is a sequence whichextinguishes expression of a targeted nucleic acid sequence in thetreated animal.

[0103] The transgene may be used to correct or ameliorate genedeficiencies, which may include deficiencies in which normal genes areexpressed at less than normal levels or deficiencies in which thefunctional gene product is not expressed. A preferred type of transgenesequence encodes a therapeutic protein or polypeptide which is expressedin a host cell. The invention further includes using multipletransgenes, e.g., to correct or ameliorate a gene defect caused by amulti-subunit protein. In certain situations, a different transgene maybe used to encode each subunit of a protein, or to encode differentpeptides or proteins. This is desirable when the size of the DNAencoding the protein subunit is large, e.g., for an immunoglobulin, theplatelet-derived growth factor, or a dystrophin protein. In order forthe cell to produce the multi-subunit protein, a cell is infected withthe recombinant virus containing each of the different subunits.Alternatively, different subunits of a protein may be encoded by thesame transgene. In this case, a single transgene includes the DNAencoding each of the subunits, with the DNA for each subunit separatedby an internal ribozyme entry site (IRES). This is desirable when thesize of the DNA encoding each of the subunits is small, e.g., the totalsize of the DNA encoding the subunits and the IRES is less than fivekilobases. As an alternative to an IRES, the DNA may be separated bysequences encoding a 2A peptide, which self-cleaves in apost-translational event. See, e.g., M. L. Donnelly, et al., J. Gen.Virol., 78(Pt 1):13-21 (January 1997); Furler, S., et al, Gene Ther.,8(11):864-873 (June 2001); Klump H., et al., Gene Ther., 8(10):811-817(May 2001). This 2A peptide is significantly smaller than an IRES,making it well suited for use when space is a limiting factor. However,the selected transgene may encode any biologically active product orother product, e.g., a product desirable for study.

[0104] Suitable transgenes may be readily selected by one of skill inthe art. The selection of the transgene is not considered to be alimitation of this invention.

[0105] 2. Regulatory Elements

[0106] In addition to the major elements identified above for theminigene, the vector also includes conventional control elementsnecessary which are operably linked to the transgene in a manner whichpermits its transcription, translation and/or expression in a celltransfected with the plasmid vector or infected with the virus producedby the invention. As used herein, “operably linked” sequences includeboth expression control sequences that are contiguous with the gene ofinterest and expression control sequences that act in trans or at adistance to control the gene of interest.

[0107] Expression control sequences include appropriate transcriptioninitiation, termination, promoter and enhancer sequences; efficient RNAprocessing signals such as splicing and polyadenylation (polyA) signals;sequences that stabilize cytoplasmic mRNA; sequences that enhancetranslation efficiency (i.e., Kozak consensus sequence); sequences thatenhance protein stability; and when desired, sequences that enhancesecretion of the encoded product. A great number of expression controlsequences, including promoters which are native, constitutive, inducibleand/or tissue-specific, are known in the art and may be utilized.

[0108] Examples of constitutive promoters include, without limitation,the retroviral Rous sarcoma virus (RSV) LTR promoter (optionally withthe RSV enhancer), the cytomegalovirus (CMV) promoter (optionally withthe CMV enhancer) [see, e.g., Boshart et al, Cell, 41:521-530 (1985)],the SV40 promoter, the dihydrofolate reductase promoter, the β-actinpromoter, the phosphoglycerol kinase (PGK) promoter, and the EF1αpromoter [Invitrogen].

[0109] Inducible promoters allow regulation of gene expression and canbe regulated by exogenously supplied compounds, environmental factorssuch as temperature, or the presence of a specific physiological state,e.g., acute phase, a particular differentiation state of the cell, or inreplicating cells only. Inducible promoters and inducible systems areavailable from a variety of commercial sources, including, withoutlimitation, Invitrogen, Clontech and Ariad. Many other systems have beendescribed and can be readily selected by one of skill in the art.Examples of inducible promoters regulated by exogenously suppliedpromoters include the zinc-inducible sheep metallothionine (MT)promoter, the dexamethasone (Dex)-inducible mouse mammary tumor virus(MMTV) promoter, the T7 polymerase promoter system [WO 98/10088]; theecdysone insect promoter [No et al, Proc. Natl. Acad. Sci. USA,93:3346-3351 (1996)], the tetracycline-repressible system [Gossen et al,Proc. Natl. Acad. Sci. USA, 89:5547-5551 (1992)], thetetracycline-inducible system [Gossen et al, Science, 268:1766-1769(1995), see also Harvey et al, Curr. Opin. Chem. Biol., 2:512-518(1998)], the RU486-inducible system [Wang et al, Nat. Biotech.,15:239-243 (1997) and Wang et al, Gene Ther., 4:432-441 (1997)] and therapamycin-inducible system [Magari et al, J. Clin. Invest.,100:2865-2872 (1997)]. Still other types of inducible promoters whichmay be useful in this context are those which are regulated by aspecific physiological state, e.g., temperature, acute phase, aparticular differentiation state of the cell, or in replicating cellsonly.

[0110] In another embodiment, the native promoter for the transgene willbe used. The native promoter may be preferred when it is desired thatexpression of the transgene should mimic the native expression. Thenative promoter may be used when expression of the transgene must beregulated temporally or developmentally, or in a tissue-specific manner,or in response to specific transcriptional stimuli. In a furtherembodiment, other native expression control elements, such as enhancerelements, polyadenylation sites or Kozak consensus sequences may also beused to mimic the native expression.

[0111] Another embodiment of the transgene includes a transgene operablylinked to a tissue-specific promoter. For instance, if expression inskeletal muscle is desired, a promoter active in muscle should be used.These include the promoters from genes encoding skeletal β-actin, myosinlight chain 2A, dystrophin, muscle creatine kinase, as well as syntheticmuscle promoters with activities higher than naturally-occurringpromoters (see Li et al., Nat. Biotech., 17:241-245 (1999)). Examples ofpromoters that are tissue-specific are known for liver (albumin,Miyatake et al., J. Virol., 71:5124-32 (1997); hepatitis B virus corepromoter, Sandig et al., Gene Ther., 3:1002-9 (1996); alpha-fetoprotein(AFP), Arbuthnot et al., Hum. Gene Ther., 7:1503-14 (1996)), boneosteocalcin (Stein et al., Mol. Biol. Rep., 24:185-96 (1997)); bonesialoprotein (Chen et al., J. Bone Miner. Res., 11:654-64 (1996)),lymphocytes (CD2, Hansal et al., J. Immunol., 161:1063-8 (1998);immunoglobulin heavy chain; T cell receptor α chain), neuronal such asneuron-specific enolase (NSE) promoter (Andersen et al., Cell. Mol.Neurobiol., 13:503-15 (1993)), neurofilament light-chain gene (Piccioliet al., Proc. Natl. Acad. Sci. USA, 88:5611-5 (1991)), and theneuron-specific vgf gene (Piccioli et al., Neuron, 15:373-84 (1995)),among others.

[0112] Optionally, plasmids carrying therapeutically useful transgenesmay also include selectable markers or reporter genes may includesequences encoding geneticin, hygromicin or purimycin resistance, amongothers. Such selectable reporters or marker genes (preferably locatedoutside the viral genome to be rescued by the method of the invention)can be used to signal the presence of the plasmids in bacterial cells,such as ampicillin resistance. Other components of the plasmid mayinclude an origin of replication. Selection of these and other promotersand vector elements are conventional and many such sequences areavailable [see, e.g., Sambrook et al, and references cited therein].

[0113] The combination of the transgene, promoter/enhancer, and 5′ and3′ ITRs is referred to as a “minigene” for ease of reference herein.Provided with the teachings of this invention, the design of such aminigene can be made by resort to conventional techniques.

[0114] 3. Delivery of the Minigene to a Packaging Host Cell

[0115] The minigene can be carried on any suitable vector, e.g., aplasmid, which is delivered to a host cell. The plasmids useful in thisinvention may be engineered such that they are suitable for replicationand, optionally, integration in prokaryotic cells, mammalian cells, orboth. These plasmids (or other vectors carrying the 5′ AAVITR-heterologous molecule-3′ITR) contain sequences permittingreplication of the minigene in eukaryotes and/or prokaryotes andselection markers for these systems. Selectable markers or reportergenes may include sequences encoding geneticin, hygromicin or purimycinresistance, among others. The plasmids may also contain certainselectable reporters or marker genes that can be used to signal thepresence of the vector in bacterial cells, such as ampicillinresistance. Other components of the plasmid may include an origin ofreplication and an amplicon, such as the amplicon system employing theEpstein Barr virus nuclear antigen. This amplicon system, or othersimilar amplicon components permit high copy episomal replication in thecells. Preferably, the molecule carrying the minigene is transfectedinto the cell, where it may exist transiently. Alternatively, theminigene (carrying the 5′ AAV ITR-heterologous molecule-3′ ITR) may bestably integrated into the genome of the host cell, either chromosomallyor as an episome. In certain embodiments, the minigene may be present inmultiple copies, optionally in head-to-head, head-to-tail, ortail-to-tail concatamers. Suitable transfection techniques are known andmay readily be utilized to deliver the minigene to the host cell.

[0116] Generally, when delivering the vector comprising the minigene bytransfection, the vector is delivered in an amount from about 5 μg toabout 100 μg DNA, and preferably about 10 to about 50 μg DNA to about1×10⁴ cells to about 1×10¹³ cells, and preferably about 10⁵ cells.However, the relative amounts of vector DNA to host cells may beadjusted, taking into consideration such factors as the selected vector,the delivery method and the host cells selected.

[0117] B. Rep and Cap Sequences

[0118] In addition to the minigene, the host cell contains the sequenceswhich drive expression of the novel AAV capsid protein (e.g., AAV7 orother novel AAV capsid or an artificial capsid protein comprising afragment of one or more of these capsids) in the host cell and repsequences of the same serotype as the serotype of the AAV ITRs found inthe minigene. The AAV cap and rep sequences may be independentlyobtained from an AAV source as described above and may be introducedinto the host cell in any manner known to one in the art as describedabove. Additionally, when pseudotyping a novel AAV capsid of theinvention, the sequences encoding each of the essential rep proteins maybe supplied by the same AAV serotype, or the sequences encoding the repproteins may be supplied by different AAV serotypes (e.g., AAV1, AAV2,AAV3, AAV4, AAV5, AAV6, or one of the novel serotypes identifiedherein). For example, the rep78/68 sequences may be from AAV2, whereasthe rep52/40 sequences may from AAV1.

[0119] In one embodiment, the host cell stably contains the capsidprotein under the control of a suitable promoter, such as thosedescribed above. Most desirably, in this embodiment, the capsid proteinis expressed under the control of an inducible promoter. In anotherembodiment, the capsid protein is supplied to the host cell in trans.When delivered to the host cell in trans, the capsid protein may bedelivered via a plasmid which contains the sequences necessary to directexpression of the selected capsid protein in the host cell. Mostdesirably, when delivered to the host cell in trans, the plasmidcarrying the capsid protein also carries other sequences required forpackaging the rAAV, e.g., the rep sequences.

[0120] In another embodiment, the host cell stably contains the repsequences under the control of a suitable promoter, such as thosedescribed above. Most desirably, in this embodiment, the essential repproteins are expressed under the control of an inducible promoter. Inanother embodiment, the rep proteins are supplied to the host cell intrans. When delivered to the host cell in trans, the rep proteins may bedelivered via a plasmid which contains the sequences necessary to directexpression of the selected rep proteins in the host cell. Mostdesirably, when delivered to the host cell in trans, the plasmidcarrying the capsid protein also carries other sequences required forpackaging the rAAV, e.g., the rep and cap sequences.

[0121] Thus, in one embodiment, the rep and cap sequences may betransfected into the host cell on a single nucleic acid molecule andexist stably in the cell as an episome. In another embodiment, the repand cap sequences are stably integrated into the genome of the cell.Another embodiment has the rep and cap sequences transiently expressedin the host cell. For example, a useful nucleic acid molecule for suchtransfection comprises, from 5′ to 3′, a promoter, an optional spacerinterposed between the promoter and the start site of the rep genesequence, an AAV rep gene sequence, and an AAV cap gene sequence.

[0122] Optionally, the rep and/or cap sequences may be supplied on avector that contains other DNA sequences that are to be introduced intothe host cells. For instance, the vector may contain the rAAV constructcomprising the minigene. The vector may comprise one or more of thegenes encoding the helper functions, e.g., the adenoviral proteins E1,E2a, and E4ORF6, and the gene for VAI RNA.

[0123] Preferably, the promoter used in this construct may be any of theconstitutive, inducible or native promoters known to one of skill in theart or as discussed above. In one embodiment, an AAV P5 promotersequence is employed. The selection of the AAV to provide any of thesesequences does not limit the invention.

[0124] In another preferred embodiment, the promoter for rep is aninducible promoter, as are discussed above in connection with thetransgene regulatory elements. One preferred promoter for rep expressionis the T7 promoter. The vector comprising the rep gene regulated by theT7 promoter and the cap gene, is transfected or transformed into a cellwhich either constitutively or inducibly expresses the T7 polymerase.See WO 98/10088, published Mar. 12, 1998.

[0125] The spacer is an optional element in the design of the vector.The spacer is a DNA sequence interposed between the promoter and the repgene ATG start site. The spacer may have any desired design; that is, itmay be a random sequence of nucleotides, or alternatively, it may encodea gene product, such as a marker gene. The spacer may contain geneswhich typically incorporate start/stop and polyA sites. The spacer maybe a non-coding DNA sequence from a prokaryote or eukaryote, arepetitive non-coding sequence, a coding sequence withouttranscriptional controls or a coding sequence with transcriptionalcontrols. Two exemplary sources of spacer sequences are the λ phageladder sequences or yeast ladder sequences, which are availablecommercially, e.g., from Gibco or Invitrogen, among others. The spacermay be of any size sufficient to reduce expression of the rep78 andrep68 gene products, leaving the rep52, rep40 and cap gene productsexpressed at normal levels. The length of the spacer may therefore rangefrom about 10 bp to about 10.0 kbp, preferably in the range of about 100bp to about 8.0 kbp. To reduce the possibility of recombination, thespacer is preferably less than 2 kbp in length; however, the inventionis not so limited.

[0126] Although the molecule(s) providing rep and cap may exist in thehost cell transiently (i.e., through transfection), it is preferred thatone or both of the rep and cap proteins and the promoter(s) controllingtheir expression be stably expressed in the host cell, e.g., as anepisome or by integration into the chromosome of the host cell. Themethods employed for constructing embodiments of this invention areconventional genetic engineering or recombinant engineering techniquessuch as those described in the references above. While thisspecification provides illustrative examples of specific constructs,using the information provided herein, one of skill in the art mayselect and design other suitable constructs, using a choice of spacers,P5 promoters, and other elements, including at least one translationalstart and stop signal, and the optional addition of polyadenylationsites.

[0127] In another embodiment of this invention, the rep or cap proteinmay be provided stably by a host cell.

[0128] C. The Helper Functions

[0129] The packaging host cell also requires helper functions in orderto package the rAAV of the invention. Optionally, these functions may besupplied by a herpesvirus. Most desirably, the necessary helperfunctions are each provided from a human or non-human primate adenovirussource, such as those described above and/or are available from avariety of sources, including the American Type Culture Collection(ATCC), Manassas, Va. (US). In one currently preferred embodiment, thehost cell is provided with and/or contains an E1a gene product, an E1bgene product, an E2a gene product, and/or an E4 ORF6 gene product. Thehost cell may contain other adenoviral genes such as VAI RNA, but thesegenes are not required. In a preferred embodiment, no other adenovirusgenes or gene functions are present in the host cell.

[0130] By “adenoviral DNA which expresses the E1a gene product”, it ismeant any adenovirus sequence encoding E1a or any functional E1aportion. Adenoviral DNA which expresses the E2a gene product andadenoviral DNA which expresses the E4 ORF6 gene products are definedsimilarly. Also included are any alleles or other modifications of theadenoviral gene or functional portion thereof. Such modifications may bedeliberately introduced by resort to conventional genetic engineering ormutagenic techniques to enhance the adenoviral function in some manner,as well as naturally occurring allelic variants thereof. Suchmodifications and methods for manipulating DNA to achieve theseadenovirus gene functions are known to those of skill in the art.

[0131] The adenovirus E1a, E1b, E2a, and/or E4ORF6 gene products, aswell as any other desired helper functions, can be provided using anymeans that allows their expression in a cell. Each of the sequencesencoding these products may be on a separate vector, or one or moregenes may be on the same vector. The vector may be any vector known inthe art or disclosed above, including plasmids, cosmids and viruses.Introduction into the host cell of the vector may be achieved by anymeans known in the art or as disclosed above, including transfection,infection, electroporation, liposome delivery, membrane fusiontechniques, high velocity DNA-coated pellets, viral infection andprotoplast fusion, among others. One or more of the adenoviral genes maybe stably integrated into the genome of the host cell, stably expressedas episomes, or expressed transiently. The gene products may all beexpressed transiently, on an episome or stably integrated, or some ofthe gene products may be expressed stably while others are expressedtransiently. Furthermore, the promoters for each of the adenoviral genesmay be selected independently from a constitutive promoter, an induciblepromoter or a native adenoviral promoter. The promoters may be regulatedby a specific physiological state of the organism or cell (i.e., by thedifferentiation state or in replicating or quiescent cells) or byexogenously-added factors, for example.

[0132] D. Host Cells and Packaging Cell Lines

[0133] The host cell itself may be selected from any biologicalorganism, including prokaryotic (e.g., bacterial) cells, and eukaryoticcells, including, insect cells, yeast cells and mammalian cells.Particularly desirable host cells are selected from among any mammalianspecies, including, without limitation, cells such as A549, WEHI, 3T3,10T1/2, BHK, MDCK, COS 1, COS 7, BSC 1, BSC 40, BMT 10, VERO, WI38,HeLa, 293 cells (which express functional adenoviral E1), Saos, C2C12, Lcells, HT1080, HepG2 and primary fibroblast, hepatocyte and myoblastcells derived from mammals including human, monkey, mouse, rat, rabbit,and hamster. The selection of the mammalian species providing the cellsis not a limitation of this invention; nor is the type of mammaliancell, i.e., fibroblast, hepatocyte, tumor cell, etc. The most desirablecells do not carry any adenovirus gene other than E1, E2a and/or E4ORF6; nor do they contain any other virus gene which could result inhomologous recombination of a contaminating virus during the productionof rAAV; and it is capable of infection or transfection of DNA andexpression of the transfected DNA. In a preferred embodiment, the hostcell is one that has rep and cap stably transfected in the cell.

[0134] One host cell useful in the present invention is a host cellstably transformed with the sequences encoding rep and cap, and which istransfected with the adenovirus E1, E2a, and E4ORF6 DNA and a constructcarrying the minigene as described above. Stable rep and/or capexpressing cell lines, such as B-50 (PCT/US98/19463), or those describedin U.S. Pat. No. 5,658,785, may also be similarly employed. Anotherdesirable host cell contains the minimum adenoviral DNA which issufficient to express E4 ORF6. Yet other cell lines can be constructedusing the novel AAV rep and/or novel AAV cap sequences of the invention.

[0135] The preparation of a host cell according to this inventioninvolves techniques such as assembly of selected DNA sequences. Thisassembly may be accomplished utilizing conventional techniques. Suchtechniques include cDNA and genomic cloning, which are well known andare described in Sambrook et al., cited above, use of overlappingoligonucleotide sequences of the adenovirus and AAV genomes, combinedwith polymerase chain reaction, synthetic methods, and any othersuitable methods which provide the desired nucleotide sequence.

[0136] Introduction of the molecules (as plasmids or viruses) into thehost cell may also be accomplished using techniques known to the skilledartisan and as discussed throughout the specification. In preferredembodiment, standard transfection techniques are used, e.g., CaPO₄transfection or electroporation, and/or infection by hybridadenovirus/AAV vectors into cell lines such as the human embryonickidney cell line HEK 293 (a human kidney cell line containing functionaladenovirus E1 genes which provides trans-acting E1 proteins).

[0137] These novel AAV-based vectors which are generated by one of skillin the art are beneficial for gene delivery to selected host cells andgene therapy patients since no neutralization antibodies to AAV7 havebeen found in the human population. Further, early studies show noneutralizing antibodies in cyno monkey and chimpanzee populations, andless than 15% cross-reactivity of AAV 7 in rhesus monkeys, the speciesfrom which the serotype was isolated. One of skill in the art mayreadily prepare other rAAV viral vectors containing the AAV7 capsidproteins provided herein using a variety of techniques known to those ofskill in the art. One may similarly prepare still other rAAV viralvectors containing AAV7 sequence and AAV capsids of another serotype.Similar advantages are conferred by the vectors based on the other novelAAV of the invention.

[0138] Thus, one of skill in the art will readily understand that theAAV7 sequences of the invention can be readily adapted for use in theseand other viral vector systems for in vitro, ex vivo or in vivo genedelivery. Similarly, one of skill in the art can readily select otherfragments of the novel AAV genome of the invention for use in a varietyof rAAV and non-rAAV vector systems. Such vectors systems may include,e.g., lentiviruses, retroviruses, poxviruses, vaccinia viruses, andadenoviral systems, among others. Selection of these vector systems isnot a limitation of the present invention.

[0139] Thus, the invention further provides vectors generated using thenucleic acid and amino acid sequences of the novel AAV of the invention.Such vectors are useful for a variety of purposes, including fordelivery of therapeutic molecules and for use in vaccine regimens.Particularly desirable for delivery of therapeutic molecules arerecombinant AAV containing capsids of the novel AAV of the invention.These, or other vector constructs containing novel AAV sequences of theinvention may be used in vaccine regimens, e.g., for co-delivery of acytokine, or for delivery of the immunogen itself.

[0140] V. Recombinant Viruses and Uses Thereof

[0141] Using the techniques described herein, one of skill in the artmay generate a rAAV having a capsid of a novel serotype of theinvention, or a novel capsid containing one or more novel fragments ofan AAV serotype identified by the method of the invention. In oneembodiment, a full-length capsid from a single serotype, e.g., AAV7 [SEQID NO: 2] can be utilized. In another embodiment, a full-length capsidmay be generated which contains one or more fragments of a novelserotype of the invention fused in frame with sequences from anotherselected AAV serotype. For example, a rAAV may contain one or more ofthe novel hypervariable region sequences of an AAV serotype of theinvention. Alternatively, the unique AAV serotypes of the invention maybe used in constructs containing other viral or non-viral sequences.

[0142] It will be readily apparent to one of skill in the art oneembodiment, that certain serotypes of the invention will be particularlywell suited for certain uses. For example, vectors based on AAV7 capsidsof the invention are particularly well suited for use in muscle; whereasvectors based on rh.10 (44-2) capsids of the invention are particularlywell suited for use in lung. Uses of such vectors are not so limited andone of skill in the art may utilize these vectors for delivery to othercell types, tissues or organs. Further, vectors based upon other capsidsof the invention may be used for delivery to these or other cells,tissues or organs.

[0143] A. Delivery of Transgene

[0144] In another aspect, the present invention provides a method fordelivery of a transgene to a host which involves transfecting orinfecting a selected host cell with a vector generated with thesequences of the AAV of the invention. Methods for delivery are wellknown to those of skill in the art and are not a limitation of thepresent invention.

[0145] In one desirable embodiment, the invention provides a method forAAV-mediated delivery of a transgene to a host. This method involvestransfecting or infecting a selected host cell with a recombinant viralvector containing a selected transgene under the control of sequenceswhich direct expression thereof and AAV capsid proteins.

[0146] Optionally, a sample from the host may be first assayed for thepresence of antibodies to a selected AAV serotype. A variety of assayformats for detecting neutralizing antibodies are well known to those ofskill in the art. The selection of such an assay is not a limitation ofthe present invention. See, e.g., Fisher et al, Nature Med.,3(3):306-312 (March 1997) and W. C. Manning et al, Human Gene Therapy,9:477-485 (Mar. 1, 1998). The results of this assay may be used todetermine which AAV vector containing capsid proteins of a particularserotype are preferred for delivery, e.g., by the absence ofneutralizing antibodies specific for that capsid serotype.

[0147] In one aspect of this method, the delivery of vector with aselected AAV capsid proteins may precede or follow delivery of a genevia a vector with a different serotype AAV capsid protein. Similarly,the delivery of vector with other novel AAV capsid proteins of theinvention may precede or follow delivery of a gene via a vector with adifferent serotype AAV capsid protein. Thus, gene delivery via rAAVvectors may be used for repeat gene delivery to a selected host cell.Desirably, subsequently administered rAAV vectors carry the sametransgene as the first rAAV vector, but the subsequently administeredvectors contain capsid proteins of serotypes which differ from the firstvector. For example, if a first vector has AAV7 capsid proteins [SEQ IDNO:2], subsequently administered vectors may have capsid proteinsselected from among the other serotypes, including AAV1, AAV2, AAV3A,AAV3B, AAV4, AAV6, AAV10, AAV11, and AAV12, or any of the other novelAAV capsids identified herein including, without limitation: A3.1, H2,H6, C1, C2, C5, A3-3, A3-7, A3-4, A3-5, 3.3b, 223.4, 223-5, 223-10,223-2, 223-7, 223-6, 44-1, 44-5, 44-2, 42-15, 42-8, 42-13, 42-3A, 42-4,42-5A, 42-1B, 42-5B, 43-1, 43-12, 43-5, 43-21, 43-25, 43-20, 24.1, 42.2,7.2, 27.3, 16.3, 42.10, 42-3B, 42-11, F1, F5, F3, 42-6B, and/or 42-12.

[0148] The above-described recombinant vectors may be delivered to hostcells according to published methods. The rAAV, preferably suspended ina physiologically compatible carrier, may be administered to a human ornon-human mammalian patient. Suitable carriers may be readily selectedby one of skill in the art in view of the indication for which thetransfer virus is directed. For example, one suitable carrier includessaline, which may be formulated with a variety of buffering solutions(e.g., phosphate buffered saline). Other exemplary carriers includesterile saline, lactose, sucrose, calcium phosphate, gelatin, dextran,agar, pectin, peanut oil, sesame oil, and water. The selection of thecarrier is not a limitation of the present invention.

[0149] Optionally, the compositions of the invention may contain, inaddition to the rAAV and carrier(s), other conventional pharmaceuticalingredients, such as preservatives, or chemical stabilizers. Suitableexemplary preservatives include chlorobutanol, potassium sorbate, sorbicacid, sulfur dioxide, propyl gallate, the parabens, ethyl vanillin,glycerin, phenol, and parachlorophenol. Suitable chemical stabilizersinclude gelatin and albumin.

[0150] The viral vectors are administered in sufficient amounts totransfect the cells and to provide sufficient levels of gene transferand expression to provide a therapeutic benefit without undue adverseeffects, or with medically acceptable physiological effects, which canbe determined by those skilled in the medical arts. Conventional andpharmaceutically acceptable routes of administration include, but arenot limited to, direct delivery to the selected organ (e.g., intraportaldelivery to the liver), oral, inhalation (including intranasal andintratracheal delivery), intraocular, intravenous, intramuscular,subcutaneous, intradermal, and other parental routes of administration.Routes of administration may be combined, if desired.

[0151] Dosages of the viral vector will depend primarily on factors suchas the condition being treated, the age, weight and health of thepatient, and may thus vary among patients. For example, atherapeutically effective human dosage of the viral vector is generallyin the range of from about 1 ml to about 100 ml of solution containingconcentrations of from about 1×10⁹ to 1×10¹⁶ genomes virus vector. Apreferred human dosage may be about 1×10¹³ to 1×10¹⁶ AAV genomes. Thedosage will be adjusted to balance the therapeutic benefit against anyside effects and such dosages may vary depending upon the therapeuticapplication for which the recombinant vector is employed. The levels ofexpression of the transgene can be monitored to determine the frequencyof dosage resulting in viral vectors, preferably AAV vectors containingthe minigene. Optionally, dosage regimens similar to those described fortherapeutic purposes may be utilized for immunization using thecompositions of the invention.

[0152] Examples of therapeutic products and immunogenic products fordelivery by the AAV-containing vectors of the invention are providedbelow. These vectors may be used for a variety of therapeutic orvaccinal regimens, as described herein. Additionally, these vectors maybe delivered in combination with one or more other vectors or activeingredients in a desired therapeutic and/or vaccinal regimen.

[0153] B. Therapeutic Transgenes

[0154] Useful therapeutic products encoded by the transgene includehormones and growth and differentiation factors including, withoutlimitation, insulin, glucagon, growth hormone (GH), parathyroid hormone(PTH), growth hormone releasing factor (GRF), follicle stimulatinghormone (FSH), luteinizing hormone (LH), human chorionic gonadotropin(hCG), vascular endothelial growth factor (VEGF), angiopoietins,angiostatin, granulocyte colony stimulating factor (GCSF),erythropoietin (EPO), connective tissue growth factor (CTGF), basicfibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF),epidermal growth factor (EGF), transforming growth factor α (TGFα),platelet-derived growth factor (PDGF), insulin growth factors I and II(IGF-I and IGF-II), any one of the transforming growth factor βsuperfamily, including TGF β, activins, inhibins, or any of the bonemorphogenic proteins (BMP) BMPs 1-15, any one of theheregluin/neuregulin/ARIA/neu differentiation factor (NDF) family ofgrowth factors, nerve growth factor (NGF), brain-derived neurotrophicfactor (BDNF), neurotrophins NT-3 and NT-4/5, ciliary neurotrophicfactor (CNTF), glial cell line derived neurotrophic factor (GDNF),neurturin, agrin, any one of the family of semaphorins/collapsins,netrin-1 and netrin-2, hepatocyte growth factor (HGF), ephrins, noggin,sonic hedgehog and tyrosine hydroxylase.

[0155] Other useful transgene products include proteins that regulatethe immune system including, without limitation, cytokines andlymphokines such as thrombopoietin (TPO), interleukins (IL) IL-1 throughIL-25 (including, IL-2, IL-4, IL-12, and IL-18), monocytechemoattractant protein, leukemia inhibitory factor,granulocyte-macrophage colony stimulating factor, Fas ligand, tumornecrosis factors α and β, interferons α, β, and γ, stem cell factor,flk-2/flt3 ligand. Gene products produced by the immune system are alsouseful in the invention. These include, without limitations,immunoglobulins IgG, IgM, IgA, IgD and IgE, chimeric immunoglobulins,humanized antibodies, single chain antibodies, T cell receptors,chimeric T cell receptors, single chain T cell receptors, class I andclass II MHC molecules, as well as engineered immunoglobulins and MHCmolecules. Useful gene products also include complement regulatoryproteins such as complement regulatory proteins, membrane cofactorprotein (MCP), decay accelerating factor (DAF), CR1, CF2 and CD59.

[0156] Still other useful gene products include any one of the receptorsfor the hormones, growth factors, cytokines, lymphokines, regulatoryproteins and immune system proteins. The invention encompasses receptorsfor cholesterol regulation, including the low density lipoprotein (LDL)receptor, high density lipoprotein (HDL) receptor, the very low densitylipoprotein (VLDL) receptor, and the scavenger receptor. The inventionalso encompasses gene products such as members of the steroid hormonereceptor superfamily including glucocorticoid receptors and estrogenreceptors, Vitamin D receptors and other nuclear receptors. In addition,useful gene products include transcription factors such as jun, fos,max, mad, serum response factor (SRF), AP-1, AP2, myb, MyoD andmyogenin, ETS-box containing proteins, TFE3, E2F, ATF1, ATF2, ATF3,ATF4, ZF5, NFAT, CREB, HNF-4, C/EBP, SP1, CCAAT-box binding proteins,interferon regulation factor (IRF-1), Wilms tumor protein, ETS-bindingprotein, STAT, GATA-box binding proteins, e.g., GATA-3, and the forkheadfamily of winged helix proteins.

[0157] Other useful gene products include, carbamoyl synthetase 1,ornithine transcarbamylase, arginosuccinate synthetase, arginosuccinatelyase, arginase, fumarylacetacetate hydrolase, phenylalaninehydroxylase, alpha-1 antitrypsin, glucose-6-phosphatase, porphobilinogendeaminase, factor VIII, factor IX, cystathione beta-synthase, branchedchain ketoacid decarboxylase, albumin, isovaleryl-coA dehydrogenase,propionyl CoA carboxylase, methyl malonyl CoA mutase, glutaryl CoAdehydrogenase, insulin, beta-glucosidase, pyruvate carboxylate, hepaticphosphorylase, phosphorylase kinase, glycine decarboxylase, H-protein,T-protein, a cystic fibrosis transmembrane regulator (CFTR) sequence,and a dystrophin cDNA sequence. Still other useful gene products includeenzymes such as may be useful in enzyme replacement therapy, which isuseful in a variety of conditions resulting from deficient activity ofenzyme. For example, enzymes that contain mannose-6-phosphate may beutilized in therapies for lysosomal storage diseases (e.g., a suitablegene includes that encoding β-glucuronidase (GUSB)).

[0158] Other useful gene products include non-naturally occurringpolypeptides, such as chimeric or hybrid polypeptides having anon-naturally occurring amino acid sequence containing insertions,deletions or amino acid substitutions. For example, single-chainengineered immunoglobulins could be useful in certain immunocompromisedpatients. Other types of non-naturally occurring gene sequences includeantisense molecules and catalytic nucleic acids, such as ribozymes,which could be used to reduce overexpression of a target.

[0159] Reduction and/or modulation of expression of a gene isparticularly desirable for treatment of hyperproliferative conditionscharacterized by hyperproliferating cells, as are cancers and psoriasis.Target polypeptides include those polypeptides which are producedexclusively or at higher levels in hyperproliferative cells as comparedto normal cells. Target antigens include polypeptides encoded byoncogenes such as myb, myc, fyn, and the translocation gene bcr/abl,ras, src, P53, neu, trk and EGRF. In addition to oncogene products astarget antigens, target polypeptides for anti-cancer treatments andprotective regimens include variable regions of antibodies made by Bcell lymphomas and variable regions of T cell receptors of T celllymphomas which, in some embodiments, are also used as target antigensfor autoimmune disease. Other tumor-associated polypeptides can be usedas target polypeptides such as polypeptides which are found at higherlevels in tumor cells including the polypeptide recognized by monoclonalantibody 17-1A and folate binding polypeptides.

[0160] Other suitable therapeutic polypeptides and proteins includethose which may be useful for treating individuals suffering fromautoimmune diseases and disorders by conferring a broad based protectiveimmune response against targets that are associated with autoimmunityincluding cell receptors and cells which produce “self”-directedantibodies. T cell mediated autoimmune diseases include Rheumatoidarthritis (RA), multiple sclerosis (MS), Sjögren's syndrome,sarcoidosis, insulin dependent diabetes mellitus (IDDM), autoimmunethyroiditis, reactive arthritis, ankylosing spondylitis, scleroderma,polymyositis, dermatomyositis, psoriasis, vasculitis, Wegener'sgranulomatosis, Crohn's disease and ulcerative colitis. Each of thesediseases is characterized by T cell receptors (TCRs) that bind toendogenous antigens and initiate the inflammatory cascade associatedwith autoimmune diseases.

[0161] C. Immunogenic Transgenes

[0162] Alternatively, or in addition, the vectors of the invention maycontain AAV sequences of the invention and a transgene encoding apeptide, polypeptide or protein which induces an immune response to aselected immunogen. For example, immunogens may be selected from avariety of viral families. Example of desirable viral families againstwhich an immune response would be desirable include, the picornavirusfamily, which includes the genera rhinoviruses, which are responsiblefor about 50% of cases of the common cold; the genera enteroviruses,which include polioviruses, coxsackieviruses, echoviruses, and humanenteroviruses such as hepatitis A virus; and the genera apthoviruses,which are responsible for foot and mouth diseases, primarily innon-human animals. Within the picornavirus family of viruses, targetantigens include the VP1, VP2, VP3, VP4, and VPG. Another viral familyincludes the calcivirus family, which encompasses the Norwalk group ofviruses, which are an important causative agent of epidemicgastroenteritis. Still another viral family desirable for use intargeting antigens for inducing immune responses in humans and non-humananimals is the togavirus family, which includes the genera alphavirus,which include Sindbis viruses, RossRiver virus, and Venezuelan, Eastern& Western Equine encephalitis, and rubivirus, including Rubella virus.The flaviviridae family includes dengue, yellow fever, Japaneseencephalitis, St. Louis encephalitis and tick borne encephalitisviruses. Other target antigens may be generated from the Hepatitis C orthe coronavirus family, which includes a number of non-human virusessuch as infectious bronchitis virus (poultry), porcine transmissiblegastroenteric virus (pig), porcine hemagglutinating encephalomyelitisvirus (pig), feline infectious peritonitis virus (cats), feline entericcoronavirus (cat), canine coronavirus (dog), and human respiratorycoronaviruses, which may cause the common cold and/or non-A, B or Chepatitis. Within the coronavirus family, target antigens include the E1(also called M or matrix protein), E2 (also called S or Spike protein),E3 (also called HE or hemagglutin-elterose) glycoprotein (not present inall coronaviruses), or N (nucleocapsid). Still other antigens may betargeted against the rhabdovirus family, which includes the generavesiculovirus (e.g., Vesicular Stomatitis Virus), and the generallyssavirus (e.g., rabies). Within the rhabdovirus family, suitableantigens may be derived from the G protein or the N protein. The familyfiloviridae, which includes hemorrhagic fever viruses such as Marburgand Ebola virus may be a suitable source of antigens. The paramyxovirusfamily includes parainfluenza Virus Type 1, parainfluenza Virus Type 3,bovine parainfluenza Virus Type 3, rubulavirus (mumps virus,parainfluenza Virus Type 2, parainfluenza virus Type 4, Newcastledisease virus (chickens), rinderpest, morbillivirus, which includesmeasles and canine distemper, and pneumovirus, which includesrespiratory syncytial virus. The influenza virus is classified withinthe family orthomyxovirus and is a suitable source of antigen (e.g., theHA protein, the N1 protein). The bunyavirus family includes the generabunyavirus (California encephalitis, La Crosse), phlebovirus (RiftValley Fever), hantavirus (puremala is a hemahagin fever virus),nairovirus (Nairobi sheep disease) and various unassigned bungaviruses.The arenavirus family provides a source of antigens against LCM andLassa fever virus. The reovirus family includes the genera reovirus,rotavirus (which causes acute gastroenteritis in children), orbiviruses,and cultivirus (Colorado Tick fever, Lebombo (humans), equineencephalosis, blue tongue).

[0163] The retrovirus family includes the sub-family oncorivirinal whichencompasses such human and veterinary diseases as feline leukemia virus,HTLVI and HTLVII, lentivirinal (which includes human immunodeficiencyvirus (HIV), simian immunodeficiency virus (SIV), felineimmunodeficiency virus (FIV), equine infectious anemia virus, andspumavirinal). Between the HIV and SIV, many suitable antigens have beendescribed and can readily be selected. Examples of suitable HIV and SIVantigens include, without limitation the gag, pol, Vif, Vpx, VPR, Env,Tat and Rev proteins, as well as various fragments thereof. In addition,a variety of modifications to these antigens have been described.Suitable antigens for this purpose are known to those of skill in theart. For example, one may select a sequence encoding the gag, pol, Vif,and Vpr, Env, Tat and Rev, amongst other proteins. See, e.g., themodified gag protein which is described in U.S. Pat. No. 5,972,596. See,also, the HIV and SIV proteins described in D. H. Barouch et al, J.Virol., 75(5):2462-2467 (March 2001), and R. R. Amara, et al, Science,292:69-74 (Apr. 6, 2001). These proteins or subunits thereof may bedelivered alone, or in combination via separate vectors or from a singlevector.

[0164] The papovavirus family includes the sub-family polyomaviruses(BKU and JCU viruses) and the sub-family papillomavirus (associated withcancers or malignant progression of papilloma). The adenovirus familyincludes viruses (EX, AD7, ARD, O.B.) which cause respiratory diseaseand/or enteritis. The parvovirus family feline parvovirus (felineenteritis), feline panleucopeniavirus, canine parvovirus, and porcineparvovirus. The herpesvirus family includes the sub-familyalphaherpesvirinae, which encompasses the genera simplexvirus (HSVI,HSVII), varicellovirus (pseudorabies, varicella zoster) and thesub-family betaherpesvirinae, which includes the genera cytomegalovirus(HCMV, muromegalovirus) and the sub-family gammaherpesvirinae, whichincludes the genera lymphocryptovirus, EBV (Burkitts lymphoma),infectious rhinotracheitis, Marek's disease virus, and rhadinovirus. Thepoxvirus family includes the sub-family chordopoxvirinae, whichencompasses the genera orthopoxvirus (Variola (Smallpox) and Vaccinia(Cowpox)), parapoxvirus, avipoxvirus, capripoxvirus, leporipoxvirus,suipoxvirus, and the sub-family entomopoxvirinae. The hepadnavirusfamily includes the Hepatitis B virus. One unclassified virus which maybe suitable source of antigens is the Hepatitis delta virus. Still otherviral sources may include avian infectious bursal disease virus andporcine respiratory and reproductive syndrome virus. The alphavirusfamily includes equine arteritis virus and various Encephalitis viruses.

[0165] The present invention may also encompass immunogens which areuseful to immunize a human or non-human animal against other pathogensincluding bacteria, fungi, parasitic microorganisms or multicellularparasites which infect human and non-human vertebrates, or from a cancercell or tumor cell. Examples of bacterial pathogens include pathogenicgram-positive cocci include pneumococci; staphylococci; andstreptococci. Pathogenic gram-negative cocci include meningococcus;gonococcus. Pathogenic enteric gram-negative bacilli includeenterobacteriaceae; pseudomonas, acinetobacteria and eikenella;melioidosis; salmonella; shigella; haemophilus; moraxella; H. ducreyi(which causes chancroid); brucella; Franisella tularensis (which causestularemia); yersinia (pasteurella); streptobacillus moniliformis andspirillum; Gram-positive bacilli include listeria monocytogenes;erysipelothrix rhusiopathiae; Corynebacterium diphtheria (diphtheria);cholera; B. anthracis (anthrax); donovanosis (granuloma inguinale); andbartonellosis. Diseases caused by pathogenic anaerobic bacteria includetetanus; botulism; other clostridia; tuberculosis; leprosy; and othermycobacteria. Pathogenic spirochetal diseases include syphilis;treponematoses: yaws, pinta and endemic syphilis; and leptospirosis.Other infections caused by higher pathogen bacteria and pathogenic fungiinclude actinomycosis; nocardiosis; cryptococcosis, blastomycosis,histoplasmosis and coccidioidomycosis; candidiasis, aspergillosis, andmucormycosis; sporotrichosis; paracoccidiodomycosis, petriellidiosis,torulopsosis, mycetoma and chromomycosis; and dermatophytosis.Rickettsial infections include Typhus fever, Rocky Mountain spottedfever, Q fever, and Rickettsialpox. Examples of mycoplasma andchlamydial infections include: mycoplasma pneumoniae; lymphogranulomavenereum; psittacosis; and perinatal chlamydial infections. Pathogeniceukaryotes encompass pathogenic protozoans and helminths and infectionsproduced thereby include: amebiasis; malaria; leishmaniasis;trypanosomiasis; toxoplasmosis; Pneumocystis carinii; Trichans;Toxoplasma gondii; babesiosis; giardiasis; trichinosis; filariasis;schistosomiasis; nematodes; trematodes or flukes; and cestode (tapeworm)infections.

[0166] Many of these organisms and/or toxins produced thereby have beenidentified by the Centers for Disease Control [(CDC), Department ofHeath and Human Services, USA], as agents which have potential for usein biological attacks. For example, some of these biological agents,include, Bacillus anthracis (anthrax), Clostridium botulinum and itstoxin (botulism), Yersinia pestis (plague), variola major (smallpox),Francisella tularensis (tularemia), and viral hemorrhagic fever, all ofwhich are currently classified as Category A agents; Coxiella burnetti(Q fever); Brucella species (brucellosis), Burkholderia mallei(glanders), Ricinus communis and its toxin (ricin toxin), Clostridiumperfringens and its toxin (epsilon toxin), Staphylococcus species andtheir toxins (enterotoxin B), all of which are currently classified asCategory B agents; and Nipan virus and hantaviruses, which are currentlyclassified as Category C agents. In addition, other organisms, which areso classified or differently classified, may be identified and/or usedfor such a purpose in the future. It will be readily understood that theviral vectors and other constructs described herein are useful todeliver antigens from these organisms, viruses, their toxins or otherby-products, which will prevent and/or treat infection or other adversereactions with these biological agents.

[0167] Administration of the vectors of the invention to deliverimmunogens against the variable region of the T cells elicit an immuneresponse including CTLs to eliminate those T cells. In rheumatoidarthritis (RA), several specific variable regions of T cell receptors(TCRs) which are involved in the disease have been characterized. TheseTCRs include V-3, V-14, V-17 and Va-17. Thus, delivery of a nucleic acidsequence that encodes at least one of these polypeptides will elicit animmune response that will target T cells involved in RA. In multiplesclerosis (MS), several specific variable regions of TCRs which areinvolved in the disease have been characterized. These TCRs include V-7and Vα-10. Thus, delivery of a nucleic acid sequence that encodes atleast one of these polypeptides will elicit an immune response that willtarget T cells involved in MS. In scleroderma, several specific variableregions of TCRs which are involved in the disease have beencharacterized. These TCRs include V-6, V-8, V-14 and Vα-16, Vα-3C, Vα-7,Vα-14, Vα-15, Vα-16, Vα-28 and Vα-12. Thus, delivery of a nucleic acidmolecule that encodes at least one of these polypeptides will elicit animmune response that will target T cells involved in scleroderma.

[0168] Optionally, vectors containing AAV sequences of the invention maybe delivered using a prime-boost regimen. A variety of such regimenshave been described in the art and may be readily selected. See, e.g.,WO 00/11140, published Mar. 2, 2000, incorporated by reference.

[0169] Such prime-boost regimens typically involve the administration ofa DNA (e.g., plasmid) based vector to prime the immune system to second,booster, administration with a traditional antigen, such as a protein ora recombinant virus carrying the sequences encoding such an antigen. Inone embodiment, the invention provides a method of priming and boostingan immune response to a selected antigen by delivering a plasmid DNAvector carrying said antigen, followed by boosting, e.g., with a vectorcontaining AAV sequences of the invention.

[0170] In one embodiment, the prime-boost regimen involves theexpression of multiproteins from the prime and/or the boost vehicle.See, e.g., R. R. Amara, Science, 292:69-74 (Apr. 6, 2001) whichdescribes a multiprotein regimen for expression of protein subunitsuseful for generating an immune response against HIV and SIV. Forexample, a DNA prine may deliver the Gag, Pol, Vif, VPX and Vpr and Env,Tat, and Rev from a single transcript. Alternatively, the SIV Gag, Poland HIV-1 Env is delivered.

[0171] However, the prime-boost regimens are not limited to immunizationfor HIV or to delivery of these antigens. For example, priming mayinvolve delivering with a first chimp vector of the invention followedby boosting with a second chimp vector, or with a composition containingthe antigen itself in protein form. In one or example, the prime-boostregimen can provide a protective immune response to the virus, bacteriaor other organism from which the antigen is derived. In another desiredembodiment, the prime-boost regimen provides a therapeutic effect thatcan be measured using convention assays for detection of the presence ofthe condition for which therapy is being administered.

[0172] The priming vaccine may be administered at various sites in thebody in a dose dependent manner, which depends on the antigen to whichthe desired immune response is being targeted. The invention is notlimited to the amount or situs of injection(s) or to the pharmaceuticalcarrier. Rather, the priming step encompasses treatment regimens whichinclude a single dose or dosage which is administered hourly, daily,weekly or monthly, or yearly. As an example, the mammals may receive oneor two priming injection containing between about 10 μg to about 50 μgof plasmid in carrier. A desirable priming amount or dosage of thepriming DNA vaccine composition ranges between about 1 μg to about10,000 μg of the DNA vaccine. Dosages may vary from about 1 μg to 1000μg DNA per kg of subject body weight. The amount or site of injection isdesirably selected based upon the identity and condition of the mammalbeing vaccinated.

[0173] The dosage unit of the DNA vaccine suitable for delivery of theantigen to the mammal is described herein. The DNA vaccine is preparedfor administration by being suspended or dissolved in a pharmaceuticallyor physiologically acceptable carrier such as isotonic saline, isotonicsalts solution or other formulations which will be apparent to thoseskilled in such administration. The appropriate carrier will be evidentto those skilled in the art and will depend in large part upon the routeof administration. The compositions of the invention may be administeredto a mammal according to the routes described above, in a sustainedrelease formulation using a biodegradable biocompatible polymer, or byon-site delivery using micelles, gels and liposomes.

[0174] Optionally, the priming step of this invention also includesadministering with the priming DNA vaccine composition, a suitableamount of an adjuvant, such as are defined herein.

[0175] Preferably, a boosting composition is administered about 2 toabout 27 weeks after administering the priming DNA vaccine to themammalian subject. The administration of the boosting composition isaccomplished using an effective amount of a boosting vaccine compositioncontaining or capable of delivering the same antigen as administered bythe priming DNA vaccine. The boosting composition may be composed of arecombinant viral vector derived from the same viral source or fromanother source. Alternatively, the “boosting composition” can be acomposition containing the same antigen as encoded in the priming DNAvaccine, but in the form of a protein or peptide, which compositioninduces an immune response in the host. In another embodiment, theboosting vaccine composition includes a composition containing a DNAsequence encoding the antigen under the control of a regulatory sequencedirecting its expression in a mammalian cell, e.g., vectors such aswell-known bacterial or viral vectors. The primary requirements of theboosting vaccine composition are that the antigen of the vaccinecomposition is the same antigen, or a cross-reactive antigen, as thatencoded by the DNA vaccine.

[0176] Suitably, the vectors of the invention are also well suited foruse in regimens which use non-AAV vectors as well as proteins, peptides,and/or other biologically useful therapeutic or immunogenic compounds.These regimens are particularly well suited to gene delivery fortherapeutic poses and for immunization, including inducing protectiveimmunity. Such uses will be readily apparent to one of skill in the art.

[0177] Further, a vector of the invention provides an efficient genetransfer vehicle which can deliver a selected transgene to a selectedhost cell in vivo or ex vivo even where the organism has neutralizingantibodies to one or more AAV serotypes. In one embodiment, the vector(e.g., an rAAV) and the cells are mixed ex vivo; the infected cells arecultured using conventional methodologies; and the transduced cells arere-infused into the patient. Further, the vectors of the invention mayalso be used for production of a desired gene product in vitro. For invitro production, a desired product (e.g., a protein) may be obtainedfrom a desired culture following transfection of host cells with a rAAVcontaining the molecule encoding the desired product and culturing thecell culture under conditions which permit expression. The expressedproduct may then be purified and isolated, as desired. Suitabletechniques for transfection, cell culturing, purification, and isolationare known to those of skill in the art.

[0178] The following examples illustrate several aspects and embodimentsof the invention.

EXAMPLES Example 1

[0179] PCR Amplification, Cloning and Characterization of Novel AAVSequences.

[0180] Tissues from nonhuman primates were screened for AAV sequencesusing a PCR method based on oligonucleotides to highly conserved regionsof known AAVs. A stretch of AAV sequence spanning 2886 to 3143 bp ofAAV1 [SEQ ID NO:6] was selected as a PCR amplicon in which ahypervariable region of the capsid protein (Cap) that is unique to eachknown AAV serotype, which is termed herein a “signature region,” isflanked by conserved sequences. In later analysis, this signature regionwas shown to be located between conserved residues spanninghypervariable region 3.

[0181] An initial survey of peripheral blood of a number of nonhumanprimate species revealed detectable AAV in a subset of animals fromspecies such as rhesus macaques, cynomologous macaques, chimpanzees andbaboons. However, there were no AAV sequences detected in some otherspecies tested, including Japanese macaques, pigtailed macaques andsquirrel monkeys. A more extensive analysis of vector distribution wasconducted in tissues of rhesus monkeys of the University of Pennsylvaniaand Tulane colonies recovered at necropsy. This revealed AAV sequencethroughout a wide array of tissues.

[0182] A. Amplification of an AAV Signature Region

[0183] DNA sequences of AAV1-6 and AAVs isolated from Goose and Duckwere aligned to each other using “Clustal W” at default settings. Thealignment for AAV1-6, and including the information for the novel AAV7,is provided in FIG. 1. Sequence similarities among AAVs were compared.

[0184] In the line of study, a 257 bp region spanning 2886 bp to 3143 bpof AAV 1 [SEQ ID NO: 6], and the corresponding region in the genomes ofAAV 2-6 genomes [See, FIG. 1], was identified by the inventors. Thisregion is located with the AAV capsid gene and has highly conservedsequences among at both 5′ and 3′ ends and is relatively variablesequence in the middle. In addition, this region contains a DraIIIrestriction enzyme site (CACCACGTC, SEQ ID NO:15). The inventors havefound that this region serves as specific signature for each known typeof AAV DNA. In other words, following PCR reactions, digestion withendonucleases that are specific to each known serotypes and gelelectrophoresis analysis, this regions can be used to definitivelyidentify amplified DNA as being from serotype 1, 2, 3, 4, 5, 6, oranother serotype.

[0185] The primers were designed, validated and PCR conditions optimizedwith AAV1, 2 and 5 DNA controls. The primers were based upon thesequences of AAV2: 5′ primer, 1S: bp 2867-2891 of AAV2 (SEQ ID NO:7) and3′ primer, 18as, bp 3095-3121 of AAV2 (SEQ ID NO:7).

[0186] Cellular DNAs from different tissues including blood, brain,liver, lung, testis, etc. of different rhesus monkeys were studiedutilizing the strategy described above. The results revealed that DNAsfrom different tissues of these monkeys gave rise to strong PCRamplifications. Further restriction analyses of PCR products indicatedthat they were amplified from AAV sequences different from any publishedAAV sequences.

[0187] PCR products (about 255 bp in size) from DNAs of a variety ofmonkey tissues have been cloned and sequenced. Bioinformatics study ofthese novel AAV sequences indicated that they are novel AAV sequences ofcapsid gene and distinct from each other. FIG. 1 includes in thealignment the novel AAV signature regions for AAV10-12 [SEQ ID NO:117,118 and 119, respectively]. Multiple sequence alignment analysis wasperformed using the Clustal W (1.81) program. The percentage of sequenceidentity between the signature regions of AAV 1-7 and AAV 10-12 genomesis provided below. TABLE 1 Sequences for Analysis Sequence # AAVSerotype Size (bp) 1 AAV1 258 2 AAV2 255 3 AAV3 255 4 AAV4 246 5 AAV5258 6 AAV6 258 7 AAV7 258 10 AAV10 255 11 AAV11 258 12 AAV12 255

[0188] TABLE 3 Pairwise Alignment (Percentage of Identity) AAV2 AAV3AAV4 AAV5 AAV6 AAV7 AAV10 AAV11 AAV12 AAV1 90 90 81 76 97 91 93 94 93AAV2 93 79 78 90 90 93 93 92 AAV3 80 76 90 92 92 92 92 AAV4 76 81 84 8281 79 AAV5 75 78 79 79 76 AAV6 91 92 94 94 AAV7 94 92 92 AAV10 95 93AAV11 94

[0189] Over 300 clones containing novel AAV serotype sequences that spanthe selected 257 bp and sequenced. Bioinformatics analysis of these 300+clones suggests that this 257 bp region is critical in serving as a goodland marker or signature sequence for quick isolation and identificationof novel AAV serotype.

[0190] B. Use of the Signature Region for PCR Amplification.

[0191] The 257 bp signature region was used as a PCR anchor to extendPCR amplifications to 5′ of the genome to cover the junction region ofrep and cap genes (1398 bp-3143 bp, SEQ ID NO:6) and 3′ of the genome toobtain the entire cap gene sequence (28866 bp-4600 bp, SEQ ID NO:6). PCRamplifications were carried out using the standard conditions, includingdenaturing at 95° C. for 0.5-1 min, annealing at 60-65° C. for 0.5-1 minand extension at 72° C. for 1 min per kb with a total number ofamplification cycles ranging from 28 to 42.

[0192] Using the aligned sequences as described in “A”, two otherrelative conserved regions were identified in the sequence located in 3′end of rep genes and 5′ to the 257 bp region and in the sequence downstream of the 257 bp fragment but before the AAV′ 3 ITR. Two sets of newprimers were designed and PCR conditions optimized for recovery ofentire capsid and a part of rep sequences of novel AAV serotypes. Morespecifically, for the 5′ amplification, the 5′ primer, AV1Ns, wasGCTGCGTCAACTGGACCAATGAGAAC [nt 1398-1423 of AAV1, SEQ ID NO:6] and the3′ primer was 18as, identified above. For the 3′ amplification, the 5′primer was 1s, identified above, and the 3′ primer was AV2Las,TCGTTTCAGTTGAACTTTGGTCTCTGCG [nt 4435-4462 of AAV2, SEQ ID NO:7].

[0193] In these PCR amplifications, the 257 bp region was used as a PCRanchor and land marker to generate overlapping fragments to construct acomplete capsid gene by fusion at the DraIII site in the signatureregion following amplification of the 5′ and 3′ extension fragmentsobtained as described herein. More particularly, to generate the intactAAV7 cap gene, the three amplification products (a) the sequences of thesignature region; (b) the sequences of the 5′ extension; and (c) thesequences of the 3′ extension were cloned into a pCR4-Topo [Invitrogen]plasmid backbone according to manufacturer's instructions. Thereafter,the plasmids were digested with DraIII and recombined to form an intactcap gene.

[0194] In this line of work, about 80% of capsid sequences of AAV7 andAAV 8 were isolated and analyzed. Another novel serotype, AAV9, was alsodiscovered from Monkey #2.

[0195] Using the PCR conditions described above, the remaining portionof the rep gene sequence for AAV7 is isolated and cloned using theprimers that amplify 108 bp to 1461 bp of AAV genome (calculated basedon the numbering of AAV2, SEQ ID NO:7). This clone is sequenced forconstruction of a complete AAV7 genome without ITRs.

[0196] C. Direct Amplification of 3.1 kb Cap Fragment

[0197] To directly amplify a 3.1 kb full-length Cap fragment from NHPtissue and blood DNAs, two other highly conserved regions wereidentified in AAV genomes for use in PCR amplification of largefragments. A primer within a conserved region located in the middle ofthe rep gene was selected (AV1ns: 5′ GCTGCGTCAACTGGACCAATGAGAAC 3′, nt1398-1423 of SEQ ID NO:6) in combination with the 3′ primer located inanother conserved region downstream of the Cap gene (AV2cas: 5′CGCAGAGACCAAAGTTCAACTGAAACGA 3′, SEQ ID NO:7) for amplification offull-length cap fragments. The PCR products were Topo-cloned accordingto manufacturer's directions (Invitrogen) and sequence analysis wasperformed by Qiagengenomics (Qiagengenomics, Seattle, Wash.) with anaccuracy of ≧99.9%. A total of 50 capsid clones were isolated andcharacterized. Among them, 37 clones were derived from Rhesus macaquetissues (rh.1-rh.37), 6 clones from cynomologous macaques (cy.1-cy.6), 2clones from Baboons (bb.1 and bb.2) and 5 clones from Chimps(ch.1-ch.5).

[0198] To rule out the possibility that sequence diversity within thenovel AAV family was not an artifact of the PCR, such as PCR-mediatedgene splicing by overlap extension between different partial DNAtemplates with homologous sequences, or the result of recombinationprocess in bacteria, a series of experiments were performed underidentical conditions for VP1 amplification using total cellular DNAs.First, intact AAV7 and AAV8 plasmids were mixed at an equal molar ratiofollowed by serial dilutions. The serially diluted mixtures were used astemplates for PCR amplification of 3.1 kb VP1 fragments using universalprimers and identical PCR conditions to that were used for DNAamplifications to see whether any hybrid PCR products were generated.The mixture was transformed into bacteria and isolated transformants tolook for hybrid clones possibly derived from recombination process inbacterial cells. In a different experiment, we restricted AAV7 and AAV8plasmids with Msp I, Ava I and HaeI, all of which cut both genomesmultiple times at different positions, mixed the digestions in differentcombinations and used them for PCR amplification of VP1 fragments underthe same conditions to test whether any PCR products could be generatedthrough overlap sequence extension of partial AAV sequences. In anotherexperiment, a mixture of gel purified 5′ 1.5 kb AAV7 VP1 fragment and 3′1.7 kb AAV8 VP1 fragment with overlap in the signature region wasserially diluted and used for PCR amplification in the presence andabsence of 200 ng cellular DNA extracted from a monkey cell line thatwas free of AAV sequences by TaqMan analysis. None of these experimentsdemonstrated efficient PCR-mediated overlap sequence production underthe conditions of the genomic DNA Cap amplification (data not shown). Asa further confirmation, 3 pairs of primers were designed, which werelocated at different HVRs, and were sequence specific to the variants ofclone 42s from Rhesus macaque F953, in different combinations to amplifyshorter fragments from mesenteric lymph node (MLN) DNA from F953 fromwhich clone 42s were isolated. All sequence variations identified infull-length Cap clones were found in these short fragments (data notshown).

Example 2

[0199] Adeno-Associated Viruses Undergo Substantial Evolution inPrimates During Natural Infections

[0200] Sequence analysis of selected AAV isolates revealed divergencethroughout the genome that is most concentrated in hypervariable regionsof the capsid proteins. Epidemiologic data indicate that all knownserotypes are endemic to primates, although isolation of clinicalisolates has been restricted to AAV2 and AAV3 from anal and throat swabsof human infants and AAV5 from a human condylomatous wart. No knownclinical sequalae have been associated with AAV infection.

[0201] In an attempt to better understand the biology of AAV, nonhumanprimates were used as models to characterize the sequlae of naturalinfections. Tissues from nonhuman primates were screened for AAVsequences using the PCR method of the invention based onoligonucleotides to highly conserved regions of known AAVs (see Example1). A stretch of AAV sequence spanning 2886 to 3143 bp of AAV1 [SEQ IDNO:6] was selected as a PCR amplicon in which conserved sequences areflanked by a hypervariable region that is unique to each known AAVserotype, termed herein a “signature region.”

[0202] An initial survey of peripheral blood of a number of nonhumanprimate species including rhesus monkeys, cynomologous monkeys,chimpanzees, and baboons revealed detectable AAV in a subset of animalsfrom all species. A more extensive analysis of vector distribution wasconducted in tissues of rhesus monkeys of the University of Pennsylvaniaand Tulane colonies recovered at necropsy. This revealed AAV sequencethroughout a wide array of tissues.

[0203] The amplified signature sequences were subcloned into plasmidsand individual transformants were subjected to sequence analysis. Thisrevealed substantial variation in nucleotide sequence of clones derivedfrom different animals. Variation in the signature sequence was alsonoted in clones obtained within individual animals. Tissues harvestedfrom two animals in which unique signature sequences were identified(i.e., colon from 98E044 and heart from 98E056) were furthercharacterized by expanding the sequence amplified by PCR usingoligonucleotides to highly conserved sequences. In this way, completeproviral structures were reconstructed for viral genomes from bothtissues as described herein. These proviruses differ from the otherknown AAVs with the greatest sequence divergence noted in regions of theCap gene.

[0204] Additional experiments were performed to confirm that AAVsequences resident to the nonhuman primate tissue represented proviralgenomes of infectious virus that is capable of being rescued and formvirions. Genomic DNA from liver tissue of animal 98E056, from which AAV8signature sequence was detected, was digested with an endonuclease thatdoes not have a site within the AAV sequence and transfected into 293cells with a plasmid containing an E1 deleted genome of human adenovirusserotype 5 as a source of helper functions. The resulting lysate waspassaged on 293 cells once and the lysate was recovered and analyzed forthe presence of AAV Cap proteins using a broadly reacting polyclonalantibody to Cap proteins and for the presence and abundance of DNAsequences from the PCR amplified AAV provirus from which AAV8 wasderived. Transfection of endonuclease restricted heart DNA and theadenovirus helper plasmid yielded high quantities of AAV8 virus asdemonstrated by the detection of Cap proteins by Western blot analysisand the presence of 10⁴ AAV8 vector genomes per 293 cell. Lysates weregenerated from a large-scale preparation and the AAV was purified bycesium sedimentation. The purified preparation demonstrated 26 nmicosohedral structures that look identical to those of AAV serotype 2.Transfection with the adenovirus helper alone did not yield AAV proteinsor genomes, ruling out contamination as a source of the rescued AAV.

[0205] To further characterize the inter and intra animal variation ofAAV signature sequence, selected tissues were subjected to extended PCRto amplify entire Cap open reading frames.

[0206] The resulting fragments were cloned into bacterial plasmids andindividual transformants were isolated and fully sequenced. Thisanalysis involved mesenteric lymph nodes from three rhesus monkeys(Tulane/V223—6 clones; Tulane/T612—7 clones; Tulane/F953—14 clones),liver from two rhesus monkeys (Tulane/V251—3 clones; Penn/00E033—3clones), spleen from one rhesus monkey (Penn/97E043—3 clones), heartfrom one rhesus monkey (IHGT/98E046-1 clone) and peripheral blood fromone chimpanzee (New Iberia/X133—5 clones), six cynomologous macaques(Charles River/A1378, A3099, A3388, A3442, A2821, A3242—6 clones total)and one Baboon (SFRB/8644—2 clones). Of the 50 clones that weresequenced from 15 different animals, 30 were considered non-redundantbased on the finding of at least 7 amino acid differences from oneanother. The non-redundant VP1 clones are numbered sequentially as theywere isolated, with a prefix indicating the species of non-human primatefrom which they were derived. The structural relationships between these30 non-redundant clones and the previously described 8 AAV serotypeswere determined using the SplitsTree program [Huson, D. H. SplitsTree:analyzing and visualizing evolutionary data. Bioinformatics 14, 68-73(1998)] with implementation of the method of split decomposition. Theanalysis depicts homoplasy between a set of sequences in a tree-likenetwork rather than a bifurcating tree. The advantage is to enabledetection of groupings that are the result of convergence and to exhibitphylogenetic relationships even when they are distorted by parallelevents. Extensive phylogenetic research will be required in order toelucidate the AAV evolution, whereas the intention here only is to groupthe different clones as to their sequence similarity.

[0207] To confirm that the novel VP1 sequences were derived frominfectious viral genomes, cellular DNA from tissues with high abundanceof viral DNA was restricted with an endonuclease that should not cleavewithin AAV and transfected into 293 cells, followed by infection withadenovirus. This resulted in rescue and amplification of AAV genomesfrom DNA of tissues from two different animals (data not shown).

[0208] VP1 sequences of the novel AAVs were further characterized withrespect to the nature and location of amino acid sequence variation. All30 VP1 clones that were shown to differ from one another by greater than1% amino acid sequence were aligned and scored for variation at eachresidue. An algorithm developed to determine areas of sequencedivergence yielded 12 hypervariable regions (HVR) of which 5 overlap orare part of the 4 previously described variable regions [Kotin, citedabove; Rutledge, cited above]. The three-fold-proximal peaks containmost of the variability (HVR5-10). Interestingly the loops located atthe 2 and 5 fold axis show intense variation as well. The HVRs 1 and 2occur in the N-terminal portion of the capsid protein that is notresolved in the X-ray structure suggesting that the N-terminus of theVP1 protein is exposed on the surface of the virion.

[0209] Real-time PCR was used to quantify AAV sequences from tissues of21 rhesus monkeys using primers and probes to highly conserved regionsof Rep (one set) and Cap (two sets) of known AAVs. Each data pointrepresents analysis from tissue DNA from an individual animal. Thisconfirmed the wide distribution of AAV sequences, although thequantitative distribution differed between individual animals. Thesource of animals and previous history or treatments did not appear toinfluence distribution of AAV sequences in rhesus macaques. The threedifferent sets of primers and probes used to quantify AAV yieldedconsistent results. The highest levels of AAV were found consistently inmesenteric lymph nodes at an average of 0.01 copies per diploid genomefor 13 animals that were positive. Liver and spleen also contained highabundance of virus DNA. There were examples of very high AAV, such as inheart of rhesus macaque 98E056, spleen of rhesus macaque 97E043 andliver of rhesus macaque RQ4407, which demonstrated 1.5, 3 and 20 copiesof AAV sequence per diploid genome respectively. Relatively low levelsof virus DNA were noted in peripheral blood mononuclear cells,suggesting the data in tissue are not due to resident blood components(data not shown). It should be noted that this method would notnecessarily capture all AAVs resident to the nonhuman primates sincedetection requires high homology to both the oligonucleotides and thereal time PCR probe. Tissues from animals with high abundance AAV DNAwas further analyzed for the molecular state of the DNA, by DNAhybridization techniques, and its cellular distribution, by in situhybridization.

[0210] The kind of sequence variation revealed in AAV proviral fragmentsisolated from different animals and within tissues of the same animalsis reminiscent of the evolution that occurs for many RNA viruses duringpandemics or even within the infection of an individual. In somesituations the notion of a wild-type virus has been replaced by theexistence of swarms of quasispecies that evolve as a result of rapidreplication and mutations in the presence of selective pressure. Oneexample is infection by HIV, which evolves in response to immunologicand pharmacologic pressure. Several mechanisms contribute to the highrate of mutations in RNA viruses, including low fidelity and lack ofproof reading capacity of reverse transcriptase and non-homologous andhomologous recombination.

[0211] Evidence for the formation of quasispecies of AAV was illustratedin this study by the systematic sequencing of multiple cloned proviralfragments. In fact, identical sequences could not be found within anyextended clones isolated between or within animals. An importantmechanism for this evolution of sequence appears to be a high rate ofhomologous recombination between a more limited number of parenteralviruses. The net result is extensive swapping of hypervariable regionsof the Cap protein leading to an array of chimeras that could havedifferent tropisms and serologic specificities (i.e., the ability toescape immunologic responses especially as it relates to neutralizingantibodies). Mechanisms by which homologous recombination could occurare unclear. One possibility is that + and − strands of different singlestranded AAV genomes anneal during replication as has been describedduring high multiplicity of infections with AAV recombinants. It isunclear if other mechanisms contribute to sequence evolution in AAVinfections. The overall rate of mutation that occurs during AAVreplication appears to be relatively low and the data do not suggesthigh frequencies of replication errors. However, substantialrearrangements of the AAV genome have been described during lyticinfection leading to the formation of defective interfering particles.Irrespective of the mechanisms that lead to sequence divergence, withfew exceptions, vp1 structures of the quasispecies remained intactwithout frameshifts or nonsense mutations suggesting that competitiveselection of viruses with the most favorable profile of fitnesscontribute to the population dynamics.

[0212] These studies have implications in several areas of biology andmedicine. The concept of rapid virus evolution, formerly thought to be aproperty restricted to RNA viruses, should be considered in DNA viruses,which classically have been characterized by serologic assays. It willbe important in terms of parvoviruses to develop a new method fordescribing virus isolates that captures the complexity of its structureand biology, such as with HIV, which are categorized as general familiesof similar structure and function called Clades. An alternative strategyis to continue to categorize isolates with respect to serologicspecificity and develop criteria for describing variants withinserologic groups.

Example 3

[0213] Vectorology of Recombinant AAV Genomes Equipped with AAV2 ITRsUsing Chimeric Plasmids Containing AAV2 Rep and Novel AAV Cap Genes forSerological and Gene Transfer Studies in Different Animal Models.

[0214] Chimeric packaging constructs are generated by fusing AAV2 repwith cap sequences of novel AAV serotypes. These chimeric packagingconstructs are used, initially, for pseudotyping recombinant AAV genomescarrying AAV2 ITRs by triple transfection in 293 cell using AdS helperplasmid. These pseudotyped vectors are used to evaluate performance intransduction-based serological studies and evaluate gene transferefficiency of novel AAV serotypes in different animal models includingNHP and rodents, before intact and infectious viruses of these novelserotypes are isolated.

[0215] A. pAAV2GFP

[0216] The AAV2 plasmid which contains the AAV2 ITRs and greenfluorescent protein expressed under the control of a constitutitivepromoter. This plasmid contains the following elements: the AAV2 ITRs, aCMV promoter, and the GFP coding sequences.

[0217] B. Cloning of Trans Plasmid

[0218] To construct the chimeric trans-plasmid for production ofrecombinant pseudotyped AAV7 vectors, p5E18 plasmid (Xiao et al., 1999,J. Virol 73:3994-4003) was partially digested with Xho I to linearizethe plasmid at the Xho I site at the position of 3169 bp only. The Xho Icut ends were then filled in and ligated back. This modified p5E18plasmid was restricted with Xba I and Xho I in a complete digestion toremove the AAV2 cap gene sequence and replaced with a 2267 bp Spe I/XhoI fragment containing the AAV7 cap gene which was isolated from pCRAAV76-5+15-4 plasmid.

[0219] The resulting plasmid contains the AAV2 rep sequences forRep78/68 under the control of the AAV2 P5 promoter, and the AAV2 repsequences for Rep52/40 under the control of the AAV2 P19 promoter. TheAAV7 capsid sequences are under the control of the AAV2 P40 promoter,which is located within the Rep sequences. This plasmid further containsa spacer 5′ of the rep ORF.

[0220] C. Production of Pseudotyped rAAV

[0221] The rAAV particles (AAV2 vector in AAV7 capsid) are generatedusing an adenovirus-free method. Briefly, the cis plasmid (pAAV2.1 lacZplasmid containing AAV2 ITRs), and the trans plasmid pCRAAV7 6-5+15-4(containing the AAV2 rep and AAV7 cap) and a helper plasmid,respectively, were simultaneously co-transfected into 293 cells in aratio of 1:1:2 by calcium phosphate precipitation.

[0222] For the construction of the pAd helper plasmids, pBG 10 plasmidwas purchased from Microbix (Canada). A RsrII fragment containing L2 andL3 was deleted from pBHG10, resulting in the first helper plasmid,pAdΔF13. Plasmid AdΔ F1 was constructed by cloning Asp700/SalI fragmentwith a PmeI/Sgfl deletion, isolating from pBHG10, into Bluescript. MLP,L2, L2 and L3 were deleted in the pAdΔF1. Further deletions of a 2.3 kbNruI fragment and, subsequently, a 0.5 kb RsrII/NruI fragment generatedhelper plasmids pAdΔF5 and pAdΔF6, respectively. The helper plasmid,termed pΔF6, provides the essential helper functions of E2a and E4 ORF6not provided by the E1-expressing helper cell, but is deleted ofadenoviral capsid proteins and functional E1 regions).

[0223] Typically, 50 μg of DNA (cis:trans:helper) was transfected onto a150 mm tissue culture dish. The 293 cells were harvested 72 hourspost-transfection, sonicated and treated with 0.5% sodium deoxycholate(37° C. for 10 min.) Cell lysates were then subjected to two rounds of aCsCl gradient. Peak fractions containing rAAV vector are collected,pooled and dialyzed against PBS.

Example 4

[0224] Creation of Infectious Clones Carrying Intact Novel AAV Serotypesfor Study of Basic Virology in Human and NHP Derived Cell Lines andEvaluation of Pathogenesis of Novel AAV Serotypes in NHP and OtherAnimal Models.

[0225] To achieve this goal, the genome walker system is employed toobtain 5′ and 3′ terminal sequences (ITRs) and complete construction ofclones containing intact novel AAV serotype genomes.

[0226] Briefly, utilizing a commercially available Universal GenomeWalker Kit [Clontech], genomic DNAs from monkey tissues or cell linesthat are identified as positive for the presence of AAV7 sequence aredigested with Dra I, EcoR V, Pvu II and Stu I endonucleases and ligatedto Genome Walker Adaptor to generate 4 individual Genome WalkerLibraries (GWLs). Using DNAs from GWLs as templates, AAV7 and adjacentgenomic sequences will be PCR-amplified by the adaptor primer 1 (AP1,provided in the kit) and an AAV7 specific primer 1, followed by a nestedPCR using the adaptor primer 2 (AP2) and another AAV7 specific primer 2,both of which are internal to the first set of primers. The major PCRproducts from the nested PCR are cloned and characterized by sequencinganalysis.

[0227] In this experiment, the primers covering the 257 bp or othersignature fragment of a generic AAV genome are used for PCRamplification of cellular DNAs extracted from Human and NHP derived celllines to identify and characterize latent AAV sequences. The identifiedlatent AAV genomes are rescued from the positive cell lines usingadenovirus helpers of different species and strains.

[0228] To isolate infectious AAV clones from NHP derived cell lines, adesired cell line is obtained from ATCC and screened by PCR to identifythe 257 bp amplicon, i.e., signature region of the invention. The 257 bpPCR product is cloned and serotyped by sequencing analysis. For thesecell lines containing the AAV7 sequence, the cells are infected withSV-15, a simian adenovirus purchased from ATCC, human Ad5 or transfectedwith plasmid construct housing the human Ad genes that are responsiblefor AAV helper functions. At 48 hour post infection or transfection, thecells are harvested and Hirt DNA is prepared for cloning of AAV7 genomefollowing Xiao et al., 1999, J. Virol, 73:3994-4003.

Example 5

[0229] Production of AAV Vectors

[0230] A pseudotyping strategy similar to that of Example 3 for AAV1/7was employed to produce AAV2 vectors packaged with AAV1, AAV5 and AAV8capsid proteins. Briefly, recombinant AAV genomes equipped with AAV2ITRs were packaged by triple transfection of 293 cells with cis-plasmid,adenovirus helper plasmid and a chimeric packaging construct where theAAV2 rep gene is fused with cap genes of novel AAV serotypes. To createthe chimeric packaging constructs, the Xho I site of p5E18 plasmid at3169 bp was ablated and the modified plasmid was restricted with Xba Iand Xho I in a complete digestion to remove the AAV2 cap gene andreplace it with a 2267 bp Spe I/Xho I fragment containing the AAV8 capgene [Xiao, W., et al., (1999) J Virol 73, 3994-4003]. A similar cloningstrategy was used for creation of chimeric packaging plasmids of AAV2/1and AAV2/5. All recombinant vectors were purified by the standard CsCl₂sedimentation method except for AAV2/2, which was purified by singlestep heparin chromatography.

[0231] Genome copy (GC) titers of AAV vectors were determined by TaqMananalysis using probes and primers targeting SV40 poly A region asdescribed previously [Gao, G., et al., (2000) Hum Gene Ther 11,2079-91].

[0232] Vectors were constructed for each serotype for a number of invitro and in vivo studies. Eight different transgene cassettes wereincorporated into the vectors and recombinant virions were produced foreach serotype. The recovery of virus, based on genome copies, issummarized in Table 4 below. The yields of vector were high for eachserotype with no consistent differences between serotypes. Datapresented in the table are average genome copy yields with standarddeviation×10¹³ of multiple production lots of 50 plate (150 mm)transfections. TABLE 4 Production of Recombinant Vectors AAV2/1 AAV2/2AAV2/5 AAV2/7 AAV2/8 CMV 7.30 ± 4.33 4.49 ± 2.89 5.19 ± 5.19 3.42 0.87LacZ (n = 9) (n = 6) (n = 8) (n = 1) (n = 1) CMV 6.43 ± 2.42 3.39 ± 2.425.55 ± 6.49 2.98 ± 2.66 3.74 ± 3.88 EGFP (n = 2) (n = 2) (n = 4) (n = 2)(n = 2) TBG LacZ 4.18 0.23 0.704 ± 0.43 2.16 0.532 (n = 1) (n = 1) (n =2) (n = 1) (n = 1) Alb A1AT 4.67 ± 0.75 4.77 4.09 5.04 2.02 (n = 2) (n= 1) (n = 1) (n = 1) (n = 1) CB A1AT 0.567 0.438 2.82 2.78 0.816 ± (n= 1) (n = 1) (n = 1) (n = 1) 0.679 (n = 2) TBG 8.51 ± 6.65 3.47 ± 2.095.26 ± 3.85 6.52 ± 3.08 1.83 ± 0.98 rhCG (n = 6) (n = 5) (n = 4) (n = 4)(n = 5) TBG cFIX 1.24 ± 1.29 0.63 ± 0.394 3.74 ± 2.48 4.05 15.8 ± 15.0(n = 3) (n = 6) (n = 7) (n = 1) (n = 5)

Example 6

[0233] Serologic Analysis of Pseudotyped Vectors

[0234] C57BL/6 mice were injected with vectors of different serotypes ofAAVCBAlAT vectors intramuscularly (5×10¹¹ GC) and serum samples werecollected 34 days later. To test neutralizing and cross-neutralizingactivity of sera to each serotype of AAV, sera was analyzed in atransduction based neutralizing antibody assay [Gao, G. P., et al.,(1996) J Virol 70, 8934-43]. More specifically, the presence ofneutralizing antibodies was determined by assessing the ability of serumto inhibit transduction of 84-31 cells by reporter viruses (AAVCMVEGFP)of different serotypes. Specifically, the reporter virus AAVCMVEGFP ofeach serotype [at multiplicity of infection (MOI) that led to atransduction of 90% of indicator cells] was pre-incubated withheat-inactivated serum from animals that received different serotypes ofAAV or from naïve mice. After 1-hour incubation at 37° C., viruses wereadded to 84-31 cells in 96 well plates for 48 or 72-hour, depending onthe virus serotype. Expression of GFP was measured by FluoroImagin(Molecular Dynamics) and quantified by Image Quant Software.Neutralizing antibody titers were reported as the highest serum dilutionthat inhibited transduction to less than 50%.

[0235] The availability of GFP expressing vectors simplified thedevelopment of an assay for neutralizing antibodies that was based oninhibition of transduction in a permissive cell line (i.e., 293 cellsstably expressing E4 from Ad5). Sera to selected AAV serotypes weregenerated by intramuscular injection of the recombinant viruses.Neutralization of AAV transduction by 1:20 and 1:80 dilutions of theantisera was evaluated (See Table 5 below). Antisera to AAV1, AAV2, AAV5and AAV8 neutralized transduction of the serotype to which the antiserumwas generated (AAV5 and AAV8 to a lesser extent than AAV1 and AAV2) butnot to the other serotype (i.e., there was no evidence of crossneutralization suggesting that AAV 8 is a truly unique serotype). TABLE5 Serological Analysis of New AAV Serotypes. % Infection on 84-31 cellswith AAVCMVEGFP virus: AAV2/1 AAV2/2 AAV2/5 AAV2/7 AAV2/8 Serumdilution: Serum dilution: Serum dilution: Serum dilution: Serumdilution: Sera: Immunization Vector 1/20 1/80 1/20 1/80 1/20 1/80 1/201/80 1/20 1/80 Group 1 AAV2/1 0 0 100 100 100 100 100 100 100 100 Group2 AAV2/2 100 100 0 0 100 100 100 100 100 100 Group 3 AAV2/5 100 100 100100 16.5 16.5 100 100 100 100 Group 4 AAV2/7 100 100 100 100 100 10061.5 100 100 100 Group 5 AAV2/8 100 100 100 100 100 100 100 100 26.3 60

[0236] Human sera from 52 normal subjects were screened forneutralization against selected serotypes. No serum sample was found toneutralize AAV2/7 and AAV2/8 while AAV2/2 and AAV2/1 vectors wereneutralized in 20% and 10% of sera, respectively. A fraction of humanpooled IgG representing a collection of 60,000 individual samples didnot neutralize AAV2/7 and AAV2/8, whereas AAV2/2 and AAV2/1 vectors wereneutralized at titers of serum equal to 1/1280 and 1/640, respectively.

Example 7

[0237] In vivo Evaluation of Different Serotypes of AAV Vectors

[0238] In this study, 7 recombinant AAV genomes, AAV2CBhAlAT,AAV2AlbhAlAT, AAV2CMVrhCG, AAV2TBGrhCG, AAV2TBGcFIX, AAV2CMVLacZ andAAV2TBGLacZ were packaged with capsid proteins of different serotypes.In all 7 constructs, minigene cassettes were flanked with AAV2 ITRs.cDNAs of human α-antitrypsin (AlAT) [Xiao, W., et al., (1999) J Virol73, 3994-4003] β-subunit of rhesus monkey choriogonadotropic hormone(CG) [Zoltick, P. W. & Wilson, J. M. (2000) Mol Ther 2, 657-9] caninefactor IX [Wang, L., et al., (1997) Proc Natl Acad Sci USA 94, 11563-6]and bacterial β-glactosidase (i.e., Lac Z) genes were used as reportergenes. For liver-directed gene transfer, either mouse albumin genepromoter (Alb) [Xiao, W. (1999), cited above] or human thyroid hormonebinding globulin gene promoter (TBG) [Wang (1997), cited above] was usedto drive liver specific expression of reporter genes. In muscle-directedgene transfer experiments, either cytomegalovirus early promoter (CMV)or chicken β-actin promoter with CMV enhancer (CB) was employed todirect expression of reporters.

[0239] For muscle-directed gene transfer, vectors were injected into theright tibialis anterior of 4-6 week old NCR nude or C57BL/6 mice(Taconic, Germantown, N.Y.). In liver-directed gene transfer studies,vectors were infused intraportally into 7-9 week old NCR nude or C57BL/6mice (Taconic, Germantown, N.Y.). Serum samples were collectedintraorbitally at different time points after vector administration.Muscle and liver tissues were harvested at different time points forcryosectioning and Xgal histochemical staining from animals thatreceived the lacZ vectors. For the re-administration experiment, C56BL/6mice initially received AAV2/1, 2/2, 2/5, 2/7 and 2/8CBAlAT vectorsintramuscularly and followed for AlAT gene expression for 7 weeks.Animals were then treated with AAV2/8TBGcFIX intraportally and studiedfor cFIX gene expression.

[0240] ELISA based assays were performed to quantify serum levels ofhAlAT, rhCG and cFIX proteins as described previously [Gao, G. P., etal., (1996) J Virol 70, 8934-43; Zoltick, P. W. & Wilson, J. M. (2000)Mol Ther 2, 657-9; Wang, L., et al., Proc Natl Acad Sci USA 94,11563-6]. The experiments were completed when animals were sacrificedfor harvest of muscle and liver tissues for DNA extraction andquantitative analysis of genome copies of vectors present in targettissues by TaqMan using the same set of primers and probe as intitration of vector preparations [Zhang, Y., et al., (2001) Mol Ther 3,697-707].

[0241] The performance of vectors base on the new serotypes wereevaluated in murine models of muscle and liver-directed gene transferand compared to vectors based on the known serotypes AAV1, AAV2 andAAV5. Vectors expressing secreted proteins (alpha-antitrypsin (AlAT) andchorionic gonadotropin (CG)) were used to quantitate relativetransduction efficiencies between different serotypes through ELISAanalysis of sera. The cellular distribution of transduction within thetarget organ was evaluated using lacZ expressing vectors and X-galhistochemistry.

[0242] The performance of AAV vectors in skeletal muscle was analyzedfollowing direct injection into the tibialis anterior muscles. Vectorscontained the same AAV2 based genome with the immediate early gene ofCMV or a CMV enhanced β-actin promoter driving expression of thetransgene. Previous studies indicated that immune competent C57BL/6 miceelicit limited humoral responses to the human AlAT protein whenexpressed from AAV vectors [Xiao, W., et al., (1999) J Virol 73,3994-4003].

[0243] In each strain, AAV2/1 vector produced the highest levels of AlATand AAV2/2 vector the lowest, with AAV2/7 and AAV2/8 vectors showingintermediate levels of expression. Peak levels of CG at 28 daysfollowing injection of nu/nu NCR mice showed the highest levels fromAAV2/7 and the lowest from AAV2/2 with AAV2/8 and AAV2/1 in between.Injection of AAV2/1 and AAV2/7 lacZ vectors yielded gene expression atthe injection sites in all muscle fibers with substantially fewer lacZpositive fibers observed with AAV2/2 and AAV 2/8 vectors. These dataindicate that the efficiency of transduction with AAV2/7 vectors inskeletal muscle is similar to that obtained with AAV2/1, which is themost efficient in skeletal muscle of the previously described serotypes[Xiao, W. (1999), cited above; Chao, H., et al., (2001) Mol Ther 4,217-22; Chao, H., et al., (2000) Mol Ther 2, 619-23].

[0244] Similar murine models were used to evaluate liver-directed genetransfer. Identical doses of vector based on genome copies were infusedinto the portal veins of mice that were analyzed subsequently forexpression of the transgene. Each vector contained an AAV2 based genomeusing previously described liver-specific promoters (i.e., albumin orthyroid hormone binding globulin) to drive expression of the transgene.More particularly, CMVCG and TBGCG minigene cassettes were used formuscle and liver-directed gene transfer, respectively. Levels of rhCGwere defined as relative units (RUs×10³). The data were from assayingserum samples collected at day 28, post vector administration (4 animalsper group). As shown in Table 3, the impact of capsid proteins on theefficiency of transduction of AlAT vectors in nu/nu and C57BL/6 mice andCG vectors in C57BL/6 mice was consistent (See Table 6). TABLE 6Expression of β-unit of Rhesus Monkey Chorionic Gonadotropin (rhCG)Vector Muscle Liver AAV2/1 4.5 ± 2.1 1.6 ± 1.0 AAV2 0.5 ± 0.1 0.7 ± 0.3AAV2/5 ND* 4.8 ± 0.8 AAV2/7 14.2 ± 2.4  8.2 ± 4.3 AAV2/8 4.0 ± 0.7 76.0± 22.8

[0245] In all cases, AAV2/8 vectors yielded the highest levels oftransgene expression that ranged from 16 to 110 greater than what wasobtained with AAV2/2 vectors; expression from AAV2/5 and AAV2/7 vectorswas intermediate with AAV2/7 higher than AAV2/5. Analysis of X-Galstained liver sections of animals that received the corresponding lacZvectors showed a correlation between the number of transduced cells andoverall levels of transgene expression. DNAs extracted from livers ofC57BL/6 mice who received the AlAT vectors were analyzed for abundanceof vector DNA using real time PCR technology.

[0246] The amount of vector DNA found in liver 56 days after injectioncorrelated with the levels of transgene expression (See Table 7). Forthis experiment, a set of probe and primers targeting the SV40 polyAregion of the vector genome was used for TaqMan PCR. Values shown aremeans of three individual animals with standard deviations. The animalswere sacrificed at day 56 to harvest liver tissues for DNA extraction.These studies indicate that AAV8 is the most efficient vector forliver-directed gene transfer due to increased numbers of transducedhepatocytes. TABLE 7 Real Time PCR Analysis for Abundance of AAV Vectorsin nu/nu Mouse Liver Following Injection of 1 × 10¹¹ Genome Copies ofVector. AAV vectors/Dose Genome Copies per Cell AAV2/1AlbA1AT  0.6 ±0.36 AAV2AlbA1AT 0.003 ± 0.001 AAV2/5AlbA1AT 0.83 ± 0.64 AAV2/7AlbA1AT2.2 ± 1.7 AAV2/8AlbA1AT 18 ± 11

[0247] The serologic data described above suggest that AAV2/8 vectorshould not be neutralized in vivo following immunization with the otherserotypes. C57BL/6 mice received intraportal injections of AAV2/8 vectorexpressing canine factor IX (10¹¹ genome copies) 56 days after theyreceived intramuscular injections of AlAT vectors of differentserotypes. High levels of factor IX expression were obtained 14 daysfollowing infusion of AAV2/8 into naïve animals (17±2 μg/ml, n=4) whichwere not significantly different that what was observed in animalsimmunized with AAV2/1 (31±23 μg/ml, n=4), AAV2/2 (16 μg/ml, n=2), andAAV2/7 (12 μg/ml, n=2). This contrasts to what was observed in AAV2/8immunized animals that were infused with the AAV2/8 factor IX vector inwhich no detectable factor IX was observed (<0.1 μg/ml, n=4).

[0248] Oligonucleotides to conserved regions of the cap gene did amplifysequences from rhesus monkeys that represented unique AAVs. Identicalcap signature sequences were found in multiple tissues from rhesusmonkeys derived from at least two different colonies. Full-length repand cap open reading frames were isolated and sequenced from singlesources. Only the cap open reading frames of the novel AAVs werenecessary to evaluate their potential as vectors because vectors withthe AAV7 or AAV8 capsids were generated using the ITRs and rep fromAAV2. This also simplified the comparison of different vectors since theactual vector genome is identical between different vector serotypes. Infact, the yields of recombinant vectors generated using this approachdid not differ between serotypes.

[0249] Vectors based on AAV7 and AAV8 appear to be immunologicallydistinct (i.e., they are not neutralized by antibodies generated againstother serotypes). Furthermore, sera from humans do not neutralizetransduction by AAV7 and AAV8 vectors, which is a substantial advantageover the human derived AAVs currently under development for which asignificant proportion of the human population has pre-existing immunitythat is neutralizing [Chirmule, N., et al., (1999) Gene Ther 6,1574-83].

[0250] The tropism of each new vector is favorable for in vivoapplications. AAV2/7 vectors appear to transduce skeletal muscle asefficiently as AAV2/1, which is the serotype that confers the highestlevel of transduction in skeletal muscle of the primate AAVs tested todate [Xiao, W., cited above; Chou (2001), cited above, and Chou (2000),cited above]. Importantly, AAV2/8 provides a substantial advantage overthe other serotypes in terms of efficiency of gene transfer to liverthat until now has been relatively disappointing in terms of the numbersof hepatocytes stably transduced. AAV2/8 consistently achieved a 10 to100-fold improvement in gene transfer efficiency as compared to theother vectors. The basis for the improved efficiency of AAV2/8 isunclear, although it presumably is due to uptake via a differentreceptor that is more active on the basolateral surface of hepatocytes.This improved efficiency will be quite useful in the development ofliver-directed gene transfer where the number of transduced cells iscritical, such as in urea cycle disorders and familialhypercholesterolemia.

[0251] Thus, the present invention provides a novel approach forisolating new AAVs based on PCR retrieval of genomic sequences. Theamplified sequences were easily incorporated into vectors and tested inanimals. The lack of pre-existing immunity to AAV7 and the favorabletropism of the vectors for muscle indicates that AAV7 is suitable foruse as a vector in human gene therapy and other in vivo applications.Similarly, the lack of pre-existing immunity to the AAV serotypes of theinvention, and their tropisms, renders them useful in delivery oftherapeutic molecules and other useful molecules.

Example 9

[0252] Tissue Tropism Studies

[0253] In the design of a high throughput functional screening schemefor novel AAV constructs, a non-tissue specific and highly activepromoter, CB promoter (CMV enhanced chicken β actin promoter) wasselected to drive an easily detectable and quantifiable reporter gene,human α anti-trypsin gene. Thus only one vector for each new AAV cloneneeds to be made for gene transfer studies targeting 3 differenttissues, liver, lung and muscle to screen for tissue tropism of aparticular AAV construct. The following table summarizes data generatedfrom 4 novel AAV vectors in the tissue tropism studies (AAVCBAlAT), fromwhich a novel AAV capsid clone, 44.2, was found to be a very potent genetransfer vehicle in all 3 tissues with a big lead in the lung tissueparticularly. Table 8 reports data obtained (in μg AlAT/mL serum) at day14 of the study. TABLE 8 Target Tissue Vector Lung Liver Muscle AAV2/1ND ND 45 ± 11 AAV2/5 0.6 ± 0.2 ND ND AAV2/8 ND 84 ± 30 ND AAV2/rh.2(43.1) 14 ± 7   25 ± 7.4 35 ± 14 AAV2/rh.10 (44.2) 23 ± 6  53 ± 19 46 ±11 AAV2/rh.13 (42.2) 3.5 ± 2     2 ± 0.8 3.5 ± 1.7 AAV2/rh.21 (42.10)3.1 ± 2     2 ± 1.4 4.3 ± 2  

[0254] A couple of other experiments were then performed to confirm thesuperior tropism of AAV 44.2 in lung tissue. First, AAV vector carriedCC10hAlAT minigene for lung specific expression were pseudotyped withcapsids of novel AAVs were given to Immune deficient animals (NCR nude)in equal volume (50 μl each of the original preps without dilution) viaintratracheal injections as provided in the following table. In Table 9,50 μl of each original prep per mouse, NCR Nude, detection limit ≧0.033μg/ml, Day 28 TABLE 9 Relative Gene Total GC transfer as in μg ofA1AT/ml compared to 50 μl μg of A1AT/ml with 1 × 10¹¹ rh.10 (cloneVector vector with 50 μl vector vector 44.2) 2/1   3 × 10¹² 2.6 ± 0.50.09 ± 0.02 2.2 2/2 5.5 × 10¹¹ <0.03 <0.005 <0.1 2/5 3.6 × 10¹² 0.65 ±0.16  0.02 ± 0.004 0.5 2/7 4.2 × 10¹²   1 ± 0.53 0.02 ± 0.01 0.5 2/8 7.5× 10¹¹ 0.9 ± 0.7 0.12 ± 0.09 2.9 2/ch.5   9 × 10¹²   1 ± 0.7  0.01 ±0.008 0.24 (A.3.1) 2/rh.8 4.6 × 10¹² 26 ± 21 0.56 ± 0.46 13.7 (43.25)2/rh.10 2.8 × 10¹² 115 ± 38  4.1 ± 1.4 100 (44.2) 2/rh.13   6 × 10¹² 7.3± 0.8 0.12 ± 0.01 2.9 (42.2) 2/rh.21 2.4 × 10¹²   9 ± 0.9 0.38 ± 0.049.3 (42.10) 2/rh.22 2.6 × 10¹²   6 ± 0.4 0.23 ± 0.02 5.6 (42.11) 2/rh.241.1 × 10¹¹ 0.4 ± 0.3 0.4 ± 0.3 1 (42.13)

[0255] The vectors were also administered to immune competent animals(C57BL/6) in equal genome copies (1×10¹¹ GC) as shown in the Table 10.(1×10¹¹ GC per animal, C57BL/6, day 14, detection limit ≧0.033 μg/ml)TABLE 10 Relative Gene transfer as μg of A1AT/ml compared to rh.10(clone AAV Vector with 1 × 10¹¹ vector 44.2) 2/1 0.076 ± 0.031 2.6 2/2 0.1 ± 0.09 3.4 2/5 0.0840.033 2.9 2/7 0.33 ± 0.01 11 2/8 1.92 ± 1.3 2.9 2/ch.5 (A.3.1) 0.048 ± 0.004 1.6 2/rh.8 (43.25) 1.7 ± 0.7 58 2/rh.10(44.2) 2.93 ± 1.7  100 2/rh.13 (42.2) 0.45 ± 0.15 15 2/rh.21 (42.10)0.86 ± 0.32 29 2/rh.22 (42.11) 0.38 ± 0.18 13 2/rh.24 (42.13)  0.3 ±0.19 10

[0256] The data from both experiments confirmed the superb tropism ofclone 44.2 in lung-directed gene transfer.

[0257] Interestingly, performance of clone 44.2 in liver and muscledirected gene transfer was also outstanding, close to that of the bestliver transducer, AAV8 and the best muscle transducer AAV1, suggestingthat this novel AAV has some intriguing biological significance.

[0258] To study serological properties of those novel AAVs, pseudotypedAAVGFP vectors were created for immunization of rabbits and in vitrotransduction of 84-31 cells in the presence and absence of antiseraagainst different capsids. The data are summarized below: TABLE 11aCross-NAB assay in 8431 cells and adenovirus (Adv) coinfection Infectionin 8431 cells (coinfected with Adv) with: Serum from rabbit 10⁹ GC 10⁹GC 10⁹ GC 10¹⁰ GC immunized rh.13 rh.21 rh.22 rh.24 with: AAV2/42.2AAV2/42.10 AAV2/42.11 AAV2/42.13 AAV2/1 1/20 1/20 1/20 No NAB AAV2/21/640 1/1280 1/5120 No NAB AAV2/5 No NAB 1/40 1/160 No NAB AAV2/71/81920 1/81920 1/40960 1/640 AAV2/8 1/640 1/640 1/320 1/5120 Ch.5AAV2/A3 1/20 1/160 1/640 1/640 rh.8 AAV2/43.25 1/20 1/20 1/20 1/320rh.10 AAV2/44.2 No NAB No NAB No NAB 1/5120 rh.13 AAV2/42.2 1/51201/5120 1/5120 No NAB rh.21 AAV2/42.10 1/5120 1/10240 1/5120 1/20 rh.22AAV2/42.11 1/20480 1/20480 1/40960 No NAB rh.24 AAV2/42.13 No NAB 1/201/20 1/5120

[0259] TABLE 11b Cross-NAB assay in 8431 cells and Adv coinfectionInfection in 8431 cells (coinfected with Adv) with: Serum 10⁹ GC 10¹⁰ GC10¹⁰ GC 10⁹ GC 10⁹ GC from rabbit rh.12 ch.5 rh.8 rh.10 rh.20 immunizedwith: AAV2/42.1B AAV2/A3 AAV2/43.25 AAV2/44.2 AAV2/42.8.2 AAV2/1 No NAB1/20480 No NAB 1/80 ND AAV2/2 1/20 No NAB No NAB No NAB ND AAV2/5 No NAB1/320 No NAB No NAB ND AAV2/7 1/2560 1/640 1/160 1/81920 ND AAV2/81/10240 1/2560 1/2560 1/81920 ND ch.5 AAV2/A3 1/1280 1/10240 ND 1/51201/320 rh.8 AAV2/43.25 1/1280 ND 1/20400 1/5120 1/2560 rh.10 AAV2/44.21/5120 ND ND 1/5120 1/5120 rh.13 AAV2/42.2 1/20 ND ND No NAB 1/320 rh.21AAV2/42.10 1/20 ND ND 1/40 1/80 rh.22 AAV2/42.11 No NAB ND ND ND No NABrh.24 AAV2/42.13 1/5120 ND ND ND 1/2560

[0260] TABLE 12 Titer of rabbit sera Titer after Vector Titer d21Boosting ch.5 AAV2/A3 1/10,240 1/40,960 rh.8 AAV2/43.25 1/20,4001/163,840 rh.10 AAV2/44.2 1/10,240 1/527,680 rh.13 AAV2/42.2 1/5,1201/20,960 rh.21 AAV2/42.10 1/20,400 1/81,920 rh.22 AAV2/42.11 1/40,960 NDrh.24 AAV2/42.13 1/5,120 ND

[0261] TABLE 13a Infection in 8431 cells (coinfected with Adv) with GFP10⁹ GC/well 10⁹ GC/well 10⁹ GC/well 10⁹ GC/well 10⁹ GC/well 10⁹ GC/wellch.5 AAV2/1 AAV2/2 AAV2/5 AAV2/7 AAV2/8 AAV2/A3 # GFU/field 128 >200 9556 13 1 83 >200 65 54 11 1

[0262] TABLE 13b Infection in 8431 cells (coinfected with Adv) with GFP10⁹ GC/well 10⁹ GC/well 10⁹ GC/well 10⁹ GC/well 10⁹ GC/well 10⁹ GC/well10⁹ GC/well rh.8 rh.10 rh.13 rh.21 rh.22 rh.24 rh.12 AAV2/43.25AAV2/44.2 AAV2/42.2 AAV2/42.10 AAV2/42.11 AAV2/42.13 AAV2/42.1B #GFU/field 3 13 54 62 10 3 18 2 12 71 60 14 2 20 48 47 16 3 12

Example 10

[0263] Mouse Model of Familial Hypercholesterolemia

[0264] The following experiment demonstrates that the AAV2/7 constructof the invention delivers the LDL receptor and express LDL receptor inan amount sufficient to reduce the levels of plasma cholesterol andtriglycerides in animal models of familial hypercholesterolemia.

[0265] A. Vector Construction

[0266] AAV vectors packaged with AAV7 or AAV8 capsid proteins wereconstructed using a pseudotyping strategy [Hildinger M, et al., J. Virol2001; 75:6199-6203]. Recombinant AAV genomes with AAV2 inverted terminalrepeats (ITR) were packaged by triple transfection of 293 cells with thecis-plasmid, the adenovirus helper plasmid and a chimeric packagingconstruct, a fusion of the capsids of the novel AAV serotypes with therep gene of AAV2. The chimeric packaging plasmid was constructed aspreviously described [Hildinger et al, cited above]. The recombinantvectors were purified by the standard CsCl₂ sedimentation method. Todetermine the yield TaqMan (Applied Biosystems) analysis was performedusing probes and primers targeting the SV40 poly(A) region of thevectors [Gao G P, et al., Hum Gene Ther. Oct. 10, 2000;11(15):2079-91].The resulting vectors express the transgene under the control of thehuman thyroid hormone binding globulin gene promoter (TBG).

[0267] B. Animals

[0268] LDL receptor deficient mice on the C57Bl/6 background werepurchased from the Jackson Laboratory (Bar Harbor, Me., USA) andmaintained as a breeding colony. Mice were given unrestricted access towater and obtained a high fat Western Diet (high % cholesterol) startingthree weeks prior vector injection. At day-7 as well at day 0, blood wasobtained via retroorbital bleeds and the lipid profile evaluated. Themice were randomly divided into seven groups. The vector was injectedvia an intraportal injection as previously described ([Chen S J et al.,Mol Therapy 2000; 2(3), 256-261]. Briefly, the mice were anaesthetizedwith ketamine and xylazine. A laparotomy was performed and the portalvein exposed. Using a 30 g needle the appropriate dose of vector dilutedin 100 ul PBS was directly injected into the portal vein. Pressure wasapplied to the injection site to ensure a stop of the bleeding. The skinwound was closed and draped and the mice carefully monitored for thefollowing day. Weekly bleeds were performed starting at day 14 afterliver directed gene transfer to measure blood lipids. Two animals ofeach group were sacrificed at the tune points week 6 and week 12 aftervector injection to examine atherosclerotic plaque size as well asreceptor expression. The remaining mice were sacrificed at week 20 forplaque measurement and determination of transgene expression. TABLE 14Vector dose n Group 1 AAV2/7-TBG-hLDLr 1 × 10¹² gc 12 Group 2AAV2/7-TBG-hLDLr 3 × 10¹¹ gc 12 Group 3 AAV2/7-TBG-hLDLr 1 × 10¹¹ gc 12Group 4 AAV2/8-TBG-hLDLr 1 × 10¹¹ gc 12 Group 5 AAV2/8-TBG-hLDLr 3 ×10¹¹ gc 12 Group 6 AAV2/8-TBG-hLDLr 1 × 10¹¹ gc 12 Group 7AAV2/7-TBG-LacZ 1 × 10¹¹ gc 16

[0269] C. Serum Lipoprotein and Liver Function Analysis

[0270] Blood samples were obtained from the retroorbital plexus after a6 hour fasting period. The serum was separated from the plasma bycentrifugation. The amount of plasma lipoproteins and livertransaminases in the serum were detected using an automatized clinicalchemistry analyzer (ACE, Schiapparelli Biosystems, Alpha Wassermann)

[0271] D. Detection of Transgene Expression

[0272] LDL receptor expression was evaluated by immuno-fluorescencestaining and Western blotting. For Western Blot frozen liver tissue washomogenized with lysis buffer (20 mM Tris, pH7.4, 130 mM NaCl, 1% TritonX 100, proteinase inhibitor (complete, EDTA-free, Roche, Mannheim,Germany). Protein concentration was determined using the Micro BCAProtein Assay Reagent Kit (Pierce, Rockford, Ill.). 40 μg of protein wasresolved on 4-15% Tris-HCl Ready Gels (Biorad, Hercules, Calif.) andtransferred to a nitrocellulose membrane (Invitrogen,). To generateAnti-hLDL receptor antibodies a rabbit was injected intravenously withan AdhLDLr prep (1×10¹³ GC). Four weeks later the rabbit serum wasobtained and used for Western Blot. A 1:100 dilution of the serum wasused as a primary antibody followed by a HRP-conjugated anti-rabbit IgGand ECL chemiluminescent detection (ECL Western Blot Detection Kit,Amershain, Arlington Heights, Ill.).

[0273] E. Immunocytochemistry

[0274] For determination of LDL receptor expression in frozen liversections immunohistochemistry analyses were performed. 10 um cryostatsections were either fixed in acetone for 5 minutes, or unfixed.Blocking was obtained via a 1 hour incubation period with 10% of goatserum. Sections were then incubated for one hour with the primaryantibody at room temperature. A rabbit polyclonal antibody anti-humanLDL (Biomedical Technologies Inc., Stoughton, Mass.) was used dilutedaccordingly to the instructions of the manufacturer. The sections werewashed with PBS, and incubated with 1:100 diluted fluorescein goatanti-rabbit IgG (Sigma, St Louis, Mo.). Specimens were finally examinedunder fluorescence microscope Nikon Microphot-FXA. In all cases, eachincubation was followed by extensive washing with PBS. Negative controlsconsisted of preincubation with PBS, omission of the primary antibody,and substitution of the primary antibody by an isotype-matchednon-immune control antibody. The three types of controls mentioned abovewere performed for each experiment on the same day.

[0275] F. Gene Transfer Efficiency

[0276] Liver tissue was obtained after sacrificing the mice at thedesignated time points. The tissue was shock frozen in liquid nitrogenand stored at −80° C. until further processing. DNA was extracted fromthe liver tissue using a QIAamp DNA Mini Kit (QIAGEN GmbH, Germany)according to the manufacturers protocol. Genome copies of AAV vectors inthe liver tissue were evaluated using Taqman analysis using probes andprimers against the SV40 poly(A) tail as described above.

[0277] G. Atherosclerotic Plaque Measurement

[0278] For the quantification of the atherosclerotic plaques in themouse aorta the mice were anaesthetized (10% ketamine and xylazine, ip),the chest opened and the arterial system perfused with ice-coldphosphate buffered saline through the left ventricle. The aorta was thencarefully harvested, slit down along the ventral midline from the aorticarch down to the femoral arteries and fixed in formalin. The lipid-richatherosclerotic plaques were stained with Sudan IV (Sigma, Germany) andthe aorta pinned out flat on a black wax surface. The image was capturedwith a Sony DXC-960 MD color video camera. The area of the plaque aswell as of the complete aortic surface was determined using Phase 3Imaging Systems (Media Cybernetics).

[0279] H. Clearance of I¹²⁵ LDL

[0280] Two animals per experimental group were tested. A bolus ofI¹²⁵-labeled LDL (generously provided by Dan Rader, U Penn) was infusedslowly through the tail vein over a period of 30 sec (1,000,000 countsof [I¹²⁵]-LDL diluted in 100 μl sterile PBS/animal). At time points 3min, 30 min, 1.5 hr, 3 hr, 6 hr after injection a blood sample wasobtained via the retro-orbital plexus. The plasma was separated off fromthe whole blood and 10 μl plasma counted in the gamma counter. Finallythe fractional catabolic rate was calculated from the lipoproteinclearance data.

[0281] 1. Evaluation of Liver Lipid Accumulation

[0282] Oil Red Staining of frozen liver sections was performed todetermine lipid accumulation. The frozen liver sections were brieflyrinsed in distilled water followed by a 2 minute incubation in absolutepropylene glycol. The sections were then stained in oil red solution(0.5% in propylene glycol) for 16 hours followed by counterstaining withMayer's hematoxylin solution for 30 seconds and mounting in warmedglycerin jelly solution.

[0283] For quantification of the liver cholesterol and triglyceridecontent liver sections were homogenized and incubated inchloroform/methanol (2:1) overnight. After adding of 0.05% H₂SO₄ andcentrifugation for 10 minutes, the lower layer of each sample wascollected, divided in two aliquots and dried under nitrogen. For thecholesterol measurement the dried lipids of the first aliquot weredissolved in 1% Triton X-100 in chloroform. Once dissolved, the solutionwas dried under nitrogen. After dissolving the lipids in ddH₂O andincubation for 30 minutes at 37° C. the total cholesterol concentrationwas measured using a Total Cholesterol Kit (Wako Diagnostics). For thesecond aliquot the dried lipids were dissolved in alcoholic KOH andincubated at 60° C. for 30 minutes. Then 1M MgCl2 was added, followed byincubation on ice for 10 minutes and centrifugation at 14,000 rpm for 30minutes. The supernatant was finally evaluated for triglycerides (WakoDiagnostics).

[0284] All of the vectors pseudotyped in an AAV2/8 or AAV2/7 capsidlowered total cholesterol, LDL and triglycerides as compared to thecontrol. These test vectors also corrected phenotype ofhypercholesterolemia in a dose-dependent manner. A reduction in plaquearea for the AAV2/8 and AAV2/7 mice was observed in treated mice at thefirst test (2 months), and the effect was observed to persist over thelength of the experiment (6 months).

Example 10

[0285] Functional Factor IX Expression and Correction of Hemophilia

[0286] A. Knock-Out Mice

[0287] Functional canine factor IX (FIX) expression was assessed inhemophilia B mice. Vectors with capsids of AAV1, AAV2, AAV5, AAV7 orAAV8 were constructed to deliver AAV2 5′ ITR—liver-specific promoter[LSP]—canine FIX—woodchuck hepatitis post-regulatory element (WPRE)—AAV23′ ITR. The vectors were constructed as described in Wang et al, 2000,Molecular Therapy 2: 154-158), using the appropriate capsids.

[0288] Knock-out mice were generated as described in Wang et al, 1997.Proc. Natl. Acad. Sci. USA 94: 11563-11566. This model closely mimic thephenotypes of hemophilia B in human.

[0289] Vectors of different serotypes (AAV1, AAV2, AAV5, AAV7 and AAV8)were delivered as a single intraportal injection into the liver of adulthemophiliac C57Bl/6 mice in a dose of 1×10¹¹ GC/mouse for the fivedifferent serotypes and one group received an AAV8 vector at a lowerdose, 1×10¹⁰ GC/mouse. Control group was injected with 1×10¹¹ GC ofAAV2/8 TBG LacZ3. Each group contains 5-10 male and female mice. Micewere bled bi-weekly after vector administration.

[0290] 1. ELISA

[0291] The canine FIX concentration in the mouse plasma was determinedby an ELISA assay specific for canine factor IX, performed essentiallyas described by Axelrod et al, 1990, Proc.Natl.Acad.Sci. USA,87:5173-5177 with modifications. Sheep anti-canine factor IX (EnzymeResearch Laboratories) was used as primary antibody and rabbitanti-canine factor IX ((Enzyme Research Laboratories) was used assecondary antibody. Beginning at two weeks following injection,increased plasma levels of cFIX were detected for all test vectors. Theincreased levels were sustained at therapeutic levels throughout thelength of the experiment, i.e., to 12 weeks. Therapeutic levels areconsidered to be 5% of normal levels, i.e., at about 250 ng/mL.

[0292] The highest levels of expression were observed for the AAV2/8 (at10¹¹) and AAV2/7 constructs, with sustained superphysiology levels cFIXlevels (ten-fold higher than the normal level). Expression levels forAAV2/8 (10¹¹) were approximately 10 fold higher than those observed forAAV2/2 and AAV2/8 (10¹⁰). The lowest expression levels, although stillabove the therapeutic range, were observed for AAV2/5.

[0293] 2. In Vitro Activated Partial Thromboplastin Time (aPTT) Assay

[0294] Functional factor IX activity in plasma of the FIX knock-out micewas determined by an in vitro activated partial thromboplastin time(aPTT) assay—Mouse blood samples were collected from the retro-orbitalplexus into 1/10 volume of citrate buffer. The aPTT assay was performedas described by Wang et al, 1997, Proc. Natl. Acad. Sci. USA 94:11563-11566.

[0295] Clotting times by aPTT on plasma samples of all vector injectedmice were within the normal range (approximately 60 sec) when measuredat two weeks post-injection, and sustained clotting times in the normalor shorter than normal range throughout the study period (12 weeks).

[0296] Lowest sustained clotting times were observed in the animalsreceiving AAV2/8 (10¹¹) and AAV2/7. By week 12, AAV2/2 also inducedclotting times similar to those for AAV2/8 and AAV2/7. However, thislowered clotting time was not observed for AAV2/2 until week 12, whereaslowered clotting times (in the 25-40 sec range) were observed for AAV2/8and AAV2/7 beginning at week two.

[0297] Immuno-histochemistry staining on the liver tissues harvestedfrom some of the treated mice is currently being performed. About 70-80%of hepatocytes are stained positive for canine FIX in the mouse injectedwith AAV2/8.cFIX vector.

[0298] B. Hemophilia B Dogs

[0299] Dogs that have a point mutation in the catalytic domain of theF.IX gene, which, based on modeling studies, appears to render theprotein unstable, suffer from hemophilia B [Evans et al, 1989, Proc.Natl. Acad. Sci. USA, 86:10095-10099). A colony of such dogs has beenmaintained for more than two decades at the University of NorthCarolina, Chapel Hill. The homeostatic parameters of these dogs are welldescribed and include the absence of plasma F.IX antigen, whole bloodclotting times in excess of 60 minutes, whereas normal dogs are 6-8minutes, and prolonged activated partial thromboplastin time of 50-80seconds, whereas normal dogs are 13-28 seconds. These dogs experiencerecurrent spontaneous hemorrhages. Typically, significant bleedingepisodes are successfully managed by the single intravenous infusion of10 ml/kg of normal canine plasma; occasionally, repeat infusions arerequired to control bleeding.

[0300] Four dogs are injected intraportally with AAV.cFIX according tothe schedule below. A first dog receives a single injection withAAV2/2.cFIX at a dose of 3.7×10¹¹ genome copies (GC)/kg. A second dogreceives a first injection of AAV2/2.cFIX (2.8×10¹¹ GC/kg), followed bya second injection with AAV2/7.cFIX (2.3×10¹³ GC/kg) at day 1180. Athird dog receives a single injection with AAV2/2.cFIX at a dose of4.6×10¹² GC/kg. The fourth dog receives an injection with AAV2/2.cFIX(2.8×10¹² GC/kg) and an injection at day 995 with AAV2/7.cFIX (5×10¹²GC/kg).

[0301] The abdomen of hemophilia dogs are aseptically and surgicallyopened under general anesthesia and a single infusion of vector isadministered into the portal vein. The animals are protected fromhemorrhage in the peri-operative period by intravenous administration ofnormal canine plasma. The dog is sedated, intubated to induce generalanesthesia, and the abdomen shaved and prepped. After the abdomen isopened, the spleen is moved into the operative field. The splenic veinis located and a suture is loosely placed proximal to a small distalincision in the vein. A needle is rapidly inserted into the vein, thenthe suture loosened and a 5 F cannula is threaded to an intravenouslocation near the portal vein threaded to an intravenous location nearthe portal vein bifurcation. After hemostasis is secured and thecatheter balloon inflated, approximately 5.0 ml of vector diluted in PBSis infused into the portal vein over a 5 minute interval. The vectorinfusion is followed by a 5.0 ml infusion of saline. The balloon is thendeflated, the callula removed and venous hemostasis is secured. Thespleen is then replaced, bleeding vessels are cauterized and theoperative wound is closed. The animal is extubated having tolerated thesurgical procedure well. Blood samples are analyzed as described. [Wanget al, 2000, Molecular Therapy 2: 154-158]

[0302] Results showing correction or partial correction are anticipatedfor AAV2/7.

[0303] All publications cited in this specification are incorporatedherein by reference. While the invention has been described withreference to a particularly preferred embodiments, it will beappreciated that modifications can be made without departing from thespirit of the invention. Such modifications are intended to fall withinthe scope of the claims.

1 120 1 4721 DNA adeno-associated virus serotype 7 1 ttggccactccctctatgcg cgctcgctcg ctcggtgggg cctgcggacc aaaggtccgc 60 agacggcagagctctgctct gccggcccca ccgagcgagc gagcgcgcat agagggagtg 120 gccaactccatcactagggg taccgcgaag cgcctcccac gctgccgcgt cagcgctgac 180 gtaaatcacgtcatagggga gtggtcctgt attagctgtc acgtgagtgc ttttgcgaca 240 ttttgcgacaccacgtggcc atttgaggta tatatggccg agtgagcgag caggatctcc 300 attttgaccgcgaaatttga acgagcagca gccatgccgg gtttctacga gatcgtgatc 360 aaggtgccgagcgacctgga cgagcacctg ccgggcattt ctgactcgtt tgtgaactgg 420 gtggccgagaaggaatggga gctgcccccg gattctgaca tggatctgaa tctgatcgag 480 caggcacccctgaccgtggc cgagaagctg cagcgcgact tcctggtcca atggcgccgc 540 gtgagtaaggccccggaggc cctgttcttt gttcagttcg agaagggcga gagctacttc 600 caccttcacgttctggtgga gaccacgggg gtcaagtcca tggtgctagg ccgcttcctg 660 agtcagattcgggagaagct ggtccagacc atctaccgcg gggtcgagcc cacgctgccc 720 aactggttcgcggtgaccaa gacgcgtaat ggcgccggcg gggggaacaa ggtggtggac 780 gagtgctacatccccaacta cctcctgccc aagacccagc ccgagctgca gtgggcgtgg 840 actaacatggaggagtatat aagcgcgtgt ttgaacctgg ccgaacgcaa acggctcgtg 900 gcgcagcacctgacccacgt cagccagacg caggagcaga acaaggagaa tctgaacccc 960 aattctgacgcgcccgtgat caggtcaaaa acctccgcgc gctacatgga gctggtcggg 1020 tggctggtggaccggggcat cacctccgag aagcagtgga tccaggagga ccaggcctcg 1080 tacatctccttcaacgccgc ctccaactcg cggtcccaga tcaaggccgc gctggacaat 1140 gccggcaagatcatggcgct gaccaaatcc gcgcccgact acctggtggg gccctcgctg 1200 cccgcggacattaaaaccaa ccgcatctac cgcatcctgg agctgaacgg gtacgatcct 1260 gcctacgccggctccgtctt tctcggctgg gcccagaaaa agttcgggaa gcgcaacacc 1320 atctggctgtttgggcccgc caccaccggc aagaccaaca ttgcggaagc catcgcccac 1380 gccgtgcccttctacggctg cgtcaactgg accaatgaga actttccctt caacgattgc 1440 gtcgacaagatggtgatctg gtgggaggag ggcaagatga cggccaaggt cgtggagtcc 1500 gccaaggccattctcggcgg cagcaaggtg cgcgtggacc aaaagtgcaa gtcgtccgcc 1560 cagatcgaccccacccccgt gatcgtcacc tccaacacca acatgtgcgc cgtgattgac 1620 gggaacagcaccaccttcga gcaccagcag ccgttgcagg accggatgtt caaatttgaa 1680 ctcacccgccgtctggagca cgactttggc aaggtgacga agcaggaagt caaagagttc 1740 ttccgctgggccagtgatca cgtgaccgag gtggcgcatg agttctacgt cagaaagggc 1800 ggagccagcaaaagacccgc ccccgatgac gcggatataa gcgagcccaa gcgggcctgc 1860 ccctcagtcgcggatccatc gacgtcagac gcggaaggag ctccggtgga ctttgccgac 1920 aggtaccaaaacaaatgttc tcgtcacgcg ggcatgattc agatgctgtt tccctgcaaa 1980 acgtgcgagagaatgaatca gaatttcaac atttgcttca cacacggggt cagagactgt 2040 ttagagtgtttccccggcgt gtcagaatct caaccggtcg tcagaaaaaa gacgtatcgg 2100 aaactctgcgcgattcatca tctgctgggg cgggcgcccg agattgcttg ctcggcctgc 2160 gacctggtcaacgtggacct ggacgactgc gtttctgagc aataaatgac ttaaaccagg 2220 tatggctgccgatggttatc ttccagattg gctcgaggac aacctctctg agggcattcg 2280 cgagtggtgggacctgaaac ctggagcccc gaaacccaaa gccaaccagc aaaagcagga 2340 caacggccggggtctggtgc ttcctggcta caagtacctc ggacccttca acggactcga 2400 caagggggagcccgtcaacg cggcggacgc agcggccctc gagcacgaca aggcctacga 2460 ccagcagctcaaagcgggtg acaatccgta cctgcggtat aaccacgccg acgccgagtt 2520 tcaggagcgtctgcaagaag atacgtcatt tgggggcaac ctcgggcgag cagtcttcca 2580 ggccaagaagcgggttctcg aacctctcgg tctggttgag gaaggcgcta agacggctcc 2640 tgcaaagaagagaccggtag agccgtcacc tcagcgttcc cccgactcct ccacgggcat 2700 cggcaagaaaggccagcagc ccgccagaaa gagactcaat ttcggtcaga ctggcgactc 2760 agagtcagtccccgaccctc aacctctcgg agaacctcca gcagcgccct ctagtgtggg 2820 atctggtacagtggctgcag gcggtggcgc accaatggca gacaataacg aaggtgccga 2880 cggagtgggtaatgcctcag gaaattggca ttgcgattcc acatggctgg gcgacagagt 2940 cattaccaccagcacccgaa cctgggccct gcccacctac aacaaccacc tctacaagca 3000 aatctccagtgaaactgcag gtagtaccaa cgacaacacc tacttcggct acagcacccc 3060 ctgggggtattttgacttta acagattcca ctgccacttc tcaccacgtg actggcagcg 3120 actcatcaacaacaactggg gattccggcc caagaagctg cggttcaagc tcttcaacat 3180 ccaggtcaaggaggtcacga cgaatgacgg cgttacgacc atcgctaata accttaccag 3240 cacgattcaggtattctcgg actcggaata ccagctgccg tacgtcctcg gctctgcgca 3300 ccagggctgcctgcctccgt tcccggcgga cgtcttcatg attcctcagt acggctacct 3360 gactctcaacaatggcagtc agtctgtggg acgttcctcc ttctactgcc tggagtactt 3420 cccctctcagatgctgagaa cgggcaacaa ctttgagttc agctacagct tcgaggacgt 3480 gcctttccacagcagctacg cacacagcca gagcctggac cggctgatga atcccctcat 3540 cgaccagtacttgtactacc tggccagaac acagagtaac ccaggaggca cagctggcaa 3600 tcgggaactgcagttttacc agggcgggcc ttcaactatg gccgaacaag ccaagaattg 3660 gttacctggaccttgcttcc ggcaacaaag agtctccaaa acgctggatc aaaacaacaa 3720 cagcaactttgcttggactg gtgccaccaa atatcacctg aacggcagaa actcgttggt 3780 taatcccggcgtcgccatgg caactcacaa ggacgacgag gaccgctttt tcccatccag 3840 cggagtcctgatttttggaa aaactggagc aactaacaaa actacattgg aaaatgtgtt 3900 aatgacaaatgaagaagaaa ttcgtcctac taatcctgta gccacggaag aatacgggat 3960 agtcagcagcaacttacaag cggctaatac tgcagcccag acacaagttg tcaacaacca 4020 gggagccttacctggcatgg tctggcagaa ccgggacgtg tacctgcagg gtcccatctg 4080 ggccaagattcctcacacgg atggcaactt tcacccgtct cctttgatgg gcggctttgg 4140 acttaaacatccgcctcctc agatcctgat caagaacact cccgttcccg ctaatcctcc 4200 ggaggtgtttactcctgcca agtttgcttc gttcatcaca cagtacagca ccggacaagt 4260 cagcgtggaaatcgagtggg agctgcagaa ggaaaacagc aagcgctgga acccggagat 4320 tcagtacacctccaactttg aaaagcagac tggtgtggac tttgccgttg acagccaggg 4380 tgtttactctgagcctcgcc ctattggcac tcgttacctc acccgtaatc tgtaattgca 4440 tgttaatcaataaaccggtt gattcgtttc agttgaactt tggtctcctg tgcttcttat 4500 cttatcggtttccatagcaa ctggttacac attaactgct tgggtgcgct tcacgataag 4560 aacactgacgtcaccgcggt acccctagtg atggagttgg ccactccctc tatgcgcgct 4620 cgctcgctcggtggggcctg cggaccaaag gtccgcagac ggcagagctc tgctctgccg 4680 gccccaccgagcgagcgagc gcgcatagag ggagtggcca a 4721 2 737 PRT capsid protein ofadeno-associated virus serotpye 7 2 Met Ala Ala Asp Gly Tyr Leu Pro AspTrp Leu Glu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile Arg Glu Trp Trp AspLeu Lys Pro Gly Ala Pro Lys Pro 20 25 30 Lys Ala Asn Gln Gln Lys Gln AspAsn Gly Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro PheAsn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn Ala Ala Asp Ala Ala AlaLeu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 Gln Gln Leu Lys Ala Gly AspAsn Pro Tyr Leu Arg Tyr Asn His Ala 85 90 95 Asp Ala Glu Phe Gln Glu ArgLeu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110 Asn Leu Gly Arg Ala ValPhe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125 Leu Gly Leu Val GluGlu Gly Ala Lys Thr Ala Pro Ala Lys Lys Arg 130 135 140 Pro Val Glu ProSer Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile 145 150 155 160 Gly LysLys Gly Gln Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln 165 170 175 ThrGly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro 180 185 190Pro Ala Ala Pro Ser Ser Val Gly Ser Gly Thr Val Ala Ala Gly Gly 195 200205 Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn 210215 220 Ala Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val225 230 235 240 Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr AsnAsn His 245 250 255 Leu Tyr Lys Gln Ile Ser Ser Glu Thr Ala Gly Ser ThrAsn Asp Asn 260 265 270 Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr PheAsp Phe Asn Arg 275 280 285 Phe His Cys His Phe Ser Pro Arg Asp Trp GlnArg Leu Ile Asn Asn 290 295 300 Asn Trp Gly Phe Arg Pro Lys Lys Leu ArgPhe Lys Leu Phe Asn Ile 305 310 315 320 Gln Val Lys Glu Val Thr Thr AsnAsp Gly Val Thr Thr Ile Ala Asn 325 330 335 Asn Leu Thr Ser Thr Ile GlnVal Phe Ser Asp Ser Glu Tyr Gln Leu 340 345 350 Pro Tyr Val Leu Gly SerAla His Gln Gly Cys Leu Pro Pro Phe Pro 355 360 365 Ala Asp Val Phe MetIle Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn 370 375 380 Gly Ser Gln SerVal Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe 385 390 395 400 Pro SerGln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr Ser 405 410 415 PheGlu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu 420 425 430Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala 435 440445 Arg Thr Gln Ser Asn Pro Gly Gly Thr Ala Gly Asn Arg Glu Leu Gln 450455 460 Phe Tyr Gln Gly Gly Pro Ser Thr Met Ala Glu Gln Ala Lys Asn Trp465 470 475 480 Leu Pro Gly Pro Cys Phe Arg Gln Gln Arg Val Ser Lys ThrLeu Asp 485 490 495 Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala ThrLys Tyr His 500 505 510 Leu Asn Gly Arg Asn Ser Leu Val Asn Pro Gly ValAla Met Ala Thr 515 520 525 His Lys Asp Asp Glu Asp Arg Phe Phe Pro SerSer Gly Val Leu Ile 530 535 540 Phe Gly Lys Thr Gly Ala Thr Asn Lys ThrThr Leu Glu Asn Val Leu 545 550 555 560 Met Thr Asn Glu Glu Glu Ile ArgPro Thr Asn Pro Val Ala Thr Glu 565 570 575 Glu Tyr Gly Ile Val Ser SerAsn Leu Gln Ala Ala Asn Thr Ala Ala 580 585 590 Gln Thr Gln Val Val AsnAsn Gln Gly Ala Leu Pro Gly Met Val Trp 595 600 605 Gln Asn Arg Asp ValTyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro 610 615 620 His Thr Asp GlyAsn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly 625 630 635 640 Leu LysHis Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro 645 650 655 AlaAsn Pro Pro Glu Val Phe Thr Pro Ala Lys Phe Ala Ser Phe Ile 660 665 670Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu 675 680685 Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser 690695 700 Asn Phe Glu Lys Gln Thr Gly Val Asp Phe Ala Val Asp Ser Gln Gly705 710 715 720 Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu ThrArg Asn 725 730 735 Leu 3 623 PRT rep protein of adeno-associated virusserotype 7 3 Met Pro Gly Phe Tyr Glu Ile Val Ile Lys Val Pro Ser Asp LeuAsp 1 5 10 15 Glu His Leu Pro Gly Ile Ser Asp Ser Phe Val Asn Trp ValAla Glu 20 25 30 Lys Glu Trp Glu Leu Pro Pro Asp Ser Asp Met Asp Leu AsnLeu Ile 35 40 45 Glu Gln Ala Pro Leu Thr Val Ala Glu Lys Leu Gln Arg AspPhe Leu 50 55 60 Val Gln Trp Arg Arg Val Ser Lys Ala Pro Glu Ala Leu PhePhe Val 65 70 75 80 Gln Phe Glu Lys Gly Glu Ser Tyr Phe His Leu His ValLeu Val Glu 85 90 95 Thr Thr Gly Val Lys Ser Met Val Leu Gly Arg Phe LeuSer Gln Ile 100 105 110 Arg Glu Lys Leu Val Gln Thr Ile Tyr Arg Gly ValGlu Pro Thr Leu 115 120 125 Pro Asn Trp Phe Ala Val Thr Lys Thr Arg AsnGly Ala Gly Gly Gly 130 135 140 Asn Lys Val Val Asp Glu Cys Tyr Ile ProAsn Tyr Leu Leu Pro Lys 145 150 155 160 Thr Gln Pro Glu Leu Gln Trp AlaTrp Thr Asn Met Glu Glu Tyr Ile 165 170 175 Ser Ala Cys Leu Asn Leu AlaGlu Arg Lys Arg Leu Val Ala Gln His 180 185 190 Leu Thr His Val Ser GlnThr Gln Glu Gln Asn Lys Glu Asn Leu Asn 195 200 205 Pro Asn Ser Asp AlaPro Val Ile Arg Ser Lys Thr Ser Ala Arg Tyr 210 215 220 Met Glu Leu ValGly Trp Leu Val Asp Arg Gly Ile Thr Ser Glu Lys 225 230 235 240 Gln TrpIle Gln Glu Asp Gln Ala Ser Tyr Ile Ser Phe Asn Ala Ala 245 250 255 SerAsn Ser Arg Ser Gln Ile Lys Ala Ala Leu Asp Asn Ala Gly Lys 260 265 270Ile Met Ala Leu Thr Lys Ser Ala Pro Asp Tyr Leu Val Gly Pro Ser 275 280285 Leu Pro Ala Asp Ile Lys Thr Asn Arg Ile Tyr Arg Ile Leu Glu Leu 290295 300 Asn Gly Tyr Asp Pro Ala Tyr Ala Gly Ser Val Phe Leu Gly Trp Ala305 310 315 320 Gln Lys Lys Phe Gly Lys Arg Asn Thr Ile Trp Leu Phe GlyPro Ala 325 330 335 Thr Thr Gly Lys Thr Asn Ile Ala Glu Ala Ile Ala HisAla Val Pro 340 345 350 Phe Tyr Gly Cys Val Asn Trp Thr Asn Glu Asn PhePro Phe Asn Asp 355 360 365 Cys Val Asp Lys Met Val Ile Trp Trp Glu GluGly Lys Met Thr Ala 370 375 380 Lys Val Val Glu Ser Ala Lys Ala Ile LeuGly Gly Ser Lys Val Arg 385 390 395 400 Val Asp Gln Lys Cys Lys Ser SerAla Gln Ile Asp Pro Thr Pro Val 405 410 415 Ile Val Thr Ser Asn Thr AsnMet Cys Ala Val Ile Asp Gly Asn Ser 420 425 430 Thr Thr Phe Glu His GlnGln Pro Leu Gln Asp Arg Met Phe Lys Phe 435 440 445 Glu Leu Thr Arg ArgLeu Glu His Asp Phe Gly Lys Val Thr Lys Gln 450 455 460 Glu Val Lys GluPhe Phe Arg Trp Ala Ser Asp His Val Thr Glu Val 465 470 475 480 Ala HisGlu Phe Tyr Val Arg Lys Gly Gly Ala Ser Lys Arg Pro Ala 485 490 495 ProAsp Asp Ala Asp Ile Ser Glu Pro Lys Arg Ala Cys Pro Ser Val 500 505 510Ala Asp Pro Ser Thr Ser Asp Ala Glu Gly Ala Pro Val Asp Phe Ala 515 520525 Asp Arg Tyr Gln Asn Lys Cys Ser Arg His Ala Gly Met Ile Gln Met 530535 540 Leu Phe Pro Cys Lys Thr Cys Glu Arg Met Asn Gln Asn Phe Asn Ile545 550 555 560 Cys Phe Thr His Gly Val Arg Asp Cys Leu Glu Cys Phe ProGly Val 565 570 575 Ser Glu Ser Gln Pro Val Val Arg Lys Lys Thr Tyr ArgLys Leu Cys 580 585 590 Ala Ile His His Leu Leu Gly Arg Ala Pro Glu IleAla Cys Ser Ala 595 600 605 Cys Asp Leu Val Asn Val Asp Leu Asp Asp CysVal Ser Glu Gln 610 615 620 4 4393 DNA adeno-associated virus serotype 84 cagagaggga gtggccaact ccatcactag gggtagcgcg aagcgcctcc cacgctgccg 60cgtcagcgct gacgtaaatt acgtcatagg ggagtggtcc tgtattagct gtcacgtgag 120tgcttttgcg gcattttgcg acaccacgtg gccatttgag gtatatatgg ccgagtgagc 180gagcaggatc tccattttga ccgcgaaatt tgaacgagca gcagccatgc cgggcttcta 240cgagatcgtg atcaaggtgc cgagcgacct ggacgagcac ctgccgggca tttctgactc 300gtttgtgaac tgggtggccg agaaggaatg ggagctgccc ccggattctg acatggatcg 360gaatctgatc gagcaggcac ccctgaccgt ggccgagaag ctgcagcgcg acttcctggt 420ccaatggcgc cgcgtgagta aggccccgga ggccctcttc tttgttcagt tcgagaaggg 480cgagagctac tttcacctgc acgttctggt cgagaccacg ggggtcaagt ccatggtgct 540aggccgcttc ctgagtcaga ttcgggaaaa gcttggtcca gaccatctac ccgcggggtc 600gagccccacc ttgcccaact ggttcgcggt gaccaaagac gcggtaatgg cgccggcggg 660ggggaacaag gtggtggacg agtgctacat ccccaactac ctcctgccca agactcagcc 720cgagctgcag tgggcgtgga ctaacatgga ggagtatata agcgcgtgct tgaacctggc 780cgagcgcaaa cggctcgtgg cgcagcacct gacccacgtc agccagacgc aggagcagaa 840caaggagaat ctgaacccca attctgacgc gcccgtgatc aggtcaaaaa cctccgcgcg 900ctatatggag ctggtcgggt ggctggtgga ccggggcatc acctccgaga agcagtggat 960ccaggaggac caggcctcgt acatctcctt caacgccgcc tccaactcgc ggtcccagat 1020caaggccgcg ctggacaatg ccggcaagat catggcgctg accaaatccg cgcccgacta 1080cctggtgggg ccctcgctgc ccgcggacat tacccagaac cgcatctacc gcatcctcgc 1140tctcaacggc tacgaccctg cctacgccgg ctccgtcttt ctcggctggg ctcagaaaaa 1200gttcgggaaa cgcaacacca tctggctgtt tggacccgcc accaccggca agaccaacat 1260tgcggaagcc atcgcccacg ccgtgccctt ctacggctgc gtcaactgga ccaatgagaa 1320ctttcccttc aatgattgcg tcgacaagat ggtgatctgg tgggaggagg gcaagatgac 1380ggccaaggtc gtggagtccg ccaaggccat tctcggcggc agcaaggtgc gcgtggacca 1440aaagtgcaag tcgtccgccc agatcgaccc cacccccgtg atcgtcacct ccaacaccaa 1500catgtgcgcc gtgattgacg ggaacagcac caccttcgag caccagcagc ctctccagga 1560ccggatgttt aagttcgaac tcacccgccg tctggagcac gactttggca aggtgacaaa 1620gcaggaagtc aaagagttct tccgctgggc cagtgatcac gtgaccgagg tggcgcatga 1680gttttacgtc agaaagggcg gagccagcaa aagacccgcc cccgatgacg cggataaaag 1740cgagcccaag cgggcctgcc cctcagtcgc ggatccatcg acgtcagacg cggaaggagc 1800tccggtggac tttgccgaca ggtaccaaaa caaatgttct cgtcacgcgg gcatgcttca 1860gatgctgttt ccctgcaaaa cgtgcgagag aatgaatcag aatttcaaca tttgcttcac 1920acacggggtc agagactgct cagagtgttt ccccggcgtg tcagaatctc aaccggtcgt 1980cagaaagagg acgtatcgga aactctgtgc gattcatcat ctgctggggc gggctcccga 2040gattgcttgc tcggcctgcg atctggtcaa cgtggacctg gatgactgtg tttctgagca 2100ataaatgact taaaccaggt atggctgccg atggttatct tccagattgg ctcgaggaca 2160acctctctga gggcattcgc gagtggtggg cgctgaaacc tggagccccg aagcccaaag 2220ccaaccagca aaagcaggac gacggccggg gtctggtgct tcctggctac aagtacctcg 2280gacccttcaa cggactcgac aagggggagc ccgtcaacgc ggcggacgca gcggccctcg 2340agcacgacaa ggcctacgac cagcagctgc aggcgggtga caatccgtac ctgcggtata 2400accacgccga cgccgagttt caggagcgtc tgcaagaaga tacgtctttt gggggcaacc 2460tcgggcgagc agtcttccag gccaagaagc gggttctcga acctctcggt ctggttgagg 2520aaggcgctaa gacggctcct ggaaagaaga gaccggtaga gccatcaccc cagcgttctc 2580cagactcctc tacgggcatc ggcaagaaag gccaacagcc cgccagaaaa agactcaatt 2640ttggtcagac tggcgactca gagtcagttc cagaccctca acctctcgga gaacctccag 2700cagcgccctc tggtgtggga cctaatacaa tggctgcagg cggtggcgca ccaatggcag 2760acaataacga aggcgccgac ggagtgggta gttcctcggg aaattggcat tgcgattcca 2820catggctggg cgacagagtc atcaccacca gcacccgaac ctgggccctg cccacctaca 2880acaaccacct ctacaagcaa atctccaacg ggacatcggg aggagccacc aacgacaaca 2940cctacttcgg ctacagcacc ccctgggggt attttgactt taacagattc cactgccact 3000tttcaccacg tgactggcag cgactcatca acaacaactg gggattccgg cccaagagac 3060tcagcttcaa gctcttcaac atccaggtca aggaggtcac gcagaatgaa ggcaccaaga 3120ccatcgccaa taacctcacc agcaccatcc aggtgtttac ggactcggag taccagctgc 3180cgtacgttct cggctctgcc caccagggct gcctgcctcc gttcccggcg gacgtgttca 3240tgattcccca gtacggctac ctaacactca acaacggtag tcaggccgtg ggacgctcct 3300ccttctactg cctggaatac tttccttcgc agatgctgag aaccggcaac aacttccagt 3360ttacttacac cttcgaggac gtgcctttcc acagcagcta cgcccacagc cagagcttgg 3420accggctgat gaatcctctg attgaccagt acctgtacta cttgtctcgg actcaaacaa 3480caggaggcac ggcaaatacg cagactctgg gcttcagcca aggtgggcct aatacaatgg 3540ccaatcaggc aaagaactgg ctgccaggac cctgttaccg ccaacaacgc gtctcaacga 3600caaccgggca aaacaacaat agcaactttg cctggactgc tgggaccaaa taccatctga 3660atggaagaaa ttcattggct aatcctggca tcgctatggc aacacacaaa gacgacgagg 3720agcgtttttt tcccagtaac gggatcctga tttttggcaa acaaaatgct gccagagaca 3780atgcggatta cagcgatgtc atgctcacca gcgaggaaga aatcaaaacc actaaccctg 3840tggctacaga ggaatacggt atcgtggcag ataacttgca gcagcaaaac acggctcctc 3900aaattggaac tgtcaacagc cagggggcct tacccggtat ggtctggcag aaccgggacg 3960tgtacctgca gggtcccatc tgggccaaga ttcctcacac ggacggcaac ttccacccgt 4020ctccgctgat gggcggcttt ggcctgaaac atcctccgcc tcagatcctg atcaagaaca 4080cgcctgtacc tgcggatcct ccgaccacct tcaaccagtc aaagctgaac tctttcatca 4140cgcaatacag caccggacag gtcagcgtgg aaattgaatg ggagctgcag aaggaaaaca 4200gcaagcgctg gaaccccgag atccagtaca cctccaacta ctacaaatct acaagtgtgg 4260actttgctgt taatacagaa ggcgtgtact ctgaaccccg ccccattggc acccgttacc 4320tcacccgtaa tctgtaattg cctgttaatc aataaaccgg ttgattcgtt tcagttgaac 4380tttggtctct gcg 4393 5 4385 DNA adeno-associated virus serotype 9 5cagagaggga gtggccaact ccatcactag gggtaatcgc gaagcgcctc ccacgctgcc 60gcgtcagcgc tgacgtagat tacgtcatag gggagtggtc ctgtattagc tgtcacgtga 120gtgcttttgc gacattttgc gacaccacat ggccatttga ggtatatatg gccgagtgag 180cgagcaggat ctccattttg accgcgaaat ttgaacgagc agcagccatg ccgggcttct 240acgagattgt gatcaaggtg ccgagcgacc tggacgagca cctgccgggc atttctgact 300cttttgtgaa ctgggtggcc gagaaggaat gggagctgcc cccggattct gacatggatc 360ggaatctgat cgagcaggca cccctgaccg tggccgagaa gctgcagcgc gacttcctgg 420tccaatggcg ccgcgtgagt aaggccccgg aggccctctt ctttgttcag ttcgagaagg 480gcgagagcta ctttcacctg cacgttctgg tcgagaccac gggggtcaag tccatggtgc 540taggccgctt cctgagtcag attcgggaga agctggtcca gaccatctac cgcgggatcg 600agccgaccct gcccaactgg ttcgcggtga ccaagacgcg taatggcgcc ggcgggggga 660acaaggtggt ggacgagtgc tacatcccca actacctcct gcccaagact cagcccgagc 720tgcagtgggc gtggactaac atggaggagt atataagcgc gtgcttgaac ctggccgagc 780gcaaacggct cgtggcgcag cacctgaccc acgtcagcca gacgcaggag cagaacaagg 840agaatctgaa ccccaattct gacgcgcccg tgatcaggtc aaaaacctcc gcgcgctaca 900tggagctggt cgggtggctg gtggaccggg gcatcacctc cgagaagcag tggatccagg 960aggaccaggc ctcgtacatc tccttcaacg ccgcctccaa ctcgcggtcc cagatcaagg 1020ccgcgctgga caatgccggc aagatcatgg cgctgaccaa atccgcgccc gactacctgg 1080taggcccttc acttccggtg gacattacgc agaaccgcat ctaccgcatc ctgcagctca 1140acggctacga ccctgcctac gccggctccg tctttctcgg ctgggcacaa aagaagttcg 1200ggaaacgcaa caccatctgg ctgtttgggc cggccaccac gggaaagacc aacatcgcag 1260aagccattgc ccacgccgtg cccttctacg gctgcgtcaa ctggaccaat gagaactttc 1320ccttcaacga ttgcgtcgac aagatggtga tctggtggga ggagggcaag atgacggcca 1380aggtcgtgga gtccgccaag gccattctcg gcggcagcaa ggtgcgcgtg gaccaaaagt 1440gcaagtcgtc cgcccagatc gaccccactc ccgtgatcgt cacctccaac accaacatgt 1500gcgccgtgat tgacgggaac agcaccacct tcgagcacca gcagcctctc caggaccgga 1560tgtttaagtt cgaactcacc cgccgtctgg agcacgactt tggcaaggtg acaaagcagg 1620aagtcaaaga gttcttccgc tgggccagtg atcacgtgac cgaggtggcg catgagtttt 1680acgtcagaaa gggcggagcc agcaaaagac ccgcccccga tgacgcggat aaaagcgagc 1740ccaagcgggc ctgcccctca gtcgcggatc catcgacgtc agacgcggaa ggagctccgg 1800tggactttgc cgacaggtac caaaacaaat gttctcgtca cgcgggcatg cttcagatgc 1860tgcttccctg caaaacgtgc gagagaatga atcagaattt caacatttgc ttcacacacg 1920gggtcagaga ctgctcagag tgtttccccg gcgtgtcaga atctcaaccg gtcgtcagaa 1980agaggacgta tcggaaactc tgtgcgattc atcatctgct ggggcgggct cccgagattg 2040cttgctcggc ctgcgatctg gtcaacgtgg acctggatga ctgtgtttct gagcaataaa 2100tgacttaaac caggtatggc tgccgatggt tatcttccag attggctcga ggacaacctc 2160tctgagggca ttcgcgagtg gtgggcgctg aaacctggag ccccgaagcc caaagccaac 2220cagcaaaagc aggacgacgg ccggggtctg gtgcttcctg gctacaagta cctcggaccc 2280ttcaacggac tcgacaaggg ggagcccgtc aacgcggcgg acgcagcggc cctcgagcac 2340ggcaaggcct acgaccagca gctgcaggcg ggtgacaatc cgtacctgcg gtataaccac 2400gccgacgccg agtttcagga gcgtctgcaa gaagatacgt cttttggggg caacctcggg 2460cgagcagtct tccaggccaa gaagcgggtt ctcgaacctc tcggtctggt tgaggaaggc 2520gctaagacgg ctcctggaaa gaagagaccg gtagagccat caccccagcg ttctccagac 2580tcctctacgg gcatcggcaa gaaaggccaa cagcccgcca gaaaaagact caattttggt 2640cagactggcg actcagagtc agttccagac cctcaacctc tcggagaacc tccagcagcg 2700ccctctggtg tgggacctaa tacaatggct gcaggcggtg gcgcaccaat ggcagacaat 2760aacgaaggcg ccgacggagt gggtaattcc tcgggaaatt ggcattgcga ttccacatgg 2820ctgggggaca gagtcatcac caccagcacc cgaacctggg cattgcccac ctacaacaac 2880cacctctaca agcaaatctc caatggaaca tcgggaggaa gcaccaacga caacacctac 2940tttggctaca gcaccccctg ggggtatttt gacttcaaca gattccactg ccacttctca 3000ccacgtgact ggcagcgact catcaacaac aactggggat tccggccaaa gagactcaac 3060ttcaagctgt tcaacatcca ggtcaaggag gttacgacga acgaaggcac caagaccatc 3120gccaataacc ttaccagcac cgtccaggtc tttacggact cggagtacca gctaccgtac 3180gtcctaggct ctgcccacca aggatgcctg ccaccgtttc ctgcagacgt cttcatggtt 3240cctcagtacg gctacctgac gctcaacaat ggaagtcaag cgttaggacg ttcttctttc 3300tactgtctgg aatacttccc ttctcagatg ctgagaaccg gcaacaactt tcagttcagc 3360tacactttcg aggacgtgcc tttccacagc agctacgcac acagccagag tctagatcga 3420ctgatgaacc ccctcatcga ccagtaccta tactacctgg tcagaacaca gacaactgga 3480actgggggaa ctcaaacttt ggcattcagc caagcaggcc ctagctcaat ggccaatcag 3540gctagaaact gggtacccgg gccttgctac cgtcagcagc gcgtctccac aaccaccaac 3600caaaataaca acagcaactt tgcgtggacg ggagctgcta aattcaagct gaacgggaga 3660gactcgctaa tgaatcctgg cgtggctatg gcatcgcaca aagacgacga ggaccgcttc 3720tttccatcaa gtggcgttct catatttggc aagcaaggag ccgggaacga tggagtcgac 3780tacagccagg tgctgattac agatgaggaa gaaattaaag ccaccaaccc tgtagccaca 3840gaggaatacg gagcagtggc catcaacaac caggccgcta acacgcaggc gcaaactgga 3900cttgtgcata accagggagt tattcctggt atggtctggc agaaccggga cgtgtacctg 3960cagggcccta tttgggctaa aatacctcac acagatggca actttcaccc gtctcctctg 4020atgggtggat ttggactgaa acacccacct ccacagattc taattaaaaa tacaccagtg 4080ccggcagatc ctcctcttac cttcaatcaa gccaagctga actctttcat cacgcagtac 4140agcacgggac aagtcagcgt ggaaatcgag tgggagctgc agaaagaaaa cagcaagcgc 4200tggaatccag agatccagta tacttcaaac tactacaaat ctacaaatgt ggactttgct 4260gtcaatacca aaggtgttta ctctgagcct cgccccattg gtactcgtta cctcacccgt 4320aatttgtaat tgcctgttaa tcaataaacc ggttaattcg tttcagttga actttggtct 4380ctgcg 4385 6 4718 DNA adeno-associated virus serotype 1 6 ttgcccactccctctctgcg cgctcgctcg ctcggtgggg cctgcggacc aaaggtccgc 60 agacggcagagctctgctct gccggcccca ccgagcgagc gagcgcgcag agagggagtg 120 ggcaactccatcactagggg taatcgcgaa gcgcctccca cgctgccgcg tcagcgctga 180 cgtaaattacgtcatagggg agtggtcctg tattagctgt cacgtgagtg cttttgcgac 240 attttgcgacaccacgtggc catttagggt atatatggcc gagtgagcga gcaggatctc 300 cattttgaccgcgaaatttg aacgagcagc agccatgccg ggcttctacg agatcgtgat 360 caaggtgccgagcgacctgg acgagcacct gccgggcatt tctgactcgt ttgtgagctg 420 ggtggccgagaaggaatggg agctgccccc ggattctgac atggatctga atctgattga 480 gcaggcacccctgaccgtgg ccgagaagct gcagcgcgac ttcctggtcc aatggcgccg 540 cgtgagtaaggccccggagg ccctcttctt tgttcagttc gagaagggcg agtcctactt 600 ccacctccatattctggtgg agaccacggg ggtcaaatcc atggtgctgg gccgcttcct 660 gagtcagattagggacaagc tggtgcagac catctaccgc gggatcgagc cgaccctgcc 720 caactggttcgcggtgacca agacgcgtaa tggcgccgga ggggggaaca aggtggtgga 780 cgagtgctacatccccaact acctcctgcc caagactcag cccgagctgc agtgggcgtg 840 gactaacatggaggagtata taagcgcctg tttgaacctg gccgagcgca aacggctcgt 900 ggcgcagcacctgacccacg tcagccagac ccaggagcag aacaaggaga atctgaaccc 960 caattctgacgcgcctgtca tccggtcaaa aacctccgcg cgctacatgg agctggtcgg 1020 gtggctggtggaccggggca tcacctccga gaagcagtgg atccaggagg accaggcctc 1080 gtacatctccttcaacgccg cttccaactc gcggtcccag atcaaggccg ctctggacaa 1140 tgccggcaagatcatggcgc tgaccaaatc cgcgcccgac tacctggtag gccccgctcc 1200 gcccgcggacattaaaacca accgcatcta ccgcatcctg gagctgaacg gctacgaacc 1260 tgcctacgccggctccgtct ttctcggctg ggcccagaaa aggttcggga agcgcaacac 1320 catctggctgtttgggccgg ccaccacggg caagaccaac atcgcggaag ccatcgccca 1380 cgccgtgcccttctacggct gcgtcaactg gaccaatgag aactttccct tcaatgattg 1440 cgtcgacaagatggtgatct ggtgggagga gggcaagatg acggccaagg tcgtggagtc 1500 cgccaaggccattctcggcg gcagcaaggt gcgcgtggac caaaagtgca agtcgtccgc 1560 ccagatcgaccccacccccg tgatcgtcac ctccaacacc aacatgtgcg ccgtgattga 1620 cgggaacagcaccaccttcg agcaccagca gccgttgcag gaccggatgt tcaaatttga 1680 actcacccgccgtctggagc atgactttgg caaggtgaca aagcaggaag tcaaagagtt 1740 cttccgctgggcgcaggatc acgtgaccga ggtggcgcat gagttctacg tcagaaaggg 1800 tggagccaacaaaagacccg cccccgatga cgcggataaa agcgagccca agcgggcctg 1860 cccctcagtcgcggatccat cgacgtcaga cgcggaagga gctccggtgg actttgccga 1920 caggtaccaaaacaaatgtt ctcgtcacgc gggcatgctt cagatgctgt ttccctgcaa 1980 gacatgcgagagaatgaatc agaatttcaa catttgcttc acgcacggga cgagagactg 2040 ttcagagtgcttccccggcg tgtcagaatc tcaaccggtc gtcagaaaga ggacgtatcg 2100 gaaactctgtgccattcatc atctgctggg gcgggctccc gagattgctt gctcggcctg 2160 cgatctggtcaacgtggacc tggatgactg tgtttctgag caataaatga cttaaaccag 2220 gtatggctgccgatggttat cttccagatt ggctcgagga caacctctct gagggcattc 2280 gcgagtggtgggacttgaaa cctggagccc cgaagcccaa agccaaccag caaaagcagg 2340 acgacggccggggtctggtg cttcctggct acaagtacct cggacccttc aacggactcg 2400 acaagggggagcccgtcaac gcggcggacg cagcggccct cgagcacgac aaggcctacg 2460 accagcagctcaaagcgggt gacaatccgt acctgcggta taaccacgcc gacgccgagt 2520 ttcaggagcgtctgcaagaa gatacgtctt ttgggggcaa cctcgggcga gcagtcttcc 2580 aggccaagaagcgggttctc gaacctctcg gtctggttga ggaaggcgct aagacggctc 2640 ctggaaagaaacgtccggta gagcagtcgc cacaagagcc agactcctcc tcgggcatcg 2700 gcaagacaggccagcagccc gctaaaaaga gactcaattt tggtcagact ggcgactcag 2760 agtcagtccccgatccacaa cctctcggag aacctccagc aacccccgct gctgtgggac 2820 ctactacaatggcttcaggc ggtggcgcac caatggcaga caataacgaa ggcgccgacg 2880 gagtgggtaatgcctcagga aattggcatt gcgattccac atggctgggc gacagagtca 2940 tcaccaccagcacccgcacc tgggccttgc ccacctacaa taaccacctc tacaagcaaa 3000 tctccagtgcttcaacgggg gccagcaacg acaaccacta cttcggctac agcaccccct 3060 gggggtattttgatttcaac agattccact gccacttttc accacgtgac tggcagcgac 3120 tcatcaacaacaattgggga ttccggccca agagactcaa cttcaaactc ttcaacatcc 3180 aagtcaaggaggtcacgacg aatgatggcg tcacaaccat cgctaataac cttaccagca 3240 cggttcaagtcttctcggac tcggagtacc agcttccgta cgtcctcggc tctgcgcacc 3300 agggctgcctccctccgttc ccggcggacg tgttcatgat tccgcaatac ggctacctga 3360 cgctcaacaatggcagccaa gccgtgggac gttcatcctt ttactgcctg gaatatttcc 3420 cttctcagatgctgagaacg ggcaacaact ttaccttcag ctacaccttt gaggaagtgc 3480 ctttccacagcagctacgcg cacagccaga gcctggaccg gctgatgaat cctctcatcg 3540 accaatacctgtattacctg aacagaactc aaaatcagtc cggaagtgcc caaaacaagg 3600 acttgctgtttagccgtggg tctccagctg gcatgtctgt tcagcccaaa aactggctac 3660 ctggaccctgttatcggcag cagcgcgttt ctaaaacaaa aacagacaac aacaacagca 3720 attttacctggactggtgct tcaaaatata acctcaatgg gcgtgaatcc atcatcaacc 3780 ctggcactgctatggcctca cacaaagacg acgaagacaa gttctttccc atgagcggtg 3840 tcatgatttttggaaaagag agcgccggag cttcaaacac tgcattggac aatgtcatga 3900 ttacagacgaagaggaaatt aaagccacta accctgtggc caccgaaaga tttgggaccg 3960 tggcagtcaatttccagagc agcagcacag accctgcgac cggagatgtg catgctatgg 4020 gagcattacctggcatggtg tggcaagata gagacgtgta cctgcagggt cccatttggg 4080 ccaaaattcctcacacagat ggacactttc acccgtctcc tcttatgggc ggctttggac 4140 tcaagaacccgcctcctcag atcctcatca aaaacacgcc tgttcctgcg aatcctccgg 4200 cggagttttcagctacaaag tttgcttcat tcatcaccca atactccaca ggacaagtga 4260 gtgtggaaattgaatgggag ctgcagaaag aaaacagcaa gcgctggaat cccgaagtgc 4320 agtacacatccaattatgca aaatctgcca acgttgattt tactgtggac aacaatggac 4380 tttatactgagcctcgcccc attggcaccc gttaccttac ccgtcccctg taattacgtg 4440 ttaatcaataaaccggttga ttcgtttcag ttgaactttg gtctcctgtc cttcttatct 4500 tatcggttaccatggttata gcttacacat taactgcttg gttgcgcttc gcgataaaag 4560 acttacgtcatcgggttacc cctagtgatg gagttgccca ctccctctct gcgcgctcgc 4620 tcgctcggtggggcctgcgg accaaaggtc cgcagacggc agagctctgc tctgccggcc 4680 ccaccgagcgagcgagcgcg cagagaggga gtgggcaa 4718 7 4675 DNA adeno-associated virusserotype 2 7 ttggccactc cctctctgcg cgctcgctcg ctcactgagg ccgggcgaccaaaggtcgcc 60 cgacgcccgg gctttgcccg ggcggcctca gtgagcgagc gagcgcgcagagagggagtg 120 gccaactcca tcactagggg ttcctggagg ggtggagtcg tgacgtgaattacgtcatag 180 ggttagggag gtcctgtatt agaggtcacg tgagtgtttt gcgacattttgcgacaccat 240 gtggtcacgc tgggtattta agcccgagtg agcacgcagg gtctccattttgaagcggga 300 ggtttgaacg cgcagccgcc atgccggggt tttacgagat tgtgattaaggtccccagcg 360 accttgacgg gcatctgccc ggcatttctg acagctttgt gaactgggtggccgagaagg 420 aatgggagtt gccgccagat tctgacatgg atctgaatct gattgagcaggcacccctga 480 ccgtggccga gaagctgcag cgcgactttc tgacggaatg gcgccgtgtgagtaaggccc 540 cggaggccct tttctttgtg caatttgaga agggagagag ctacttccacatgcacgtgc 600 tcgtggaaac caccggggtg aaatccatgg ttttgggacg tttcctgagtcagattcgcg 660 aaaaactgat tcagagaatt taccgcggga tcgagccgac tttgccaaactggttcgcgg 720 tcacaaagac cagaaatggc gccggaggcg ggaacaaggt ggtggatgagtgctacatcc 780 ccaattactt gctccccaaa acccagcctg agctccagtg ggcgtggactaatatggaac 840 agtatttaag cgcctgtttg aatctcacgg agcgtaaacg gttggtggcgcagcatctga 900 cgcacgtgtc gcagacgcag gagcagaaca aagagaatca gaatcccaattctgatgcgc 960 cggtgatcag atcaaaaact tcagccaggt acatggagct ggtcgggtggctcgtggaca 1020 aggggattac ctcggagaag cagtggatcc aggaggacca ggcctcatacatctccttca 1080 atgcggcctc caactcgcgg tcccaaatca aggctgcctt ggacaatgcgggaaagatta 1140 tgagcctgac taaaaccgcc cccgactacc tggtgggcca gcagcccgtggaggacattt 1200 ccagcaatcg gatttataaa attttggaac taaacgggta cgatccccaatatgcggctt 1260 ccgtctttct gggatgggcc acgaaaaagt tcggcaagag gaacaccatctggctgtttg 1320 ggcctgcaac taccgggaag accaacatcg cggaggccat agcccacactgtgcccttct 1380 acgggtgcgt aaactggacc aatgagaact ttcccttcaa cgactgtgtcgacaagatgg 1440 tgatctggtg ggaggagggg aagatgaccg ccaaggtcgt ggagtcggccaaagccattc 1500 tcggaggaag caaggtgcgc gtggaccaga aatgcaagtc ctcggcccagatagacccga 1560 ctcccgtgat cgtcacctcc aacaccaaca tgtgcgccgt gattgacgggaactcaacga 1620 ccttcgaaca ccagcagccg ttgcaagacc ggatgttcaa atttgaactcacccgccgtc 1680 tggatcatga ctttgggaag gtcaccaagc aggaagtcaa agactttttccggtgggcaa 1740 aggatcacgt ggttgaggtg gagcatgaat tctacgtcaa aaagggtggagccaagaaaa 1800 gacccgcccc cagtgacgca gatataagtg agcccaaacg ggtgcgcgagtcagttgcgc 1860 agccatcgac gtcagacgcg gaagcttcga tcaactacgc agacaggtaccaaaacaaat 1920 gttctcgtca cgtgggcatg aatctgatgc tgtttccctg cagacaatgcgagagaatga 1980 atcagaattc aaatatctgc ttcactcacg gacagaaaga ctgtttagagtgctttcccg 2040 tgtcagaatc tcaacccgtt tctgtcgtca aaaaggcgta tcagaaactgtgctacattc 2100 atcatatcat gggaaaggtg ccagacgctt gcactgcctg cgatctggtcaatgtggatt 2160 tggatgactg catctttgaa caataaatga tttaaatcag gtatggctgccgatggttat 2220 cttccagatt ggctcgagga cactctctct gaaggaataa gacagtggtggaagctcaaa 2280 cctggcccac caccaccaaa gcccgcagag cggcataagg acgacagcaggggtcttgtg 2340 cttcctgggt acaagtacct cggacccttc aacggactcg acaagggagagccggtcaac 2400 gaggcagacg ccgcggccct cgagcacgta caaagcctac gaccggcagctcgacagcgg 2460 agacaacccg tacctcaagt acaaccacgc cgacgcggag tttcaggagcgccttaaaga 2520 agatacgtct tttgggggca acctcggacg agcagtcttc caggcgaaaaagagggttct 2580 tgaacctctg ggcctggttg aggaacctgt taagacggct ccgggaaaaaagaggccggt 2640 agagcactct cctgtggagc cagactcctc ctcgggaacc ggaaaggcgggccagcagcc 2700 tgcaagaaaa agattgaatt ttggtcagac tggagacgca gactcagtacctgaccccca 2760 gcctctcgga cagccaccag cagccccctc tggtctggga actaatacgatggctacagg 2820 cagtggcgca ccaatggcag acaataacga gggcgccgac ggagtgggtaattcctccgg 2880 aaattggcat tgcgattcca catggatggg cgacagagtc atcaccaccagcacccgaac 2940 ctgggccctg cccacctaca acaaccacct ctacaaacaa atttccagccaatcaggagc 3000 ctcgaacgac aatcactact ttggctacag caccccttgg gggtattttgacttcaacag 3060 attccactgc cacttttcac cacgtgactg gcaaagactc atcaacaacaactggggatt 3120 ccgacccaag agactcaact tcaagctctt taacattcaa gtcaaagaggtcacgcagaa 3180 tgacggtacg acgacgattg ccaataacct taccagcacg gttcaggtgtttactgactc 3240 ggagtaccag ctcccgtacg tcctcggctc ggcgcatcaa ggatgcctcccgccgttccc 3300 agcagacgtc ttcatggtgc cacagtatgg atacctcacc ctgaacaacgggagtcaggc 3360 agtaggacgc tcttcatttt actgcctgga gtactttcct tctcagatgctgcgtaccgg 3420 aaacaacttt accttcagct acacttttga ggacgttcct ttccacagcagctacgctca 3480 cagccagagt ctggaccgtc tcatgaatcc tctcatcgac cagtacctgtattacttgag 3540 cagaacaaac actccaagtg gaaccaccac gcagtcaagg cttcagttttctcaggccgg 3600 agcgagtgac attcgggacc agtctaggaa ctggcttcct ggaccctgttaccgccagca 3660 gcgagtatca aagacatctg cggataacaa caacagtgaa tactcgtggactggagctac 3720 caagtaccac ctcaatggca gagactctct ggtgaatccg gccatggcaagccacaagga 3780 cgatgaagaa aagttttttc ctcagagcgg ggttctcatc tttgggaagcaaggctcaga 3840 gaaaacaaat gtgaacattg aaaaggtcat gattacagac gaagaggaaatcggaacaac 3900 caatcccgtg gctacggagc agtatggttc tgtatctacc aacctccagagaggcaacag 3960 acaagcagct accgcagatg tcaacacaca aggcgttctt ccaggcatggtctggcagga 4020 cagagatgtg taccttcagg ggcccatctg ggcaaagatt ccacacacggacggacattt 4080 tcacccctct cccctcatgg gtggattcgg acttaaacac cctcctccacagattctcat 4140 caagaacacc ccggtacctg cgaatccttc gaccaccttc agtgcggcaaagtttgcttc 4200 cttcatcaca cagtactcca cgggacacgg tcagcgtgga gatcgagtgggagctgcaga 4260 aggaaaacag caaacgctgg aatcccgaaa ttcagtacac ttccaactacaacaagtctg 4320 ttaatcgtgg acttaccgtg gatactaatg gcgtgtattc agagcctcgccccattggca 4380 ccagatacct gactcgtaat ctgtaattgc ttgttaatca ataaaccgtttaattcgttt 4440 cagttgaact ttggtctctg cgtatttctt tcttatctag tttccatggctacgtagata 4500 agtagcatgg cgggttaatc attaactaca aggaacccct agtgatggagttggccactc 4560 cctctctgcg cgctcgctcg ctcactgagg ccgggcgacc aaaggtcgcccgacgcccgg 4620 gctttgcccg ggcggcctca gtgagcgagc gagcgcgcag agagggagtggccaa 4675 8 4726 DNA adeno-associated virus serotype 3 8 ttggccactccctctatgcg cactcgctcg ctcggtgggg cctggcgacc aaaggtcgcc 60 agacggacgtgctttgcacg tccggcccca ccgagcgagc gagtgcgcat agagggagtg 120 gccaactccatcactagagg tatggcagtg acgtaacgcg aagcgcgcga agcgagacca 180 cgcctaccagctgcgtcagc agtcaggtga cccttttgcg acagtttgcg acaccacgtg 240 gccgctgagggtatatattc tcgagtgagc gaaccaggag ctccattttg accgcgaaat 300 ttgaacgagcagcagccatg ccggggttct acgagattgt cctgaaggtc ccgagtgacc 360 tggacgagcgcctgccgggc atttctaact cgtttgttaa ctgggtggcc gagaaggaat 420 gggacgtgccgccggattct gacatggatc cgaatctgat tgagcaggca cccctgaccg 480 tggccgaaaagcttcagcgc gagttcctgg tggagtggcg ccgcgtgagt aaggccccgg 540 aggccctcttttttgtccag ttcgaaaagg gggagaccta cttccacctg cacgtgctga 600 ttgagaccatcggggtcaaa tccatggtgg tcggccgcta cgtgagccag attaaagaga 660 agctggtgacccgcatctac cgcggggtcg agccgcagct tccgaactgg ttcgcggtga 720 ccaaaacgcgaaatggcgcc gggggcggga acaaggtggt ggacgactgc tacatcccca 780 actacctgctccccaagacc cagcccgagc tccagtgggc gtggactaac atggaccagt 840 atttaagcgcctgtttgaat ctcgcggagc gtaaacggct ggtggcgcag catctgacgc 900 acgtgtcgcagacgcaggag cagaacaaag agaatcagaa ccccaattct gacgcgccgg 960 tcatcaggtcaaaaacctca gccaggtaca tggagctggt cgggtggctg gtggaccgcg 1020 ggatcacgtcagaaaagcaa tggattcagg aggaccaggc ctcgtacatc tccttcaacg 1080 ccgcctccaactcgcggtcc cagatcaagg ccgcgctgga caatgcctcc aagatcatga 1140 gcctgacaaagacggctccg gactacctgg tgggcagcaa cccgccggag gacattacca 1200 aaaatcggatctaccaaatc ctggagctga acgggtacga tccgcagtac gcggcctccg 1260 tcttcctgggctgggcgcaa aagaagttcg ggaagaggaa caccatctgg ctctttgggc 1320 cggccacgacgggtaaaacc aacatcgcgg aagccatcgc ccacgccgtg cccttctacg 1380 gctgcgtaaactggaccaat gagaactttc ccttcaacga ttgcgtcgac aagatggtga 1440 tctggtgggaggagggcaag atgacggcca aggtcgtgga gagcgccaag gccattctgg 1500 gcggaagcaaggtgcgcgtg gaccaaaagt gcaagtcatc ggcccagatc gaacccactc 1560 ccgtgatcgtcacctccaac accaacatgt gcgccgtgat tgacgggaac agcaccacct 1620 tcgagcatcagcagccgctg caggaccgga tgtttgaatt tgaacttacc cgccgtttgg 1680 accatgactttgggaaggtc accaaacagg aagtaaagga ctttttccgg tgggcttccg 1740 atcacgtgactgacgtggct catgagttct acgtcagaaa gggtggagct aagaaacgcc 1800 ccgcctccaatgacgcggat gtaagcgagc caaaacggga gtgcacgtca cttgcgcagc 1860 cgacaacgtcagacgcggaa gcaccggcgg actacgcgga caggtaccaa aacaaatgtt 1920 ctcgtcacgtgggcatgaat ctgatgcttt ttccctgtaa aacatgcgag agaatgaatc 1980 aaatttccaatgtctgtttt acgcatggtc aaagagactg tggggaatgc ttccctggaa 2040 tgtcagaatctcaacccgtt tctgtcgtca aaaagaagac ttatcagaaa ctgtgtccaa 2100 ttcatcatatcctgggaagg gcacccgaga ttgcctgttc ggcctgcgat ttggccaatg 2160 tggacttggatgactgtgtt tctgagcaat aaatgactta aaccaggtat ggctgctgac 2220 ggttatcttccagattggct cgaggacaac ctttctgaag gcattcgtga gtggtgggct 2280 ctgaaacctggagtccctca acccaaagcg aaccaacaac accaggacaa ccgtcggggt 2340 cttgtgcttccgggttacaa atacctcgga cccggtaacg gactcgacaa aggagagccg 2400 gtcaacgaggcggacgcggc agccctcgaa cacgacaaag cttacgacca gcagctcaag 2460 gccggtgacaacccgtacct caagtacaac cacgccgacg ccgagtttca ggagcgtctt 2520 caagaagatacgtcttttgg gggcaacctt ggcagagcag tcttccaggc caaaaagagg 2580 atccttgagcctcttggtct ggttgaggaa gcagctaaaa cggctcctgg aaagaagggg 2640 gctgtagatcagtctcctca ggaaccggac tcatcatctg gtgttggcaa atcgggcaaa 2700 cagcctgccagaaaaagact aaatttcggt cagactggag actcagagtc agtcccagac 2760 cctcaacctctcggagaacc accagcagcc cccacaagtt tgggatctaa tacaatggct 2820 tcaggcggtggcgcaccaat ggcagacaat aacgagggtg ccgatggagt gggtaattcc 2880 tcaggaaattggcattgcga ttcccaatgg ctgggcgaca gagtcatcac caccagcacc 2940 agaacctgggccctgcccac ttacaacaac catctctaca agcaaatctc cagccaatca 3000 ggagcttcaaacgacaacca ctactttggc tacagcaccc cttgggggta ttttgacttt 3060 aacagattccactgccactt ctcaccacgt gactggcagc gactcattaa caacaactgg 3120 ggattccggcccaagaaact cagcttcaag ctcttcaaca tccaagttag aggggtcacg 3180 cagaacgatggcacgacgac tattgccaat aaccttacca gcacggttca agtgtttacg 3240 gactcggagtatcagctccc gtacgtgctc gggtcggcgc accaaggctg tctcccgccg 3300 tttccagcggacgtcttcat ggtccctcag tatggatacc tcaccctgaa caacggaagt 3360 caagcggtgggacgctcatc cttttactgc ctggagtact tcccttcgca gatgctaagg 3420 actggaaataacttccaatt cagctatacc ttcgaggatg taccttttca cagcagctac 3480 gctcacagccagagtttgga tcgcttgatg aatcctctta ttgatcagta tctgtactac 3540 ctgaacagaacgcaaggaac aacctctgga acaaccaacc aatcacggct gctttttagc 3600 caggctgggcctcagtctat gtctttgcag gccagaaatt ggctacctgg gccctgctac 3660 cggcaacagagactttcaaa gactgctaac gacaacaaca acagtaactt tccttggaca 3720 gcggccagcaaatatcatct caatggccgc gactcgctgg tgaatccagg accagctatg 3780 gccagtcacaaggacgatga agaaaaattt ttccctatgc acggcaatct aatatttggc 3840 aaagaagggacaacggcaag taacgcagaa ttagataatg taatgattac ggatgaagaa 3900 gagattcgtaccaccaatcc tgtggcaaca gagcagtatg gaactgtggc aaataacttg 3960 cagagctcaaatacagctcc cacgactgga actgtcaatc atcagggggc cttacctggc 4020 atggtgtggcaagatcgtga cgtgtacctt caaggaccta tctgggcaaa gattcctcac 4080 acggatggacactttcatcc ttctcctctg atgggaggct ttggactgaa acatccgcct 4140 cctcaaatcatgatcaaaaa tactccggta ccggcaaatc ctccgacgac tttcagcccg 4200 gccaagtttgcttcatttat cactcagtac tccactggac aggtcagcgt ggaaattgag 4260 tgggagctacagaaagaaaa cagcaaacgt tggaatccag agattcagta cacttccaac 4320 tacaacaagtctgttaatgt ggactttact gtagacacta atggtgttta tagtgaacct 4380 cgccctattggaacccggta tctcacacga aacttgtgaa tcctggttaa tcaataaacc 4440 gtttaattcgtttcagttga actttggctc ttgtgcactt ctttatcttt atcttgtttc 4500 catggctactgcgtagataa gcagcggcct gcggcgcttg cgcttcgcgg tttacaactg 4560 ctggttaatatttaactctc gccatacctc tagtgatgga gttggccact ccctctatgc 4620 gcactcgctcgctcggtggg gcctggcgac caaaggtcgc cagacggacg tgctttgcac 4680 gtccggccccaccgagcgag cgagtgcgca tagagggagt ggccaa 4726 9 3098 DNA new AAVserotype, clone 42.2 9 gaattcgccc tttctacggc tgcgtcaact ggaccaatgagaactttccc ttcaacgatt 60 gcgtcgacaa gatggtgatc tggtgggagg agggcaagatgacggccaag gtcgtggagt 120 ccgccaaggc cattctcggc ggcagcaagg tgcgcgtggaccaaaagtgc aagtcttccg 180 cccagatcga tcccaccccc gtgatcgtca cttccaacaccaacatgtgc gctgtgattg 240 acgggaacag caccaccttc gagcaccagc agccgttacaagaccggatg ttcaaatttg 300 aactcacccg ccgtctggag cacgactttg gcaaggtgacaaagcaggaa gtcaaagagt 360 tcttccgctg ggcgcaggat cacgtgaccg aggtggcgcatgagttctac gtcagaaagg 420 gtggagccaa caagagaccc gcccccgatg acgcggataaaagcgagccc aagcgggcct 480 gcccctcagt cgcggatcca tcgacgtcag acgcggaaggagctccggtg gactttgccg 540 acaggtacca aaacaaatgt tctcgtcacg cgggcatgcttcagatgctg tttccctgca 600 agacatgcga gagaatgaat cagaatttca acatttgcttcacgcacggg accagagact 660 gttcagaatg tttccccggc gtgtcagaat ctcaaccggtcgtcagaaag aggacgtatc 720 ggaaactctg tgccattcat catctgctgg ggcgggctcccgagattgct tgctcggcct 780 gcgatctggt caacgtggac ctggatgacc gtgtttctgagcaataaatg acttaaacca 840 ggtatggctg ccgatggtta tcttccagat tggctcgaggacaacctctc tgagggcatt 900 cgcgagtggt gggacttgaa acctggagcc ccgaaacccaaagccaacca gcaaaagcag 960 gacgacggcc ggggtctggt gcttcctggc tacaagtacctcggaccctt caacggactc 1020 gacaagggag agccggtcaa cgaggcagac gccgcggccctcgagcacga caaggcctac 1080 gacaagcagc tcgagcaggg ggacaacccg tacctcaagtacaaccacgc cgacgccgag 1140 tttcaggagc gtcttcaaga agatacgtct tttgggggcaacctcgggcg agcagtcttc 1200 caggccaaga agcgggttct cgaacctctc ggtctggttgaggaaggcgc taagacggct 1260 cctggaaaga agagacccat agaatccccc gactcctccacgggcatcgg caagaaaggc 1320 cagcagcccg ctaaaaagaa gctcaacttt gggcagactggcgactcaga gtcagtgccc 1380 gacccccaac ctctcggaga acctcccgcc gcgccctcaggtctgggatc tggtacaatg 1440 gctgcaggcg gtggcgcacc aatggcagac aataacgaaggcgccgacgg agtgggtaat 1500 gcctccggaa attggcattg cgattccaca tggctgggcgacagagtcat caccaccagc 1560 acccgcacct gggccctgcc cacctacaac aaccacctctacaagcagat atcaagtcag 1620 agcggggcta ccaacgacaa ccacttcttc ggctacagcaccccctgggg ctattttgac 1680 ttcaacagat tccactgcca cttctcacca cgtgactggcagcgactcat caacaacaac 1740 tggggattcc ggcccagaaa gctgcggttc aagttgttcaacatccaggt caaggaggtc 1800 acgacgaacg acggcgttac gaccatcgct aataaccttaccagcacgat tcaggtcttc 1860 tcggactcgg agtaccaact gccgtacgtc ctcggctctgcgcaccaggg ctgcctccct 1920 ccgttccctg cggacgtgtt catgattcct cagtacggatatctgactct aaacaacggc 1980 agtcagtctg tgggacgttc ctccttctac tgcctggagtactttccttc tcagatgctg 2040 agaacgggca ataactttga attcagctac acctttgaggaagtgccttt ccacagcagc 2100 tatgcgcaca gccagagcct ggaccggctg atgaatcccctcatcgacca gtacctgtac 2160 tacctggccc ggacccagag cactacgggg tccacaagggagctgcagtt ccatcaggct 2220 gggcccaaca ccatggccga gcaatcaaag aactggctgcccggaccctg ttatcggcag 2280 cagagactgt caaaaaacat agacagcaac aacaacagtaactttgcctg gaccggggcc 2340 actaaatacc atctgaatgg tagaaattca ttaaccaacccgggcgtagc catggccacc 2400 aacaaggacg acgaggacca gttctttccc atcaacggagtgctggtttt tggcgaaacg 2460 ggggctgcca acaagacaac gctggaaaac gtgctaatgaccagcgagga ggagatcaaa 2520 accaccaatc ccgtggctac agaagaatac ggtgtggtctccagcaacct gcaatcgtct 2580 acggccggac cccagacaca gactgtcaac agccagggggctctgcccgg catggtctgg 2640 cagaaccggg acgtgtacct gcagggtccc atctgggccaaaattcctca cacggacggc 2700 aactttcacc cgtctcccct gatgggcgga tttggactcaaacacccgcc tcctcaaatt 2760 ctcatcaaaa acaccccggt acctgctaat cctccagaggtgtttactcc tgccaagttt 2820 gcctcattta tcacgcagta cagcaccggc caggtcagcgtggagatcga gtgggaactg 2880 cagaaagaaa acagcaaacg ctggaatcca gagattcagtacacctcaaa ttatgccaag 2940 tctaataatg tggaatttgc tgtcaacaac gaaggggtttatactgagcc tcgccccatt 3000 ggcacccgtt acctcacccg taacctgtaa ttgcctgttaatcaataaac cggttaattc 3060 gtttcagttg aactttggtc tctgcgaagg gcgaattc3098 10 3098 DNA new AAV serotype, clone 16.3 10 gaattcgccc ttcgcagagaccaaagttca actgaaacga atcaaccggt ttattgatta 60 acaagtaatt acaggttacgggtgaggtaa cgggtgccaa tggggcgagg ctcagtataa 120 accccttcgt tgttgacagcaaattccaca ttattagact tggcataatt tgaggtgtac 180 tgaatctctg gattccagcgtttgctgttt tctttctgca gttcccactc gatctccacg 240 ctgacctggc cggtgctgtactgcgtgata aatgaggcaa actaggcagg agtaaacacc 300 cctggaggat tagcaggtaccggggtgttt ttgatgagaa tttgaggagg cgggtgtttg 360 agtccaaatc cgcccatcaggggagacggg tgaaagttgc cgtccgtgtg aggaattttg 420 gcccagatgg gaccctgcaggtacacgtcc cggttctgcc agaccatgcc gggcagagcc 480 ccctggctgt tgacagtctgtgtctggggt ccggccgtag acgattgcag gttgctggag 540 accacaccgt attcttctgtagccacggga ttggtggttt tgatctcctc ctcgctggtc 600 attagcacgt tttccagcgttgtcttgttg gcagcccccg ttttgccaaa aaccagcact 660 ccgttgatgg gaaagaactggccctcgtcg tccttgttgg tggccatggc tacgcccggg 720 ttggttaatg aatttctaccattcagatgg tatttagtgg ccccggtcca ggcaaagtta 780 ctgttgttgt tgctgtctatgttttttgac agtctctgct gccgataaca gggtccgggc 840 agccagttct ttgattgctcggccatggtg ttgggcccag cctgatggaa ctgcagctcc 900 cttgtggacc ccgtagtgctctgggtccgg gccaggtagt acaggtactg gtcgatgagg 960 ggattcatca gccggtccaggctctggctg tgcgcatagc tgctgtggaa aggcacttcc 1020 tcaaaggtgt agctgaattcaaagttattg cccgttctca gcatctgaga aggaaagtac 1080 tccaggcagt agaaggaggaacgtcccata gactgactgc cgttgtttag agtcagatat 1140 ccgtactgag gaatcatgaacacgtccgca gggaacggag ggaggcagcc ctggtgcgca 1200 gagccgagga cgtacggcagttggtactcc gagtccgaga agacctgaat cgtgctggta 1260 aggttattag cgatggtcgtaacgccgtcg ttcgtcgtga cctccttgac ctggatgttg 1320 aacaacttga accgcagctttctgggccgg aatccccagt tgttgttgat gagtcgctgc 1380 cagtcacgtg gtgagaagtggcagtggaat ctgttgaagt caaaatagcc ccagggggtg 1440 ctgtagccga agaagtggttgtcgttggta gccccgctct gacttgatat ctgcttgtag 1500 aggtggttgt tgtaggtgggcagggcccag gtgcgggtgc tggtggtgat gactctgtcg 1560 cccagccatg tggaatcgcaatgccaattt ccggaggcat tacccactcc gtcggcgcct 1620 tcgttattgt ctgccattggtgcgccaccg cctgcagcca ttgtaccaga tcccagacct 1680 gagggcgcgg cgggaggttctccgagaggt tgggggtcgg gcactgactc tgagtcgcca 1740 gtctgcccaa agttgagcttctttttagcg ggctgctggc ctttcttgcc gatgcccgtg 1800 gaggagtcgg gggattctatgggtctcttc tttccaggag ccgtcttagc gccttcctca 1860 accagaccga gaggttcgagaacccgcttc ttggcctgga agactgctcg cccgaggttg 1920 cccccaaaag acgtatcttcttgaagacgc tcctgaaact cagcgtcggc gtggttgtac 1980 ttgaggtacg ggttgtccccctgctcgagc tgcttgtcgt aggccttgtc gtgctcgagg 2040 gccgcggcgt ctgcctcgttgaccggctct cccttgtcga gtccgttgaa gggtccgagg 2100 tacttgtagc caggaagcaccagaccccgg ccgtcgtcct gcttttgctg gttggctttg 2160 ggtttcgggg ctccaggtttcaagtcccac cactcgcgaa tgccctcaga gaggttgtcc 2220 tcgagccaat ctggaagataaccatcggca gccatacctg gtttaagtca tttattgctc 2280 agaaacacag tcatccaggtccacgttgac cagatcgcag gccgagcaag caatctcggg 2340 agcccgcccc agcagatgatgaatggcaca gagtttccga tacgtcctct ttctgacgac 2400 cggttgagat tctgacacgccggggaaaca ttctgaacag tctctggtcc cgtgcgtgaa 2460 gcaaatgttg aaattctgattcattctctc gcatgtcttg cagggaaaca gcatctgaag 2520 catgcccgcg tgacgagaacatttgttttg gtacctgtcg gcaaagtcca ccggagctcc 2580 ttccgcgtct gacgtcgatggatccgcgac tgaggggcag gcccgcttgg gctcgctttt 2640 atccgcgtca tcgggggcgggcctcttgtt ggctccaccc tttctgacgt agaactcatg 2700 cgccacctcg gtcacgtgatcctgcgccca gcggaagaac tctttgactt cctgctttgt 2760 caccttgcca aagtcctgctccagacggcg ggtgagttca aatttgaaca tccggtcttg 2820 taacggctgc tggtgctcgaaggtggtgct gttcccgtca atcacggcgc acatgttggt 2880 gttggaagtg acgatcacgggggtgggatc gatctgggcg gacgacttgc acttttggtc 2940 cacgcgcacc ttgctgccgccgagaatggc cttggcggac tccacgacct tggccgtcat 3000 cttgccctcc tcccaccagatcaccatctt gtcgacgcaa tcgttgaagg gaaagttctc 3060 attggtccag ttgacgcagccgtagaaagg gcgaattc 3098 11 3121 DNA new AAV serotype, clone 29.3 11gaattcgccc ttcgcagaga ccaaagttca actgaaacga atcaaccggt ttattgatta 60acaagcaatt acagattacg ggtgaggtaa cgggtgccga tggggcgagg ctcagaataa 120gtgccatctg tgttaacagc aaagtccaca tttgtagatt tgtagtagtt ggaagtgtat 180tgaatctctg ggttccagcg tttgctgttt tctttctgca gctcccattc aatttccacg 240ctgacctgtc cggtgctgta ctgcgtgatg aacgacgcca gcttagcttg actgaaggta 300gttggaggat ccgcgggaac aggtgtattc ttaatcagga tctgaggagg cgggtgtttc 360agtccaaagc cccccatcag cggcgaggga tgaaagtttc cgtccgtgtg aggaatcttg 420gcccagatag gaccctgcag gtacacgtcc cggttctgcc agaccatgcc aggtaaggct 480ccttgactgt tgacggcccc tacaatagga gcggcgtttt gctgttgcag gttatcggcc 540accacgccgt actgttctgt ggccactggg ttggtggttt taatttcttc ctcactggtt 600agcataacgc tgctatagtc cacgttgcct tttccagctc cctgtttccc aaacattaag 660actccgctgg acggaaaaaa tcgctcttcg tcgtccttgt gggttgccat agcgacaccg 720ggatttacca gagagtctct gccattcaga tgatacttgg tggcaccggt ccaggcaaag 780ttgctgttgt tattttgcga cagtgtcgtg gagacgcgtt gctgccggta gcagggcccg 840ggtagccagt ttttggcctg agccgacatg ttattaggcc cggcctgaga aaatagcaac 900tgctgagttc ctgcggtacc tcccgtggac tgagtccgag acaggtagta caggtactgg 960tcgatgaggg ggttcatcag ccggtccagg ctttggctgt gcgcgtagct gctgtgaaaa 1020ggcacgtcct caaactggta gctgaactca aagttgttgc ccgttctcag catttgagaa 1080ggaaagtact ccaggcagta gaaggaggaa cggcccacgg cctgactgcc attgttcaga 1140gtcaggtacc cgtactgagg aatcatgaag acgtccgccg ggaacggagg caggcagccc 1200tggcgcgcag agccgaggac gtacgggagc tggtattccg agtccgtaaa gacctgaatc 1260gtgctggtaa ggttattggc gatggtcttg gtgccttcat tctgcgtgac ctccttgacc 1320tggatgttga agagcttgaa gttgagtctc ttgggccgga atccccagtt gttgttgatg 1380agtcgctgcc agtcacgtgg tgagaagtgg cagtggaatc tgttaaagtc aaaatacccc 1440cagggggtgc tgtagccgaa gtaggtgttg tcgttggtgc ttcctcccga agtcccgttg 1500gagatttgct tgtagaggtg gttgttgtag gtggggaggg cccaggttcg ggtgctggtg 1560gtgatgactc tgtcgcccag ccatgtggaa tcgcaatgcc aatttcctga ggaactaccc 1620actccgtcgg cgccttcgtt attgtctgcc attggagcgc caccgcctgc agccattgta 1680ccagatccca gaccagaggg gcctgcgggg ggttctccga ttggttgagg gtcgggcact 1740gactctgagt cgccagtctg cccaaagttg agtctctttt tcgcgggctg ctggcctttc 1800ttgccgatgc ccgtagtgga gtctggagaa cgctggggtg atggctctac cggtctcttc 1860tttccaggag ccgtcttagc gccttcctca accagaccga gaggttcgag aacccgcttc 1920ttggcctgga agactgctcg tccgaggttg cccccaaaag acgtatcttc ttgcagacgc 1980tcctgaaact cggcgtcggc gtggttatac cgcaggtacg gattgtcacc cgctttgagc 2040tgctggtcgt aggccttgtc gtgctcgagg gccgctgcgt ccgccgcgtt gacgggctcc 2100cccttgtcga gtccgttgaa gggtccgagg tacttgtagc caggaagcac cagaccccgg 2160ccgtcgtcct gcttttgctg gttggctttg ggcttcgggg ctccaggttt cagcgcccac 2220cactcgcgaa tgccctcaga gaggttgtcc tcgagccaat ctggaagata accatcggca 2280gccatacctg atctaaatca tttattgttc aaagatgcag tcatccaaat ccacattgac 2340cagatcgcag gcagtgcaag cgtctggcac ctttcccatg atatgatgaa tgtagcacag 2400tttctgatac gcctttttga cgacagaaac gggttgagat tctgacacgg gaaagcactc 2460taaacagtct ttctgtccgt gagtgaagca gatatttgaa ttctgattca ttctctcgca 2520ttgtctgcag ggaaacagca tcagattcat gcccacgtga cgagaacatt tgttttggta 2580cctgtccgcg tagttgatcg aagcttccgc gtctgacgtc gatggctgcg caactgactc 2640gcgcacccgt ttgggctcac ttatatctgc gtcactgggg gcgggtcttt tcttggctcc 2700accctttttg acgtagaatt catgctccac ctcaaccacg tgatcctttg cccaccggaa 2760aaagtctttg acttcctgct tggtgacctt cccaaagtca tgatccagac ggcgggtgag 2820ttcaaatttg aacatccggt cttgcaacgg ctgctggtgt tcgaaggtcg ttgagttccc 2880gtcaatcacg gcgcacatgt tggtgttgga ggtgacgatc acgggagtcg ggtctatctg 2940ggccgaggac ttgcatttct ggtccacgcg caccttgctt cctccgagaa tggctttggc 3000cgactccacg accttggcgg tcatcttccc ctcctcccac cagatcacca tcttgtcgac 3060acagtcgttg aagggaaagt tctcattggt ccagttgacg cagccgtaga agggcgaatt 3120 c3121 12 3121 DNA new AAV serotype, clone 29.4 12 gaattcgccc ttctacggctgcgtcaactg gaccaatgag aactttccct tcaacgactg 60 tgtcgacaag atggtgatctggtgggagga ggggaagatg accgccaagg tcgtggagtc 120 ggccaaagcc attctcggaggaagcaaggt gcgcgtggac cagaaatgca agtcctcggc 180 ccagatagac ccgactcccgtgatcgtcac ctccaacacc aacatgtgcg ccgtgattga 240 cgggaactca acgaccttcgaacaccagca gccgttgcaa gaccggatgt tcaaatttga 300 actcacccgc cgtctggatcatgactttgg gaaggtcacc aagcaggaag tcaaagactt 360 tttccggtgg gcaaaggatcacgtggttga ggtggagcac gaattctacg tcaaaaaggg 420 tggagccaag aaaagacccgcccccagtga cgcagatata agtgagccca aacgggtgcg 480 cgagtcagtt gcgcagccatcgacgtcaga cgcggaagct tcgatcaact acgcagacag 540 gtaccaaaac aaatgttctcgtcacgcggg catgaatctg atgctgtttc cctgcagaca 600 atgcgagaga atgaatcagaattcaaatat ctgcttcact cacggacaga aagactgttt 660 agagtgcttt cccgtgtcagaatctcaacc cgtttctgtc gtcaaaaagg cgtatcagaa 720 actgtgctac attcatcatatcatgggaaa ggtgccagac gcttgcactg cctgcgatct 780 ggtcgatgtg gatttggatgactgcatctt tgaacaataa atgatttaaa tcaggtatgg 840 ctgccgatgg ttatcttccagattggctcg aggacaacct ctctgagggc attcgcgagt 900 ggtgggcgct gaaacctggagccccgaagc ccaaagccaa ccagcaaaag caggacggcg 960 gccggggtct ggtgcttcctggctacaagt acctcggacc cttcaacgga ctcgacaagg 1020 gggagcccgt caacgcggcggacgcagcgg ccctcgagca cgacaaggcc tacgaccagc 1080 agctcaaagc gggtgacaatccgtacctgc ggtataacca cgccgacgcc gagtttcagg 1140 agcgtctgca agaagatacgtcttttgggg gcaacctcgg gcgagcagtc ttccaggcca 1200 agaagcgggt tctcgaacctctcggtctgg ttgaggaagg cgctaagacg gctcctggaa 1260 agaagagacc ggtagagccatcaccccagc gttctccaga ctcctctacg ggcatcggca 1320 agaaaggcca gcagcccgcgaaaaagagac tcaactttgg gcagactggc gactcagagt 1380 cagtgcccga ccctcaaccaatcggagaac cccccgcagg cccctctggt ctgggatctg 1440 gtacaatggc tgcaggcggtggcgctccaa tggcagacaa taacgaaggc gccgacggag 1500 tgggtagttc ctcaggaaattggcattgcg attccacatg gctgggcgac tgagtcatca 1560 ccaccagcac ccgaacctgggccctcccca cctacaacaa ccacctctac aagcaaatct 1620 ccaacgggac ttcgggaggaagcaccaacg acaacaccta cttcggctac agcaccccct 1680 gggggtattt tgactttaacagattccact gccacttctc accacgtgac tggcagcgac 1740 tcatcaacaa caactggggattccggccca agagactcaa cttcaagctc ttcaacatcc 1800 aggtcaagga ggtcacgcagaatgaaggca ccaagaccat cgccaataac cttaccagca 1860 cgattcaggt ctttacggactcggaatacc agctcccgta cgtcctcggc tctgcgcacc 1920 agggctgcct gcctccgttcccggcggacg tcttcatgat tcctcagtac gggtacctga 1980 ctctgaacaa tggcagtcaggccgtgggcc gttcctcctt ctactgcctg gagtactttc 2040 cttctcaaat gctgagaacgggcaacaact ttgagttcag ctaccagttt gaggacgtgc 2100 cttttcacag cagctacgcgcacagccaaa gcctggaccg gctgatgaac cccctcatcg 2160 accagtacct gtactacctgtctcggactc agtccacggg aggtaccgca ggaactcagc 2220 agttgctatt ttctcaggccgggcctaata acatgtcggc tcaggccaaa aactggctac 2280 ccgggccctg ctaccggcagtaacgcgtct ccacgacact gtcgcaaaat aacaacagca 2340 actttgtctg gaccggtgccaccaagtatc atctgaatgg cagagactct ctggtagatc 2400 ccggtgtcgc tatggcaacccacaaggacg acgaagagcg attttttccg tccagcggag 2460 tcataatgtt tgggaaacagggagctggaa aagacaacgt ggactatagc agcgtcatgc 2520 taaccagtga ggaagaaattaaaaccacca acccagtggc cacagaacag tacggcgtgg 2580 tggccgataa cctgcaacagcaaaacgccg ctcctattgt aggggccgtc aacagtcaag 2640 gagccttacc tggcatggtctggcagaacc gggacgtgta cctgcagggt cctacctggg 2700 ccaagattcc tcacacggacggaaactttc atccctcgcc gctgatggga ggctttggac 2760 tgaaacaccc gcctcctcagatcctgatta agaatacacc tgttcccgcg gatcctccaa 2820 ctaccttcag tcaagctaagctggcgtcgt tcatcacgca gtacagcacc ggacaggtca 2880 gcgtggaaat tgaatgggagctgcaggaag aaaacagcaa acgctggaac ccagagattc 2940 aatacacttc caactactacaaatctacaa atgtggactt tgctgttaac acagatggca 3000 cttattctga gcctcgccccatcggcaccc gttacctcac ccgtaatctg taattgcttg 3060 ttaatcaata aaccggttgattcgtttcag ttgaactttg gtctctgcga agggcgaatt 3120 c 3121 13 3121 DNA newAAV serotype, clone 29.5 13 gaattcgccc ttcgcgagac caaagttcaa ctgaaacgaatcaaccggtt tattgattaa 60 caagcaatta cagattacgg gtgaggtaac gggtgccgatggggcgaggc tcagaataag 120 tgccatctgt gttaacagca aagtccacat ttgtagatttgtagtagttg gaagtgtatt 180 gaatctctgg gttccagcgt ttgctgtttt ctttctgcagctcccattca atttccacgc 240 tgacctgtcc ggtgctgtac tgcgtgatga acgacgccagcttagcttga ctgaaggtag 300 ttggaggatc cgcgggaaca ggtgtattct taatcaggatctgaggaggc gggtgtttca 360 gtccaaagcc tcccatcagc ggcgagggat gaaagtttccgtccgtgtga ggaatcttgg 420 cccagatagg accctgcagg tacacgtccc ggttctgccagaccatgcca ggtaaggctc 480 cttgactgtt gacggcccct acaataggag cggcgttttgctgttgcagg ttatcggcca 540 ccacgccgta ctgttctgtg gccactgggt tggtggttttaatttcttcc tcactggtta 600 gcataacgct gctatagtcc acgttgtctt ttccagctccctgtttccca aacattaaga 660 ctccgctgga cggaaaaaat cgctcttcgt cgtccttgtgggttgccata gcgacaccgg 720 gatttaccag agagtctctg ccattcagat gatacttggtggcaccggtc caggcaaagt 780 tgctgttgtc attttgcgac agtgtcgtgg agacgcgttgctgccggtag cagggcccgg 840 gtagccagtt tttggcctga gccgacatgt tattaggcccggcctgagaa aatagcaact 900 gctgagttcc tgcggtacct cccgtggact gagtccgagacaggtagtac aggtactggt 960 cgatgagggg gttcatcagc cggtccaggc tttggctgtgcgcgtagctg ctgtgaaaag 1020 gcacgtcctc aaactggtag ctgaactcaa agttgttgcccgttctcagc atttgagaag 1080 gaaagtactc caggcagtag aaggaggaac ggcccacggcctgactgcca ttgttcagag 1140 tcaggtaccc gtactgagga atcatgaaga cgtccgccgggaacggaggc aggcagccct 1200 ggtgcgcaga gccgaggacg tacgggagct ggtattccgagtccgtaaag acctgaatcg 1260 tgctggtaag gttattggcg atggtcttgg tgccttcattctgcgtgacc tccttgacct 1320 ggatgttgaa gagcttgaag ttgaggctct tgggccggaatccccagttg ttgttgatga 1380 gtcgctgcca gtcacgtggt gagaagtggc agtggaatctgttaaagtca aaataccccc 1440 agggggtgct gtagccgaag taggtgttgt cgttggtgcttcctcccgaa gtcccgttgg 1500 agatttgctt gtagaggtgg ttgttgtagg tggggagggcccaggttcgg gtgctggtgg 1560 tgatgactcc gtcgcccagc catgtggaat cgcaatgccaatttcctgag gaactaccca 1620 ctccgtcggc gccttcgtta ttgtctgcca ttggagcgccaccgcctgca gccattgtac 1680 cagatcccag accagagggg cctgcggggg gttctccgattggttgaggg tcgggcactg 1740 actctgagtc gccagtctgc ccaaagttga gtctctttttcgcgggctgc tggcctttct 1800 tgccgatgcc cgtagaggag tctggagaac gctggggtgatggctctacc ggtctcttct 1860 ttccaggagc cgtcttagcg ccttcctcaa ccagaccgagaggttcgaga acccgcttct 1920 tggcctggaa gactgctcgc ccgaggttgc ccccaaaagacgtatcttct tgcagacgct 1980 cctgaaactc ggcgtcggcg tggttatacc gcaggtacggattgtcaccc gctttgagct 2040 gctggtcgta ggccttgtcg tgctcgaggg ccgctgcgtccgccgcgttg acgggctccc 2100 ccttgtcgag tccgttgaag ggtccgaggt acttgtagccaggaagcacc agaccccggc 2160 cgtcgtcctg cttttgctgg ttggctttgg gcttcggggctccaggtttc agcgcccacc 2220 actcgcgaat gccctcagag aggttgtcct cgagccaatctggaagataa ccatcggcag 2280 ccatacctga tttaaatcat ttattgttca aagatgcagtcatccaaatc cacattgacc 2340 agatcgcagg cagtgcaagc gtctggcacc tttcccatgatatgatgaat gtagcacagt 2400 ttctgatacg cctttttgac gacagaaacg ggttgagattctgacacggg aaagcactct 2460 aaacagtctt tctgtccgtg agtgaagcag atatttgaattctgattcat tctctcgcat 2520 tgtctgcagg gaaacagcat cagattcatg cccacgtgacgagaacattt gttttggtac 2580 ctgtctgcgt agttgatcga agcttccgcg tctgacgtcgatggctgcgc aactgactcg 2640 cgcacccgtt tgggctcact tatatctgcg tcactgggggcgggtctttt cttggctcca 2700 ccctttttga cgtagaattc atgctccacc tcaaccacgtgatcctttgc ccaccggaaa 2760 aagtctttga cttcctgctt ggtgaccttc ccaaagtcatgatccagacg gcgggtgagt 2820 tcaaatttga acatccggtc ttgcaacggc tgctggtgttcgaaggtcgt tgagttcccg 2880 tcaatcacgg cgcacatgtt ggtgttggag gtgacgatcacgggagtcgg gtctatctgg 2940 gccgaggact tgcatttctg gtccacgcgc accttgcttcctccgagaat ggctttggcc 3000 gactccacga ccttggcggt catcttcccc tcctcccaccagatcaccat cttgtcgaca 3060 cagtcgttga agggaaagtt ctcattggtc cagttgacgcagccgtagaa agggcgaatt 3120 c 3121 14 3131 DNA new AAV serotype, clone1-3 14 gcggccgcga attcgccctt ggctgcgtca actggaccaa tgagaacttt cccttcaatg60 attgcgtcga caagatggtg atctggtggg aggagggcaa gatgacggcc aaggtcgtgg 120agtccgccaa ggccattctc ggcggcagca aggtgcgcgt ggaccaaaag tgcaagtcgt 180ccgcccagat cgaccccacc cccgtgatcg tcacctccaa caccaacatg tgcgccgtga 240ttgacgggaa cagcaccacc ttcgagcacc agcagcctct ccaggaccgg atgtttaagt 300tcgaactcac ccgccgtctg gagcacgact ttggcaaggt gacaaagcag gaagtcaaag 360agttcttccg ctgggccagt gatcacgtga ccgaggtggc gcatgagttt tacgtcagaa 420agggcggagc cagcaaaaga cccgcccccg atgacgcgga taaaagcgag cccaagcggg 480cctgcccctc agtcgcggat ccatcgacgt cagacgcgga aggagctccg gtggactttg 540ccgacaggta ccaaaacaaa tgttctcgtc acgcgggcat gcttcagatg ctgtttccct 600gcaaaacgtg cgagagaatg aatcggaatt tcaacatttg cttcacacac ggggtcagag 660actgctcaga gtgtttcccc ggcgtgtcag aatctcaacc ggtcgtcaga aagaggacgt 720atcggaaact ccgtgcgatt catcatctgc tggggcgggc tcccgagatt gcttgctcgg 780cctgcgatct ggtcaacgtg gacctggatg actgtgtttc tgagcaataa atgacttaaa 840ccaggtatgg ctgccgatgg ttatcttcca gattggctcg aggacaacct ctctgagggc 900attcgcgagt ggtgggcgct gaaacctgga gccccgaagc ccaaagccaa ccagcaaaag 960caggacgacg gccggggtct ggtgcttcct ggctacaagt acctcggacc cttcaacgga 1020ctcgacaagg gggagcccgt caacgcggcg gacgcagcgg ccctcgagca cgacaaggct 1080tacgaccagc agctgcaggc gggtgacaat ccgtacctgc ggtataacca cgccgacgcc 1140gagtttcagg agcgtctgca agaagatacg tcttttgggg gcaacctcgg gcgagcagtc 1200ttccaggcca agaagcgggt tctcgaacct ctcggtctgg ttgaggaagg cgctaagacg 1260gctcctggaa agaagagacc ggtagagcca tcaccccagc gttctccaga ctcctctacg 1320ggcatcggca agaaaggcca acagcccgcc agaaaaagac tcaattttgg tcagactggc 1380gactcagagt cagttccaga ccctcaacct ctcggagaac ctccagcagc gccctctggt 1440gtgggaccta atacaatggc tgcaggcggt ggcgcaccaa tggcagacaa taacgaaggc 1500gccgacggag tgggtagttc ctcgggaaat tggcattgcg attccacatg gctgggcgac 1560agagtcatca ccaccagcac ccgaacctgg gccctgccca cctacaacaa ccacctctac 1620aagcaaatct ccaacgggac atcgggagga gccaccaacg acaacaccta cttcggctac 1680agcaccccct gggggtattt tgactttaac agattccact gccacctttc accacgtgac 1740tggcagcgac tcatcaacaa caactgggga ttccgaccca agagactcag cttcaagctc 1800ttcaacatcc aggtcaagga ggtcacgcag aatgaaggca ccaagaccat cgccaataac 1860ctcaccagca ccatccaggt gtttacggac tcggagtacc agctgccgta cgttctcggc 1920tctgtccacc agggctgcct gcctccgttc ccggcggacg tgttcatgat tccccagtac 1980ggctacctaa cactcaacaa cggtagtcag gccgtgggac gctcctcctt ctactgcctg 2040gaatactttc cttcgcagat gctgagaacc ggcaacaact tccagtttac ttacaccttc 2100gaggacgtgc ctttccacag cagctacgcc cacagctaga gcttggaccg gctgatgaat 2160cctctgattg accagtacct gtactacttg tctcggactc aaacaacagg aggcacggca 2220aatacgcaga ctctgggctt cagccaaggt gggcctaata caatggccaa tcaggcaaag 2280aactggctgc caggaccctg ttaccgccaa caacgcgtct caacgacaac cgggcaaaac 2340aacaatagca actttgcctg gactgctggg accaaatacc atctgaatgg aagaaattca 2400ttggctaatc ctggcatcgc tatggcaaca cacaaagacg acgaggagcg tttttttccc 2460agtaacggga tcctgatttt tggcaaacaa aatgctgcca gagacaatgc ggattacagc 2520gatgtcatgc tcaccagcga ggaagaaatc aaaaccacta accctgtggc tacagaggaa 2580tacggtatcg tggcagataa cttgcagcag caaaacacgg ctcctcaaat tggaactgtc 2640aacagccagg gggccttacc cggtatggtc tggcagaacc gggacgtgta cctgcagggt 2700cccatctggg ccaagattcc tcacacggac ggcaacttcc acccgtctcc gctgatgggc 2760ggctttggcc tgaaacatcc tccgcctcag atcctgatca agaacacgcc tgtacctgcg 2820gatcctccga ccaccttcaa ccagtcaaag ctgaactctt tcatcacgca atacagcacc 2880ggacaggtca gcgtggaaat tgaatgggag ctgcagaagg aaaacagcaa gcgctggaac 2940cccgagatcc agtacacctc caactactac aaatctataa gtgtggactt tgctgttaat 3000acagaaggcg tgtactctga accccgcccc attggcaccc gttacctcac ccgtaatctg 3060taattgcctg ttaatcaata aaccggttga ttcgtttcag ttgaactttg gtctctgcga 3120agggcgaatt c 3131 15 3127 DNA new AAV serotype, clone 13-3b 15gcggccgcga attcgccctt cgcagagacc aaagttcaac tgaaacgaat caaccggttt 60attgattaac atgcaattac agattacggg tgaggtaacg agtgccaata gggcgaggct 120cagagtaaac accctggctg tcaacggcaa agtccacacc agtctgcttt tcaaagttgg 180aggtgtactg aatctccggg tcccagcgct tgctgttttc cttctgcagc tcccactcga 240tttccacgct gacttgtccg gtgctgtact gtgtgatgaa cgaagcaaac ttggcaggag 300taaacacctc cggaggatta gcgggaacgg gagtgttctt gatcaggatc tgaggaggcg 360gatgtttaag tccaaagccg cccatcaaag gagacgggtg aaagttgcca tccgtgtgag 420gaatcttggc ccagatggga ccctgcaggt acacgtcccg gttctgccag accatgccag 480gtaaggctcc ctggttgttg acaacttgtg tctgggctgc agtattagcc gcttgtaagt 540tgctgctgac tatcccgtat tcttccgtgg ctacaggatt agtaggacga atttcttctt 600catttgtcat taacacattt tccaatgtag ttttgttagt tgctccagtt tttccaaaaa 660tcaggactcc gctggatggg aaaaagcggt cctcgtcgtc cttgtgagtt gccatggcga 720cgccgggatt aaccaacgag tttctgccgt tcaggtgata tttggtggca ccagtccaag 780caaagttgct gttgttgttt tgatccagcg ttttggagac cctttgttgc cggaagcagg 840gtccaggtaa ccaattcttg gcttgttcgg ccatagttga aggcccgccc tggtaaaact 900gcagttcccg attgccagct gtgcctcctg ggtcactctg tgttctggcc aggtagtaca 960agtactggtc gatgagggga ttcatcagcc ggtccaggct ctggctgtgt gcgtagctgc 1020tgtggaaagg cacgtcctcg aagctgtagc tgaactcaaa gttgttgccc gttctcagca 1080tctgagaggg gaagtactcc aggcagtaga aggaggaacg tcccacagac tgactgccat 1140tgttgagagt caggtagccg tactgaggaa tcatgaagac gtccgccggg aacggaggca 1200ggcagccctg gtgcgcagag ccgaggacgt acggcagctg gtattccgag tccgagaata 1260cctgaatcgt gctggtaagg ttattagcga tggtcgtaac gccgtcattc gtcgtgacct 1320ccttgacctg gatgttgaag agcttgaacc gcagcttctt gggccggaat ccccagttgt 1380tgttgatgag tcgctgccag tcacgtggtg agaagtggca gtggaatctg ttaaagtcaa 1440aataccccca gggggtgctg tagccgaagt aggtgttgtc gttggtacta cctgcagttt 1500cactggagat ttgctcgtag aggtggttgt tgtaggtggg cagggcccag gttcgggtgc 1560tggtggtaat gactctgtcg cccagccatg tggaatcgca atgccaattt cctgaggcat 1620tacccactcc gtcggcacct tcgttattgt ctgccattgg tgcgccaccg cctgcagcca 1680ctgtaccaga tcccacacta gagggcgctg ctggaggttc tccgagaggt tgagggtcgg 1740ggactgactc tgagtcgcca gtctgaccga aattgagtct ctttctggcg ggctgctggc 1800ccttcttgcc gatgcccgtg gaggagtcgg gggaacgctg aggtgacggc tctaccggtc 1860tcttctttgc aggagccgtc ttagcgcctt cctcaaccag accgagaggt tcgagaaccc 1920gcttcttggc ctggaagact gctcgcccga ggttgccccc aaatgacgta tcttcttgca 1980gacgctcctg aaactcggcg tcggcgtggt tataccgcag gtacgggttg tcacccgcat 2040tgagctgctg gtcgtaggcc ttgtcgtgct cgagggccgc tgcgtccgcc gcgttgacgg 2100gctccccctt gtcgagtccg ttgaagggtc cgaggtactt gtagccagga agcaccagac 2160cccggccgtt gtcctgcttt tgctggttgg ctttgggttt cggggctcca ggtttcaggt 2220cccaccactc gcgaatgccc tcagagaggt tgtcctcgag ccaatctgga agataaccat 2280cggcagccat acctgattta aatcatttat tgttcaaaga tgcagtcatc caaatccaca 2340ttgaccagat cgcaggcagt gcaagcgtct ggcacctttc ccatgatatg atgaatgtag 2400cacagtttct gatacgcctt tttgacgaca gaaacgggtt tagattctga cacgggaaag 2460cactctaaac agtctttctg tccgtgagtg aagcagatat ttgaattctg attcattctc 2520tcgcattgtc tgcagggaaa cagcatcaga ttcatgccca cgtgacgaga acatttgttt 2580tggtacctgt ctgcgtagtt gatcgaagct tccgcgtctg acgtcgatgg ctgcgcaact 2640gactcgcgca cccgtttggg ctcacttata tctgcgtcac tgggggcggg tcttttcttg 2700gctccaccct ttttgacgta gaattcatgc tccacctcaa ccacgtaatc ctttgcccac 2760cggaaaaagt ctttgacttc ctgcttggtg accttcccaa agtcatgatc cagacggcgg 2820gtgagttcaa atttgaacat ccggtcttgc aacggctgct ggtgttcgaa ggtcgttgag 2880ttcccgtcga tcacggcgca catgttggtg ttggagatga cgatcgcggg agtcgggtct 2940atctgggccg aggacttgca tttctggtcc acgcgcacct tgcttcctcc gagaatggct 3000ttggccgact ccacgacctt ggcggtcatc ttcccctcct cccaccagat caccatcttg 3060tcgacacagt cgttgaaggg aaagttctca ttggtccagt tgacgcagcc gtagaaaggg 3120cgaattc 3127 16 3106 DNA new AAV serotype, clone 24-1 16 gcggccgcgaattcgccctt cgcagagacc aaagttcaac tgaaacgaat caaccggttt 60 attgattaacaagtaattac aggttacggg tgaggtaacg ggtgccaatg gggcgaggct 120 cagtataaaccccttcgttg ttgacagcaa attccacatt attagacttg gcataatttg 180 aggtgtactgaatctctgga ttccagcgtt tgctgttttc tttctgcagt tcccactcga 240 tctccacgctgacctggccg gtgctgtact gcgtgataaa tgaggcaaac ttggcaggag 300 taaacacctctggaggatta gcaggtaccg gggtgttttt gatgagaatt tgaggaggcg 360 ggtgtttgagtccaaatccg cccatcaggg gagacgggtg aaagttgccg tccgtgtgag 420 gaattttggcccagatggga ccctgcaggc acacgtcccg gttctgccag accatgccgg 480 gcagagccccctggctgttg acagtctgtg tctggggtcc ggccgtagac gattgcaggt 540 tgctggagaccacaccgtat tcttctgtag ccacgggatt ggtggttttg atctcctcct 600 cgctggtcattagcacgttt tccagcgttg tcttgttggc agcccccgtt ttgccaaaaa 660 ccagcactccgttgatggga aagaactggt cctcgtcgtc cttgttggtg gccatggcta 720 cgcccgggttggttaatgaa tttctaccat tcagatggta tttagtggcc ccggtccagg 780 caaagttactgttgttgttg ctgtctatgt tttttgacag tctctgctgc cgataacagg 840 gtccgggcagccagttcttt gattgctcgg ccatggtgtt gggcccagcc tgatggaact 900 gcagctcccttgtggacccc gtagtgctct gggtccgggc caggtagtac aggtactggt 960 cgatgaggggattcatcagc cggtctaggc tctggctgtg cacatagctg ctgtggaaag 1020 gcacttcctcaaaggtgtag ctgaattcaa agttattgcc cgttctcagc atctgagaag 1080 gaaagtactccaggcagtag aaggaggaac gtcccacaga ctgactgccg ttgtttagag 1140 tcagatatccgtactgagga atcatgaaca cgtccgcagg gaacggaggg aggcagccct 1200 ggtgcgcagagccgaggacg tacggcagtt ggtactccga gtccgagaag acctgaatcg 1260 tgctggtaaggttattagcg atggtcgtaa cgccgtcgtt cgtcgtgacc tccttgacct 1320 ggatgttgaacaacttgaac cgcagctttc tgggccggaa tccccagttg ttgttgatga 1380 gtcgctgccagtcacgtggt gagaagtggc agtggaatct gttgaagtca aaatagcccc 1440 agggggtgctgtagctgaag aagtggttgt cgttggtagc cccgctctga cttgatatct 1500 gcttgtagaggtggttgttg taggtgggca gggcccaggt gcgggtgctg gtggtgatga 1560 ctctgtcgcccagccatgtg gaatcgcaat gccaatttcc ggaggcatta cccactccgt 1620 cggcgccttcgttattgtct gccattggtg cgccaccgcc tgcagccatt gtaccagatc 1680 ccagacctgagggcgcggcg ggaggttctc cgagaggttg ggggtcgggc actgactctg 1740 agtcgccagtctgcccaaag ttgagcttct ttttagcggg ctgctggcct ttcttgccga 1800 tgcccgtggaggagtcgggg gattctatgg gtctcttctt tccaggagcc gtcttagcga 1860 cttcctcaaccagaccgaga ggttcgagaa cccgcttctt ggcctggaag actgctcgcc 1920 cgaggttgcccccaaaagac gtatcttctt gaagacgctc ctgaaactcg gcgtcggcgt 1980 ggttgtacttgaggtacggg ttgtccccct gctcgagctg cttgtcgtag gccttgtcgt 2040 gctcgagggccgcggcgtct gcctcgttga ccggctctcc cttgtcgagt ccgttgaagg 2100 gtctgaggtacttgtagcca ggaagcacca gaccccggcc gtcgtcctgc ttttgctggt 2160 tggctttgggtttcggggct ccaggtttca agtcccacca ctcgcgaatg ccctcagaga 2220 ggttgtcctcgagccaatct ggaagataac catcggcagc catacctggt ttaagtcatt 2280 tattgctcagaaacacagtc atccaggtcc acgttgacca gatcgcaggc cgagcaagca 2340 atctcgggagcccgccccag cagatgatga atggcacaga gtttccgata cgtcctcttt 2400 ctgacgaccggttgagattc tgacacgccg gggaaacatt ctgaacagtc tctggtcccg 2460 tgcgtgaagcaaatgttgaa attctgattc actctctcgc atgtcttgca gggaaacagc 2520 atctgaagcatgcccgcgtg acgagaacat ttgttttggt acctgtcggc aaagtccacc 2580 ggagctccttccgcgtctga cgtcgatgga ttcgcgactg aggggcaggc ccgcttgggc 2640 tcgcttttatccgcgtcatc gggggcgggt ctcttgttgg ccccaccctt tctgacgtag 2700 aacccatgcgccacctcggt cacgtgatcc tgcgcccagc ggaagaacct tttgacttcc 2760 tgctttgtcaccttgccaaa gttatgctcc agacggcggg tgggttcaaa tttgaacatc 2820 cggtcctgcaacggctgctg gtgctcgaag gtggcgctgt tcccgtcaat cacggcgcac 2880 atgttggtgttggaggtgac ggtcacgggg gtggggtcga tctgggcgga cgacttgcac 2940 ttttggtccacgcgcacctt gctgccgccg agaatggcct tggcggactc cacgaccttg 3000 gccgtcatcttgccctcctc ccaccagatc accatcttgt cggcgcaatc gttgaaggga 3060 aagttctcattggtccagtt gacgcagccg tagaaagggc gaattc 3106 17 3102 DNA new AAVserotype, clone 27-3 17 gcggccgcga attcgccctt cgcagagacc aaagttcaactgaaacgaat caaccggttt 60 attgattaac aagtaattac aggttacggg tgaggtaacgggtgccaatg gggcgaggct 120 cagtataaac cccttcgttg ttgacagcaa attccacattattagacttg gcataatttg 180 aggtgtactg aatctctgga ttccagcgtt tgctgttttctttctgcagt tcccactcga 240 tctccacgct gacctggccg gtgctgtact gcgtgataaatgaggcaaac ttggcaggag 300 taaacacctc tggaggatta gcaggtaccg gggtgtttttgatgagaatt tgaggaggcg 360 ggtgtttgag tccaaatccg cccatcaggg gagacgggtgaaagttgccg tccgtgtgag 420 gaatttcggc ccagatggga ccctgcaggt acacgtcccggttctgccag accatgccgg 480 gcagagcccc ctggctgttg acagtctgtg tccggggtccggccgtagac gattgcaggt 540 tgctggagac cacaccgtat tcttctgtag ccacgggattggtggttttg atctcctcct 600 cgctggtcat tagcacgttt tccagcgttg tcttgttggcagcccccgtt ttgccaaaaa 660 ccagcactcc gttgatggga aggaactggt cctcgtcgtccttgttggtg gccatggcta 720 cgcccgggtt ggttaatgaa tttctaccat tcagatggtatttagtggcc ccggtccagg 780 caaagttact gttgttgttg ctgtctatgt tttttgacagtctctgctgc cgataacagg 840 gtccgggcag ccagttcttt gattgctcgg ccacggtgttgggcccagcc tgatggaact 900 gcagctccct tgtggacccc gtagtgctct gggtccgggccaggtagtac aggtactggt 960 cgatgagggg attcatcagc cggtccaggc tctggctgtgcgcatagctg ctgtggaaag 1020 gcacttcctc aaaggtgtag ctgaattcaa agttattgcccgttctcagc atctgagaag 1080 gaaagtactc caggcagcag aaggaggaac gtcccacagactgactgccg ttgtttagag 1140 tcagatatcc gtactgagga atcatgaaca cgtccgcagggaacggaggg aggcagccct 1200 ggtgcgcaga gccgaggacg tacggcagtt ggtactccgagtccgagaag acctgaatcg 1260 tgctggtaag gttattagcg atggtcgtaa cgccgtcgttcgtcgtgacc tccttgacct 1320 ggatgttgaa caacttgaac cgcagctttc tgggccggaatccccagttg ttgttgatga 1380 gtcgctgcca gtcacgtggt gagaagtggc agtggaatctgttgaagtca aaatagcccc 1440 agggggtgct gtagccgaag aagtggttgt cgttggtagccccgctctga cttgatatct 1500 gcttgtagag gtggttgttg taggtgggca gggcccaggtgcgggtgctg gtggtgatga 1560 ctctgtcgcc cagccatgtg gaatcgcaat gccaatttccggaggcatta cccactccgt 1620 cggcgccttc gttattgtct gccattggtg cgccaccgcctgcagccatt gtaccagatc 1680 ccagacctga gggcgcggcg ggaggttctc cgagaggttgggggtcgggc actgactctg 1740 agtcgccagt ctgcccaaag ttgagcttct ttttagcgggctgctggcct ttcttgccga 1800 tgcccgtgga ggagtcgggg gattctatgg gtctcttctttccggaagcc gtcttagcgc 1860 cttcctcaac cagaccgaga ggttcgagaa cccgcttcttggcctggaag actgctcgcc 1920 cgaggttgcc cccaaaagac gtatcttctt gaagacgctcctgaaactcg gcgtcggcgt 1980 ggttgtactt gaggtacggg ttgtccccct gctcgagctgcttgtcgtag gccttgtcgt 2040 gctcgagggc cgcggcgtct gcctcgttga ccggctctcccttgtcgagt ccgttgaagg 2100 gtccgaggta cttgtagcca ggaagcacca gaccccggccgtcgtcctgc ttttgctggt 2160 tggctttggg tttcggggct ccaggtttca agtcccaccactcgcgaatg ccctcagaga 2220 ggttgtcctc gagccaatct ggaagataac catcggcagccatacctggt ttaagtcatt 2280 tattgctcag aaacacagtc atccaggtcc acgttgaccagatcgcaggc cgagcaagca 2340 atctcgggag cccgccccag cagatgatga atggcacagagtttccgata cgtcctcttt 2400 ctgacgaccg gttgagattc tgacacgccg gggaaacattctgaacagtc tctggtcccg 2460 tgcgtgaagc aaatgttgaa attctgattc attctctcgcatgtcttgca gggaaacagc 2520 atctgaagca tgcccgcgtg acgagaacat ttgttttggtacctgtcggc aaagtccacc 2580 ggagctcctt ccgcgtctga cgtcgatgga tccgcgactgaggggcaagc ccgcttgggc 2640 tcgcttttat ccgcgtcatc gggggcgggt ctcttgttggctccaccctt tctgacgtag 2700 aactcatgcg ccacctcggt cacgtgatcc tgcgcccagcggaagaactc tttgacttcc 2760 tgctttgtca ccttgccaaa gtcatgctcc agacggcgggtgagttcaaa tttgaacatc 2820 cggtcttgta acggctgctg gtgctcgaag gtggtgctgttcccgtcaat cacggcgcac 2880 atgttggtgt tggaagtgac gatcacgggg gtgggatcgatctgggcgga cgacttgcac 2940 ttttggtcca cgcgcacctt gctgccgccg agaatggccttggcggactc cacgaccttg 3000 gccgtcatct tgccctcctc ccaccagatc accatcttgtcgacgcaatc gttgaaggga 3060 aagttctcat tggtccagtt gacgcagccg aagggcgaattc 3102 18 3106 DNA new AAV serotype, clone 7-2 18 gcggccgcga attcgcccttcgcagagacc aaagttcaac tgaaacgaat cagccggttt 60 attgattaac aagtaattacaggttacggg tgaggtaacg ggtgccaatg gggcgaggct 120 cagtataaac cccttcgttgttgacagcaa attccacatt attagacttg gcataatttg 180 aggtgtactg aatctctggattccagcgtt tgctgttttc tttctgcagt tcccactcga 240 tctccacgct gacctggccggtgctgtact gcgtgataaa tgaggcaaac ttggcaggag 300 taaacacctc tggaggattagcaggtaccg gggtgttttt gatgagaatt tgaggaggcg 360 ggtgtttgag tccaaatccgcccatcaggg gagacgggtg aaagttgccg tccgtgtgag 420 gaattttggc ccagatgggaccctgcaggt acacgtcccg gttctgccag accatgccgg 480 gcagagcccc ctggctgttgacagtctgtg tctggggtcc ggccgtagac gattgcaggt 540 tgctggagac cacaccgtattcttctgtag ccacgggatt ggtggttttg atctcctcct 600 cgctggtcat tagcacgttttccagcgttg tcttgttggc agcccccgtt ttgccaaaaa 660 ccagcactcc gttgatgggaaagaactggt cctcgtcgtc cttgttggtg gccatggcta 720 cgcccgggtt ggttaatgaatttctaccat tcagatggta tttagtggcc ccggtccagg 780 caaagttact gttgttgttgctgtctatgt tttttgacag tctctgctgc cgataacagg 840 gtccgggcag ccagttctttgattgctcgg ccatggtgtt gggcccagcc tgatggaact 900 gcagctccct tgtggaccccgtagtgctct gggtccgggc caggtagtac aggtactggt 960 cgatgagggg attcatcagccggtccaggc tctggctgtg cgcatagctg ctgtggaaag 1020 gcacttcctc aaaggtgtagctgaattcaa agttatcgcc cgttctcagc atctgagaag 1080 gaaagtactc caggcagtagaaggaggaac gtcccacaga ctgactgccg ttgtttagag 1140 tcagatatcc gtactgaggaatcatgaaca cgtccgcagg gaacggaggg aggcagccct 1200 ggtgcgcaga gccgaggacgtacggcagtt ggtactccga gtccgagaag acctgaatcg 1260 tgctggtaag gttattagcgatggtcgtaa cgccgtcgtt cgtcgtgacc tccttgacct 1320 ggatgttgaa caacttgaaccgcagctttc tgggccggaa tccccagttg ttgttgatga 1380 gtcgctgcca gtcacgtggtgagaagtggc agtggaatct gttgaagtca aaatagcccc 1440 agggggtgct gtagccgaagaagtggttgt cgttggtagc cccgctctga cttgatatct 1500 gcttgtagag gtggttgttgtaggtgggca gggcccaggt gcgggtgctg gtggtgatga 1560 ctctgtcgcc cagccatgtggaatcgcaat gccaatttcc ggaggcatta cccactccgt 1620 cggcgccttc gttattgtctgccattggtg cgccaccgcc tgcagccatt gtaccagatc 1680 ccagacctga gggcgcggcgggaggttctc cgagaggttg ggggtcgggc actgactctg 1740 agtcgccagt ctgcccaaagttgagcttct ttttagcggg cggctggccg ttcttgccga 1800 tgcccgtgga ggagtcgggggattctatgg gtctcttctt tccaggagcc gtcttagcgc 1860 cttcctcaac cagaccgagaggttcgagaa cccgcttctt ggcctggaag actgctcgcc 1920 cgaggttgcc cccaaaagacgtatcttctt gaagacgctc ctgaaactcg gcgtcggcgt 1980 ggttgtactt gaggtacgggttgtccccct gctcgagctg cttgtcgtag gccttgtcgt 2040 gctcgagggc cgcggcgtctgcctcgttga ccggctctcc cttgtcgagt ccgttgaagg 2100 gtccgaggta cctgtagccaggaagcacca gaccccggcc gtcgtcctgc ttttgctggt 2160 tggctttggg tttcggggctccaggtttca agtcccacca ctcgcgaatg ccctcagaga 2220 ggttgccctc gagccaatctggaagataac catcggcagc catacctggt ttaagtcatt 2280 tattgctcag aaacacagtcatccaggtcc acgttggcca gatcgcaggc cgagcaagca 2340 atctcgggag cccgccccagcagatgatga atggcacaga gtttccgata cgtcctcttt 2400 ctgacgaccg gttgagattctgacacgccg gggaaacatt ctgaacagtc tctggtcccg 2460 tgcgtgaagc aaatgttgaaattctgattc attctctcgc atgtcttgca ggggaacagc 2520 atctgaagca tgcccgcgtgacgagaacat ttgttttggt acctgtcggc aaagtccacc 2580 ggagctcctt ccgcgtctgacgtcgatgga tccgcgactg aggggcaggc ccgcttgggc 2640 tcgcttttat ccgcgtcatcgggggcgggt ctcttgttgg ctccaccctt tctgacgtag 2700 aactcatacg ccacctcggtcacgtgatcc tgcgcccagc ggaagaactc tttgacttcc 2760 tgctttgtca ccttgccaaagtcatgctcc agacggcggg tgagttcaaa tttgaacatc 2820 cggtcttgta acggctgctggtgctcgaag gtggtgctgt tcccgtcaat cacggcgcac 2880 atgttggtgt tggaagtgacgatcacgggg gtgggatcga tctgggcgga cgacttgcac 2940 ttttggtcca cgcgcaccttgctgccgccg agaatggcct tggcggactc cacgaccttg 3000 gccgtcatcc tgccctcctcccaccagatc accatcttgt cgacgcaatc gttgaaggga 3060 aagttctcat tggtccagttgacgcagccg tagaaagggc gaattc 3106 19 3105 DNA new AAV serotype, clone C119 gaattcgccc ttgctgcgtc aactggacca atgagaactt tcccttcaac gattgcgtcg 60acaagatggt gatctggtgg gaggagggca agatgaccgc caaggtcgtg gagtccgcca 120aggccattct gggcggaagc aaggtgcgcg tggaccaaaa gtgcaagtca tcggcccaga 180tcgaccccac gcccgtgatc gtcacctcca acaccaacat gtgcgccgtg atcgacggga 240acagcaccac cttcgagcac cagcagccgc tgcaggaccg catgttcaag ttcgagctca 300cccgccgtct ggagcacgac tttggcaagg tgaccaagca ggaagtcaaa gagttcttcc 360gctgggctca ggatcacgtg actgaggtgg cgcatgagtt ctacgtcaga aagggcggag 420ccaccaaaag acccgccccc agtgacgcgg atataagcga gcccaagcgg gcctgcccct 480cagttgcgga gccatcgacg tcagacgcgg aagcaccggt ggactttgcg gacaggtacc 540aaaacaaatg ttctcgtcac gcgggcatgc ttcagatgct gtttccctgc aagacatgcg 600agagaatgaa tcagaatttc aacgtctgct tcacgcacgg ggtcagagac tgctcagagt 660gcttccccgg cgcgtcagaa tctcaacccg tcgtcagaaa aaagacgtat cagaaactgt 720gcgcgattca tcatctgctg gggcgggcac ccgagattgc gtgttcggcc cgcgatctcg 780tcaacgtgga cttggatgac tgtgtttctg agcaataaat gacttaaacc aggtatggct 840gctgacggtt atcttccaga ttggctcgag gacaacctct ctgagggcat tcgcgagtgg 900tgggacctga aacctggagc ccccaagccc aaggccaacc agcagaagca ggacgacggc 960cggggtctgg tgcttcctgg ctacaagtac ctcggaccct tcaacggact cgacaagggg 1020gagcccgtca acgcggcgga cgcagcggcc ctcgagcacg acaaggccta cgaccagcag 1080ctcaaagcgg gtgacaatcc gtacctgcgg tataaccacg ccgacgccga gtttcaggag 1140cgtctgcaag aagatacgtc ttttgggggc aacctcgggc gagcagtctt ccaggccaag 1200aagagggtac tcgaacctct gggcctggtt gaagaaggtg ctaagacggc tcctggaaag 1260aagagaccgt tagagtcacc acaagagccc gactcctcct caggaatcgg caaaaaaggc 1320aaacaaccag ccaaaaagag actcaacttt gaagaggaca ctggagccgg agacggaccc 1380cctgaaggat cagataccag cgccatgtct tcagacattg aaatgcgtgc agcaccgggc 1440ggaaatgctg tcgatgcggg acaaggttcc gatggagtgg gtaatgcctc gggtgattgg 1500cattgcgatt ccacctggtc tgagggcaag gtcacaacaa cctcgaccag aacctgggtc 1560ttgcccacct acaacaacca cttgtacctg cggctcggaa caacatcaaa cagcaacacc 1620tacaacggat tctccacccc ctggggatac tttgacttta acagattcca ctgtcacttc 1680tcaccacgtg actggcaaag actcatcaac aacaactggg gactacgacc aaaagccatg 1740cgcgttaaaa tcttcaatat ccaagttaag gaggtcacaa cgtcgaacgg cgagactacg 1800gtcgctaata accttaccag cacggttcag atatttgcgg actcgtcgta tgagctcccg 1860tacgtgatgg acgctggaca agagggaagt ctgtctcctt tccccaatga cgtcttcatg 1920gtgcctcaat atggctactg tggcattgtg actggcgaaa atcagaacca gacggacaga 1980aatgctttct actgcctgga gtattttcct tcacaaatgc tgagaactgg caataacttt 2040gaaatggctt acaactttgg gaaggtgccg ttccactcaa tgtatgctta cagccagagc 2100ccggacagac tgatgaatcc cctcctggac cagtacctgt ggcacttaca gtcgaccacc 2160tctggagaga ctctgaatca aggcaatgca gcaaccacat ttggaaaaat caggagtgga 2220gactttgcct tttacagaaa gaactggctg cctgggcctt gtgttaaaca gcagagactc 2280tcaaaaactg ccagtcaaaa ttacaagatt cctgccagcg ggggcaacgc tctgttaaag 2340tatgacaccc actatacctt aaacaaccgc tggagcaaca tagcgcctgg acctccaatg 2400gcaacagctg gaccttcaga tggggacttc agcaacgccc agctcatctt ccctggacca 2460tcagtcaccg gaaacacaac aacctcagca aacaatctgt tgtttacatc agaagaagaa 2520attgctgcca ccaacccaag agacacggac atgtttggtc agattgctga caataatcag 2580aatgctacaa ctgctcccat aaccggcaac gtgactgcta tgggagtgct tcctggcatg 2640gtgtggcaaa acagagacat ttactaccaa gggccaattt gggccaagat cccacacgcg 2700gacggacatt ttcatccttc accgctaatt ggcggttttg gactgaaaca tccgcctccc 2760cagatattta tcaaaaacac ccccgtacct gccaatcctg cgacaacctt cactgcagcc 2820agagtggact ctttcatcac acaatacagc accggccagg tcgctgttca gattgaatgg 2880gaaatcgaaa aggaacgctc caaacgctgg aatcctgaag tgcagtttac ttcaaactat 2940gggaaccagt cttctatgtt gtgggctccc gatacaactg ggaagtatac agagccgcgg 3000gttattggct ctcgttattt gactaatcat ttgtaactgc ctagttaatc aataaaccgt 3060gtgattcgtt tcagttgaac tttggtctct gcgaagggcg aattc 3105 20 3105 DNA newAAV serotype, clone C3 20 gaattcgccc ttgctgcgtc aactggacca atgagaactttcccttcaac gattgcgtcg 60 acaagatggt gatctggtgg gaggagggca agatgaccgccaaggtcgtg gagtccgcca 120 aggccattct gggcggaagc aaggtgcgcg tggaccaaaagtgcaagtca tcggcccaga 180 tcgaccccac gcccgtgatc gtcacctcca acaccaacatgtgcgccgtg atcgacggga 240 acagcaccac cttcgagcac cagcagccgc tgcaggaccgcatgttcaag ttcgagctca 300 cccgccgtct ggagcacgac tttggcaagg tgaccaagcaggaagtcaaa gagttcttcc 360 gctgggctca ggatcacgtg actgaggtgg cgcatgagttctacgtcaga aagggcggag 420 ccaccaaaag acccgccccc agtgacgcgg atataagcgagcccaagcgg gcctgcccct 480 cagttgcgga gccatcgacg tcagacgcgg aagcaccggtggactttgcg gacaggtacc 540 aaaacaaatg ttctcgtcac gcgggcatgc ttcagatgctgtttccctgc aagacatgcg 600 agagaatgaa tcagaatttc aacgtctgct tcacgcacggggtcagagac tgctcagagt 660 gcttccccgg cgcgtcagaa tctcaacccg tcgtcagaaaaaagacgtat cagaaactgt 720 gcgcgattca tcatctgctg gggcgggcac ccgagattgcgtgttcggcc tgcgatctcg 780 tcaacgtgga cttggatgac tgtgtttctg agcaataaatgacttaaacc aggtatggct 840 gctgacggtt atcttccaga ttggctcgag gacaacctctctgagggcat tcgcgagtgg 900 tgggacctga aacctggagc ccccaagctc aaggccaaccagcagaagca ggacgacggc 960 cggggtctgg tgcttcctgg ctacaagtac ctcggacccttccacggact cgacaagggg 1020 gagcccgtca acgcggcgga cgcagcggcc ctcgagcacgacaaggccta cgaccagcag 1080 ctcaaagcgg gtgacaatcc gtacctgcgg tataaccacgccgacgccga gtttcaggag 1140 cgtctgcaag aagatacgtc ttttgggggc aacctcgggcgagcagtctt ccaggccaag 1200 aagagggtac tcgaaccact gggcctggtt gaagaaggtgctaagacggc tcctggaaag 1260 aagagaccgt tagagtcacc acaagagccc gactcctcctcaggaatcgg caaaaaaggc 1320 aaacaaccag ccaaaaagag actcaacttt gaagaggacactggagccgg agacggaccc 1380 cctgaaggat cagataccag cgccatgtct tcagacattgaaatgcgtgc agcaccgggc 1440 ggaaatgctg tcgatgcggg acaaggttcc gatggagtgggtaatgcctc gggtgattgg 1500 cattgcgatt ccacctggtc tgagggcaag gtcacaacaacctcgaccag aacctgggtc 1560 ttgcccacct acaacaacca cttgtacctg cggctcggaacaacatcaaa cagcaacacc 1620 tacaacggat tctccacccc ctggggatac tttgactttaacagattcca ctgtcacttc 1680 tcaccacgtg actggcaaag actcatcaac aacaactggggactacgacc aaaagccatg 1740 cgcgttaaaa tcttcaatat ccaagttaag gaggtcacaacgtcgaacgg cgagactacg 1800 gtcgctaata accttaccag cacggttcag atatttgcggactcgtcgta tgagctcccg 1860 tacgtgatgg acgctggaca agagggaagt ctgcctcctttccccaatga cgtcttcatg 1920 gtgcctcaat atggctactg tggcattgtg actggcgaaaatcagaacca gacggacaga 1980 aatgctttct actgcctgga gtattttcct tcacaaatgctgagaactgg caataacttt 2040 gaaatggctt acaactttga gaaggtgccg ttccactcaatgtatgctca cagccagagc 2100 ctggacagac tgatgaatcc cctcctggac cagtacctgtggcacttaca gtcgaccacc 2160 tctggagaga ctctgaatca aggcaatgca gcaaccacatttggaaaaat caggagtgga 2220 gactttgcct tttacagaaa gaactggctg cctgggccttgtgttaaaca gcagagattc 2280 tcaaaaactg ccagtcaaaa ttacaagatt cctgccagcgggggcaacgc tctgttaaag 2340 tatgacaccc actatacctt aaacaaccgc tggagcaacatagcgcctgg acctccaatg 2400 gcaacagctg gaccttcaga tggggacttc agcaacgcccagctcatctt ccctggacca 2460 tcagtcaccg gaaacacaac aacctcagca aacaatctgttgtttacatc agaaggagaa 2520 attgctgcca ccaacccaag agacacggac atgtttggtcagattgctga caataatcag 2580 aatgctacaa ctgctcccat aaccggcaac gtgactgctatgggagtgct tcctggcatg 2640 gtgtggcaaa acagagacat ttactaccaa gggccaatttgggccaagat cccacacgcg 2700 gacggacatt ttcatccttc accgctaatt ggcggttttggactgaaaca tccgcctccc 2760 cagatattta tcaaaaacac ccccgtacct gccaatcctgcgacaacctt cactgcagcc 2820 agagtggact ctttcatcac acaatacagc accggccaggtcgctgttca gattgaatgg 2880 gaaatcgaaa aggaacgctc caaacgccgg aatcctgaagtgcagtttac ttcaaactat 2940 gggaaccagt cttctatgtt gtgggctccc gatacaactgggaagtatac agagccgcgg 3000 gttattggct ctcgttattt gactaatcat ttgtaactgcctagttaatc aataaaccgt 3060 gtgattcgtt tcagttgaac tttggtctct gcgaagggcgaattc 3105 21 3105 DNA new AAV serotype, clone C5 21 gaattcgcccttcgcagaga ccaaagttca actgaaacga atcacacggt ttattgatta 60 actaggcagttacaaatgat tagtcaaata acgagagcca ataacccgcg gctctgtata 120 cttcccagttgtatcgggag cccacaacat agaagactgg ttcccacagt ttgaagtaaa 180 ctgcacttcaggattccagc gtttggagcg ttccttttcg atttcccatt caatctgaac 240 agcgacctggccggtgctgt attgtgtgat gaaagagtcc actctggctg cagtgaaggt 300 tgtcgcaggataggcaggta cgggggtgtt tttgataaat atctggggag gcggatgttt 360 cagtccaaaaccgccaatta gcggtgaagg atgaaaatgt ccgtccgcgt gtgggatctt 420 ggcccaaattggcccttggt agtaaatgtc tctgttttgc cacaccatgc caggaagcac 480 tcccatagcagtcacgttgc cggttatggg agcagttgta gcattctgat tattgtcagc 540 aatctgaccaaacatgtccg tgtctcttgg gttggtggca gcaatttctt cttctgatgt 600 aaacaacagattgtttgctg aggttgttgt gtttccggtg actgatggtc cagggaagat 660 gagctgggcgttgctgaagt ccccatctga aggtccagct gttgccattg gaggtccagg 720 cgctatgttgctccagcggt tgtttaaggt atagtgggtg tcatacttta acagagcgtt 780 gcccccgctggcaggaatct tgtaattttg actggcagtt tttgagaatc tctgctgttt 840 aacacaaggcccaggcagcc agttctttct gtaaaaggca aagtctccac tcctgatttt 900 tccaaatgtggttgctgcat tgccttgatt cagagtctct ccagaggtgg tcgactgtaa 960 gtgccacaggtactggtcca ggaggggatt catcagtccg tccaggctct ggctgtgagc 1020 atacattgagtggaacggca ccttctcaaa gttgtaagcc gtttcaaagt tattgccagt 1080 tctcagcatttgtgaaggaa aatactccag gcagtagaaa gcatttctgt ccgtctggtt 1140 ctgattttcgccagtcacaa tgccacagta gccatattga ggcaccatga agacgtcatt 1200 ggggaaaggaggcagacttc cctcttgtcc agcgtccatc acgtacggga gctcatacga 1260 cgagtccgcaaatatctgaa ccgtgctggt aaggttatta gcgaccgtag tctcgccgtt 1320 cgacgttgtgacctccttaa cttggatatt gaagatttta acgcgcatgg cttttggtcg 1380 tagtccccagttgttgttga tgagtctttg ccagtcacgt ggtgagaagt gacagtggaa 1440 tctgttaaagtcaaagtatc cccagggggt ggagaatccg ttgtaggtgt tgctgtttga 1500 tgttgttccgagccgcaggt acaagtggtt gttgtaggtg ggcaagaccc aggttctggt 1560 cgaggttgttgtgaccttgc cctcagacca ggtggaatcg caatgccaat cacccgaggc 1620 attacccactccatcggaac cttgtcccgc atcgacagca tttccgcccg gtgctgcacg 1680 catttcaatgtctgaagaca tggcgctggt atctgatcct tcagggggtc cgtctccggc 1740 tccagtgtcctcttcaaagt tgagtctctt tttggctggt tgtttgcctt ttttgccgat 1800 tcctgaggaggagtcgggct cttgtggtga ctctaacggt ctcttctttc caggagccgt 1860 cttagcaccttcttcaacca ggcccagagg ttcgagtacc ctcttcttgg cctggaagac 1920 tgctcgcccgaggttgcccc caaaagacgt atcttcttgc agacgctcct gaaactcggc 1980 gtcggcgtggttataccgca ggtacggatt gtcacccgct ttgagctgct ggtcgtaggc 2040 cttgtcgtgctcgagggccg ctgcgtccgc cgcgttgacg ggctccccct tgtcgagtcc 2100 gttgaagggtccgaggtact cgtagccagg aagcaccaga ccccggccgt cgtcctgctt 2160 ctgctggttggccttgggct tgggggctcc aggtttcagg tcccaccact cgcgaatgcc 2220 ctcagagaggttgtcctcga gccaatctgg aagataaccg tcagcagcca tacctggttt 2280 aagtcatttattgctcagaa acacagtcat ccaagtccac gttgacgaga tcgcaggccg 2340 aacacgcaatctcgggtgcc cgccccagca gatgatgaat cgcgcacagt ttctgatacg 2400 tcttttttctgacgacgggt tgagattctg acgcgccggg gaagcactct gagcagtctc 2460 tgaccccgtgcgtgaagcag acgttgaaat tctgattcat tctctcgcat gtcttgcagg 2520 gaaacagcatctgaagcatg cccgcgtgac gagaacattt gttttggtac ctgtccgcaa 2580 ggtccaccggtgcttccgcg tctgacgtcg atggctccgc aactgagggg caggcccgct 2640 tgggctcgcttatatccgcg tcactggggg cgggtctttt ggtggctccg ccctttctga 2700 cgtagaactcatgcgccacc tcagtcacgt gatcctgagc ccagcggaag aactctttga 2760 cttcctgcttggtcaccttg ccaaagtcgt gctccagacg gcgggtgagc tcgaacttga 2820 acatgcggtcctgcagcggc tgctggtgct cgaaggtggt gctgttcccg tcgatcacgg 2880 cgcacatgttggtgttggag gtgacgatca cgggcgtggg gtcgatctgg gccgatgact 2940 tgcacttttggtccacgcgc accttgcttc cgcccagaat ggccttggcg gactccacga 3000 ccttggcggtcatcttgccc tcctcccacc agatcaccat cttgtcgacg caatcgttga 3060 agggaaagttctcattggtc cagttgacgc agcaagggcg aattc 3105 22 3094 DNA new AAVserotype, clone F1 22 gaattcgccc ttgctgcgtc aactggacca agagaactttcccttcaacg attgcgtcga 60 caagatggtg atctggtggg aggagggcaa gatgacggccaaggtcgtgg agtccgccaa 120 agccattctg ggcggaagca aggtgcgcgt cgaccaaaagtgcaagtcct cggcccagat 180 cgatcccacc cccgtgatcg tcacctccaa caccaacatgtgcgccgtga tcgacgggaa 240 cagcaccacc ttcgagcacc agcagccgtt gcaggaccggatgttcaaat ttgaactcac 300 ccgccgtctg gaacacgact ttggcaaggt gaccaagcaggaagtcaaag agttcttccg 360 ctgggctagt gatcacgtga ctgaggtgac gcatgagttctacgtcagaa agggcggagc 420 cagcaaaaga cccgcccccg atgacgcgga tataagcgagcccaagcggg cctgtccctc 480 agtcacggac ccatcgacgt cagacgcgga aggagctccggtggactttg ccgacaggta 540 ccaaaacaaa tgttctcgtc acgcgggcat gcttcagatgctgtttccct gcaaaacgtg 600 cgagagaatg aatcagaatt tcaacatttg cttcacgcacggggtcagag actgtttaga 660 atgtttcccc ggcgtgtcag aatctcaacc ggtcgtcagaaaaaagacgt atcggaagct 720 gtgtgcgatt catcatctgc tggggcgggc acccgagattgcttgctcgg cctgcgacct 780 ggtcaacgtg gacctggacg actgtgtttc tgagcaataaatgacttaaa ccgggtatgg 840 ctgccgatgg ttatcttcca gattggctcg aggacaacctctctgagggc attcgcgagt 900 ggtgggacct gaaacctgga gccccgaaac ccaaagccaaccagcaaaag caggacgacg 960 gccggggtct ggtgcttcct ggctacaagt acctcggacccttcaacgga ctcgacaagg 1020 gggagcccgt caacgcggcg gacgcagcgg ccctcgagcacgacaaggcc tacgaccagc 1080 agctcaaagc gggtgacaat ccgtacctgc ggtataaccacgccgacgcc gagtttcagg 1140 agcgtctgca agaagatacg tcatttgggg gcaacctcgggcgagcagtc ttccaggcca 1200 agaagcgggt tctcgaacct ctcggtctgg ttgaggaaggcgctaagacg gctcctggaa 1260 agaagagacc catagactct ccagactcct ccacgggcatcggcaaaaaa ggccagcagc 1320 ccgctaaaaa gaagctcaat tttggtcaga ctggcgactcagagtcagtc cccgaccctc 1380 aacctcttgg agaacctcca gcagcgccct ctagtgtgggatctggtaca atggctgcag 1440 gcggtggcgc accaatggca gacaataacg aaggtgccgacggagtgggt aatgcctcag 1500 gaaattggca ttgcgattcc acatggctgg gcgacagagtcatcaccacc agcaccagaa 1560 cctgggccct ccccacctac aacaaccacc tctacaagcaaatctccagc agcagctcag 1620 gagccaccaa tgacaaccac tacttcggct acagcaccccctgggggtat tttgacttta 1680 acagattcca ctgccacttc tcaccacgtg actggcagcgactcatcaac aacaactggg 1740 gattccggcc caagaagctg cggttcaagc tcttcaacatccaggtcaag gaggtcacaa 1800 cgaatgacgg cgtcacgacc atcgctaata accttaccagcacggttcag gtcttctcgg 1860 actcggaata ccagctgccg tacgtcctcg gctctgcgcaccagggctgc ctgcctccgt 1920 tcccggcgga cgtcttcatg attcctcagt acggctacctgactctgaac aacggcagcc 1980 aatcggtggg ccgttcctcc ttctactgcc tggaatatttcccctctcaa atgctgagaa 2040 cgggcaacaa ctttgagttc agttacagct tcgaggacgtgcctttccac agcagctacg 2100 cgcacagcca gagcctagac cggctgatga accctctcatcgaccagtac ctgtactacc 2160 tggcccggac ccagagcacc acgggttcca ccagggaactgcaatttcat caagctgggc 2220 ccaatactat ggccgagcag tcaaagaact ggctgcctggaccctgctat aggcaacagg 2280 gactgtcaaa gaacttggac tttaacaaca acagcaattttgcctggact gctgccacta 2340 aatatcatct gaatggcaga aactctttga ccaatcctggcattcccatg gcaaccaaca 2400 aggatgatga ggaccagttc tttcccatca acggggtactggtttttggc aagacgggag 2460 ctgccaacaa aactacgctg gaaaacgttc tgatgaccagcgaggaggag atcaagacca 2520 ctaaccctgt ggctacagaa gaatacggtg tggtctccagcaacctgcag ccgtctacag 2580 ccgggcctca atcacagact atcaacagcc agggagcactgcctggcatg gtctggcaga 2640 accgggacgt gtatctgcag ggtcccatct gggccaaaattcctcacacg gatggcaact 2700 ttcacccgtc tcctctgatg ggcggttttg gactcaaacacccgcctcca cagatcctga 2760 tcaaaaacac acctgtacct gctaatcctc cggaggtgtttactcctgcc aagtttgcct 2820 ccttcatcac gcagtacagc accggacaag tcagcgtggaaatcgagtgg gagctgcaga 2880 aagaaaacag caagcgctgg aacccagaaa ttcagtatacttccaattat gccaagtcta 2940 ataatgttga atttgctgtg aaccctgatg gtgtttatactgagcctcgc cccattggca 3000 ctcgttacct cccccgtaat ctgtaattgc ttgttaatcaataaaccggt tgattcgttt 3060 cagttgaact ttggtctctg cgaagggcga attc 3094 233095 DNA new AAV serotype, clone F3 23 gaattcgccc ttcgcagaga ccaaagttcaactgaaacga atcaaccggt ttattgatta 60 acaagcaatt acagattacg ggtgaggtaacgagtgccaa tggggcgagg ctcagtataa 120 acaccatcag ggttcacagc aaattcaacattattagact tggcataatt ggaagtatac 180 tgaatttctg ggttccagcg cttgctgttttctttctgca gctcccactc gatttccacg 240 ctgacttgtc cggtgctgta ctgcgtgatgaaggaggcaa acttggcagg agtaaacacc 300 tccggaggat tagcaggtac aggtgtgtttttgatcagga tctgtggagg cgggtgtttg 360 agtccaaaac cgcccatcag aggagacgggtgaaagttgc catccgtgtg aggaattttg 420 gcccagatgg gaccctgcag atacacgtcccggttctgcc agaccatgcc aggcagtgct 480 ccctggctgt tgatagtctg tgattgaggcccggctgtag acgactgcag gttgctggag 540 accacaccgt attcttctgt agccacagggttagtggtct tgatctcctc ctcgctggtc 600 atcagaacgt tttccagcgt agttttgttggcagctcccg tcttgccaaa aaccagtacc 660 ccgttgatgg gaaagaactg gtcctcatcatccttgttgg ttgccatggg aatgccagga 720 ttggtcaaag agtttctgcc attcagatgatatttagtgg cagcagtcca ggcaaaattg 780 ctgttgttgt taaagtccaa gttctttgacagtctctgtt gcctatagca gggtccaggc 840 agccagttct ttgactgctc ggccatagtattgggcccag cttgatgaaa ttgcagttcc 900 ctggtggaac ccgtggtgct ctgggtccgggccaggtagt acaggtactg gtcgatgaga 960 gggttcatca gccggtctag gctctggctgtgcgcgtagc tgctgtggaa aggcacgtcc 1020 tcgaagctgt aactgaactc aaagttgttgcccgttctca gcatttgaga ggggaaatat 1080 tccaggcagt agaaggagga acggcccaccgattggctgc cgttgtccag agtcaggtag 1140 ccgtactgag gaatcatgaa gacgtccgccgggaacggag gcaggcagcc ctggtgcgca 1200 gagccgagga cgtacggcag ctggtattccgagtccgaga agacctgaac cgtgctggta 1260 aggttattag cgatggtcgt gacgccgtcattcgttgtga cctccttgac ctggatgttg 1320 aggagcttga accgcagctt cttgggccggaatccccagt tgttgttgat gagtcgctgc 1380 cagtcacgtg gtgagaagtg gcagtggaatctgttaaagt caaaataccc ccagggggtg 1440 ctgtagccga agtagtggtt gtcattggtggctcctgagc tgctgctgga gatttgcttg 1500 tagaggtggt tgttgtaggt ggggagggcccaggttctgg tgctggtggt gatgactctg 1560 tcgcccagcc atgtggaatc gcaatgccaatttcctgagg cattacccac tccgtcggca 1620 ccttcgttat tgtctgccat tggtgcgccaccgcctgcag ccattgtacc agatcccaca 1680 ctagagggcg ctgctggagg ttctccaagaggttgagggt cggggactga ctctgagtcg 1740 ccagtctgac caaaattgag cttctttttagcgggctgct ggcctttttt gccgatgccc 1800 gtggaggagt ctggagagcc tatgggtctcttctttccag gagccgtctt agcgccttcc 1860 tcaaccagac cgagaggttc gagaacccgcttcttggcct ggaagactgc tcgcccgagg 1920 ttgcccccaa atgacgtatc ttcttgcagacgctcctgaa actcggcgtc ggcgtggtta 1980 taccgcaggt acggattgtc acccgctttgagctgctggt cgtaggcctt gtcgtgctcg 2040 agggccgctg cgtccgccgc gttgacgggctcccccttgt cgagtccgtt gaagggtccg 2100 aggtacttgt agccaggaag caccagaccccggccgtcgt cctgcttttg ctggttggct 2160 ttgggtttcg gggctccagg tttcaggtcccaccactcgc gaatgccctc agagaggttg 2220 tcctcgagcc aatctggaag ataaccatcggcagccatac ctggtttaag tcatttattg 2280 ctcagaaaca cagtcgtcca ggtccacgttgaccaggtcg caggccgagc aagcaatctc 2340 gggtgcccgc cccagcagat gatgaatcgcacacagcttc cgatacgtct tttttctgac 2400 gaccggttga gattctgaca cgccggggaaacattctaaa cagtctctga ccccgtgcgt 2460 gaagcaaatg ttgaaattct gattcattctctcgcacgtt ttgcagggaa acagcacctg 2520 aagcatgccc gcgtgacgag aacatttgttttggtacctg tcggcaaagt ccaccggagc 2580 tccttccgcg tctgacgtcg atgggtccgtgactgaggga cgggcccgct tgggctcgct 2640 tatatccgcg tcatcggggg cgggtcttttgctggctccg ccctttctga cgtagaactc 2700 atgcgtcacc tcagtcacgt gatcactagcccagcggaag aactctttga cttcctgctt 2760 tgtcaccttg ccaaagtcgt gttccagacggcgggtgagt tcaaatttga acatccggtc 2820 ctgcaacggt tgctggtgct cgaaggtggtgctgttcccg tcgatcacgg cgcacatgtt 2880 ggtgttggag gtgacgatca cgggggtgggatcgatctgg gcggacgact tgcacttttg 2940 gtccacgcgc accttgctgc cgccgagaatggccttggcg gactccacga ccttggccgt 3000 catcttgccc tcctcccacc agatcaccatcttgtcgacg caatcgttga agggaaagtt 3060 ctcattggtc cagttgacgc agcaagggcgaattc 3095 24 3095 DNA new AAV serotype, clone F5 24 gaattcgcccttcgcagaga ccaaagttca actgaaacga atcaaccggt ttattgatta 60 acaagcaattacagattacg ggtgaggtaa cgagtgccaa tggggcgagg ctcagtataa 120 acaccatcagggttcacagc aaattcaaca ttattagact tggcataatt ggaagtatac 180 tgaatttctgggttccagcg cttgctgttt tctttctgca gctcccactc gatttccacg 240 ctgacttgtccggtgctgta ctgcgtgatg aaggaggcaa acttggcagg agtaaacacc 300 tccggaggattagcaggtac aggtgtgttt ttgatcagga tctgtggagg cgggtgttcg 360 agtccaaaaccgcccatcag aggagacggg tgaaagttgc catccgtgtg aggaattttg 420 gcccagatgggaccctgcag atacacgtcc cggttctgcc agaccatgcc aggcagtgct 480 ccctggctgttgatagtctg tgattgaggc ccggctgtag acgactgcag gttgctggag 540 accacaccgtattcttctgt agccacaggg ttagtggtct tgatctcctc ctcgctggtc 600 atcagaacgttttccagcgt agttttgttg gcagctcccg tcttgccaaa aaccagtacc 660 ccgttgatgggaaagaactg gtcctcatca tccttgttgg ttgccatggg aatgccagga 720 ttggtcaaagagtttctgcc attcagatga tatttagtgg cagcagtcca ggcaaaattg 780 ctgttgttgttaaagtccaa gttctttgac agtctctgtt gcctatagca gggtccaggc 840 agccagttctttgactgctc ggccatagta ttgggcccag cttgatgaaa ttgcagttcc 900 ctggtggaacccgtggtgct ctgggtccgg gccaggtagt acaggtactg gtcgatgaga 960 gggttcatcagccggtctag gctctggctg tgcgcgtagc tgctgtggaa aggcacgtcc 1020 tcgaagctgtaactgaactc aaagttgttg cccgttctca gcatttgaga ggggaaatat 1080 tccaggcagtagaaggagga acggcccacc gattggctgc cgttgttcag agtcaggtag 1140 ccgtactgaggaatcatgaa gacgtccgcc gggaacggag gcaggcagcc ctggtgcgca 1200 gagccgaggacgtacggcag ctggtattcc gagtccgaga agacctgaac cgtgctggta 1260 aggttattagcgatggtcgt gacgccgtca ttcgttgtga cctccttgac ctggatgttg 1320 aagagcttgaaccgcagctt cttgggccgg aatccccagt tgttgttgat gagtcgctgc 1380 cagtcacgtggtgagaagtg gcagtggaat ctgttaaagt caaaataccc ccagggggtg 1440 ctgtagccgaagtagtggtt gtcattggtg gctcctgagc tgctgctgga gatttgcttg 1500 tagaggtggttgttgtaggt ggggagggcc caggttctgg tgctggtggt gatgactctg 1560 tcgcccagccatgtggaatc gcaatgccaa tttcctgagg cattacccac tccgtcggca 1620 ccttcgttattgtctgccgt tggtgcgcca ccgcctgcag ccattgtacc agatcccaca 1680 ctagagggcgctgctggagg ttctccaaga ggttgagggt cggggactga ctctgagtcg 1740 ccagtctgaccaaaattgag cttcttttta gcgggctgct ggcctttttt gccgatgccc 1800 gtggaggagtctggagagtc tatgggtctc ttctttccag gagccgtctt agcgccttcc 1860 tcaaccagaccgagaggttc gagaacccgc ttcttggcct ggaagactgc tcgcccgagg 1920 ttgcccccaaatgacgtatc ttcttgcagg cgctcctgaa actcggcgtc ggcgtggtta 1980 taccgcaggtacggattgtc acccgctttg agctgctggt cgtaggcctt gtcgtgctcg 2040 agggccgctgcgtccgccgc gttgacgggc tcccccttgt cgagtccgtt gaagggtccg 2100 aggtacttgtagccaggaag caccagaccc cggccgtcgt cctgcttttg ctggttggct 2160 ttgggtttcggggctccagg tttcaggtcc caccactcgc gaatgccctc agagaggttg 2220 tcctcgagccaatctggaag ataaccatcg gcagccatac ctggtttaag ccatttattg 2280 ctcagaaacacagtcgtcca ggtccacgtt gaccaggtcg caggccgagc aggcaatctc 2340 gggtgcccgccccagcagat gatgaatcgc acacagcttc cgatacgtct tttttctgac 2400 gaccggttgagattctgaca cgccggggaa acattctaaa cagtctctga ccccgtgcgt 2460 gaagcaaatgttgaaattct gattcattct ctcgcacgtt ttgcagggaa acagcatctg 2520 aagcatgcccgcgtggcgag aacatttgtt ttggtacctg tcggcaaagt ccaccggagc 2580 tccttccgcgtctgacgtcg atgggtccgt gactgaggga caggcccgct tgggctcgct 2640 tatatccgcgtcatcggggg cgggtctttt gctggctccg ccctttctga cgtagaactc 2700 atgcgtcacctcagtcacgt gatcactagc ccagcggaag aactctttga cttcctgctt 2760 tgtcaccttgccaaagtcgt gttccagacg gcgggtgagt tcaaatttga acatccggtc 2820 ctgcaacggctgctggtgct cgaaggtggt gctgttcccg tcgatcacgg cgcgcatgtt 2880 ggtgttggaggtgacgatca cgggggtggg atcgatctgg gcggacgact tgcacttttg 2940 gtccacgcgcaccttgctgc cgccgagaat ggccttggcg gactccacga ccttggccgt 3000 catcttgccctcctcccacc agatcaccat cttgtcgacg caatcgttga agggaaagtt 3060 ctcattggtccagttgacgc agcaagggcg aattc 3095 25 3142 DNA new AAV serotype, clone H625 aaaacgacgg gccagtgatt gtaatacgac tcactatagg gcgaaattga aattagcggc 60cgcgaattcg cctttcgcag agaccaaagt tcaactgaaa cgaattaaac ggtttattga 120ttaacaagca attacagatt acgagtcagg tatctggtgc caatggggcg aggctctgaa 180tacacaccat tagtgtccac agtaaagtcc acattaacag acttgttgta gttggaagtg 240tactgaattt cgggattcca gcgtttgctg ttctccttct gcagctccca ctcgatctcc 300acgctgacct gtcccgtgga atactgtgtg atgaaagaag caaacttggc agaactgaag 360tttgtgggag gattggctgg aacgggagtg tttttgatca tgatctgagg aggcgggtgt 420ttgagtccaa aacctcccat cagtggagaa ggatgaaagt gtccatcggt gtgaggaatc 480ttggcccaaa tgggtccctg caggtacacg tctcgatcct gccacaccat accaggtaac 540gctccttggt gattgacagt tccagtagtt ggaccagtgt ttgagttttg caaattattt 600gacacagtcc cgtactgctc cgtagccacg ggattggtgg ccctgatttc ttcttcatct 660gtaatcatga cattttccaa atccgcgtcg ttggcatttg ttccttgttt accaaatatc 720agggttccat gcatggggaa aaacttttct tcgtcatcct tgtgactggc catagctggt 780cctggattaa ccaacgagtc ccggccattt agatgatact ttgtagctgc agtccaggga 840aagttgctgt tgttgttgtc gtttgcctgt tttgacagac gctgctgtct gtagcaaggt 900ccaggcagcc agtttttagc ttgaagagac atgttggttg gtccagcttg gctaaacagt 960agccgagact gctgaagagt tccactattt gtttgtgtct tgttcagata atacaggtac 1020tggtcgatca gaggattcat cagccgatcc agactctggc tgtgagcgta gctgctgtgg 1080aaaggcacgt cttcaaaagt gtagctgaac tgaaagttgt ttccagtacg cagcatctga 1140gaaggaaagt actccaggca gtaaaaggaa gagcgtccta ccgcctgact cccgttgttc 1200agggtgaggt atccatactg tgggaccatg aagacgtccg ctggaaacgg cgggaggcat 1260ccttgatgcg ccgagcccag gacgtacggg agctggtact ccgagtcagt aaacacctga 1320accgtgctgg taaggttatt ggcaatcgtc gtcgtaccgt cattctgcgt gacctctttg 1380acttgaatat taaagagctt gaagttgagt cttttgggcc ggaatccccg gttgttgttg 1440acgagtcttt gccagtcacg tggtgaaaag tggcagtgga atctgttgaa gtcaaaatac 1500ccccaggggg tgctgtagcc aaagtagtgg ttgtcgttgc tggctcctga ttggctggag 1560atttgcttgt agaggtggtt gttgtatgtg ggcagggccc aggttcgggt gctggtggtg 1620atgactctgt cgcccagcca ttgggaatcg caatgccaat ttcctgagga attacccact 1680ccatcggcac cctcgttatt gtctgccatt ggtgcgccac tgcctgtagc cattgtagta 1740gatcccagac cagagggggc tgctggtggc tgtccgagag gctgggggtc aggtacggag 1800tctgcgtctc cagtctgacc aaaatttaat ctttttcttg caggctgctg gcccgctttt 1860ccggttcccg aggaggagtc tggctccaca ggagagtgct ctaccggcct cttttttccc 1920ggagccgtct taacaggctc ctcaaccagg cccagaggtt caagaaccct ctttttcgcc 1980tggaagactg ctcgtccgag gttgccccca aaagacgtat cttctttaag gcgctcctga 2040aactctgcgt cggcgtggtt gtacttgagg tacgggttgt ctccgctgtc gagctgccgg 2100tcgtaggcct tgtcgtgctc gagggccgcg gcgtctgcct cgttgaccgg ctcccccttg 2160tcgagtccgt tgaagggtcc gaggtacttg tacccaggaa gcacaagacc cctgctgtcg 2220tccttatgcc gctctgcggg ctttggtggt ggtgggccag gtttgagctt ccaccactgt 2280cttattcctt cagagagagt gtcctcgagc caatctggaa gataaccatc ggcagccata 2340cctgatttaa atcatttatt gttcagagat gcagtcatcc aaatccacat tgaccagatc 2400gcaggcagtg caagcgtctg gcacctttcc catgatatga tgaatgtagc acagtttctg 2460atacgccttt ttgacgacag aaacgggttg agattctgac acgggaaagc actctaaaca 2520gtctttctgt ccgtgagtga agcagatatt tgaattctga ttcattctct cgcattgtct 2580gcagggaaac agcatcagat tcatgcccac gtgacgagaa catttgtttt ggtacctgtc 2640cgcgtagttg atcgaagctt ccgcgtctga cgtcgatggc tgcgcaactg actcgcgcgc 2700ccgtttgggc tcacttatat ctgcgtcact gggggcgggt cttttcttag ctccaccctt 2760tttgacgtag aattcatgct ccacctcaac cacgtgatcc tttgcccacc ggaaaaagtc 2820tttcacttcc tgcttggtga cctttccaaa gtcatgatcc agacggcggg taagttcaaa 2880tttgaacatc cggtcttgca acggctgctg gtgctcgaag gtcgttgagt tcccgtcaat 2940cacggcgcac atgttggtgt tggaggtgac gatcacggga gtcgggtcta tctgggccga 3000ggacttgcat ttctggtcca cacgcacctt gcttcctcca agaatggctt tggccgactc 3060cacgaccttg gcggtcatct tcccctcctc ccaccagatc accatcttgt cgacgcaatg 3120gtaaaaggaa agttctcatt gg 3142 26 3075 DNA new AAV serotype, clone H2 26tgagaacttt cctttcaacg attgcgtcgg acaagatggt gatctggtgg gaggagggga 60agatgaccgc caaggtcgtg gagtcggcca aagccattct tggaggaagc aaggtgcgtg 120tggaccagaa atgcaagtcc tcggcccaga tagacccgac tcccgtgatc gtcacctcca 180acaccaacat gtgcgccgtg attgacggga actcaacgac cttcgagcac cagcagccgt 240tgcaagaccg gatgttcaaa tttgaactta cccgccgtct ggatcatgac tttggaaagg 300tcaccaagca ggaagtgaaa gactttttcc ggtgggcaaa ggatcacgtg gttgaggtgg 360agcatgaatt ctacgtcaaa aagggtggag ctaagaaaag acccgccccc agtgacgcag 420atataagtga gcccaaacgg gcgcgcgagt cagttgcgca gccatcaacg tcagacgcgg 480aagcttcgat caactacgcg gacaggtacc aaaaacaaat gttctcgtca cgtgggcatg 540aatctgatgc tgtttccctg cagacaatgc gagagaatga atcagaattc aaatatctgc 600ttcactcacg gacagaaaga ctgtttagag tgctttcccg tgtcagaatc tcaacccgtt 660tctgtcgtca aaaaggcgta tcagaaactg tgctacattc atcatatcat gggaaaggtg 720ccagacgctt gcactgcctg cgatctggtc aatgtggatt tggatgactg catctctgaa 780caataaatga tttaaatcag gtatggctgc cgatggttat cctccagatt ggctcgagga 840cactctctct gaagggataa gacagtggtg gaagctcaaa cctggcccac caccaccaaa 900gcccgcagag cggcataagg acgacagcag gggtcttgtg cttcctgggt acaagtacct 960cggacccttc aacggactcg acaaggggga gccggtcaac gaggcagacg ccgcggccct 1020cgagcacgac aaggcctacg accggcagct cgacagcgga gacaacccgt acctcaagta 1080caaccacgcc gacgcagagt ttcaggagcg ccttaaagaa gatacgtctt ttgggggcaa 1140cctcggacga gcagtcttcc aggcgaaaaa gagggttctt gaacctctgg gcctggttga 1200ggaacctgtt aagacggctc cgggaaaaaa gaggccggta gagcactctc ctgtggagcc 1260agactcctcc tcgggaaccg gaaaagcggg ccagcggcct gcaagaaaaa gattaaattt 1320tggtcagact ggagacgcag actccgtacc tgacccccag cctctcggac agccaccagc 1380agccccctct ggtctgggat ctactacaat ggctacaggc agtggcgcac caatggcaga 1440caataacgag ggtgccgatg gagtgggtaa ttcctcagga aattggcatt gcgattccca 1500atggctgggc gacagagtca tcaccaccag cacccgaacc tgggccctgc ccacatacaa 1560caaccacctc tacaagcaaa tctccagcca atcaggagcc agcaacgaca accactactt 1620tggctacagc accccctggg ggtattttga cttcaacaga ttccactgcc acttttcacc 1680acgtgactgg caaagactca tcaacaacaa ctggggattc cggcccaaaa gactcaactt 1740caagctcttt aatattcaag tcaaagaggt cacgcagaat gacggtacga cgacgattgc 1800caataacctt accagcacgg ttcaggtgtt tactgactcg gagtaccagc tcccgtacgt 1860cctgggctcg gcgcatcaag gatgcctccc gccgtttcca gcggacgtct tcatggtccc 1920acagtatgga tacctcaccc tgaacaacgg gagtcaggcg gtaggacgct cttcctttta 1980ctgcctggag tactttcctt ctcagatgct gcgtactgga aacaactttc agttcagcta 2040cacttttgaa gacgtgcctt tccacagcag ctacgctcac agccagagtc tggatcggct 2100gatgaatcct ctgatcgacc agtacctgta ttatctgaac aagacacaaa caaatagtgg 2160aactcttcag cagtctcggc tactgtttag ccaagctgga ccaaccaaca tgtctcttca 2220agctaaaaac tggctgcctg gaccttgcta cagacagcag cgtctgtcaa aacaggcaaa 2280cgacaacaac aacagcaact ttccctggac tgcagctaca aagtatcatc taaatggccg 2340ggactcgttg gttaatccag gaccagctat ggccagtcac aaggatgacg aagaaaagtt 2400tttccccatg catggaaccc tgatatttgg taaacaagga acaaatgcca acgacgcgga 2460tttggaaaat gtcatgatta cagatgaaga agaaatcagg gccaccaatc ccgtggctac 2520ggagcagtac gggactgtgt caaataattt gcaaaactca aacactggtc caactactgg 2580aactgtcaat cgccaaggag cgttacctgg tatggtgtgg caggatcgag acgtgtacct 2640gcagggaccc atttgggcca agattcctca caccgatgga cactttcatc cttctccact 2700gatgggaggt tttggactca aacacccgcc tcctcagatc atgatcaaaa acactcccgt 2760tccagccaat cctcccacaa acttcagttc tgccaagttt gcttctttca tcacacagta 2820ttccacggga caggtcagcg tggagatcga gtgggagctg cagaaggaga acagcaaacg 2880ctggaatccc gaaattcagt acacttccaa ctacaacaag tctgttaatg tggactttac 2940tgtggacact aatggtgtgt attcagagcc tcgccccatt ggcaccagat acctgactcg 3000taatctgtaa ttgcttgtta atcaataaac cgtttaattc gtttcagttg aactttggtc 3060tctgcgaagg gcgaa 3075 27 3128 DNA 42.8 27 gaattcgccc tttctacggctgcgtcaact ggaccaatga gaactttccc ttcaacgatt 60 gcgtcgacaa gatggtgatctggtgggagg agggcaagat gacggccaag gtcgtggagt 120 ccgccaaggc cattctcggcggcagcaagg tgcgcgtgga ccaaaagtgc aagtcttccg 180 cccagatcga tcccacccccgtgatcgtca cttccaacac caacatgtgc gccgtgattg 240 acgggaacag caccaccttcgagcaccagc agccgttaca agaccggatg ttcaaatttg 300 aactcacccg ccgtctggagcacgactttg gcaaggtgac aaagcaggaa gtcaaagagt 360 tcttccgctg ggcgcaggatcacgtgaccg aggtggcgca tgagttctac gtcagaaagg 420 gtggagccaa caagagacccgcccccgatg acgcggataa aagcgagccc aagcgggcct 480 gcccctcagt cgcggatccatcgacgtcag acgcggaagg agctccggtg gactttgccg 540 acaggtacca aaacaaatgttctcgtcacg cgggcatgct tcagatgctg tttccctgca 600 agacatgcga gagaatgaatcagaatttca acatttgctt cacgcacggg accagagact 660 gttcagaatg tttccccggcgtgtcagaat ctcaaccggt cgtcagaaag aggacgtatc 720 ggaaactctg tgccattcatcatctgctag ggcgggctcc cgagattgct tgctcggcct 780 gcgatctggt caacgtggacctggatgact gtgtttctga gcaataaatg acttaaacca 840 ggtatggctg ccgatggttatcttccagat tggctcgagg acaacctctc tgagggcatt 900 cgcgagtggt gggacttgaaacctggagcc ccgaaaccca aagccaacca gcaaaagcag 960 gacgacggcc ggggtctggtgcttcctggc tacaagtacc tcggaccctt caacggactc 1020 gacaaggggg agcccgtcaacgcggcggac gcagcggccc tcgagcacga caaggcctac 1080 gaccagcagc tcaaagcgggtgacaatccg tacctgcggt ataaccacgc cgacgccgag 1140 tttcaggagc gtctgcaagaagatacgtct tttgggggca acctcgggcg agcagtcttc 1200 caggccaaga agcgggttctcgaacctctc ggtctggttg aggaaggcgc taagacggct 1260 cctggaaaga agagaccggtagagccatca ccccagcgtt ctccagactc ctctacgggc 1320 atcggcaaga caggccagcagcccgcgaaa aagagactca actttgggca gactggcgac 1380 tcagagtcag tgcccgaccctcaaccaatc ggagaacccc ccgcaggccc ctctggtctg 1440 ggatctggta caatggctgcaggcggtggc gctccaatgg cagacaataa cgaaggcgcc 1500 gacggagtgg gtagttcctcaggaaattgg cattgcgatt ccacatggct gggcgacaga 1560 gtcatcacca ccagcacccgaacctgggcc ctccccacct acaacaacca cctctacaag 1620 caaatctcca acgggacatcgggaggaagc accaacgaca acacctactt cggctacagc 1680 accccctggg ggtattttgactttaacaga ttccactgcc acttctcacc acgtgactgg 1740 cagcgactca tcaacaacaactggggattc cggcccaaga gactcaactt caagctcttc 1800 aacatccagg tcaaggaggtcacgcagaat gaaggcacca agaccatcgc caataacctt 1860 accagcacga ttcaggtctttacggactcg gaataccagc tcccgtacgt cctcggctct 1920 gcgcaccagg gctgcctgcctccgttcccg gcggacgtct tcatgattcc tcagtacggg 1980 tacctgactc tgaacaacggcagtcaggcc gtgggccgtt cctccttcta ctgcctggag 2040 tactttcctt ctcaaatgctgagaacgggc aacaactttg agttcagcta ccagtttgag 2100 gacgtgcctt ttcacagcagctacgcgcac agccaaagcc tggaccggct gatgaacccc 2160 ctcatcgacc agtacctgtactacctgtct cggactcagt ccacgggagg taccgcagga 2220 actcagcagt tgctattttctcaggccggg cctaataaca tgtcggctca ggccaaaaac 2280 tggctacccg ggccctgctaccggcagcaa cgcgtctcca cgacactgtc gcaaaataac 2340 aacagcaact ttgcttggaccggtgccacc aagtatcatc tgaatggcag agactctctg 2400 gtaaatcccg gtgtcgctatggcaacgcac aaggacgacg aagagcgatt ttttccatcc 2460 agcggagtct tgatgtttgggaaacaggga gctggaaaag acaacgtgga ctatagcagc 2520 gttatgctaa ccagtgaggaagaaatcaaa accaccaacc cagtggccac agaacagtac 2580 ggcgtggtgg ccgataacctgcaacagcaa aacgccgctc ctattgtagg ggccgtcaac 2640 agtcaaggag ccttacctggcatggtctgg cagaaccggg acgtgtacct gcagggtcct 2700 atctgggcca agattcctcacacggacggc aactttcatc cttcgccgct gatgggaggc 2760 tttggactga aacacccgcctcctcagatc ctgattaaga atacacctgt tcccgcggat 2820 cctccaacta ccttcagtcaagccaagctg gcgtcgttca tcacgcagta cagcaccgga 2880 caggtcagcg tggaaattgaatgggagctg cagaaagaga acagcaagcg ctggaaccca 2940 gagattcagt atacttccaactactacaaa tctacaaatg tggactttgc tgtcaatact 3000 gagggtactt attcagagcctcgccccatt ggcacccgtt acctcacccg taacctgtaa 3060 ttgcctgtta atcaataaaccggctaattc gtttcagttg aactttggtc tctgcgaagg 3120 gcgaattc 3128 28 3128DNA new AAV serotype, clone 42.15 28 gaattcgccc tttctacggc tgcgtcaactggaccaatga gaactttccc ttcaacgatt 60 gcgtcgacaa gatggtgatc tggtgggaggagggcaagat gacggccaag gtcgtggagt 120 ccgccaaggc cattctcggc ggcagcaaggtgcgcgtgga ccaaaagtgc aagtcgtccg 180 cccagatcga ccccaccccc gtgatcgtcacctccaacac caacatgtgc gccgtgattg 240 acgggaacag caccaccttc gagcaccagcagccgttgca ggaccggatg ttcaaatttg 300 aactcacccg ccgtctggag catgactttggcaaggtgac aaagcaggaa gtcaaagagt 360 tcttccgctg ggcgcaggat cacgtgaccgaggtggcgca tgagttctac gtcagaaagg 420 gtggagccaa caagagaccc gcccccgatgacgcggataa aagcgagccc aagcgggcct 480 gcccctcagt cgcggatcca tcgacgtcagacgcggaagg agctccggtg gactttgccg 540 acaggtacca aaacaaatgt tctcgtcacgcgggcatgct tcagatgctg tttccctgca 600 agacatgcga gagaatgaat cagaatttcaacatttgctt cacgcgcggg accagagact 660 gttcagaatg tttcccgggc gtgtcagaatctcaaccggt cgtcagaaag aggacgtatc 720 ggaaactctg tgccattcat catctgctggggcgggctcc cgagattgct tgctcggcct 780 gcgatctggt caacgtggac ctggatgactgtgtttctga gcaataaatg acttaaacca 840 ggtatggctg ccgatggtta tcttccagattggctcgagg acaacctctc tgagggcatt 900 cgcgagtggt gggacttgaa acctggagccccgaaaccca aagccaacca gcaaaagcag 960 gacgacggcc ggggtctggt gcttcctggctacaagtacc tcggaccctt caacggactc 1020 gacaaggggg agcccgtcaa cgcggcggacgcagcggccc tcgagcacga caaggcctac 1080 gaccagcagc tcaaagcggg tgacaatccgtacctgcggt ataaccacgc cgacgccgag 1140 tttcaggagc gtctgcaaga agatacgtcttttgggggca acctcgggcg agcagtcttc 1200 caggccaaga agcgggttct cgaacctctcggtctggttg aggaaggcgc taagacggct 1260 cctggaaaga agagaccggt agagccatcaccccagcgtt ctccagactc ctctacgggc 1320 atcggcaaga caggccagca gcccgcgaaaaagagactca actttgggca gactggcgac 1380 tcagagtcag tgcccgaccc tcaaccaatcggagaacccc ccgcaggccc ctctggtctg 1440 ggatctggta caatggctgc aggcggtggcgctccaatgg cagacaataa cgaaggcgcc 1500 gacggagtgg gtagttcctc aggaaattggcattgcgatt ccacatggct gggcgacaga 1560 gtcatcacca ccagcacccg aacctgggccctccccacct acaacaacca cctctacaag 1620 caaatctcca acgggacatc gggaggaagcaccaacgaca acacctactt cggctacagc 1680 accccctggg ggtattttga ctttaacagattccactgcc acttctcacc acgtgactgg 1740 cagcgactca tcaacaacaa ctggggattccggcccaaga gactcaactt caagctcttc 1800 aacatccagg tcaaggaggt cacgcagaatgaaggcacca agaccatcgc caataacctt 1860 accagcacga ttcaggtctt tacggactcggaataccagc tcccgtacgt cctcggctct 1920 gcgcaccagg gctgcccgcc tccgttcccggcggacgtct tcatgattcc tcagtacggg 1980 tacctgactc tgaacaacgg cagtcaggccgtgggccgtt cctccttcta ctgcctggag 2040 tactttcctt ctcaaatgcg gagaacgggcaacaactttg agttcagcta ccagtttgag 2100 gacgtgcctt ttcacagcag ctacgcgcatagccaaagcc tggaccggct gatgaacccc 2160 ctcatcgacc agtacctgta ctacctgtctcggactcagt ccacgggagg taccgcagga 2220 actcagcagt tgctattttc tcaggccgggcctaataaca tgtcggctca ggccaaaaac 2280 tggctacccg ggccctgcta ccggcagcaacgcgtctcca cgacactgtc gcaaaataac 2340 aacagcaact ttgcttggac cggtgccaccaagtatcatc tgaatggcag agactctctg 2400 gtaaatcccg gtgtcgctat ggcaacgcacaaggacgacg aagagcgatt ttttccatcc 2460 agcggagtct tgatgtttgg gaaacagggagctggaaaag acaacgtgga ctatagcagc 2520 gttatgctaa ccagtgagga agaaatcaaaaccaccaacc cagtggccac agaacagtac 2580 ggcgtggtgg ccgataacct gcaacagcaaaacgccgctc ctattgtagg ggccgtcaac 2640 agtcaaggag ccttacctgg catggtctggcagaaccggg acgtgtacct gcagggtcct 2700 atctgggcca agattcctca cacggacggcaactttcatc cttcgccgct gatgggaggc 2760 tttggactga aacacccgcc tcctcagatcctgattaaga atacacctgt tcccgcggat 2820 cctccaacta ccttcagtca agccaagctggcgtcgttca tcacgcagta cagcaccgga 2880 caggtcagcg tggaaattga atgggagctgcagaaagaga acagcaagcg ctggaaccca 2940 gagattcagt atacttccaa ctactacaaatctacaaatg tggactttgc tgtcaatact 3000 gagggtactt attcagagcc tcgccccattggcacccgtt acctcacccg taacctgtaa 3060 ttgcctgtta atcaataaac cggttaattcgtttcagttg aactttggtc tctgcgaagg 3120 gcgaattc 3128 29 3197 DNA new AAVserotype. clone 42.5b 29 gaattcgccc tttctacggc tgcgtcaact ggaccaatgagaactttccc ttcaacgatt 60 gcgtcgacaa gatggtgatc tggtgggagg agggcaagatgacggccaag gtcgtggagt 120 ccgccaaggc cattctcggc ggcagcaagg tgcgcgtggaccaaaagtgc aagtcgtccg 180 cccagatcga ccccaccccc gtgatcgtca cctccaacaccaacatgtgc gccgtgattg 240 acgggaacag caccaccttc gagcaccagc agccgttacaagaccggatg ttcaaatttg 300 aactcacccg ccgtctggag cacgactttg gcaaggtgacaaagcaggaa gtcaaagagt 360 tcttccgctg ggcgcaggat cacgtgaccg aggtggcgcatgagttctac gtcagaaagg 420 gtggagccaa caagagaccc gcccccgatg acgcggataaaagcgagccc aagcgggcct 480 gcccctcagt cgcggatcca tcgacgtcag acgcggaaggagctccggtg gactttgccg 540 acaggtacca aaacaaatgt tctcgtcacg cgggcatgcttcagatgctg tttccctgca 600 agacatgcga gagaatgaat cagaatttca acatttgcttcacgcacggg accagagact 660 gttcagaatg tttccccggc gtgtcagaat ctcaaccggtcgtcagaaag aggacgtatc 720 ggaaactctg tgccattcat catctgctgg ggcgggctcccgagattgct tgctcggcct 780 gcgatctggt caacgtggac ctggatgact gtgtttctgagcaataaatg acttaaacca 840 ggtatggctg ccgatggtta tcttccagat tggctcgaggacaacctctc tgagggcatt 900 cgcgagtggt gggacttgaa acctggagcc ccgaaacccaaagccaacca gcaaaagcag 960 gacgacggcc ggggtctggt gcttcctggc tacaagtacctcggaccctt caacggactc 1020 gacaagggag agccggtcaa cgaggcagac gccgcggccctcgagcacga caaggcctac 1080 gacaagcagc tcgagcaggg ggacaacccg tacctcaagtacaaccacgc cgacgccgag 1140 tttcaggagc gtcttcaaga agatacgtct tttgggggcaacctcgggcg agcagtcttc 1200 caggccaaga agcgggttct cgaacctctc ggtctggttgaggaaggcgc taagacggct 1260 cctggaaaga agagaccggt agagccatca ccccagcgttctccagactc ctctacgggc 1320 atcggcaaga caggccagca gcccgcgaaa aagagactcaactttgggca gactggcgac 1380 tcagagtcag tgcccgaccc tcaaccaatc ggagaaccccccgcaggccc ctctggtctg 1440 ggatctggta caatggctgc aggcggtggc gctccaatggcagacaataa cgaaggcgcc 1500 gacggagtgg gtagttcctc aggaaattgg cattgcgattccacatggct gggcgacaga 1560 gtcatcacca ccagcacccg aacctgggcc ctccccacctacaacaacca cctctacaag 1620 caaatctcca acgggacatc gggaggaagc accaacgacaacacctactt cggctacagc 1680 accccctggg ggtattttga ctttaacaga ttccactgccacttctcacc acgtgactgg 1740 cagcgactca tcaacaacaa ctggggattc cggcccaagagactcaactt caagctcttc 1800 aacatccagg tcaaggaggt cacgcagaat gaaggcaccaagaccatcgc caataacctt 1860 accagcacga ttcaggtctt tacggactcg gaataccagctcccgtacgt cctcggctct 1920 gcgcaccagg gctgcctgcc tccgttcccg gcggacgtcttcatgattcc tcagtacggg 1980 tacctgactc tgaacaacgg cagtcaggcc gtgggccgttcctccttcta ctgcctggag 2040 tactttcctt ctcaaatgct gagaacgggc aacaactttgagttcagcta ccagtttgag 2100 gacgtgcctt ttcacagcag ctacgcgcac agccaaagcctggaccggct gatgaacccc 2160 ctcatcgacc agtacctgta ctacctgtct cggactcagtccacgggagg taccgcagga 2220 actcagcagt tgctattttc tcaggccggg cctaataacatgtcggctca ggccaaaaac 2280 tggctacccg ggccctgcta ccggcagcaa cgcgtctccacgacactgtc gcaaaataac 2340 aacagcaact ttgcttggac cggtgccacc aagtatcatctgaatggcag agactctctg 2400 gtaaatcccg gtgtcgctat ggcaacgcac aaggacgacgaagagcgatt ttttccatcc 2460 agcggagtct tgatgtttgg gaaacaggga gctggaaaagacaacgtgga ctatagcagc 2520 gttatgctaa ccagtgagga agaaatcaaa accaccaacccagtggccac agaacagtac 2580 ggcgtggtgg ccgataacct gcaacagcaa aacgccgctcctattgtagg ggccgtcaac 2640 agtcaaggag ccttacctgg catggtctgg cagaaccgggacgtgtacct gcagggtcct 2700 atctgggcca agattcctca cacggacggc aactttcatccttcgccgct gatgggaggc 2760 tttggactga aacacccgcc tcctcagatc ctgattaagaatacacctgt tcccgcggat 2820 cctccaacta ccttcagtca agccaagctg gcgtcgttcatcacgcagta cagcaccgga 2880 caggtcagcg tggaaattga atgggagctg cagaaagagaacagcaagcg ctggaaccca 2940 gagattcagt atacttccaa ctactacaaa tctacaaatgtggactttgc tgtcaatact 3000 gagggtactt attcagagcc tcgccccatt ggcacccgttacctcacccg taacctgtaa 3060 ttgcctgtta atcaataaac cggttaattc gtttcagttgaactttggtc tctgcgaagg 3120 gcgaattcgt ttaaacctgc aggactagtc cctttagtgagggttaattc tgagcttggc 3180 gtaatcatgg gtcatag 3197 30 2501 DNA new AAVserotype, clone 42.1b 30 gaattcgccc ttggctgcgt caactggacc aatgagaactttcccttcaa cgattgcgtc 60 gacaagatgg tgatctggtg ggaggagggc aagatgacggccaaggtcgt ggagtccgcc 120 aaggccattc atcatctgct ggggcgggct cccgagattgcttgctcggc ctgcgatctg 180 gtcaacgtgg acctggatga ctgtgtttct gagcaataaatgacttaaac caggtatggc 240 tgccgatggt tatcttccag attggctcga ggacaacctctctgagggca ttcgcgagtg 300 gtgggacttg agacctggag ccccgaaacc caaagccaaccagcaaaagc aggacgacgg 360 ccggggtctg gtgcttcctg gctacaagta cctcggacccttcaacggac tcgacaaggg 420 agagccggtc aacgaggcag acgccgcggc cctcgagcacgacaaggcct acgacaagca 480 gctcgagcag ggggacaacc cgtacctcaa gtacaaccacgccgacgccg agtttcagga 540 gcgtcttcaa gaagatacgt cttttggggg caacctcgggcgagcagtct tccaggccaa 600 gaagcgggtt ctcgaacctc tcggtctggt tgaggaaggcgctaagacgg ctcctggaaa 660 gaagagaccc atagaatccc ccgactcctc cacgggcatcggcaagaaag gccagcagcc 720 cgctaaaaag agactcaact ttgggcagac tggcgactcagagtcagtgc ccgaccctca 780 accaatcgga gaaccccccg caggcccctc tggtctgggatctggcacaa tggctgcagg 840 cggtggcgct ccaatggcag acaataacga aggcgccgacggagtgggta gttcctcagg 900 aaattggcat tgcgattcca catggctggg cgacagagtcatcaccacca gcacccgaac 960 ctgggccctc cccacctaca acaaccacct ctacaagcaaatctccaacg ggacatcggg 1020 aggaagcacc aacgacaaca cctacttcgg ctacagcaccccctgggggt attttgactt 1080 taacagattc cactgccact tctcaccacg tgactggcagcgactcatca acaacaactg 1140 gggattccgg cccaagagac tcaacttcaa gctcttcaacatccaggtca aggaggtcac 1200 gcagaatgaa ggcaccaaga ccatcgccaa taaccttaccagcacgattc aggtctttac 1260 ggactcggaa taccagctcc cgtacgtcct cggctctgcgcaccagggct gcctgcctcc 1320 gttcccggcg gacgtcttca tgattcctca gtacgggtacctgactctga acaacggcag 1380 tcaggccgtg ggccgttcct ccttctactg cctggagtactttccttctc aaatgctgag 1440 aacgggcaac aactttgagt tcagctacca gtttgaggacgtgccttttc acagcagcta 1500 tgcgcacagc caaagcctgg accggctgat gaaccccctcatcgaccagt acctgtacta 1560 cctgtctcgg actcagtcca cgggaggtac cgcaggaactcagcagttgc tattttctca 1620 ggccgggcct aataacatgt cggctcaggc caaaaactggctacccgggc cctgctaccg 1680 gcagcaacgc gtctccacga cagtgtcgca aaataacaacagcaactttg cttggaccgg 1740 tgccaccaag tatcatctga atggcagaga ctctctggtaaatcccggtg tcgctatggc 1800 aacgcacaag ggcgacgaag agcgattttt tccatccagcggagtcttga tgtttgggaa 1860 acagggagct ggaaaagaca acgtagacta tagcagcgttatgctaacca gtgaggaaga 1920 aatcaaaacc accaacccag tggccacaga acagtacggcgtggtggccg ataacctgca 1980 acagcaaaac gccgctccta ttgtaggggc cgtcaacagtcaaggagcct tacctggcat 2040 ggtctggcag aaccgggacg tgtacctgca gggtcctatctgggccaaga ttcctcacac 2100 ggacggcaac tttcatcctt cgccgctgat gggaggctttggactgaaac acccgcctcc 2160 tcagatcctg attaagaata cacctgttcc cgcggatcctccaactacct tcagtcaagc 2220 caagctggcg tcgttcatca cgcagtacag caccggacaggtcagcgtgg aaattgaatg 2280 ggagctgcag aaagagaaca gcaagcgctg gaacccagagattcagtata cttccaacta 2340 ctacaaatct acaaatgtgg actttgctgt caatactgagggtacttatt cagagcctcg 2400 ccccattggc acccgttacc tcacccgtaa cctgtaattgcctgttaatc aataaaccgg 2460 ttgattcgtt tcagttgaac tttggtctca agggcgaatt c2501 31 3113 DNA new AAV serotype, clone 42.13 31 gaattcgccc tttctacggctgcgtcaact ggaccaatga gaactttccc ttcaacgatt 60 gcgtcgacaa gatggtgatctggtgggagg agggcaagat gacggccaag gtcgtggagt 120 ccgccaaggc cattctcggcggcagcaagg tgcgcgtgga ccaaaagtgc aagtcgtccg 180 cccagatcga tcccacccccgtgatcgtca cttccaacac caacatgtgc gccgtgattg 240 acgggaacag caccaccttcgagcaccagc agccgttaca agaccggatg ttcaaatttg 300 aactcacccg ccgtctggagcatgactttg gcaaggtgac aaagcaggaa gtcaaagagt 360 tcttccgctg ggcgcaggatcacgtgaccg aggtggcgca tgagttctac gtcagaaagg 420 gtggagccaa caagagacccgcccccgatg acgcggataa aagcgagccc aagcgggcct 480 gcccctcagt cgcggatccatcgacgtcag acgcggaagg agctccggtg gactttgccg 540 acaggtacca aaacaaatgttctcgtcacg cgggcatgct tcagatgctg tttccctgca 600 agacatgcga gagaatgaatcagaatttca acatttgctt cacgcacggg accagagact 660 gttcagaatg tttccccggcgtgtcagaat ctcaaccggt cgtcagaaag aggacgtatc 720 ggaaactctg tgccattcatcatctgctgg ggcgggctcc cgagattgct tgctcggcct 780 gcgatctggt caacgtggacctggatgact gtgtttctga gcaataaatg acttaaacca 840 ggtatggctg ccgatggttatcttccagat tggctcgagg acaacctctc tgagggcatt 900 cgcgagtggt gggacttgaaacctggagcc ccgaaaccca aagccaacca gcaaaagcag 960 gacgacggcc ggggtctggtgcttcctggc tacaagtacc tcggaccctt caacggactc 1020 gacaaggggg agcccgtcaacgcggcggac gcagcggccc tcgagcacga caaggcctac 1080 gaccagcagc tcaaagcgggtgacaatccg tacctgcggt ataaccacgc cgacgccgag 1140 tttcaggagc gtcttcaagaagatacgtct tttgggggca acctcgggcg agcagtcttc 1200 caggccaaga agcgggttctcgaacctctc ggtctggttg aggaaggcgc taagacggct 1260 cctggaaaga agagacccatagaatccccc gactcctcca cgggcatcgg caagaaaggc 1320 cagcagcccg ctaaaaagaagctcaacttt gggcagactg gcgactcaga gtcagtgccc 1380 gaccctcaac caatcggagaaccccccgca ggcccctctg gtctgggatc tggtacaatg 1440 gctgcaggcg gtggcgctccaatggcagac aataacgaag gcgccgacgg agtgggtagt 1500 tcctcaggaa attggcattgcgattccaca tggctgggcg acagagtcat caccaccagc 1560 acccgaacct gggccctccccacctacaac aaccacctct acaagcaaat ctccaacggg 1620 acatcgggag gaagcaccaacgacaacacc tacttcggct acagcacccc ctgggggtat 1680 tttgacttta acagattccactgccacttc tcaccacgtg actggcagcg actcatcaac 1740 aacaactggg gattccggcccaagagactc aacttcaagc tcttcaacat ccaggtcaag 1800 gaggtcacgc agaatgaaggcaccaagacc atcgccaata accttaccag cacgattcag 1860 gtctttacgg actcggaataccagctcccg tacgtcctcg gctctgcgca ccagggctgc 1920 ctgcctccgt tcccggcggacgtcttcatg attcctcagt acgggtacct gactctgaac 1980 aacggcagtc aggccgtgggccgttcctcc ttctactgcc tggagtactt tccttctcaa 2040 atgctgagaa cgggcaacaactttgagttc agctaccagt ttgaggacgt gccttttcac 2100 agcagctatg cgcacagccaaagcctggac cggctgatga accccctcat cgaccagtac 2160 ctgtactacc tgtctcggactcagtccacg ggaggtaccg caggaactca gcagttgcta 2220 ttttctcagg ccgggcctaataacatgtcg gctcaggcca aaaactggct acccgggccc 2280 tgctaccggc agcaacgcgtctccacgaca gtgtcgcaaa ataacaacag caactttgct 2340 tggaccggtg ccaccaagtatcatctgaat ggcagagact ctctggtaaa tcccggtgtc 2400 gctatggcaa cgcacaagggcgacgaagag cgattttttc catccagcgg agtcttgatg 2460 tttgggaaac agggagctggaaaagacaac gtggactata gcagcgttat gctaaccagt 2520 gaggaagaaa tcaaaaccaccaacccagtg gccacagaac agtacggcgt ggtggccgat 2580 aacctgcaac agcaaaacgccgctcctatt gtaggggccg tcaacagtca aggagcctta 2640 cctggcatgg tctggcagaaccgggacgtg tacctgcagg gtcctatctg ggccaagatt 2700 cctcacacgg acggcaactttcatccttcg ccgctgatgg gaggctttgg actgaaacac 2760 ccgcctcctc agatcctgattaagaataca cctgttcccg cggatcctcc aactaccttc 2820 agtcaagcca agctggcgtcgttcatcacg cagtacagca ccggacaggt cagcgtggaa 2880 attgaatggg agctgcagaaagagaacagc aagcgctgga acccagagat tcagtatact 2940 tccaactact acaaatctacaaatgtggac tttgctgtca atactgaggg tacttattca 3000 gagcctcgcc ccattggcacccgttacctc acccgtagcc tgtaattgcc tgttaatcaa 3060 taaaccggtt gattcgtttcagttgaactt tggtctctgc gaagggcgaa ttc 3113 32 3113 DNA new AAV serotype,clone 42.3a 32 gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttcccttcaacgatt 60 gcgtcgacaa gatggtgatc tggtgggagg agggcaagat gacggccaaggtcgtggagt 120 ccgccaaggc cattctcggc ggcagcaagg tgcgcgtgga ccaaaagtgcaagtcgtccg 180 cccagatcga tcccaccccc gtgatcgtca cttccaacac caacatgtgcgccgtgattg 240 acgggaacag caccaccttc gagcaccagc agccgttaca agaccggatgttcaaatttg 300 aactcacccg ccgtctggag catgactttg gcaaggtgac aaagcaggaagtcaaagagt 360 tcttccgctg ggcgcaggat cacgtgaccg aggtggcgca tgagttctacgtcagaaagg 420 gtggagccaa caagagaccc gcccccgatg acgcggataa aagcgagcccaagcgggcct 480 gcccctcagt cgcggatcca tcgacgtcag acgcggaagg agctccggtggactttgccg 540 acaggtacca aaacaaatgt tctcgtcacg cgggcatgct tcagatgctgcttccctgca 600 agacatgcga gagaatgaat cagaatttca gcatttgctt cacgcacgggaccagagact 660 gttcagaatg tttccccggc gtgtcagaat ctcaaccggt cgtcagaaagaggacgtatc 720 ggaaactctg tgccattcat catctgctgg ggcgggctcc cgagattgcttgctcggcct 780 gcgatctggt caacgtggac ctggatgact gtgtttctga gcaataaatgacttaaacca 840 ggtatggctg ccgatggtca tcttccagat tggctcgagg acaacctctctgagggcatt 900 cgcgagtggt gggacttgaa acctggagcc ccgaaaccca aagccaaccagcaaaagcag 960 gacgacggcc ggggtctggt gcttcctggc tacaagtacc tcggacccttcaacggactc 1020 gacaaggggg agcccgtcaa cgcggcggac gcagcggccc tcgagcacgacaaggcctac 1080 gaccagcagc tcaaagcggg tgacaatccg tacctgcggt ataaccacgccgacgccgag 1140 tttcaggagc gtcttcaaga agatacgtct tttgggggca acctcgggcgagcagtcttc 1200 caggccaaga agcgggttct cgaacctctc ggtctggttg aggaaggcgctaagacggct 1260 cctggaaaga agagacccat agaatccccc gactcctcca cgggcatcggcaagaaaggc 1320 cagcagcccg ctaaaaagaa gctcaacttt gggcagactg gcgactcagagtcagtgccc 1380 gaccctcaac caatcggaga accccccgca ggcccctctg gtctgggatctggtacaatg 1440 gctgcaggcg gtggcgctcc aatggcagac aataacgaag gcgccgacggagtgggtagt 1500 tcctcaggaa attggcattg cgattccaca tagctgggcg acagagtcatcaccaccagc 1560 acccgaacct gggccctccc cacctacaac aaccacctct acaagcaaatctccaacggg 1620 acatcgggag gaagcaccaa cgacaacacc tacttcggct acagcaccccctgggggtat 1680 tttgacttta acagattcca ctgccacttc tcaccacgtg actggcagcgactcatcaac 1740 aacagctggg gattccggcc caagagactc aacttcaagc tcttcaacatccaggtcaag 1800 gaggtcacgc agaatgaagg caccaagacc atcgccaata accttaccagcacgattcag 1860 gtctttacgg actcggaata ccagctcccg tacgtcctcg gctctgcgcaccagggctgc 1920 ctgcctccgt tcccggcgga cgtcttcatg attcctcagt acgggtacctgactctgaac 1980 aacggcagtc aggccgtggg ccgttcctcc ttctactgcc tggagtactttccttctcaa 2040 atgctgagaa cgggcaacaa ctttgagttc agctaccagt ttgaggacgtgccttttcac 2100 agcagctacg cgcacagcca aagcctggac cggctgatga accccctcatcgaccagtac 2160 ctgtactacc tgtctcggac tcagtccacg ggaggtaccg caggaactcagcagttgcta 2220 ttttctcagg ccgggcctaa taacatgtcg gctcaggcca aaaactggctacccgggccc 2280 tgctaccggc agcaacgcgt ctccacgaca ctgtcgcaaa ataacaacagcaactttgct 2340 tggaccggtg ccaccaagta tcatctgaat ggcagagact ctctggtaaatcccggtgtc 2400 gctatggcaa cgcacaagga cgacgaagag cgattttttc catccagcggagtcttgatg 2460 tttgggaaac agggagctgg aaaagacaac gtggactata gcagcgttatgctaaccagt 2520 gaggaagaaa tcaaaaccac caacccagtg gccacagaac agtacggcgtggtggccgat 2580 aacctgcaac agcaaaacgc cgctcctatt gtaggggccg tcaacagtcaaggagcctta 2640 cctggcatgg tctggcagaa ccgggacgtg tacctgcagg gtcctatctgggccaagatt 2700 cctcacacgg acggcaactt tcatccttcg ccgctgatgg gaggctttggactgaaacac 2760 ccgcctcctc agatcctgat taagaataca cctgttcccg cggatcctccaactaccttc 2820 agtcaagcca agctggcgtc gttcatcacg cagtacagca ccggacaggtcagcgtggaa 2880 attgaatggg agctgcagaa agagaacagc aagcgctgga acccagagattcagtatact 2940 tccaactact acaaatctac aaatgtggac tttgctgtca atactgagggtacttattca 3000 gagcctcgcc ccattggcac ccgttacctc acccgtaacc tgtaattgcctgttaatcaa 3060 taaaccggtt aattcgtttc agttgaactt tggtctctgc gaagggcgaattc 3113 33 2504 DNA new AAV serotype, clone 42.4 33 gaattcgccctttctacggc tgcgtcaact ggaccaatga gaactttccc ttcaacgatt 60 gcgtcgacaagatggtgatc tggtgggagg agggcaagat gacggccaag gtcgtggagt 120 ccgccaaggccattcatcat ctgctggggc gggctcccga gattgcttgc tcggcctgcg 180 atctggtcaacgtggacctg gatgactgtg tttctgagca ataaatgact taaaccaggt 240 atggctgccgatggttatct tccagattgg ctcgaggaca acctctctga gggcattcgc 300 gagtggtgggacttgaaacc tggagccccg aaacccaaag ccaaccagca aaagcaggac 360 gacggccggggtctggtgct tcctggctac aagtacctcg gacccttcaa cggactcgac 420 aagggagagccggtcaacga ggcagacgcc gcggccctcg agcacgacaa ggcctacgac 480 aagcagctcgagcaggggga caacccgtac ctcaagtaca accacgccga cgccgagttt 540 caggagcgtcttcaagaaga tacgtctttt gggggcaacc tcgggcgagc agtcttccag 600 gccaagaagcgggttctcga acctctcggt ctggttgagg aaggcgctaa gacggctcct 660 ggaaagaagagacccataga atcccccgac tcctccacgg gcatcggcaa gaaaggccag 720 cagcccgctaaaaagaagct caactttggg cagactggcg actcagagtc agtgcccgac 780 cctcaaccaatcggagaacc ccccgcaggc ccctctggtc tgggatctgg tacaatggct 840 gcaggcggtggcgctccaat ggcagacaat aacgaaggcg ccgacggagt gggtaatgcc 900 tccggaaattggcattgcga ttccacatgg ctgggcgaca gagtcatcac caccagcacc 960 cgcacctgggccctgcccac ctacaacaac cacctctaca agcagatatc aagtcagagc 1020 ggggctaccaacgacaacca cttcttcggc tacagcaccc cctggggcta ttttgacttc 1080 aacagattccactgccactt ctcatcacgt gactggcagc gactcatcaa caacaactgg 1140 ggattccggcccaagagact caacttcaag ctcttcaaca tccaggtcaa ggaggtcacg 1200 cagaatgaaggcaccaagac catcgccaat aaccttacca gcacgattca ggtctttacg 1260 gactcggaataccggctccc gtacgtcctc ggctctgcgc accagggctg cctgcctccg 1320 ttcccggcggacgtcttcat gattcctcag tacgggtacc tgactctgaa caacggcagt 1380 caggccgtgggccgttcctc cttctactgc ctggagtact ttccttctca aatgctgaga 1440 acgggcaacaactttgagtt cagctaccag tttgaggacg tgccttttca cagcagctac 1500 gcgcacagccaaagcctgga ccggctgatg aaccccctca tcgaccagta cctgtactac 1560 ctgtctcggactcagtccac gggaggtacc gcaggaactc agcagttgct attttctcag 1620 gccgggcctaataacatgtc ggctcaggcc aaaaactggc tacccgggcc ctgctaccgg 1680 cagcaacgcgtctccacgac actgtcgcaa aataacaaca gcaactttgc ttggaccggt 1740 gccaccaagtatcatctgaa tggcagagac tctctggtaa atcccggtgt cgctatggca 1800 acgcacaaggacgacgaaga gcgatttttt ccatccagcg gagtcttgat gtttgggaaa 1860 cagggagctggaaaagacaa cgtggactat agcagcgtta tgctaaccag tgaggaagaa 1920 atcaaaaccaccaacccagt ggccacagaa cagtacggcg tggtggccga taacctgcaa 1980 cagcaaaacgccgctcctat tgtaggggcc gtcaacagtc aaggagcctt acctggcatg 2040 gtctggcagaaccgggacgt gtacctgcag ggtcctatct gggccaagat tcctcacacg 2100 gacggcaactttcatccttc gccgctgatg ggaggctttg gactgaaaca cccgcctcct 2160 cagatcctgattaagaatac acctgttccc gcggatcctc caactacctt cagtcaagcc 2220 aagccggcgtcgttcatcac gcagtacagc accggacagg tcagcgtgga aattgaatgg 2280 gagctgcagaaagagaacag caagcgctgg aacccagaga ttcagtatac ttccaactac 2340 tacaaatctacaaatgtgga ctttgctgtc aatactgagg gtacttattc agagcctcgc 2400 cccattggcacccgttacct cacccgtaac ctgtaattgc ctgttaatca ataaaccggt 2460 taattcgtttcagttgaact ttggtctctg cgaagggcga attc 2504 34 3106 DNA new AAV serotype,clone 42.5a 34 gaattcgccc ttctacggct gcgtcaactg gaccaatgag aactttcccttcaacgattg 60 cgtcgacaag atggtgatct ggtgggagga gggcaagatg acggccaaggtcgtggagtc 120 cgccaaggcc attctcggcg gcagcaaggt gcgcgtggac caaaagtgcaagtcgtccgc 180 ccagatcgac cccacccccg tgatcgtcac ctccaacacc aacatgtgcgccgtgattga 240 cgggaacagc accaccttcg agcaccagca gccgttgcag gaccggatgttcaaatttga 300 actcacccgc cgtctggagc atgactttgg caaggcgaca aagcaggaagtcaaagagtt 360 cttccgctgg gcgcaggatc acgtgaccga ggtggcgcat gagttctacgtcagaaaggg 420 tggagccaac aagagacccg cccccgatga cgcggataaa agcgagcccaagcgggcccg 480 cccctcagtc gcggatccat cgacgtcaga cgcggaagga gctccggtggactttgccga 540 caggtaccaa aacaaatgtt ctcgtcacgc gggcatgctt cagatgctgtttccctgcaa 600 aacatgcgag agaatgaatc agaatttcaa catttgcttc acgcacgggaccagagactg 660 ttcagaatgt ttccccggcg tgtcagaatc tcaaccggtc gtcagaaagaggacgtatcg 720 gaaactctgt gccattcatc atctgctggg gcgggctccc gagattgcttgctcggcctg 780 cgatctggtc aacgtggacc tggatgactg tgtttctgag caataaatgacttaaaccag 840 gtatggctgc cgatggttat cttccagatt ggctcgagga caacctctctgagggcattc 900 gcgagtggtg ggacttgaaa cctggagccc cgaaacccaa agccaaccagcaaaagcagg 960 acgacggccg gggtctggtg cttcctggct acaagtacct cggacccttcaacggactcg 1020 acaagggaga gccggtcaac gaggcagacg ccgcggccct cgagcacgacaaggcctacg 1080 acaagcagct cgagcagggg gacaacccgt acctcaagta caaccacgccgacgccgagt 1140 ttcaggagcg tcttcaagaa gatacgtctt ttgggggcaa cctcgggcgagcagtcttcc 1200 gggccaagaa gcgggttctc gaacctctcg gtctggttga ggaaggcgctaagacggctc 1260 ctggaaagaa gagacccata gaatcccccg actcctccac gggcatcggcaagaaaggcc 1320 agcagcccgc taaaaagaag ctcaactttg ggcagactgg cgactcagagtcagtgcccg 1380 acccccaacc tctcggagaa cctcccgccg cgccctcagg tctgggatctggtacaatgg 1440 ctgcaggcgg tggcgcacca atggcagaca ataacgaagg cgccgacggagtgggtaatg 1500 cctccggaaa ttggcattgc gattccacat ggctgggcga cagagtcatcaccaccagca 1560 cccgcacctg ggccctgccc acctacaaca accacctcta caagcagatatcaagtcaga 1620 gcggggctac caacgacaac cacttcttcg gctacagcac cccctggggctattttgact 1680 tcaacagatt ccactgccac ttctcaccac gtgactggca gcgactcatcaacaacaacc 1740 ggggattccg gcccagaaag ctgcggttca agttgttcaa catccaggtcaaggaggtca 1800 cgacgaacga cggcgttacg accatcgcta ataaccttac cagcacgattcaggtcttct 1860 cggactcgga gtaccaactg ccgtacgtcc tcggctctgc gcaccagggctgcctccctc 1920 cgttccctgc ggacgtgttc atgattcctc agtacggata tctgactctaaacaacggca 1980 gtcagtctgt gggacgttcc tccttctact gcctggagta ctttccttctcagatgctga 2040 gaacgggcaa taactttgaa ttcagctacc agtttgagga cgtgccctttcacagcagct 2100 acgcgcacag ccaaagcctg gaccggctga tgaaccccct catcgaccagtacctgtact 2160 acctgtctcg gactcagtcc acgggaggta ccgcaggaac tcagcagttgctattttctc 2220 aggccgggcc taataacatg tcggctcagg ccaaaaactg gctacccgggccctgctacc 2280 ggcagcaacg cgtctccacg acactgtcgc aaaataacaa cagcaactttgcttggaccg 2340 gtgccaccaa gtatcatctg aatggcagag actctctggt aaatcccggtgtcgctatgg 2400 caacgcacaa ggacgacgaa gagcgatttt ttccatccag cggagtcttgatgtttggga 2460 aacagggagc tggaaaagac aacgtggact atagcagcgt tatgctaaccagtgaggaag 2520 aaatcaaaac caccaaccca gtggccacag aacagtacgg cgtggtggccgataacctgc 2580 aacagcaaaa cgccgctcct attgtagggg ccgtcaacag tcaaggagccttacctggca 2640 tggcctggca gaaccgggac gtgtacctgc agggtcctat ctgggccaagattcctcaca 2700 cggacggcaa ctttcatcct tcgccgctga tgggaggctt tggactgaaacacccgcctc 2760 ctcagatcct gattaagaat acacctgttc ccgcggatcc tccaactaccttcagtcaag 2820 ccaagctggc gtcgttcatc acgcagtaca gcaccggaca ggtcagcgtggaaattgaat 2880 gggagctgca gaaagagaac agcaagcgct ggaacccaga gattcagtatacttccaact 2940 actacaaatc tacaaatgtg gactttgctg tcaatactga gggtacttattcagagcctc 3000 gccccattgg cacccgttac ctcacccgta acctgtaatt gcctgttaatcaataaaccg 3060 gttaattcgt ttcagttgaa ctttggtctc tgcgaagggc gaattc 310635 2489 DNA new AAV serotype, clone 42.10 35 gaattcgccc tttctacggctgcgtcaact ggaccaatga gaactttccc ttcaacgatt 60 gcgtcgacaa gatggtgatctggtgggagg agggcaagat gacggccaag gtcgtgaagt 120 ccgccaaggc cattcatcatctgctggggc gggctcccga gattgcttgc tcggcctgcg 180 atctggtcaa cgtggacctggatgactgtg tttctgagca ataaatgact taaaccaggt 240 atggctgccg atggttatcttccagattgg ctcgaggaca acctctctga gggcattcgc 300 gagtggtggg acttgaaacctggagccccg aaacccaaag ccaaccagca aaagcaggac 360 gacggccggg gtctggtgcttcctggctac aagtacctcg gacccttcaa cggactcgac 420 aagggagagc cggtcaacgaggcagacgcc gcggccctcg agcacgacaa ggcctacgac 480 aagcagctcg agcagggggacaacccgtac ctcaagtaca accacgccga cgccgagttt 540 caggagcgtc ttcaagaagatacgtctttt gggggcaacc tcgggcgagc agtcttccag 600 gccaagaagc gggttctcgaacctctcggt ctggttgagg aaggcgctaa gacggctcct 660 ggaaagaaga gacccatagaatcccccgac tcctccacgg gcatcggcag gaaaggccag 720 cagcccgcta aaaagaagctcaactttggg cagactggcg actcagagtc agtgcccgac 780 cctcaaccaa tcggagaaccccccgcaggc ccctctggtc tgggatctgg tacaatggct 840 gcaggcggtg gcgctccaatggcagacaat aacgaaggcg ccgacggagt gggtaatgcc 900 tccggaaatt ggcattgcgattccacatgg ctgggcgaca gagtcatcac caccagcacc 960 cgcacctggg ccctgcccacctacaacaac cacctctaca agcagatatc aagtcagagc 1020 ggggctacca acgacaaccacttcttcggc tacagcaccc cctggggcta ttttgacttc 1080 aacagattcc actgccacttctcaccacgt gactggcagc gactcatcaa caacaactgg 1140 ggattccggc ccagaaagctgcggttcaag ttgttcaaca tccaggtcaa ggaggtcacg 1200 acgaacgacg gcgttacgaccatcgccaat aaccttacca gcacgattca ggtcttctcg 1260 gactcggagt accaactgccgtacgtcctc ggctctgcgc accagggctg cctccctccg 1320 ttccctgcgg acgtgttcatgattcctcag tacggatatc tgactctaaa caacggcagt 1380 cagtctgtgg gacgttcctccttctactgc ctggagtact ttccttctca gatgctgaga 1440 acgggcaata actttgaattcagctacacc tttgaggaag tgcctttcca cagcagctat 1500 gcgcacagcc agagcctggaccggctgatg aatcccctca tcgaccagta cctgtactac 1560 ctggcccgga cccagagcactacggggtcc acaagggagc tgcagttcca tcaggctggg 1620 cccaacacca tggccgagcaatcaaagaac tggctgcccg gaccctgtta tcggcagcag 1680 agactgtcaa aaaacatagacagcaacaac aacagtaact ttgcctggac cggggccact 1740 aaataccatc tgaatggtagaaattcatta accaacccgg gcgtagccat ggccaccaac 1800 aaggacgacg aggaccagttctttcccatc aacggagtgc tggtttttgg caaaacgggg 1860 gctgccaaca agacaacgctggaaaacgtg ctaatgacca gcgaggagga gatcaaaacc 1920 accaatcccg tggctacagaagaatacggt gtggtctcca gcaacctgca atcgtctacg 1980 gccggacccc agacacagactgtcaacagc cagggggctc tgcccggcat ggtctggcag 2040 aaccgggacg tgtacctgcagggtcccatc tgggccaaaa ttcctcacac ggacggcaac 2100 tttcacccgt ctcccctgatgggcggattt ggactcaaac acccgcctcc tcaaattctc 2160 atcaaaaaca ccccggtacctgctaatcct ccagaggtgt ttactcctgc caagtttgcc 2220 tcatttatca cgcagtacagcaccggccag gtcagcgtgg agatcgagtg ggaactgcag 2280 aaagaaaaca gcaaacgctggaatccagag attcagtaca cctcaaatta tgccaagtct 2340 aataatgtgg aatttgctgtcaacaacgaa ggggtttata ctgagcctcg ccccattggc 2400 acccgttacc tcacccgtaacctgtaattg cctgttaatc aataaaccgg ttaattcgtt 2460 tcagttgaac tttggtcaagggcgaattc 2489 36 2495 DNA new AAV serotype, clone 42.3b 36 gaattcgccctttctacggc tgcgtcaact agaccaatga gaactttccc ttcaacgatt 60 gcgtcgacaagatggtgatc tggtgggagg agggcaagat gacggccaag gtcgtggagt 120 ccgccaaggccattcatcat ctgctggggc gggctcccga gattgcttgc tcggcctgcg 180 atctggtcaacgtggacctg gatgactgtg tttctgagca ataaatgact taaaccaggt 240 atggctgccgatggttatct tccagattgg ctcgaggaca acctctctga gggcattcgc 300 gagtggtgggacttgaaacc tggagccccg aaacccaaag ccaaccagca aaagcaggac 360 gacggccggggtctggtgct tcctggctac aagtacctcg gacccttcaa cggactcgac 420 aagggagagccggtcaacga ggcagacgcc gcggccctcg agcacgacaa ggcctacgac 480 aagcagctcgagcaggggga caacccgtac ctcaagtaca accacgccga cgccgagttt 540 caggagcgtcttcaagaaga tacgtctttt gggggcaacc tcgggcgagc agtcttccag 600 gccaagaagcgggttctcga acctctcggt ctggttgagg aaggcgctaa gacggctcct 660 ggaaagaagagacccataga atcccccgac tcctccacgg gcatcggcaa gaaaggccag 720 cagcccgctaaaaagaagct caactttggg cagactggcg actcagagtc agtgcccgac 780 cctcaaccaatcggagaacc ccccgcaggc ccctctggtc tgggatctgg tacaatggct 840 gcaggcggtggcgctccaat ggcagacaat aacgaaggcg ccgacggagt gggtaatgcc 900 tccggaaattggcattgcga ttccacatgg ctgggcgaca gagtcatcac caccagcacc 960 cgcacctgggccctgcccac ctacaacaac cacctctaca agcagatatc aagtcagagc 1020 ggggctaccaacgacaacca cttcttcggc tacagcaccc cctggggcta ttttgacttc 1080 aacagattccactgccactt ctcaccacgt gactggcagc gactcatcaa caacaactgg 1140 ggattccggcccagaaagct gcggttcaag ttgttcaaca tccaggtcaa ggaggtcacg 1200 acgaacgacggcgttacgac catcgctaat aaccttacca gcacgattca ggtcttctcg 1260 gactcggagtaccaactgcc gtacgtcctc ggctctgcgc accagggctg cctccctccg 1320 ttccctgcggacgtgttcat gattcctcag tacggatatc tgactctaaa caacggcagt 1380 cagtctgtgggacgttcctc cttctactgc ctggagtact ttccttctca gatgctgaga 1440 acgggcaataactttgaatt cagctacacc tttgaggaag tgcctttcca cagcagctat 1500 gcgcacagccagagcctgga ccggctgatg aatcccctca tcgaccagta cctgtactac 1560 ctggcccggacccagagcac tacggggtcc acaagggagc tgcagttcca tcaggctggg 1620 cccaacaccatggccgagca atcaaagaac tggctgcccg gaccctgtta tcggcagcag 1680 agactgtcaaaaaacataga cagcaacaac accagtaact ttgcctggac cggggccact 1740 aaataccatctgaatggtag aaattcatta accaacccgg gcgtagccat ggccaccaac 1800 aaggacgacgaggaccagtt ctttcccatc aacggagtgc tggtttttgg caaaacgggg 1860 gctgccaacaagacaacgct ggaaaacgtg ctaatgacca gcgaggagga gatcaaaacc 1920 accaatcccgtggctacaga acagtacggt gtggtctcca gcaacctgca atcgtctacg 1980 gccggaccccagacacagac tgtcaacagc cagggggctc tgcccggcat ggtctggcag 2040 aaccgggacgtgtacctgca gggtcccatc tgggccaaaa ttcctcacac ggacggcaac 2100 tttcacccgtctcccctgat gggcggattt ggactcaaac acccgcctcc tcaaattctc 2160 atcaaaaacaccccggtacc tgctaatcct ccagaggtgt ttactcctgc caagtttgcc 2220 tcatttatcacgcagtacag caccggccag gtcagcgtgg agatcgagtg ggaactgcag 2280 aaagaaaacagcaaacgctg gaatccagag attcagtaca cctcaaatta tgccaagtct 2340 aataatgtggaatttgctgt caacaacgaa ggggtttata ctgagcctcg ccccattggc 2400 acccgttacctcacccgtaa cctgtaattg cctgttaatc aataaaccgg ttaattcgtt 2460 tcagttgaactttggtctct gcgaagggcg aattc 2495 37 3098 DNA new AAV serotype, clone42.11 37 gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttcccttcaacgatt 60 gcgtcgacaa gatggtgatc tggtgggagg agggcaagat gacggccaaggtcgtggagt 120 ccgccaaggc cattctcggc ggcagcaagg tgcgcgtgga ccaaaagtgcaagtcttccg 180 cccagatcga tcccaccccc gtgatcgtca cttccaacac caacatgtgcgccgtgattg 240 acgggaacag caccaccttc gagcaccagc agccgttaca agaccggatgttcaaatttg 300 aactcacccg ccgtctggag cacgactttg gcaaggtgac aaagcaggaagtcaaagagt 360 tcttccgctg ggcgcaggat cacgtgaccg aggtggcgca tgagttctacgtcagaaagg 420 gtggagccaa caagagaccc gcccccgatg acgcggataa aagcgagcccaagcgggcct 480 gcccctcagt cgcggatcca tcgacgtcag acgcggaagg agctccggtggactttgccg 540 acaggtacca aaacaaatgt tctcgtcacg cgggcatgct tcagatgctgtttccctgca 600 agacatgcga gagaatgaat cagaatttca acatttgctt cacgcacgggaccggagact 660 gttcagaatg tttccccggc gtgtcagaat ctcaaccggt cgtcagaaagaggacgtatc 720 ggaaactctg tgccattcat catctgctgg ggcgggctcc cgagattgcttgctcggcct 780 gcgatctggt caacgtggac ctggatgact gtgtttctga gcaataaatgacttaaacca 840 ggtatggctg ccgatggtta tcttccagat tggctcgagg acaacctctctgagggcatt 900 cgcgagtggt gggacttgaa acctggagcc ccgaaaccca aagccaaccagcaaaagcag 960 gacgacggcc ggggtctggt gcttcctggc tacaagtacc tcggacccttcaacggactc 1020 gacaagggag agccggtcaa cgcggcggac gcagcggccc tcgagcacgacaaggcctac 1080 gaccagcagc tcaaagcggg tgacaatccg tacctgcggt ataaccacgccgacgccgag 1140 tttcaggagc gtcttcaaga agatacgtct tttgggggca acctcgggcgagcagtcttc 1200 caggccaaga agcgggttct cgaacctctc ggtctggttg aggaaggcgctaagacggct 1260 cctggaaaga agagacccat agaatccccc gactcctcca cgggcatcggcaagaaaggc 1320 cagcagcccg ctaaaaagaa gctcaacttt gggcagactg gcgactcagagtcagtgccc 1380 gaccctcaac caatcggaga accccccgca ggcccctctg gtctgggatctggtacaatg 1440 gctgcaggcg gtggcgctcc aatggcagac aataacgaag gcgccgacggagtgggtaat 1500 gcctccggaa attggcattg cgattccaca tggctgggcg acagagtcatcaccaccagc 1560 acccgcacct gggccctgcc cacctacaac aaccacctct acaagcagatatcaagtcag 1620 agcggggcta ccaacgacaa ccacttcttc ggctacagca ccccctggggctattttgac 1680 ttcaacagat tccactgcca cttctcacca cgtgactggc agcgactcatcaacaacaac 1740 tggggattcc ggcccagaaa gctgcggttc aagttgttca acatccaggtcaaggaggtc 1800 acgacgaacg acggcgttac gaccatcgct aataacctta ccagcacgattcaggtcttc 1860 tcggactcgg agtaccaact gccgtacgtc ctcggctctg cgcaccagggctgcctccct 1920 ccgttccctg cggacgtgtt catgattcct cagtacggat atctgactctaaacaacggc 1980 agtcagtctg tgggacgttc ctccttctac tgcctggagt actttccttctcagatgctg 2040 agaacgggca ataactttga attcagctac acctttgagg aagtgcctttccacagcagc 2100 tatgcgcaca gccagagcct ggaccggctg atgaatcccc tcatcgaccagtacctgtac 2160 tacctggccc ggacccagag cactacgggg tccacaaggg agctgcagttccatcaggct 2220 gggcccaaca ccatggccga gcaatcaaag aactggctgc ccggaccctgttatcggcgg 2280 cagagactgt caaaagacat agacagcaac aacaacagta actttgcctggaccggggcc 2340 actaaatacc atctgaatgg tagaaattca ttaaccaacc cgggcgtagccatggccacc 2400 aacaaggacg acgaggacca gttctttccc atcaacggag tgctggtttttggcaaaacg 2460 ggggctgcca acaagacaac gctggaaaac gtgctaatga ccagcgaggaggagatcaaa 2520 accaccaatc ccgtggctac agaagaatac ggtgtggtct ccagcaacctgcaatcgtct 2580 acggccggac cccagacaca gactgtcaac agccaggggg ctctgcccggcatggtctgg 2640 cagaaccggg acgtgtacct gcagggtccc atctgggcca aaattcctcacacggacggc 2700 aactttcacc cgtctcccct gatgggcgga tttggactca aacacccgcctcctcaaatt 2760 ctcatcaaaa acaccccggt acctgctaat cctccagagg tgtttactcctgccaagttt 2820 gcctcattta tcacgcagta cagcaccggc caggtcagcg tggagatcgagtgggaactg 2880 cagaaagaga acagcaaacg ctggaatcca gagattcagt acacctcaaattatgccaag 2940 tctaataatg tggaatttgc tgtcaacaac gaaggggttt atactgagcctcgccccatt 3000 ggcacccgtt acctcacccg taacctgtaa ttacttgtta atcaataaaccggttgattc 3060 gtttcagttg aactttggtc tctgcgaagg gcgaattc 3098 38 3276DNA new AAV serotype, clone 42.6a 38 gaattcgccc ttcgcagaga ccaaagttcaactgaaacga attaaccggt ttattgatta 60 acaggcaatt acaggttacg ggtgaggtaacgggtgccaa tggggcgagg ctcagtataa 120 accccttcgt tgttgacagc aaattccacattattagact tggcataatt tgaggtgtac 180 tgaatctctg gattccagcg tttgctgttttctttctgca gttcccactc gatctccacg 240 ctgacctggc cggtgctgta ctgcgtgataaatgaggcaa acttggcagg agtaaacacc 300 tctggaggat tagcaggtac cggggtgtttttgatgagaa tttgaggagg cgggtgtttg 360 agtccaaatc cgtccatcag gggagacgggtgaaagttgc cgtccgtgtg aggaattttg 420 gcccagatgg gaccctgcag gtacacgtcccggttctgcc agaccatgcc gggcagagcc 480 ccctggctgt tgacagtctg tgtctggggtccggccgtag acgattgcag gttgctggag 540 accacaccgt attcttctgt agccacgggattggtggttt tgatctcctc ctcgctggtc 600 attagcacgt tttccagcgt tgtcttgttggcagcccccg ttttgccaaa aaccagcact 660 ccgttgatgg gaaagaactg gtcctcgtcgtccttgttgg tggccatggc tacgcccggg 720 ttggttaatg aatttctacc attcagatggtatttagtgg ccccggtcca ggcaaagtta 780 ctgttgttgt tgctgtctat gttttttgacagtctctgct gccgataaca gggtccgggc 840 agccagttct ttgattgctc ggccatggtgttgggcccag cctgatggaa ctgcagctcc 900 cttgtggacc ccgtagtgct ctgggtccgggccaggtagt acaggtactg gtcgatgagg 960 ggattcatca gccggtccag gctctggctatgcgcatagc tgctgtggaa aggcacttcc 1020 tcaaaggtgt agctgaattc aaagttattgcccgttctca gcatctgaga aggaaagtac 1080 tccaggcagt agaaggagga acgtcccacagactgactgc cgttgtttag agtcagatat 1140 ccgtactgag gaatcatgaa cacgtccgcagggaacggag ggaggcagcc ctggtgcgca 1200 gagccgagga cgtacggcag ttggtactccgagtccgaga agacctgaat cgtgctggta 1260 aggttattag cgatggtcgt aacgccgtcgtccgtcgtga cctccttgac ctggatgttg 1320 aacaacttga accgcagctt tctgggccggaatccccagt tgttgttgat gagtcgctgc 1380 cagtcacgtg gtgagaagtg gcagtggaatctgttaaagt caaaataccc ccagggggtg 1440 ctgtagccga agtaggtgtt gtcgttggtgcttcctcccg atgtcccgtt ggagatttgc 1500 ttgtagaggt ggttgttgta ggtggggagggcccaggttc gggtgctggt ggtgatgact 1560 ctgtcgccca gccatgtgga atcgcaatgccaatttcctg aggaactacc cactccgtcg 1620 gcgccttcgt tattgtctgc cattggagcgccaccgcctg cagccattgt accagatccc 1680 agaccagagg ggcctgcggg gggttctccgattggttgag ggtcgggcac tgactctgag 1740 tcgccagtct gcccaaagtt gagtctctttttcgcgggct gctggcctgt cttgccgatg 1800 cccgtagagg agtctggaga acgctggggtgatggctcta ccggtctctt ctttccagga 1860 gccgtcttag cgccttcctc aaccagaccgagaggttcga gaacccgctt cttggcctgg 1920 aagactgctc gcccgaggtt gcccccaaaagacgtatctt cttgaagacg ctcctgaaac 1980 tcggcgtcgg cgtggttgta cttgaggtacgggttgtccc cctgctcgag ctgcttgtcg 2040 taggccttgt cgtgctcgag ggccgcggcgtctgcctcgt tgaccggctc tcccttgtcg 2100 agtccgttga agggtccgag gtacttgtagccaggaagca ccagaccccg gccgtcgtcc 2160 tgcttttgct ggttggcttt gggtttcggggctccaggtt tcaagtccca ccactcgcga 2220 atgccctcag agaggttgtc ctcgagccaatctggaagat aaccatcggc agccatacct 2280 ggtttaagtc atttattgct cagaaacacagtcatccagg tccacgttga ccagatcgca 2340 ggccgagcaa gcaatctcgg gagcccgccccagcagatga tgaatggcac agagtttccg 2400 atacgtcctc tttctgacga ccggttgagattctgacacg ccggggaaac attctgaaca 2460 gtctctggtc ccgtgcgtga agcaaatgttgaaattctga ttcattctct cgcatgtctt 2520 gcagggaaac agcatctgaa gcatgcccgcgtgacgagaa cacttgtttt ggtacctgtc 2580 ggcaaagtcc accggagctc cttccgcgtctgacgtcgat ggatgcaaaa tgtcgcaaaa 2640 gcactcacgt gacagctaat acaggaccactcccctatga cgtgatttac gtcagcgcta 2700 tgcccgcgtg acgagaacat ttgttttggtacctgtcggc aaagtccacc ggagctcctt 2760 ccgcgtctga cgtcgatgga tccgcgactgaggggcaggc ccgcttgggc tcgcttttat 2820 ccgcgtcatc gggggcgggt ctcttgttggctccaccctt tctgacgtag aactcatgcg 2880 ccacctcggt cacgtgatcc tgcgcccagcggaagaactc tttgacttcc tgctttgtca 2940 ccttgccaaa gtcatgctcc agacggcgggtgagttcaaa tttgaacatc cggtcctgca 3000 acggctgctg gtgctcgaag gtggtgctgttcccgtcaat cacggcgcac atgttggtgt 3060 tggaagtgac gatcacgggg gtgggatcgatctgggcgga agacttgcac ttttggtcca 3120 cgcgcacctt gctgccgccg agaatggccttggcggactc cacgaccttg gccgtcatct 3180 tgccctcctc ccaccagatc accatcttgtcgacgcaatc gttgaaggga aagttctcat 3240 tggtccagtt gacgcagccg tagaaagggcgaattc 3276 39 3084 DNA 43.1 39 gaattcgccc tttctacggc tgcatcaactggaccaatga gaactttccc ttcaacgatt 60 gcgtcgacaa gatggtgatc tggtgggaggagggcaagat gacggccaag gtcgtggagt 120 ccgccaaggc cattctcggc ggcagcaaggtgcgcgtgga ccaaaagtgc aagtcgtccg 180 cccagatcga ccccaccccc gtgatcgtcacctccaacac caacatgtgc gccgtgattg 240 acgggaacag caccaccttc gagcaccagcagccgttgca ggaccggatg ttcaagttcg 300 aactcacccg ccgtctggag cacgactttggcaaggtgac caagcaggaa gtcaaagagt 360 tcttccgctg ggcgcaggat cacgtgaccgaggtggcgca tgagttctac gtcagaaagg 420 gcggagccag caaaagaccc gcccccgatgacgcggatat aagcgagccc aagcgggcct 480 gcccctcagt cgcggatcca tcgacgtcagacgcggaagg agctccggtg gactttgccg 540 acaggtacca aaacaaatgt tctcgtcacgcgggcatgct tcagatgctg tttccctgca 600 aaacgtgcga gaaaatgaat cagaatttcaacatttgctt cacgcacggg gtcagagact 660 gctcagaatg tttccccggt gcatcagaatctcaaccggt cgtcagaaaa aaaacgtatc 720 agaaactgtg tgccattcat catctgctggggcgggcacc cgagattgct tgctcggcct 780 gcgatctggt caacgtggac ctggacgactgtgtttctga gcaataaatg acttaaacca 840 ggtatggctg ccgatggtta tcttccagattggcttgagg acaacctctc tgagggcatt 900 cgcgagtggt gggacctgaa acctggagccccgaaaccca aagccaacca gcaaaagcag 960 gacgacggcc ggggtctggt gcttcctggctacaagtacc tcggaccctt caacggactc 1020 gacaaggggg agcccgtcaa cgcggcggacgcagcggccc tcgagcacga caaggcctac 1080 gaccagcagc tcaaagcggg tgacaatccgtacctgcggt ataaccacgc cgacgccgag 1140 tttcaggagc gtctgcaaga agatacgtcttttgggggca acctcgggcg agcagtcttc 1200 caggccaaga agcgggttct cgaacctctcggtctggttg aggaaggcgc taagacggct 1260 cctggaaaga agagaccggt agagccatcacctcagcgtt cccccgactc ctccacgggc 1320 atcggcaaga aaggccacca gcccgcgagaaagagactga actttgggca gactggcgac 1380 tcggagtcag tccccgaccc tcaaccaatcggagaaccac cagcaggccc ctctggtctg 1440 ggatctggta caatggctgc aggcggtggcgctccaatgg cagacaataa cgaaggcgcc 1500 gacggagtgg gtagttcctc aggaaattggcattgcgatt ccacatggct gggcgacaga 1560 gtcatcacca ccagcacccg aacctgggccctgcccacct acaacaacca tctctacaag 1620 caaatctcca acgggacatc gggaggaagcactaacgaca acacctactt tggctacagc 1680 accccctggg ggtattttga cttcaacagattccactgcc acttctcacc acgtgactgg 1740 cagcgactca tcaacaataa ctggggattccggcccaaga gactcaactt caagctcttc 1800 aacatccagg tcaaggaggt cacgcagaatgaaggcacca agaccatcgc caataacctt 1860 accagcacga ttcaggtgtt tacggactcggaataccagc tcccgtacgt ccccggctct 1920 gcgcaccagg gctgcctccc tccgttcccggcggacgtct tcatgattcc tcagtacggg 1980 tatctgaccc taaacaatgg cagtcaggctgtgggccgtt cctccttcta ctgcctggaa 2040 tacttccctt ctcaaatgct gaggacgggcaacaactttg aattcagcta caccttcgag 2100 gacgtgcctt tccacagcag ctacgcgcacagccagagcc tggaccggct gatgaaccct 2160 ctcatcgacc agtacctgta ttacttatccagaactcagt ccacaggagg aactcaaggt 2220 actcagcaat tgttattttc tcaagccgggcccgcaaaca tgtcggctca ggccaagaac 2280 tggctacctg gaccgtgtta ccgtcagcaacgagtttcca cgacactgtc gcaaaacaac 2340 aacagcaatt ttgcttggac cggtgccaccaagtatcacc tgaatggcag agactccctg 2400 gttaatcccg gcgttgccat ggctacccacaaggacgacg aggagcgctt cttcccgtca 2460 agcggagttc taatgtttgg caagcagggggctggaaaag acaatgtgga ctacagcagc 2520 gtgatgctca ccagcgaaga agaaattaaaactactaacc cagtggctac agagcagtat 2580 ggtgtggtgg cagacaacct gcagcagaccaacggagctc ccattgtggg aactgtcaac 2640 agccaggggg ccttacctgg tatggtctggcaaaaccggg acgtgtacct gcagggcccc 2700 atctgggcca aaattcctca cacggacggcaactttcatc cttcgccgct gatgggaggc 2760 tttggactga aacacccgcc tcctcagatcctggtgaaaa acactcctgt tcctgcggat 2820 cctccgacca ccttcagcca ggccaagctggcttctttta tcacgcagta cagcaccgga 2880 caggtcagcg tggaaatcga atgggagctgcagaaagaaa acagcaagcg ctggaaccca 2940 gagattcagt atacttccaa ctactacaaatctacaaatg tggactttgc tgtcaatact 3000 gagggtactt attcagagcc tcgccccattggcactcgtt atctcacccg taatctgtaa 3060 ttgcttgtta atcaataaac cggt 3084 402370 DNA new AAV serotype, clone 43.5 40 gaattcgccc tttctacggctgcgtcaact ggaccaatga gaactttccc ttcaacgatt 60 gcgtcgacaa gatggtgatctggtgggagg agggcaagat gacggccaag gtcgtggagt 120 ccgccaaggc cattctcggcggcagcaagg tgcgcgtgga ccaaaagtgc aagtcgtccg 180 cccagatcga ccccacccccgtgatcgtca cctccaacac caacatgtgc gccgtgattg 240 acgggaacag caccaccttcgagcaccagc agccgttgca ggaccggatg ttcaagttcg 300 aactcacccg ccgtctggagcacgactttg gcaaggtgac caagcaggaa gtcaaagagt 360 tcttccgctg ggcgcaggatcacgtgaccg aggtggcgca tgagttctac gtcagaaagg 420 gcggagccag caaaagacccgcccccgatg acgcggatat aagcgagccc aagcgggcct 480 gcccctcagt cgcggatccatcgacgtcag acgcggaagg agctccggtg gactttgccg 540 acaggtacca aaacaaatgttctcgtcacg cgggcatgct tcagacgctg tttccctgca 600 aaacgtgcga gagaatgaatcagaatttca acatttgctt cacgcacggg gtcagagact 660 gctcagaatg tttccccggtgcatcagaat ctcaaccggt cgtcagaaaa aaaacgtatc 720 agaaactgtg tgccattcatcatctgctgg ggcgggcacc cgagattgct tgctcggcct 780 gcgatctggt caacgtggacctggacgact gtgtttctga gcaataaatg acttaaacca 840 ggtatggctg ccgatggttatcttccagat tggcttgagg acaacctctc tgagggcatt 900 cgcgagtggt gggacctgaaacctggagcc ccgaaaccca aagccaacca gcaaaagcag 960 gacgacggcc ggggtctggtgcttcctggc tacaagtacc tcggaccctt caacggactc 1020 gacaaggggg agcccgtcaacgcggcggac gcagcggccc tcgagcacga caaggcctac 1080 gaccagcagc tcaaagcgggtgacaatccg tacctgcggt ataaccacgc cgacgccgag 1140 tttcaggagc gtctgcaagaagatacgtct tttgggggca acctcgggcg agcagtcttc 1200 caggccaaga agcgggttctcgaacctctc ggtctggttg aggaaggcgc taagacggct 1260 cctggaaaga agagaccggtagagccatca cctcagcgtt cccccgactc ctccacgggc 1320 atcggcaaga aaggccaccagcccgcgaga aagagactga actttgggca gactggcgac 1380 tcggagtcag tccccgaccctcaaccaatc ggagaaccac cagcaggccc ctctggtctg 1440 ggatctggta caatggctgcaggcggtggc gctccaatgg cagacaataa cgaaggcgcc 1500 gacggagtgg gtagttcctcaggaaattgg cattgcgatt ccacatggct gggcgacaga 1560 gtcatcacca ccagcacccgaacctgggcc ctgcccacct acaacaacca tctctacaag 1620 caaatctcca acgggacatcgggaggaagc actaacgaca acacctactt tggctacagc 1680 accccctggg ggtattttgacttcaacaga ttccactgcc acttctcacc acgtgactgg 1740 cagcgactca tcaacaataactggggattc cggcccaaga gactcaactt caagctcttc 1800 aacatccagg tcaaggaggtcacgcagaat gaaggcacca agaccatcgc caataacctt 1860 accagcacga ttcaggtgtttacggactcg gaataccagc tcccgtacgt cctcggctct 1920 gcgcaccagg gctgcctccctccgttcccg gcggacgtct tcatgattcc tcagtacggg 1980 tatctgaccc taaacaatggcagtcaggct gtgggccgtt cctccttcta ctgcctggaa 2040 tacttccctt ctcaaatgctgaggacgggc aacaactttg aattcagcta caccttcgag 2100 gacgtgcctt tccacagcagctacgcgcac agccagagcc tggaccggct gatgaaccct 2160 ctcatcgacc agtacctgtattacttatcc agaactcagt ccacaggagg aactcaaggt 2220 actcagcaat tgttattttctcaagccggg cccgcaaaca tgtyggctca ggccaagaac 2280 tggctacctg gaccgtgttaccgtcagcaa cgagtttcca cgacactgtc gcaaaacaac 2340 aacagcaatt ttgctggaccggtgccacca 2370 41 3123 DNA 43.12 41 gaattcgccc ttggctgcgt caactggaccaatgagaact ttcccttcaa cgattgcgtc 60 gacaagatgg tgatctggtg ggaggagggcaagatgacgg ccaaggtcgt ggagtccgcc 120 aaggccattc tcggcggcag caaggtgcgcgtggaccaaa agtgcaagtc gtccgcccag 180 atcgacccca cccccgtgat cgtcacctccaacaccaaca tgtgcgccgt gattgacggg 240 aacagcacca ccttcgagca ccagcagccgttgcaggacc ggatgttcaa gttcgaactc 300 acccgccgtc tggagcacga ctttggcaaggtgaccaagc aggaagtcaa agagttcttc 360 cgctgggcgc aggatcacgt gaccgaggtggcgcatgagt tctacgtcag aaagggcgga 420 gccagcaaaa gacccgcccc cgatgacgcggatataagcg agcccaagcg ggcctgcccc 480 tcagtcgcgg atccatcgac gtcagacgcggaaggagctc cggtggactt tgccgacagg 540 taccaaaaca aatgttctcg tcacgcgggcatgctccaga tgctgtttcc ctgcaaaacg 600 tgcgagagaa tgaatcagaa tttcaacatttgcttcacgc acggggtcag agactgctca 660 gaatgtttcc ccggtgcatc agaatctcaaccggtcgtca gaaaaaaaac gtatcagaaa 720 ctgtgtgcca ttcatcatct gctggggcgggcacccgaga ttgcttgctc ggcctgcgat 780 ctggtcaacg tggacctgga cgactgtgtttctgagcaat aaatgactta aaccaggtat 840 ggctgccgat ggttatcttc cagattggcttgaggacaac ctctctgagg gcattcgcga 900 gtggtgggac ctgaaacctg gagccccgaaacccaaagcc aaccagcaaa agcaggacga 960 cggccggggt ctggtgcttc ctggctacaagtacctcgga cccttcaacg gactcgacaa 1020 gggggagccc gtcaacgcgg cggacgcagcggccctcgag cacgacaagg cctacgacca 1080 gcagctcaaa gcgggtgaca atccgtacctgcggtataac cacgccgacg ccgagtttca 1140 ggagcgtctg caagaagata cgtcttttgggggcaacctc gggcgagcag tcttccaggc 1200 caagaagcgg gttctcgaac ctctcggtctggttgaggaa ggcgctaaga cggctcctgg 1260 aaagaagaga ccggtagagc catcacctcagcgttccccc gactcctcca cgggcatcgg 1320 caagaaaggc caccagcccg cgagaaagagactgaacttt gggcagactg gcgactcgga 1380 gtcagtcccc gaccctcaac caatcggagaaccaccagca ggcccctctg gtctgggatc 1440 tggtacaatg gctgcaggcg gtggcgctccaatggcagac aataacgaag gcgccgacgg 1500 agtgggtagt tcctcaggaa attggcattgcgattccaca tggctgggcg acagagtcat 1560 caccaccagc acccgaacct gggccctgcccacctacaac aaccatctct acaagcaaat 1620 ctccaacggg acatcgggag gaagcactaacgacaacacc tactttggct acagcacccc 1680 ctgggggtat tttgacttca acagattccactgccacttc tcaccacgtg actggcagcg 1740 actcatcaac aataactggg gattccggcccaagagactc aacttcaagc tcttcaacat 1800 ccaggtcaag gaggtcacgc agaatgaaggcaccaagacc atcgccaata accttaccag 1860 cacgattcag gtgtttacgg actcggaataccagctcccg tacgtcctcg gctctgcgca 1920 ccagggctgc ctccctccgt tcccggcggacgtcttcatg attcctcagt acgggtatct 1980 gaccctaaac aatggcagtc aggctgtgggccgttcctcc ttctactgcc tggaatactt 2040 cccttctcaa atgctgagga cgggcaacaactttgaattc agctacacct tcgaggacgt 2100 gcctttccac agcagctacg cgcacagccagagcctggac cggctgatga accctctcat 2160 cgaccagtac ctgtattact tatccagaactcagtccaca ggaggaactc aaggtactca 2220 gcaattgtta ttttctcaag ccgggcccgcaaacatgtcg gctcaggcca agaactggct 2280 acctggaccg tgttaccgtc agcaacgagtttccacgaca ctgtcgcaaa acaacaacag 2340 caattttgct tggaccggtg ccaccaagtatcacctgaat ggcagagact ccctggttaa 2400 tcccggcgtt gccatggcta cccacaaggacgacgaggag cgcttcttcc cgtcaagcgg 2460 agttctaatg tttggcaagc agggggctggaaaagacaat gtggactaca gcagcgtgat 2520 gctcaccagc gaagaagaaa ttaaaactactaacccagtg gctacagagc agtatggtgt 2580 ggtggcagac aacctgcagc agaccaacggagctcccatt gtgggaactg tcaacagcca 2640 gggggcctta cctggtatgg tctggcaaaaccgggacgtg tacctgcagg gccccatctg 2700 ggccaaaatt cctcacacgg acggcaactttcatccttcg ccgctgatgg gaggctttgg 2760 actgaaacac ccgcctcctc agatcctggtgaaaaacact cctgttcctg cggatcctcc 2820 gaccaccttc agccaggcca agctggcttcttttatcacg cagtacagca ccggacaggt 2880 cagcgtggaa atcgaatggg agctgcagaaagaaaacagc aagcgctgga acccagagat 2940 tcagtatact tccaactact acaaatctacaaatgtggac tttgctgtca atactgaggg 3000 tacttattca gagcctcgcc ccattggcactcgttatctc acccgtaatc tgtaattgct 3060 tgttaatcaa taaaccggtt aattcgtttcagttgaactt tggtctctgc gaagggcgaa 3120 ttc 3123 42 3122 DNA 43.20 42gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttccc ttcaacgatt 60gcgtcgacaa gatggtgatc tggtgggagg agggcaagat gacggccaag gtcgtggagt 120ccgccaaggc cattctcggc ggcagcaagg tgcgtgtgga ccaaaagtgc aagtcttccg 180cccagatcga tcccaccccc gtgatcgtca cctccaacac caacatgtgc gccgtgattg 240acgggaacag cgccaccttc gagcaccagc agccgttgca ggaccggatg ttcaaatttg 300aactcacccg ccgtctggag catgactttg gcaaggtgac gaagcaggaa gtcaaagagt 360tcttccgctg ggcgcaggat cacgtgaccg aggtggcgca tgagttccac gtcagaaagg 420gtggagccaa caagagaccc gcccccgatg acgcggatat aagcgagccc aagcgggcct 480gcccctcagt cgcggatcca tcgacgtcag acgcggaagg agctccggtg gactttgccg 540acaggtacca aaacaaatgt tctcgtcacg cgggcatgct tcagatgctg tttccctgca 600agacatgcga gagaatgaat cagaatttca acatttgctt cacgcacggg accagagact 660gttcagaatg tttccccggc gtgtcagaat ctcaaccggt cgtcagaaag aggacgtatc 720ggaaactctg tgcgattcat catctgctgg ggcgggctcc cgagattgct tgctcggcct 780gcgatctggt caacgtggac ctggatgact gtgtttctga gcaataaatg acttaaacca 840ggtatggctg ccgatggtta tcttccagat tggctcgagg acaacctctc tgagggcatt 900cgcgagtggt gggacttgaa acctggagcc ccgaaaccca aagccaacca gcaaaagcag 960gacgacggcc ggggtctggt gcttcctggc tacaagtacc tcggaccctt caacggactc 1020gacaaggggg agcccgtcaa cgcggcggac gcagcggccc tcgagcacga caaagcctac 1080gaccagcagc tcaaagcggg tgacaatccg tacctgcggt ataatcacgc cgacgccgag 1140tttcaggagc gtctgcaaga agatacgtct tttgggggca acctcgggcg agcagtcttc 1200caggccaaga agcgggttct cgaacctctc ggtctggttg aggaaggcgc taagacggct 1260cctggaaaga agagactggt agagcagtcg ccacaagagc cagactcctc ctcgggcatc 1320ggcaagacag gccagcagcc cgctaaaaag agactcaatt ttggtcagac tggcgactca 1380gagtcagtcc ccgacccaca acctctcgga gaacctccag cagccccctc aggtctggga 1440cctaatacaa tggcttcagg cggtggcgct ccaatggcag acaataacga aggcgccgac 1500ggagtgggta attcctcggg aaattggcat tgcgattcca catggctggg ggacagagtc 1560atcaccacca gcacccgaac ctgggccctg cccacctaca acaaccacct ctacaagcaa 1620atctccaacg gcacctcggg aggaagcacc aacgacaaca cctattttgg ctacagcacc 1680ccctgggggt attttgactt caacagattc cactgtcact tttcaccacg tgactggcaa 1740cgactcatca acaacaattg gggattccgg cccaaaagac tcaacttcaa gctgttcaac 1800atccaggtca aggaagtcac gacgaacgaa ggcaccaaga ccatcgccaa taatctcacc 1860agcaccgtgc aggtctttac ggactcggag taccagttac cgtacgtgct aggatccgct 1920caccagggat gtctgcctcc gttcccggcg gacgtcttca cggttcctca gtacggctat 1980ttaactttaa acaatggaag ccaagccctg ggacgttcct ccttctactg tctggagtat 2040ttcccatcgc agatgctgag aaccggcaac aactttcagt tcagctacac cttcgaggac 2100gtgcctttcc acagcagcta cgcgcacagc cagagcctgg acaggctgat gaatcccctc 2160atcgaccagt acctgtacta cctggtcaga acgcaaacga ctggaactgg agggacgcag 2220actctggcat tcagccaagc gggtcctagc tcaatggcca accaggctag aaattgggtg 2280cccggacctt gctaccggca gcagcgcgtc tccacgacaa ccaaccagaa caacaacagc 2340aactttgcct ggacgggagc tgccaagttt aagctgaacg gccgagactc tctaatgaat 2400ccgggcgtgg caatggcttc ccacaaggat gacgacgacc gcttcttccc ttcgagcggg 2460gtcctgattt ttggcaagca aggagccggg aacgatggag tggattacag ccaagtgctg 2520attacagatg aggaagaaat caaggctacc aaccccgtgg ccacagaaga atatggagca 2580gtggccatca acaaccaggc cgccaatacg caggcgcaga ccggactcgt gcacaaccag 2640ggggtgattc ccggcatggt gtggcagaat agagacgtgt acctgcaggg tcccatctgg 2700gccaaaattc ctcacacgga cggcaacttt cacccgtctc ccctgatggg cggctttgga 2760ctgaagcacc cgcctcctca aattctcatc aagaacacac cggttccagc ggacccgccg 2820cttaccttca accaggccaa gctgaactct ttcatcacgc agtacagcac cggacaggtc 2880agcgtggaaa tcgagtggga gctgcagaaa gaaaacagca aacgctggaa tccagagatt 2940caatacactt ccaactacta caaatctaca aatgtggact ttgctgtcaa cacggaagga 3000gtttatagcg agcctcgccc cattggcacc cgttacctca cccgcaacct gtaattacat 3060gttaatcaat aaaccggtta attcgtttca gttgaacttt ggtctctgcg aagggcgaat 3120tc 3122 43 3117 DNA 43.21 43 gaattcgccc ttggctgcgt caactggacc aatgagaactttcccttcaa cgattgcgtc 60 gacaagatgg tgatctggtg ggaggagggc aagatgacggccaaggtcgt ggagtccgcc 120 aaggccattc tcggcggcag caaggtgcgt gtggaccaaaagtgcaagtc ttccgcccag 180 atcgatccca cccccgtgat cgtcacctcc aacaccaacatgtgcgccgt gattgacggg 240 aacagcacca ccttcgagca ccagcagccg ttgcaggaccggatgttcaa atttgaactc 300 acccgccgtc tggagcatga ctttggcaag gtgacgaagcaggaagtcaa agagttcttc 360 cgctgggcgc aggatcacgt gaccgaggtg gcgcatgagttccacgtcag aaagggtgga 420 gccaacaaga gacccgcccc cgatgacgcg gatataagcgagcccaagcg ggcctgcccc 480 tcagtcgcgg atccatcgac gtcagacgcg gaaggagctccggtggactt tgccgacagg 540 taccaaaaca aatgttctcg tcacgcgggc atgcttcagatgctgtttcc ctgcaagaca 600 tgcgagagaa tgaatcagaa tttcaacatt tgcttcacgcacgggaccag agactgttca 660 gaatgtttcc ccggcgtgtc agaatctcaa ccggtcgtcagaaagaggac gtatcggaaa 720 ctctgtgcga ttcatcatct gctggggcgg gctcccgagattgcttgctc ggcctgcgat 780 ctggtcaacg tggacctgga tgactgtgtt tctgagcaataaatgactta aaccaggtat 840 ggctgccgat ggttatcttc cagattggct cgaggacaacctctctgagg gcattcgcga 900 gtggtgggac ttgaaacctg gagccccgaa acccaaagccaaccagcaaa agcaggacga 960 cggccggggt ctggtgcttc ctggctacaa gtacctcggacccttcaacg gactcgacaa 1020 gggggagccc gtcaacgcgg cggacgcagc ggccctcgagcacgacaaag cctacgacca 1080 gcagctcaaa gcgggtgaca atccgtacct gcggtataatcacgccgacg ccgagtttca 1140 ggagcgtctg caagaagata cgtcttttgg gggcaacctcgggcgagcag tcttccaggc 1200 caagaagcgg gttctcgaac ctctcggtct ggttgaggaaggcgctaaga cggctcctgg 1260 aaagaagaga ccggtagagc agtcgccaca agagccagactcctcctcgg gcatcggcaa 1320 gacaggccag cagcccgcta aaaagagact caattttggtcagactggcg actcagagtc 1380 agtccccgac ccacaacctc tcggagaacc tccagcagccccctcaggtc tgggacctaa 1440 tacaatggct tcaggcggtg gcgctccaat ggcagacaataacgaaggcg ccgacggagt 1500 gggtaattcc tcgggaaatt ggcattgcga ttccacatggctgggggaca gagtcatcac 1560 caccagcacc cgaacctggg ccctgcccac ctacaacaaccacctctaca agcaaatctc 1620 caacggcacc tcgggaggaa gcaccaacga caacacctattttggctaca gcaccccctg 1680 ggggtatttt gacttcaaca gattccactg tcacttttcaccacgtgact ggcaacgact 1740 catcaacaac aattggggat tccggcccaa aagactcaacttcaagctgt tcaacatcca 1800 ggtcaaggaa gtcacgacga acgaaggcac caagaccatcgccaataatc tcaccagcac 1860 cgtgcgggtc tttacggact cggagtacca gttaccgtacgtgctaggat ccgctcacca 1920 gggatgtctg cctccgttcc cggcggacgt cttcatggttcctcagtacg gctatttaac 1980 tttaaacaat ggaagccaag ccctgggacg ttcctccttctactgtctgg agtatttccc 2040 atcgcagatg ctgagaaccg gcaacaactt tcagttcagctacaccttcg aggacgtgcc 2100 tttccacagc agctacgcgc acagccagag cctggacaggctgatgaatc ccctcatcga 2160 ccagtacctg tactacctgg tcagaacgca aacgactggaactggaggga cgcagactct 2220 ggcattcagc caagcgggtc ctagctcaat ggccaaccaggctagaaatt gggtgcccgg 2280 accttgctac cggcagcagc gcgtctccac gacaaccaaccagagcaaca acagcaactt 2340 tgcctggacg ggagctgcca agtttaagct gaacggccgagactctctaa tgaatccggg 2400 cgtggcaatg gcttcccaca aggatgacga cgaccgcttcttcccttcga gcggggtcct 2460 gatttttggc aagcaaggag ccgggaacga tggagtggattacagccaag tgctgattac 2520 agatgaggaa gaaatcaagg ctaccaaccc cgtggccacagaagaatatg gagcagtggc 2580 catcaacaac caggccgcca atacgcaggc gcagaccggactcgtgcaca accagggggt 2640 gattcccggc atggtgtggc agaatagaga cgtgtacctgcagggtccca tctgggccaa 2700 aattcctcac acggacggca actttcaccc gtctcccctgatgggcggct ttggactgaa 2760 gcacccgcct cctcaaattc tcatcaagaa cacaccggttccagcggacc cgccgcttac 2820 cttcaaccag gccaagctga actctttcat cacgcagtacagcaccggac aggtcagcgt 2880 ggaaatcgag tgggagctgc agaaagaaaa cagcaaacgctggaatccag agattcaata 2940 cacttccaac tactacaaat ctacaaatgt ggactttgctgtcaacacgg aaggagttta 3000 tagcgagcct cgccccattg gcacccgtta cctcacccgcaacctgtaat tacatgttaa 3060 tcaataaacc ggttaattcg tttcagttga actttggtctctgcgaaggg cgaattc 3117 44 3121 DNA 43.23 44 gaattcgccc ttctacggctgcgtcaactg gaccaatgag aactttccct tcaacgattg 60 cgtcgacaag atggtgatctggtgggagga gggcaagatg acggccaagg tcgtggagtc 120 cgccaaggcc attctcggcggcagcaaggt gcgtgtggac caaaagtgca agtcttccgc 180 ccagatcgat cccacccccgtgatcgtcac ctccaacacc aacatgtgcg ccgtgattga 240 cgggaacagc accaccttcgagcaccagca gccgttgcag gaccggatgt tcaaatttga 300 actcacccgc cgtctggagcatgactttgg caaggtgacg aagcaggaag tcaaagagtt 360 cttccgctgg gcgcaggatcacgtgaccga ggtggcgcat gagttccacg tcagaaaggg 420 tggcgccaac aagagacccgcccccgatga cgcggatata agcgagccca agcgggcctg 480 cccctcagtc gcggatccatcgacgtcaga cgcggaagga gctccggtgg actttgccga 540 caggtaccaa aacaaatgttctcgtcacgc gggcatgctt cagatgctgt ttccctgcaa 600 gacatgcgag agaatgaatcagaatttcaa catttgcttc acgcacggga ccagagactg 660 ttcagaatgt ttccccggcgtgtcagaatc tcaaccggtc gtcagaaaga ggacgtatcg 720 gaaactctgt gcgattcatcatctgctggg gcgggctccc gagattgctt gctcggcctg 780 cgatctggtc aacgtggacctggatgactg tgtttctgag caataaatga cttaaaccag 840 gtatggctgc cgatggttatcttccagatt ggctcgagga caacctctct gagggcattc 900 gcgagtggtg ggacttgaaacctggagccc cgaaacccaa agccaaccag caaaagcagg 960 acgacggccg gggtctggtgcttcctggct acaagtacct cggacccttc aacggactcg 1020 acaaggggga gcccgtcaacgcggcggacg cagcggccct cgagcacgac aaagcctacg 1080 accagcagct caaagcgggtgacaatccgt acctgcggta taatcacgcc gacgccgagt 1140 ttcaggagcg tctgcaagaagatacgtcct ttgggggcaa cctcgggcga gcagtcttcc 1200 aggccaagaa gcgggttctcgaacctctcg gtctggttga ggaaggcgct aagacggctc 1260 ctggaaagaa gagaccggtagagcagtcgc cacaagagcc agactcctcc tcgggcatcg 1320 gcaagacagg ccagcagcccgctaaaaaga gactcaattt tggtcagact ggcgactcag 1380 agtcagtccc cgacccacaacctctcggag aacctccagc agccccctca ggtctgggac 1440 ctaatacaat ggcttcaggcggtggcgctc caatggcaga caataacgaa ggcgccgacg 1500 gagtgggtaa ttcctcgggaaattggcatt gcgattccac atggctgggg gacagagtca 1560 tcaccaccag cacccgaacctgggccctgc ccacctacaa caaccacctc tacaagcaaa 1620 tctccaacgg cacctcgggaggaagcacca acgacaacac ctattttggc tacagcaccc 1680 cctgggggta ttttgacttcaacagattcc actgtcactt ttcaccacgt gactggcaac 1740 gactcatcaa caacaattggggattccggc ccaaaagact caacttcaag ctgttcaaca 1800 tccaggtcaa ggaagtcacgacgaacgaag gcaccaagac catcgccaat aatctcacca 1860 gcaccgtgca ggtctttacggacttggagt accagttacc gtacgtgcta ggatccgctc 1920 accagggatg tctgcctccgttcccggcgg acgtcttcat ggttcctcag tacggctatt 1980 taactttaaa caatggaagccaagccctgg gacgttcctc cttctactgt ctggagtatt 2040 tcccatcgca gatgccgagaaccggcaaca actttcagtt cagctacacc ttcgaggacg 2100 tgcctttcca cagcagctacgcgcacagcc agagcctgga caggctgatg aatcccctca 2160 tcgaccagta cctgtactacctggtcagaa cgcaaacgac tggaactgga gggacgcaga 2220 ctctggcatt cagccaagcgggtcctagct caatggccaa ccaggctaga aattgggtgc 2280 ccggaccttg ctaccggcagcagcgcgtct ccacgacaac caaccagaac aacaacagca 2340 actttgcctg gacgggagctgccaagttta agctgaacgg ccgagactct ctaatgaatc 2400 cgggcgtggc aatggcttcccacaaggatg acgacgaccg cttcttccct tcgagcgggg 2460 tcctgatttt tggcaagcaaggagccggga acgatggagt ggattacagc caagtgctga 2520 ttacagatga ggaagaaatcaaggctacca accccgtggc cacagaagaa tatggagcag 2580 tggccatcaa caaccaggccgccaatacgc aggcgcagac cggactcgtg cacaaccagg 2640 gggtgattcc cggcatggtgtggcagaata gagacgtgta cctgcagggt cccatctggg 2700 ccaaaattcc tcacacggacggcaactttc acccgtctcc cctgatgggc ggctttggac 2760 tgaagcaccc gcctcctcaaattctcatca agaacacacc ggttccagcg gacccgccgc 2820 ttaccttcaa ccaggccaagctgaactctt tcatcacgca gtacagcacc ggacaggtca 2880 gcgtggaaat cgagtgggagctgcagaaag aaaacagcaa acgctggaat ccagagattc 2940 aatacacttc caactactacaaatctacaa atgtggactt tgctgtcaac acggaaggag 3000 tttatagcga gcctcgccccattggcaccc gttacctcac ccgcaacctg taattacatg 3060 ttaatcaata aaccggttaattcgtttcag ttgaactttg gtctctgcga agggcgaatt 3120 c 3121 45 3122 DNA43.25 45 gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttcccttcaacgatt 60 gcgtcgacaa gatggtgatc tggtgggagg agggcaagat gacggccaaggtcgtggagt 120 ccgccaaggc cattctcggc ggcagcaagg tgcgtgtgga ccaaaagtgcaagtcttccg 180 cccagatcga tcccaccccc gtgatcgtca cctccaacac caacatgtgcgccgtgattg 240 acgggaacag caccaccttc gagcaccagc agccgttgca ggaccggatgttcaaatttg 300 aactcacccg ccgtctggag catgactttg gcaaggtgac gaagcaggaagtcaaagggt 360 tcttccgctg ggcgcaggat cacgtgaccg aggtggcgca tgagttccacgtgcgagccc 420 aagcgggcct gcccctcagt cgcggatcca tcgacgtcag accagaaagggtggagccaa 480 caagagaccc gcccccgatg acgcggatat aagcggaagg agctccggtggactttgccg 540 acaggtacca aaacaaatgt tctcgtcacg cgggcatgct tcagatgctgtttccctgca 600 agacatgcga gagaatgaat cagaatttca acatttgctt cacgcacgggaccagagact 660 gttcagaatg tttccccggc gtgtcagaat ctcaaccggt cgtcagaaagaggacgtatc 720 ggaaactctg tgcgattcat catctgctgg ggcgggctcc cgagattgcttgctcggcct 780 gcgatctggt caacgtggac ctggatgact gtgtttctga gcaataaatgacttaaacca 840 ggtatggctg ccgatggtta tcttccagat tggctcgagg acaacctctctgagggcatt 900 cgcgagtggt gggacttgaa acctggagcc ccgaaaccca aagccaaccagcaaaagcag 960 gacgacggcc ggggtctggt gcttcctggc tacaagtacc tcggacccttcaacggactc 1020 gacaaggggg agcccgtcaa cgcggcggac gcagcggccc tcgagcacgacaaagcctac 1080 gaccagcagc tcaaagcggg tgacaatccg tacctgcggt ataatcacgccgacgccgag 1140 tttcaggagc gtctgcaaga agatacgtct tttgggggca acctcgggcgagcagtcttc 1200 caggccaaga agcgggttct cgaacctctc ggtctggttg aggaaggcgctaagacggct 1260 cctggaaaga agagaccggt agagcagtcg ccacaagagc cagactcctcctcgggcatc 1320 ggcaagacag gccagcagcc cgctaaaaag agactcaatt ttggtcagactggcgactca 1380 gagtcagtcc ccgacccaca acctctcgga gaacctccag cagccccctcaggtctggga 1440 cctaatacaa tggcttcagg cggtggcgct ccaatggcag acaataacgaaggcgccgac 1500 ggagtgggta attcctcggg aaattggcat tgcgattcca catggctgggggacagagtc 1560 atcaccacca gcacccgaac ctgggccctg cccacctaca acaaccacctctacaagcaa 1620 atctccaacg gcacctcggg aggaagcacc aacgacaaca cctattttggctacagcacc 1680 ccctgggggt attttgactt caacagattc cactgtcact tttcaccacgtgactggcaa 1740 cgactcatca acaacaattg gggattccgg cccaaaagac tcaacttcaagctgttcaac 1800 atccaggtca aggaagtcac gacgaacgaa ggcaccaaga ccatcgccaataatctcacc 1860 agcaccgtgc aggtctttac ggactcggag taccagttac cgtacgtgctaggatccgct 1920 caccagggat gtctgcctcc gttcccggcg gacgtcttca tggttcctcagtacggctat 1980 ttaactttaa acaatggaag ccaagccctg ggacgttcct ccttctactgtctggagtat 2040 ttcccatcgc agatgctgag aaccggcaac aactttcagt tcagctacaccttcgaggac 2100 gtgcctttcc acagcagcta cgcgcacagc cagagcctgg acaggctgatgaatcccctc 2160 atcgaccagt acctgtacta cctggtcaga acgcaaacga ctggaactggagggacgcag 2220 actctggcat tcagccaagc gggtcctagc tcaatggcca accaggctagaaattgggtg 2280 cccggacctt gctaccggca gcagcgcgtc tccacgacaa ccaaccagaacaacaacagc 2340 aactttgcct ggacgggagc tgccaagttt aagctgaacg gccgagactctctaatgaat 2400 ccgggcgtgg caatggcttc ccacaaggat gacgacgacc gcttcttcccttcgagcggg 2460 gtcctgattt ttggcaagca aggagccggg aacgatggag tggattacagccaagtgctg 2520 attacagatg aggaagaaat caaggctacc aaccccgtgg ccacagaagaatatggagca 2580 gtggccatca acaaccaggc cgccaatacg caggcgcaga ccggactcgtgcacaaccag 2640 ggggtgattc ccggcatggt gtggcagaat agagacgtgt acctgcagggtcccatctgg 2700 gccaaaattc ctcacacgga cggcaacttt cacccgtctc ccctgatgggcggctttgga 2760 ctgaagcacc cgcctcctca aattctcatc aagaacacac cggttccagcggacccgccg 2820 cttaccttca accaggccaa gctgaactct ttcatcacgc agtacagcaccggacaggtc 2880 agcgtggaaa tcgagtggga gctgcagaaa gaaaacagca aacgctggaatccagagatt 2940 caatacactt ccaactacta caaatctaca aatgtggact ttgctgtcaacacggagggg 3000 gtttatagcg agcctcgccc cattggcacc cgttacctca cccgcaacctgtaattacat 3060 gttaatcaat aaaccggtta attcgtttca gttgaacttt ggtctctgcgaagggcgaat 3120 tc 3122 46 3128 DNA 44.1 46 gaattcgccc tttctacggctgcgtcaact ggaccaatga gaactttccc ttcaacgatt 60 gcgtcgacaa gatgttgatctggtgggagg agggcaagat gacggccaag gtcgtggagt 120 ccgccaaggc cattctcggcggcagcaaag tgcgcgtgga ccaaaagtgc aagccgtccg 180 cccagatcga ccccacccccgtgatcgtca cctccaacac caacatgtgc gccgtgattg 240 acgggaacag caccaccttcgagcaccagc agccgttgcg ggaccggatg ttcaagtttg 300 aactcacccg ccgtctggagcacgactttg gcaaggtgac aaagcaggaa gtcagagagt 360 tcttccgctg ggcgcaggatcacgtgaccg aggtggcgca cgagttctac gtcagaaagg 420 gtggagccaa caagagacccgcccccgatg acgcggataa aagcgagccc aagcgggcct 480 gcccctcagt cgcggatccatcgacgtcag acgcggaagg agctccggtg gactttgccg 540 acaggtacca aaacaaatgttctcgtcacg cgggcatgct tcagatgctg tttccctgca 600 aaacatgcga gagaatgaatcagaatttca acatttgctt cacgcacggg accagagact 660 gttcagaatg tttccccggcgtgtcagaat ctcaaccggt cgtcagaaaa aagacgtatc 720 ggaaactctg tgcgattcatcatctgctgg ggcgggcacc cgagattgct tgctcggcct 780 gcgatctggt caacgtggacctagatgact gtgtttctga gcaataaatg acttaaacca 840 ggtatggctg ccgatggttatcttccagat tggctcgagg acaacctctc tgagggcatt 900 cgcgagtggt gggacttgaaacctggagcc ccgaaaccca aagccaacca gcaaaagcag 960 gacgacggcc ggggtctggtgcttcctggc tacaagtacc tcggaccctt caacggactc 1020 gacaaggggg agcccgtcaacgcggcggac gcagcggccc tcgagcacga caaggcctac 1080 gaccagcagc tcaaagcgggtgacaatccg tacctgcggt ataaccacgc cgacgccgag 1140 tttcaggagc gtctgcaagaagatacgtct tttgggggca acctcgggcg agcagtcttc 1200 caggccaaga agcgggttctcgaacctctc ggtctggttg aggaaggcgc taagacggct 1260 cctggaaaga agagaccggtagagccatca ccccagcgtt ctccagactc ctctacgggc 1320 atcggcaaga aaggccagcagcccgcgaaa aagagactca actttgggca gactggcgac 1380 tcagagtcag tgcccgaccctcaaccaatc ggagaacccc ccgcaggccc ctctggtctg 1440 ggatctggta caatggctgcaggcggtggc gctccaatgg cagacaataa cgaaggcgcc 1500 gacggagtgg gtagttcctcaggaaattgg cattgcgatt ccacatggct gggcgacaga 1560 gtcatcacca ccagcacccgaacctgggcc ctccccacct acaacaacca cctctacaag 1620 caaatctcca acgggacttcgggaggaagc accaacgaca acacctactt cggctacagc 1680 accccctggg ggtattttgactttaacaga ttccactgcc acttctcacc acgtgactgg 1740 cagcgactca tcaacaacaactggggattc cggcccaaga gactcaactt caagctcttc 1800 aacatccagg tcaaggaggtcacgcagaat gaaggcacca agaccatcgc caataacctt 1860 accagcacga ttcaggtctttacggactcg gaataccagc tcccgtacgt cctcggctct 1920 gcgcaccagg gctgcctgcctccgttcccg gcggacgtct tcatgattcc tcagtacggg 1980 tacctgactc tgaacaatggcagtcaggcc gtgggccgtt cctccttcta ctgcctggag 2040 tactttcctt ctcaaatgctgagaacgggc aacaactttg agttcagcta ccagtttgag 2100 gacgtgcctt ttcacagcagctacgcgcac agccaaagcc tggaccggct gatgaacccc 2160 ctcatcgacc agtacctgtactacctgtct cggactcagt ccacgggagg taccgcagga 2220 actcagcagt tgctattttctcaggccggg cctaataaca tgtcggctca ggccaaaaac 2280 tggctacccg ggccctgctaccggcagcaa cgcgtctcca cgacactgtc gcaaaataac 2340 aacagcaact gtaaatcccggtgtcgctat ggcaacccac aaggacgacg aagagcgatt 2400 ttgcctggac cggtgccaccaagtatcatc tgaatggcag agactctctg ttttccgtcc 2460 agcggagtct taatgtttgggaaacaggga gctggaaaag acaacgtgga ctatagcagc 2520 gttatgctaa ccagtgaggaagaaattaaa accaccaacc cagtggccac ggaacagtac 2580 ggcgtggtgg ccgataacctgcaacagcaa aacgccgctc ctattgtagg ggccgtcaac 2640 agtcaaggag ccttacctggcatggtctgg cagaaccggg acgtgtacct gcagggtcct 2700 atctgggcca agattcctcacacggacgga aactttcatc cctcgccgct gatgggaggc 2760 tttggactga aacacccgcctcctcagatc ctgattaaga atacacctgt tcccgcggat 2820 cctccaacta ccttcagtcaagctaagctg gcgtcgttca tcacgcagta cagcaccgga 2880 caggtcagcg tggaaattgaatgggagctg cagaaagaaa acagcaaacg ctggaaccca 2940 gagattcaat acacttccaactactacaaa tctacaaatg tggacttcgc tgttaacaca 3000 gatggcactt attctgagcctcgccccatt ggcacccgtt acctcacccg taatctgtaa 3060 ttgctcgtta atcaataaaccggttgattc gtttcagttg aactttggtc tctgcgaagg 3120 gcgaattc 3128 47 3128DNA 44.5 47 gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttcccttcaacgatt 60 gcgtcgacaa gatggtgatc tggtgggagg agggcaagat gacggccaaggtcgtggagt 120 ccgccaaggc cattctcggc ggcagcaaag tgcgcgtgga ccaaaagtgcaagtcgtccg 180 cccagatcga ccccaccccc gtgatcgtca cctccaacac caacatgtgcgccgtgattg 240 acgggaacag caccaccttc gagcaccagc agccgttgca ggaccggatgttcaagtttg 300 aactcacccg ccgtctggag cacgactttg gcaaggtgac aaagcaggaagtcagagagt 360 tcttccgctg ggcgcaggat cacgtgaccg aggtggcgca cgagttctacgtcagaaagg 420 gtggagccaa caagagaccc gcccccgatg acgcggataa aagcgagcccaagcgggcct 480 gcccctcagt cgcggatcca tcgacgtcag acgcggaagg agctccggtggactttgccg 540 acaggtacca aaacaaatgt tctcgtcacg cgggcatgct tcagatgctgtttccctgca 600 aaacatgcga gagaatgaat cagaatttca acatttgctt cacgcacgggaccagagact 660 gttcagaatg tttccccggc gtgtcagaat ctcaaccggt tgtcagaaaaaagacgtatc 720 ggaaactctg tgcgattcat catctgctgg ggcgggcacc cgagattgcttgctcggcct 780 gcgatctggt caacgtggac ctagatgact gtgtttctga gcaataaatgacttaaacca 840 ggtatggctg ccgatggtta tcttccagat tggctcgagg acaacctctctgagggcatt 900 cgcgagtggt gggacttgaa acctggagcc ccgaaaccca aagccaaccagcaaaagcag 960 gacgacggcc ggggtctggt gcttcctggc tacaagtacc tcggacccttcaacggactc 1020 gacaaggggg agcccgtcaa cgcggcggac gcagcggccc tcgagcacgacaaggcctac 1080 gaccagcagc tcaaagcggg tgacaatccg tacctgcggt ataaccacgccgacgccgag 1140 tttcaggagc gtctgcaaga agatacgtct tttgggggca acctcgggcgagcagtcttc 1200 caggccaaga agcgggttct cgaacctctc ggtctggttg aggaaggcgctaagacggct 1260 cctggaaaga agagaccggt agagccatca ccccagcgtt ctccagactcctctacgggc 1320 atcggcaaga aaggccagca gcccgcgaaa aagagactca actttgggcagactggcgac 1380 tcagagtcag tgcccgaccc tcaaccaatc ggagaacccc ccgcaggcccctctggtctg 1440 ggatctggta caatggctgc aggcggtggc gctccaatgg cagacaataacgaaggcgcc 1500 gacggagtgg gtagttcctc aggaaattgg cattgcgatt ccacatggctgggcgacaga 1560 gtcatcacca ccagcacccg aacctgggcc ctccccacct acaacaaccacctctacaag 1620 caaatctcca acgggacttc gggaggaagc accaacgaca acacctacttcggctacagc 1680 accccctggg ggtattttga ctttaacaga ttccactgcc acttctcaccacgtgactgg 1740 cagcgactca tcaacaacaa ctggggattc cggcccaaga gacccaacttcaagctcttc 1800 aacatccagg tcaaggaggt cacgcagaat gaaggcacca agaccatcgccaataacctt 1860 accagcacga ttcaggtctt tacggactcg gaataccagc tcccgtacgtcctcggctct 1920 gcgcaccagg gctgcctgcc tccgttcccg gcggacgtct tcatgattcctcagtacggg 1980 tacctgactc tgaacaatgg cagtcaggcc gtgggccgtt cctccttctactgcctggag 2040 tactttcctt ctcaaatgct gagaacgggc aacaactttg agttcagctaccagtttgag 2100 gacgtgcctt ttcacagcag ctacgcgcac agccaaagcc tggaccggctgatgaacccc 2160 ctcatcgacc agtacctgta ctacctgtct cggactcagt ccacgggaggtaccgcagga 2220 actcagcagt tgctattttc tcaggccggg cctaataaca tgtcggctcaggccaaaaac 2280 tggctacccg ggccctgcta ccggcagcaa cgcgtctcca cgacactgtcgcaaaataac 2340 aacagcaact ttgcctggac cggtgccacc aagtatcatc tgaatggcagagactctctg 2400 gtaaatcccg gtgtcgctat ggcaacccac aaggacgacg aagagcgattttttccgtcc 2460 agcggagtct taatgtttgg gaaacaggga gctggaaaag acaacgtggactatagcagc 2520 gttatgctaa ccagtgagga agaaattaaa accaccaacc cagtggccacagaacagtac 2580 ggcgtggtgg ccgataacct gcaacagcaa aacgccgctc ctattgtaggggccgtcaac 2640 agtcaaggag ccttacctgg catggtctgg cagaaccggg acgtgtacctgcagggtcct 2700 atctgggcca agattcctca cacggacgga aactttcatc cctcgccgctgatgggaggc 2760 tttggactga aacacccgcc tcctcagatc ctgattaaga atacacctgttcccgcggat 2820 cctccaacta ccttcagtca agctaagctg gcgtcgttca tcacgcagtacagcaccgga 2880 caggtcagcg tggaaattga atgggagctg cagaaagaaa acagcaaacgctggaaccca 2940 gagattcaat acacttccaa ctactacaaa tctacaaatg tggactttgctgttaacaca 3000 gatggcactt attctgagcc tcgccccatt ggcacccgtt acctcacccgtaatctgtaa 3060 ttgcttgtta atcaataaac cggttgattc gtttcagttg aactttggtctctgcgaagg 3120 gcgaattc 3128 48 1933 DNA new AAV serotype, clone 223.10misc_feature (1302)..(1302) can be a, c, g or t 48 caaggcctac gaccagcagctcaaagcggg tgacaatccg tacctgcggt ataaccacgc 60 cgacgccgag tttcaggagcgtcttcaaga agatacgtct tttgggggca acctcgggcg 120 agcagtcttc caggccaaaaagcgggttct cgaacctctt ggtctggttg agacgccagc 180 taagacggca cctggaaagaagcgaccggt agactcgcca gactccacct cgggcatcgg 240 caagaaaggc cagcagcccgcgaaaaagag actcaacttt gggcagactg gcgactcaga 300 gtcagtcccc gaccctcaaccaatcggaga accaccagca ggcccctctg gtctgggatc 360 tggtacaatg gctgcaggcggtggcgcacc aatggctgac aataacgagg gcgccgacgg 420 agtgggtaat gcctcaggaaattggcattg cgattccaca tggctgggcg acagagtcat 480 caccaccagc acccgaacctgggccctgcc cacctacaac aaccacctct acaagcaaat 540 ctccagtcag tcagcagggagcaccaacga taacgtctat ttcggctaca gcaccccctg 600 ggggtatttt gacttcaacagattccattg ccacttctca ccacgtgact ggcagcgact 660 tatcaacaac aactggggattccggcccaa gaagctcaac ttcaagctct tcaacatcca 720 ggtcaaggag gtcacgacgaatgacggtgt cacaaccatc gctaataacc ttaccagcac 780 ggttcaggtc ttttcggactcggaatatca actgccgtac gtcctcggct ccgcgcacca 840 gggctgcctg cctccgttcccggcagacgt gttcatgatt ccgcagtacg gatacctgac 900 tctgaacaat ggcagccaatcggtaggccg ttcctccttc tactgcctgg agtactttcc 960 ttctcagatg ctgagaacgggcaacaactt cacctttagc tacaccttcg aggacgtgcc 1020 tttccacagc agctacgcgcacagccagag tctggaccgg ctgatgaatc ccctcatcga 1080 ccagtacctg tactacttggccagaacaca gagcaacgca ggaggtactg ctggcaatcg 1140 ggaactgcag ttttatcagggcggacctac caccatggcc gaacaagcaa agaactggct 1200 gcccggacct tgcttccggcaacagagagt atccaagacg ctggatcaaa ataacaacag 1260 caactttgcc tggactggtgccacaaaata ccatttaaat gnaagaaatt cattggttaa 1320 tcccggtgtc gccatggcaacccacaagga cgacgaggaa cgcttcttcc cttcgagcgg 1380 agttctaatt tttggcaaaactggagcagc taataaaact acattagaaa acgtgctcat 1440 gacaaatgaa gaagaaattcgtcctaccaa cccggtagct accgaggaat acgggattgt 1500 aagcagcaac ttgcaggcggctagcaccgc agcccagaca caagttgtta acaaccaggg 1560 agccttacct ggcatggtctggcagaaccg ggacgtgtac ctgcaaggtc ccatttgggc 1620 caagattcct cacacggacggcaactttca cccgtctcct ctaatgggtg gctttggact 1680 gaaacacccg cctccccagatcctgatcaa aaacacaccg gtacctgcta atcctccaga 1740 agtgtttact cctgccaagtttgcttcctt catcacgcag tacagcaccg ggcaagtcag 1800 cgttgagatc gagtgggagctgcagaaaga gaacagcaag cgctggaacc cagagattca 1860 gtacacctcc aactttgacaaacagactgg agtggacttt gctgttgaca gccagggtgt 1920 ttactctgag cct 1933 491933 DNA new AAV serotype, clone 223.2 49 caaggcctac gaccagcagctcaaagcggg tgacaatccg tacctgcggt ataaccacgc 60 cgacgccgag tttcaggagtgtcttcaaga agatacgtct tttgggggca acctcgggcg 120 agcagtcttc caggccaaaaagcgggttct cgaacctctt ggtctggttg agacgccagc 180 taagacggca cctggaaagaagcgaccggt agactcgcca gactccacct cgggcatcgg 240 caagaaaggc cagcagcccgcgaaaaagag actcaacttt gggcagactg gcgactcaga 300 gtcagtcccc gaccctcaaccaatcggaga accaccagca ggcccctctg gtctgggatc 360 tggtacaatg gttgcaggcggtggcgcacc aatggctgac aataacgagg gcgccgacgg 420 agtgggtaat gcctcaggaaattggcattg cgattccaca tggctgggcg acagagtcat 480 caccaccagc acccgaacctgggccctgcc cacctacaac aaccacctct acaagcaaat 540 ctccagtcag tcagcagggagcaccaacga taacgtctat ttcggctaca gcaccccctg 600 ggggtatttt gacttcaacagattccattg ccacttctca ccacgtgact ggcagcgact 660 tatcaacaac aactggggattccggcccaa gaagctcaac ttcaagctct tcaacatcca 720 ggtcaaggag gtcacgacgaatgacggtgt cacaaccatc gctaataacc ttaccagcac 780 ggttcaggtc ttttcggactcggaatatca actgccgtac gtcctcggct ccgcgcacca 840 gggctgcctg cctccgttcccggcagacgt gttcatgatt ccgcagtacg gatacctgac 900 tctgaacaat ggcagccaatcggtaggccg ttcctccttc tactgcctgg agtactttcc 960 ttctcagatg ctgagaacgggcaacaactt cacctttagc tacaccttcg aggacgtgcc 1020 tttccacagc agctacgcgcacagccagag tctggaccgg ctgatgaatc ccctcatcga 1080 ccagtacctg tactacttggccagaacaca gagcaacgca ggaggtactg ctggcaatcg 1140 ggaactgcag ttttatcagggcggacctac caccatggcc gaacaagcaa agaactggct 1200 gcccggacct tgcttccggcaacagagagt atccaagacg ctggatcaaa ataacaacag 1260 caactttgcc tggactggtgccacaaaata ccatttaaat ggaagaaatt cattggttaa 1320 tcccggtgtc gccatggcaacccacaagga cgacgaggaa cgcttctccc cttcgagcgg 1380 agttctaatt tttggcaaaactggagcagc taataaaact acattagaaa acgtgctcat 1440 gacaaatgaa gaagaaattcgtcctaccaa cccggtagct accgaggaat acgggattgt 1500 aagcagcaac ttgcaggcggctagcaccgc agcccagaca caagttgtta acaaccaggg 1560 agccttacct ggcatggtctggcagaaccg ggacgtgtac ctgcaaggtc ccatttgggc 1620 caagattcct cacacggacggcaactttca cccgtctcct ctaatgggtg gctttggact 1680 gaaacacccg cctccccagatcctgatcaa aaacacgccg gtacctgcta atcctccaga 1740 agtgtttact cctgccaagtttgcttcctt catcacgcag tacagcaccg ggcaagtcag 1800 cgttgagatc gagtgggagctgcagaaaga gaacagcaag cgctggaacc cagagattca 1860 gtacacctcc aactttgacaaacagactgg agtggacttt gctgttgaca gccagggtgt 1920 ttactctgag cct 1933 501933 DNA new AAV serotype, clone 223.4 50 caaggcctac gaccagcagctcaaagcggg tgacaatccg tacctgcggt ataaccacgc 60 cgacgccgag tttcaggagcgtcttcaaga agatacgtct tttgggggca acctcgggcg 120 agcagtcttc caggccaaaaagcgggttct cgaacctctt ggtctggttg agacgccagc 180 taagacggca cctggaaagaagcgaccggt agactcgcca gactccacct cgggcatcgg 240 caagaaaggc cagcagcccgcgaaaaagag actcaacttt gggcagactg gcgactcaga 300 gccagtcccc gaccctcaaccaatcggaga accaccagca ggcccctctg gtctgggatc 360 tggtacaatg gctgcaggcggtggcgcacc aatggctgac aataacgagg gcgccgacgg 420 agtgggtaat gcctcaggaaattggcattg cgattccaca cggctgggcg acagagtcat 480 caccaccagc acccgaacctgggccctgcc cacctacaac aaccacctct acaagcaaat 540 ctccagtcag tcagcagggagcaccaacga taacgtctat ttcggctaca gcaccccctg 600 ggggtatttt gacttcaacagattccattg ccacttctca ccacgtgact ggcagcgact 660 tatcaacaac aactggggattccggcccaa gaagctcaac ttcaagctct tcaacatcca 720 ggtcaaggag gtcacgacgaatgacggcgt cacaaccatc gctaataacc ttaccagcac 780 ggttcaggtc ttttcggactcggaatatca actgccgtac gtcctcggct ccgcgcacca 840 gggctgcctg cctccgttcccggcagacgt gttcatgatt ccgcagtacg gatacctgac 900 tctgaacaat ggcagccaatcggtaggccg ttcctccttc tactgcctgg agtactttcc 960 ttctcagatg ctgagaacgggcaacaactt cacctttagc tacaccttcg aggacgtgcc 1020 tttccacagc agctacgcgcacagccagag tctgggccgg ctgatgaatc ccctcatcga 1080 ccagtacctg tactacttggccagaacaca gagcaacgca ggaggtactg ctggcaatcg 1140 ggaactgcag ttttatcagggcggacctac caccatggcc gaacaagcaa agaactggct 1200 gcccggacct tgcttccggcaacagagagt atccaagacg ctggatcaaa ataacaacag 1260 caactttgcc tggactggtgccacaaaata ccatttaaat ggaagaaatt cattggttaa 1320 tcccggtgtc gccatggcaacccacaagga cgacgaggaa cgcttcttcc cttcgagcgg 1380 agttctaatt tttggcaaaactggagcagc taataaaact acattagaaa acgtgctcat 1440 gacaaatgaa gaagaaattcgtcctaccaa cccggtagct accgaggaat acgggattgt 1500 aagcagcaac ttgcaggcggctagcaccgc agcccagaca caagttgtta acaaccaggg 1560 agccttacct ggcatggtctggcagaaccg ggacgtgtac ctgcaaggtc ccatttgggc 1620 caagattcct cacacggacggcaactttca cccgtctcct ctaatgggtg gctttggact 1680 gaaacacccg cctccccagatcctgatcaa aaacacaccg gtacctgcta atcctccaga 1740 agtgtttact cctgccaagtttgcttcctt catcacgcag tacagcaccg ggcaagtcag 1800 cgttgagatc gaatgggagctgcagaaaga gaacagcaag cgctggaacc cagagattca 1860 gtacacctcc aactttgacaaacagactgg agtggacttt gctgttgaca gccagggtgt 1920 ttactctgag cct 1933 511933 DNA new AAV serotype, clone 223.5 51 caaggcctac gaccagcagctcaaagcggg tgacaatccg tacctgcggt ataaccacgc 60 cgacgccgag tttcaggagcgtcttcaaga agatacgtct tttgggggca acctcgggcg 120 agcagtcttc caggccaaaaagcgggttct cgaacctctt ggtctggttg agacgccagc 180 taagacggca cctggaaagaagcgaccggt agactcgcca gactccacct cgggcatcgg 240 caagaaaggc cagcagcccgcgaaaaagag actcaacttt gggcagactg gcgactcaga 300 gccagtcccc gaccctcaaccaatcggaga accaccagca ggcccctctg gtctgggatc 360 tggtacaatg gctgcaggcggtggcgcacc aatggctgac aataacgagg gcgccgacgg 420 agtgggtaat gcctcaggaaattggcattg cgattccaca cggctgggcg acagagtcat 480 caccaccagc acccgaacctgggccctgcc cacctacaac aaccacctct acaagcaaat 540 ctccagtcag tcagcagggagcaccaacga taacgtctat ttcggctaca gcaccccctg 600 ggggtatttt gacttcaacagattccattg ccacttctca ccacgtgact ggcagcgact 660 tatcaacaac aactggggattccggcccaa gaagctcaac ttcaagctct tcaacatcca 720 ggtcaaggag gtcacgacgaatgacggcgt cacaaccatc gctaataacc ttaccagcac 780 ggttcaggtc ttttcggactcggaatatca actgccgtac gtcctcggct ccgcgcacca 840 gggctgcctg cctccgttcccggcagacgt gttcatgatt ccgcagtacg gatacctgac 900 tctgaacaat ggcagccaatcggtaggccg ttcctccttc tactgcctgg agtactttcc 960 ttctcagatg ctgagaacgggcaacaactt cacctttagc tacaccttcg aggacgtgcc 1020 tttccacagc agctacgcgcacagccagag tctgggccgg ctgatgaatc ccctcatcga 1080 ccagtacctg tactacttggccagaacaca gagcaacgca ggaggtactg ctggcaatcg 1140 ggaactgcag ttttatcagggcggacctac caccatggcc gaacaagcaa agaactggct 1200 gcccggacct tgcttccggcaacagagagt atccaagacg ctggatcaaa ataacaacag 1260 caactttgcc tggactggtgccacaaaata ccatttaaat ggaagaaatt cattggttaa 1320 tcccggtgtc gccatggcaacccacaagga cgacgaggaa cgcttcttcc cttcgagcgg 1380 agttctaatt tttggcaaaactggagcagc taataaaact acattagaaa acgtgctcat 1440 gacaaatgaa gaagaaattcgtcctaccaa cccggtagct accgaggaat acgggattgt 1500 aagcagcaac ttgcaggcggctagcaccgc agcccagaca caagttgtta acaaccaggg 1560 agccttacct ggcatggtctggcagaaccg ggacgtgtac ctgcaaggtc ccatttgggc 1620 caagattcct cacacggacggcaactttca cccgtctcct ctaatgggtg gctttggact 1680 gaaacacccg cctccccagatcctgatcaa aaacacaccg gtacctgcta atcctccaga 1740 agtgtttact cctgccaagtttgcttcctt catcacgcag tacagcaccg ggcaagtcag 1800 cgttgagatc gaatgggagctgcagaaaga gaacagcaag cgctggaacc cagagattca 1860 gtacacctcc aactttgacaaacagactgg agtggacttt gctgttgaca gccagggtgt 1920 ttactctgag cct 1933 521933 DNA new AAV serotype, clone 223.6 52 caaggcctac gaccagcagctcaaagcggg tgacaatccg tacctgcggt ataaccacgc 60 cgacgccgag tttcaggagcgtcttcaaga agatacgtct tttgggggca acctcgggcg 120 agcagtcttc caggccaaaaagcgggttct cgaacctctt ggtctggttg agacgccagc 180 taagacggca cctggaaagaagcgaccggt agactcgcca gactccacct cgggcatcgg 240 caagaaaggc cagcagcccgcgaaaaagag actcaacttt gggcagactg gcgactcaga 300 gtcagtcccc gaccctcaaccaatcggaga accaccagca ggcccctctg gtctgggatc 360 tggtacaatg gctgcaggcggtggcgcacc aatggctgac aatagcgagg gcgccgacgg 420 agtgggtaat gcctcaggaaattggcattg cgattccaca tggctgggcg acagagtcat 480 caccaccagc acccgaacctgggccctgcc cacctacaac aaccacctct acaagcaaat 540 ctccagtcag tcagcagggagcaccaacga taacgtctat ttcggctaca gcaccccctg 600 ggggtatttt gacttcaacagattccattg ccacttctca ccacgtgact ggcagcgact 660 tatcaacaac aactggggattccggcccaa gaagctcaac ttcaagctct tcaacatcca 720 ggtcaaggag gtcacgacgaatgacggtgt cacaaccatc gctaataacc ttaccagcac 780 ggttcaggtc ttttcggactcggaatatca actgccgtac gtcctcggct ccgcgcacca 840 gggctgcctg cctccgttcccggcagacgt gttcatgatt ccgcagtacg gatacctgac 900 tctgaacaat ggcagccaatcggtaggccg ttcctccttc tactgcctgg agtactttcc 960 ttctcagatg ctgagaacgggcaacaactt cacctttagc tacaccttcg aggacgtgcc 1020 tttccacagc agctacgcgcacagccagag tctggaccgg ctgatgaatc ccctcatcga 1080 ccagtacctg tactacttggccagaacaca gagcaacgca ggaggtactg ctggcaatcg 1140 ggaactgcag ttttatcagggcggacctac caccatggcc gaacaagcaa agaactggct 1200 gcccggacct tgcttccggcaacagagagt atccaagacg ctggatcaaa ataacaacag 1260 caactttgcc tggactggtgccacaaaata ccatttaaat ggaagaaatt cattggttaa 1320 tcccggtgtc gccatggcaacccacaagga cgacgaggaa cgcttcttcc cttcgagcgg 1380 agttctaatt tttggcaaaactggagcagc taataaaact acattagaaa acgtgctcat 1440 gacaaatgaa gaagaaattcgtcctaccaa cccggtagct accgaggaat acgggattgt 1500 aagcagcaac ttgcaggcggctagcaccgc agcccagaca caagttgtta acaaccaggg 1560 agccttacct ggcatggtctggcagaaccg ggacgtgtac ctgcaaggtc ccatttgggc 1620 caagattcct cacacggacggcaactttca cccgtctcct ctaatgggtg gctttggact 1680 gaaacacccg cctccccagatcctgatcaa aaacacaccg gtacctgcta atcctccaga 1740 agtgtttact cctgccaagcttgcttcctt catcacgcag tacagcaccg ggcaagtcag 1800 cgttgagatc gagtgggagctgcagaaaga gaacagcaag cgctggaacc cagagattca 1860 gtacacctcc aactttgacaaacagactgg agtggacttt gctgttgaca gccagggtgt 1920 ttactctgag cct 1933 531933 DNA new AAV serotype, clone 223.7 53 caaggcctac gaccagcagctcaaagcggg tgacaatccg tacctgcggt ataaccacgc 60 cgacgccgag tttcaggagcgtcttcaaga agatacgtct tttgggggca acctcgggcg 120 agcagtcttc caggccaaaaagcgggttct cgaacctctt ggtctggttg agacgccagc 180 taagacggca cctggaaagaagcgaccggt agactcgcca gactccacct cgggcatcgg 240 caagaaaggc cagcagcccgcgaaaaagag actcaacttt gggcagactg gcgactcaga 300 gtcagtcccc gaccctcaaccaatcggaga accaccagca ggcccctctg gtctgggatc 360 tggtacaatg gctgcaggcggtggcgcacc aatggctgac aataacgagg gcgccgacgg 420 agtgggtaat gcctcaggaaattggcattg cgattccaca tggctgggcg acagagtcat 480 caccaccagc acccgaacctgggccctgcc cacctacaac aaccacctct acaagcaaat 540 ctccagtcag tcagcagggagcaccaacga taacgtctat ttcggctaca gcaccccctg 600 ggggtatttt gacttcaacagattccattg ccacttctca ccacgtgact ggcagcgact 660 tatcaacaac aactggggattccggcccaa gaagctcaac ttcaagctct tcaacatcca 720 ggtcaaggag gtcacgacgaatgacggcgt cacaaccatc gctaataacc ttaccagcac 780 ggttcaggtc ttttcggacccggaatatca actgccgtac gtcctcggct ccgcgcacca 840 gggctgcctg cctccgttcccggcagacgt gttcatgatt ccgcagtacg gatacctgac 900 tctgaacaat ggcagccaatcggtaggccg ttcctccttc tactgcctgg agtactttcc 960 ttctcagatg ctgagaacgggcaacaactt cacctttagc tacaccttcg aggacgtgcc 1020 tttccacagc agctacgcgcacagccagag tctggaccgg ctgatgaatc ccctcatcga 1080 ccagtacctg tactacttggccagaacaca gagcaacgca ggaggtactg ctggcaatcg 1140 ggaactgcag ttttatcagggcggacctac caccatggcc gaacaagcaa agaactggct 1200 gcccggacct tgcttccggcaacagagagt atccaagacg ctggatcaaa ataacaacag 1260 caactttgcc tggactggtgccacaaaata ccatttaaat ggaagaaatt cattggttaa 1320 tcccggtgtc gccatggcaacccacaagga cgacgaggaa cgcttcttcc cttcgagcgg 1380 agttctaatt tttggcaaaactggagcagc taataaaact acattagaaa acgtgctcat 1440 gacaaatgaa gaagaaattcgtcctaccaa cccggtagct accgaggaat acgggattgt 1500 aagcagcaac ttgcaggcggctagcaccgc agcccagaca caagttgtta acaaccaggg 1560 agccttacct ggcatggtctggcagaaccg ggacgtgtac ctgcaaggtc ccatttgggc 1620 caagattcct cacacggacggcaactttca cccgtctcct ctaatgggtg gctttggact 1680 gaaacacccg cctccccagatcctgatcaa aaacacaccg gtacctgcta atcctccaga 1740 agtgtttact cctgccaagattgcttcctt catcacgcag tacagcaccg ggcaagtcag 1800 cgttgagatc gagtgggagctgcagaaaga gaacagcaag cgctggaacc cagagattca 1860 gtacacctcc aactttgacaaacagactgg agtggacttt gctgttgaca gccagggtgt 1920 ttactctgag cct 1933 543123 DNA new AAV serotype, clone A3.4 54 gaattcgccc tttctacggctgcgtcaact ggaccaatga aaactttccc ttcaacgatt 60 gcgtcgacaa gatggtgatctggtgggagg agggaaagat gaccgccaag gtcgtggaat 120 ctgccaaagc cattctgggtggaagcaagg ttcgtgtgga ccagaaatgc aagtcttcgg 180 cccagatcga cccgactccggtgattgtca cctctaacac caacatgtgc gccgtgattg 240 acggaaactc gaccaccttcgagcaccagc agccgttgca agaccggatg ttcaaatttg 300 aacttacccg ccgtttggatcatgactttg ggaaggtcac caagcaggaa gtcaaagact 360 ttttccggtg ggctcaagatcacgtgactg aggtggagca tgagttctac gtcaaaaagg 420 gtggagccaa gaaaaggcccgcccccgatg atgtatatat aaatgagccc aagcgggcgc 480 gcgagtcagt tgcgcagccatcgacgtcag acgcggaagc ttcgataaac tacgcgggca 540 ggtaccaaaa caaatgttctcgtcacgtgg gcatgaatct gatgctgttt ccctgtcgac 600 aatgcgaaag aatgaatcagaattcaaata tctgcttcac acacgggcaa aaagactgtt 660 tggaatgctt tcccgtgtcagaatctcaac ccgtttctgt cgtcagaaaa acgtatcaga 720 aactttgtta cattcatcatatcatgggaa aagaaccaga cgcctgcact gcctgcgacc 780 tggtaaatgt ggacttggatgactgtattt ctgagcaata aatgacttaa atcaggtatg 840 gctgctgacg gttatcttccagattggctc gaggacactc tctctgaagg aatcagacag 900 tggtggaagc tcaaacctggcccaccaccg ccgaaaccta accaacaaca ccgggacgac 960 agtaggggtc ttgtgcttcctgggtacaag tacctcggac ccttcaacgg actcgacaaa 1020 ggagagccgg tcaacgaggcagacgccgcg gccctcgagc acgacaaagc ctacgaccac 1080 cagctcaagc aaggggacaacccgtacctc aaatacaacc acgcggacgc tgaatttcag 1140 gagcgtcttc aagaagatacgtctttcggg ggcaacctcg ggcgagcagt cttccaggcc 1200 aaaaagaggg tactcgagcctcttggtctg gttgaggaag ctgttaagac ggctcctgga 1260 aaaaagagac ctatagagcagtctcctgca gaaccggact cttcctcggg catcggcgaa 1320 tcaggccagc agcccgctaagaaaagactc aattttggtc agactggcga cacagagtca 1380 gtcccagacc ctcaaccaatcggagaaccc cccgcagccc cctctggtgt gggatctaat 1440 acaatggctt caggcggtggggcaccaatg gcagacgata acgaaggcgc cgacggagtg 1500 ggtaattcct cgggaaattggcattgcgat tccacatgga tgggcgacag agttatcacc 1560 accagcacaa gaacctgggccctccccacc tacaataatc acctctacaa gcaaatctcc 1620 agcgaatcgg gagccaccaacgacaaccac tacttcggct acagcacccc ctgggggtat 1680 tttgacttta acagattccactgtcacttc tcaccacgtg actggcagcg actcatcaac 1740 aacaactggg gatttagacccaagaaactc aatttcaagc tcttcaacat ccaagtcaag 1800 gaggtcacgc agaatgatggaaccacgacc atcgccaata accttaccag cacggtgcag 1860 gtcttcacag actctgagtaccagctgccc tacgtcctcg gttcggctca ccagggctgc 1920 cttccgccgt tcccagcagacgtcttcatg attcctcagt acggctactt gactctgaac 1980 aatggcagcc aagcggtaggacgttcttca ttctactgtc tagagtattt tccctctcag 2040 atgctgagga cgggaaacaacttcaccttc agctacactt ttgaagacgt gcctttccac 2100 agcagctacg cgcacagccagagtctggat cggctgatga atcctctcat tgaccagtac 2160 ctgtattacc tgagcaaaactcagggtaca agtggaacaa cgcagcaatc gagactgcag 2220 ttcagccaag ctgggcctagctccatggct cagcaggcca aaaactggct accgggaccc 2280 agctaccgac agcagcgaatgtctaagacg gctaatgaca acaacaacag tgaatttgct 2340 tggactgcag ccaccaaatattacctgaat ggaagaaatt ctctggtcaa tcccgggccc 2400 ccaatggcca gtcacaaggacgatgaggaa aagtatttcc ccatgcacgg aaatctcatc 2460 tttggaaaac aaggcacaggaactaccaat gtggacattg aatcagtgct tattacagac 2520 gaagaagaaa tcagaacaactaatcctgtg gctacagaac aatacggaca ggttgccacc 2580 aaccatcaga gtcaggacaccacagcttcc tatggaagtg tggacagcca gggaatctta 2640 cctggaatgg tgtggcaggaccgcgatgtc tatcttcaag gtcccatttg ggccaaaact 2700 cctcacacgg acggacactttcatccttct ccgctcatgg gaggctttgg actgaaacac 2760 cctcctcccc agatcctgatcaaaaacaca cctgtgccag cgaatcccgc gaccactttc 2820 actcctggaa agtttgcttcgttcattacc cagtattcca ccggacaggt cagcgtggaa 2880 atagagtggg agctgcagaaagaaaacagc aaacgctgga acccagaaat tcagtacacc 2940 tccaactaca acaagtcggtgaatgtggag tttaccgtgg acgcaaacgg tgtttattct 3000 gaaccccgcc ctattggcactcgttacctt acccggaact tgtaatttcc tgttaatgaa 3060 taaaccgatt tatgcgtttcagttgaactt tggtctctgc gaagggcgaa ttcgcggccg 3120 cta 3123 55 3113 DNAnew AAV serotype, clone A3.5 55 gaattcgccc tttctacggc tgcgtcaactggaccaatga aaactttccc ttcaacgatt 60 gcgtcgacaa gatggtgatc tggtgggaggagggaaagat gaccgccaag gtcgtggaat 120 ctgccaaagc cattctgggt ggaagcaaggttcgtgtgga ccagaaatgc aagtcttcgg 180 cccagatcga cccgactccg gtgattgtcacctctaacac caacatgtgc gccgtgattg 240 acggaaactc gaccaccttc gagcaccagcagccgttgca agaccggatg ttcaaatttg 300 aacttacccg ccgtttggat catgactttgggaaggtcac caagcaggaa gtcaaagact 360 ttttccggtg ggctcaagat cacgtgactgaggtggagca tgagttctac gtcaaaaagg 420 gtggagccaa gaaaaggccc gcccccgatgatgtatatat aaatgagccc aagcgggcgc 480 gcgagtcagt tgcgcagcca tcgacgtcagacgcggaagc ttcgataaac tacgcggaca 540 ggtaccaaaa caaatgttct cgtcacgtgggcatgaatct gatgctgttt ccctgtcgac 600 aatgcgaaag aatgaatcag aattcaaatatctgcttcac acacgggcaa aaagactgtt 660 tggaatgctt tcccgtgtca gaatctcaacccgttcctgt cgtcagaaaa acgtatcaga 720 aactttgtta cattcatcat atcatgggaaaagtaccaga cgcctgcact gcctgcgacc 780 tggtaaatgt ggacttggat gactgtatttctgagcaata aatgacttaa atcaggtatg 840 gctgctgacg gttatcttcc agattggctcgaggacactc tctctgaagg aatcagacag 900 tggtggaagc tcaaacctgg cccaccaccgccgaaaccta accaacaaca ccgggacgac 960 agtaggggtc ttgtgcttcc tgggtacaagtacctcggac ccttcaacgg actcgacaaa 1020 ggagagccgg tcaacgaggc agacgccgcggccctcgagc acgacaaagc ctacgaccac 1080 cagctcaagc aaggggacaa cccgtacctcaaatacaacc acgcggacgc tgaatttcag 1140 gagcgtcttc aagaagatac gtctttcgggggcaacctcg ggcgagcagt cttccaggcc 1200 aaaaagaggg tactcgagcc tcttggtctggttgaggaag ctgttaagac ggctcctgga 1260 aaaaagagac ctatagagca gtctcctgcagaaccggact cttcctcggg catcggcaaa 1320 tcaggccagc agcccgctaa gaaaagactcaattttggtc agactggcga cacagagtca 1380 gtcccagacc ctcaaccaat cggagaaccccccgcagccc cctctggtgt gggatctaat 1440 acaatggctt caggcggtgg ggcaccaatggcagacaata acgaaggcgc cgacggagtg 1500 ggtaattcct cgggaaattg gcattgcgattccacatgga tgggcgacag agttatcacc 1560 accagcacaa gaacctgggc cctccccacctacaataatc acctctacaa gcaaatctcc 1620 agcgaatcgg gagccaccaa cgacaaccactacttcggct acagcacccc ctgggggtat 1680 tttgacttta acagattcca ctgtcacttctcaccacgtg actggcagcg actcatcaat 1740 aacaactggg gatttagacc caagaaactcaatttcaagc tcttcaacat ccaagtcaag 1800 gaggtcacgc agaatgatgg aaccacgaccatcgccaata accttaccag cacggtgcag 1860 gtcttcacag actctgagta ccagctgccctacgtcctcg gttcggctca ccagggctgc 1920 cttccgccgt tcccagcaga cgtcttcatgattcctcagt acggctactt gactctgaac 1980 aatggcagcc aagcggtagg acgttcttcattctactgtc tagagtattt tccctctcag 2040 atgctgagga cgggaaacaa cttcaccttcagctacactt ttgaagacgt gcctttccac 2100 agcagctacg cgcacagcca gagtctggatcggctgatga atcctctcat tgaccagtac 2160 ctgtattacc tgagcaaaac tcagggtacaagtggaacaa cgcagcaatc gagactgcag 2220 ttcaaccaag ctgggcctag ctccatggctcagcaggcca aaaactggct accgggaccc 2280 agctaccgac agcagcgaat gtctaagacggctaatgaca acaacaacag tgaatttgct 2340 tggactgcag ccaccaaata ttacccgaatggaagaaatt ctctggtcaa tcccgggccc 2400 ccaatggcca gtcacaagga cgatgaggaaaagtatttcc ccatgcacgg aaatctcatc 2460 tttggaaaac aaggcacagg aactaccaatgtggacattg aatcagtgct tattacagac 2520 gaagaagaaa tcagaacgac taatcctgtggctacagaac aatacggaca ggttgccacc 2580 aaccgtcaga gtcagaacac cacagcttcctatggaagtg tggacagcca gggaatctta 2640 cctggaatgg tgtggcagga ccgcgatgtctatcttcaag gtcccatttg ggccaaaact 2700 cctcacacgg acggacactt tcatccttctccgctcatgg gaggctttgg actgaaacac 2760 cctcctcccc agatcctgat caaaaacacacctgtgccag cgaatcccgc gaccactttc 2820 actcctggaa agtttgcttc gttcattacccagtattcca ccggacaggt cagcgtggaa 2880 atagagtggg agctgcagaa agaaaacagcaaacgctgga acccggaaat tcagtacacc 2940 tccaactaca acaagtcggt gaatgtggagtttaccgtgg acgcaaacgg tgtttattct 3000 gaaccccgcc ctattggcac tcgttaccttacccggaact tgtaatttcc tgttaatgaa 3060 taaaccgatt tatgcgtttc agttgaactttggtctctgc gaagggcgaa ttc 3113 56 3122 DNA new AAV serotype, clone A3.756 agcggccgcg aattcgccct ttctacggct gcgtcaactg gaccaatgaa aactttccct 60tcaacgattg cgtcgacaag atggtgatct ggtgggagga gggaaagatg accgccaagg 120tcgtggaatc tgccaaagcc attctgggtg gaagcaaggt tcgtgtggac cagaaatgca 180ggtcttcggc ccagatcgac ccgactccgg tgattgtcac ctctaacacc aacatgtgcg 240ccgtgattga cggaaactcg accaccttcg agcaccagca gccgttgcaa gaccggatgt 300tcaaatttga acttacccgc cgtttggatc atgactttgg gaaggtcacc aagcaggaag 360tcaaagactt tttccggtgg gctcaagatc acgtgactga ggtggagcat gagttctacg 420tcaaaaaggg tggagccaag aaaaggcccg cccccgatga tgtatatata aatgagccca 480agcgggcgcg cgagtcagtt gcgcagccat cgacgtcaga cgcggaagct tcgataaact 540acgcggacag gtaccaaaac aaatgttctc gtcacgtggg catgaatctg atgctgtttc 600cctgtcgaca atgcgaaaga atgaatcaga attcaaatat ctgcttcaca cacgggcaaa 660aagactgttt ggaatgcttt cccgtgtcag aatctcaacc cgtttctgtc gtcagaaaaa 720cgtatcagaa actttgttac attcatcata tcatgggaaa agtaccagac gcctgcactg 780cctgcgacct ggtaaatgtg gacttggatg actgtatttc tgagcaataa atgacttaaa 840tcaggtatgg ctgctgacgg ttatcttcca gattggctcg aggacactct ctctgaagga 900atcagacagt ggtggaagct caaacctggc ccaccaccgc cgaaacctaa ccaacaacac 960cgggacgaca gtaggggtct tgtgcttcct gggtacaagt acctcggacc cttcaacgga 1020ctcgacaaag gagagccggt caacgaggca gacgccgcgg ccctcgagca cgacaaagcc 1080tacgaccacc agctcaagca aggggacaac ccgtacctca aatacaacca cgcggacgct 1140gaatttcagg agcgtcttca agaagatacg tctttcgggg gcaacctcgg gcgagcagtc 1200ttccaggcca aaaagagggt actcgagcct cttggtctgg ttgaggaagc tgttaagacg 1260gctcctggaa aaaagagacc tatagagcag tctcctgcag aaccggactc ttcctcgggc 1320atcggcaaat caggccagca gcccgctaag aaaagactca attttggtca gactggcgac 1380acagagtcag tcccagaccc tcaaccaatc ggagaacccc ccgcagcccc ctctggtgtg 1440ggatctaata caatggcttc aggcggtggg gcaccaatgg cagacaataa cgaaggcgcc 1500gacggagtgg gtaattcctc gggaaattgg cattgcgatt ccacatggat gggcgacaga 1560gttatcacca ccagcacaag aacctgggcc ctccccacct acaataatcg cctctacaag 1620caaatctcca gcgaatcggg agccaccaac gacaaccact acttcggcta cagcaccccc 1680tgggggtatt ttgactttaa cagattccac tgtcacttct caccacgtga ctggcagcga 1740ctcatcaaca acaactgggg atttagaccc aagaaactca atttcaagct cttcaacatc 1800caagtcaagg aggtcacgca gaatgatgga accacgacca tcgccaataa ccttaccagc 1860acggtgcagg tcttcacaga ctctgagtac cagctgccct acgtcctcgg ttcggctcac 1920cagggctgcc ttccgccgtt cccagcagac gtcttcatga ttcctcagta cggctacttg 1980actctgaaca atggcagcca agcggtagga cgttcttcat tctactgtct agagtatttt 2040ccctctcaga tgctgaggac gggaaacaac ttcaccttca gctacacttt tgaagacgtg 2100cctttccaca gcagctacgc gcacagccag agtctggatc ggctgatgaa tcctctcatt 2160gaccagtacc tgtattacct gagcaaaact cagggtacaa gtggaacaac gcagcaatcg 2220agactgcagt tcagccaagc tgggcctagc tccatggctc agcaggccaa aaactggcta 2280ccgggaccca gctaccgaca gcagcgaatg tctaagacgg ctaatgacaa caacaacagt 2340gaatttgctt ggactgcagc caccaaatat tacctgaatg gaagaaattc tctggtcaat 2400cccgggcccc caatggccag tcacaaggac gatgaggaaa agtatttccc catgcacgga 2460aatctcatct ttggaaaaca aggcacagga actaccaatg tggacattga atcagtgctt 2520attacagacg aagaagaaat cagaacaact aatcctgtgg ctacagaaca atacggacag 2580gttgccacca accatcagag tcagaacacc acagcttcct atggaagtgt ggacagccag 2640ggaatcttac ctggaatggt gtggcaggac cgcgatgtct atcttcaagg tcccatttgg 2700gccaaaactc ctcacacgga cggacacttt catccttctc cgctcatggg aggctttgga 2760ctgaaacacc ctcctcccca gatcctgatc aaaaacacac ctgtgccagc gaatcccgcg 2820accactttca ctcctggaaa gtttgcttcg ttcattaccc agtattccac cggacaggtc 2880agcgtggaaa tagagtggga gctgcagaaa gaaaacagca aacgctggaa cccagaaatt 2940cagtacacct ccaactacaa caagtcggtg aatgtggagt ttaccgtgga cgcaaacggt 3000gtttattctg aaccccgccc tattggcact cgttacctta cccggaactt gtaatttcct 3060gttaatgaat aaaccgattt atgcgtttca gttgaacttt ggtctctgcg aagggcgaat 3120tc 3122 57 3123 DNA new AAV serotype, clone A3.3 57 gaattcgccctttctacggc tgcgtcaact ggaccaatga aaactttccc ttcaacgatt 60 gcgtcgacaagatggtgatc tggtgggagg agggaaagat gaccgccaag gtcgtggaat 120 ctgccaaagccattctgggt ggaggcaagg ttcgtgtgga ccagaaatgc aagtcttcgg 180 cccagatcgacccgactccg gtgattgtca cctctaacac caacatgtgc gccgtgattg 240 acggaaactcgaccaccttc gagcaccagc agccgttgca agaccggatg ttcaaatttg 300 aacttacccgccgtttggat catgactttg ggaaggtcac caagcaggaa gtcaaagact 360 ttttccggtgggctcaagat cacgtgactg aggtggagca tgagttctac gtcaaaaagg 420 gtggagccaagaaaaggccc gcccccgatg atgtatatat aaatgagccc aagcgggcgc 480 gcgagtcagttgcgcagcca tcgacgtcag acgcggaagc ttcgataaac tacgcggaca 540 ggtaccaaaacaaatgttct cgtcacgtgg gcatgaatct gatgctgttt ccctgtcgac 600 aatgcgaaagaatgaatcag aattcaaata tctgcttcac acacgggcaa aaagactgtt 660 tggaatgctttcccgtgtca gaatctcaac ccgtttctgt cgtcagaaaa acgtatcaga 720 aactttgttacattcatcat atcatgggaa aagtaccaga cgcctgcact gcctgcgacc 780 tggtaaatgtggacttggat gactgtattt ctgagcaata aatgacttaa atcaggtatg 840 gctgctgacggttatcttcc agattggctc gaggacactc tctctgaagg aatcagacag 900 tggtggaagctcaaacctgg cccaccaccg ccgaaaccta accaacaaca ccgggacgac 960 agtaggggtcttgtgcttcc tgggtacaag tacctcggac ccttcaacgg actcgacaaa 1020 ggagagccggtcaacgaggc agacgccgcg gccctcgagc acgacaaagc ctacgaccac 1080 cagctcaagcaaggggacaa cccgtacctc aaatacaacc acgcggacgc tgaatttcag 1140 gagcgtcttcaagaagatac gtctttcggg ggcaacctcg ggcgagcagt cttccaggcc 1200 aaaaagagggtactcgagcc tcttggtctg gttgaggaag ctgttaagac ggctcctgga 1260 aaaaagagacctatagagca gtctcctgca gaaccggact cttcctcggg catcggcaaa 1320 tcaggccagcagcccgctaa gaaaagactc aattttggtc agactggcga cacagagtca 1380 gtcccaggccctcaaccaat cggagaaccc cccgcagccc cctctggtgt gggatctaat 1440 acaatggcttcaggcggtgg ggcaccaatg gcagacaata acgaaggcgc cgacggagtg 1500 ggtaattcctcgggaaattg gcattgcgat tccacatgga tgggcgacag agttatcacc 1560 accagcacaagaacctgggc cctccccacc tacaataatc acctctacaa gcaaatctcc 1620 agcgaatcgggagccaccaa cgacaaccac tacttcggct acagcacccc ctgggggtat 1680 tttgactttaacagattcca ctgtcacttc tcaccacgtg actggcagcg actcatcaac 1740 aacaactggggatttagacc caagaaactc aatttcaagc tcttcaacat ccaagtcaag 1800 gaggtcacgcagaatgatgg aaccacgacc atcgccaata accttaccag cgcggtgcag 1860 gtcttcacagactctgagta ccagctgccc tacgtcctcg gttcggctca ccagggctgc 1920 cttccgccgttcccagcaga cgtcttcatg attcctcagt acggctactt gactctgaac 1980 aatggcagccaagcggtagg acgttcttca ttctactgtc tagagtattt tccctctcag 2040 atgctgaggacgggaaacaa cttcaccttc agctacactt ttgaagacgt gcctttccac 2100 agcagctacgcgcacagcca gagtctggat cggctgatga atcctctcat tgaccagtac 2160 ctgtattacctgagcaaaac tcagggtaca agtggaacaa cgcagcaatc gagactgcag 2220 ttcagccaagctgggcctag ctccatggct cagcaggcca aaaactggct accgggaccc 2280 agctaccgacagcagcgaat gtctaagacg gctaatgaca acaacaacag tgaatttgct 2340 tggactgcagccaccaaata ttacctgaat ggaagaaatt ctctggtcaa tcccgggccc 2400 ccagtggccagtcacaagga cgatgaggaa aagtatttcc ccatgcacgg aaatctcatc 2460 tttggaaaacaaggcacagg aactaccaat gtggacattg aatcagtgct tattacagac 2520 gaagaagaaatcagaacaac taatcctgtg gctacagaac aatacggaca ggttgccacc 2580 aaccatcagagtcagaacac cacagcttcc tatggaagtg tggacagcca gggaatctta 2640 cctggaatggtgtggcagga ccgcgatgtc tatcttcaag gtcccatttg ggccaaaact 2700 cctcacacggacggacactt tcatccttct ccgctcatgg gaggctttgg actgaaacac 2760 cctcctccccagatcctgat caaaaacaca cctgtgccag cgaatcccgc gaccactttc 2820 actcctggaaagtttgcttc gttcattacc cagtattcca cctgacaggt cagcgtggaa 2880 atagagtgggagctgcagaa agaaaacagc aaacgctgga acccagaaat tcagtacacc 2940 tccaactacaacaagtcggt gaatgtggag tttaccgtgg acgcaaacgg tgtttattct 3000 gaaccccgccctattggcac tcgttacctt acccggaact tgtaatttcc tgttaatgaa 3060 taagccgatttatgcgtttc agttgaactt tggtctctgc gaagggcgaa ttcgtttaaa 3120 cct 3123 582969 DNA 42.12 58 gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttcccttcaacgatt 60 gcgtcgacaa gatggtgatc tggtgggagg agggcaagat gacggccaaggtcgtggagt 120 ccgccaaggc cattctcggc ggcagcaagg tgcgcgtgga ccaaaagtgcaagtcgtccg 180 cccagatcga ccccaccccc gtgatcgtca cctccaacac caacatgtgcgccgtgattg 240 acgggaacag caccaccttc gagcaccagc agccgttaca agaccggatgttcaaatttg 300 aactcacccg ccgtctggag cacgactttg gcaaggtgac aaagcaggaagtcaaagagt 360 tcttccgctg ggcgcaggat cacgtgaccg aggtggcgca tgagttctacgtcagaaagg 420 gtggagccaa caagagaccc gcccccgatg acgcggataa aagcgagcccaagcgggcct 480 gcccctcagt cgcggatcca tcgacgtcag acgcggaagg agctccggtggactttgccg 540 acaggtacca aaacaaatgt tctcgtcacg cgggcatgct tcagatgctgtttccctgca 600 agacatgcga gagaatgaat cagaatttca acatttgctt cacgcacgggaccagagact 660 gttcagaatg tttccccggc gtgtcagaat ctcaaccggt cgtcagaaagaggacgtatc 720 ggaaactctg tgccattcat catctgctgg ggcgggctcc cgagattgcttgctcggcct 780 gcgatctggt caacgtggac ctggatgact gtgtttctga gcaataaatgacttaaacca 840 ggtatggctg ccgatggtta tcttccagat tggctcgagg acaacctctctgagggcatc 900 cgcgagtggt gggacttgaa acctggagcc ccgaaaccca aagccaaccagcaaaagcag 960 gacgacggcc ggggtctggt gcttcctggc tacaagtacc tcggacccttcaacggactc 1020 gacaagggag agccggtcaa cgaggcagac gccgcggccc tcgagcacgacaaggcctac 1080 gacaagcagc tcgagcaggg ggacaacccg tacctcaagt acaaccacgccgacgccgag 1140 tttcaggagc gtcttcaaga agatacgtct tttgggggca acctcgggcgagcagtcttc 1200 caggccaaga agcgggttct cgaacctctc ggtctggttg aggaaggcgctaagacggct 1260 cctggaaaga agagaccggt agagccatca ccccagcgtt ctccagactcctctacgggc 1320 atcggcaaga caggccagca gcccgcgaaa aagagactca actttgggcagactggcgac 1380 tcagagtcag tgcccgaccc tcaaccaatc ggagaacccc ccgcaggcccctctggtctg 1440 ggatctggta caatggctgc aggcggtggc gctccaatgg cagacaataacgaaggcgcc 1500 gacggagtgg gtagttcctc aggaaattgg cattgcgatt ccacatggctgggcgacaga 1560 gtcatcacca ccagcacccg aacctgggcc ctccccacct acaacaaccacctctacaag 1620 caaatctcca acgggacatc gggaggaagc accaacgaca acacctacttcggctacagc 1680 accccctggg ggtattttga ctttaacaga ttccactgcc acttctcaccacgtgactgg 1740 cagcgactca tcaacaacaa ctggggattc cggcccaaga gactcaacttcaagctcttc 1800 aacatccagg tcaaggaggt cacgcagaat gaaggcacca agaccatcgccaataacctt 1860 accagcacga ttcaggtctt tacggactcg gaataccagc tcccgtacgtcctcggctct 1920 gcgcaccagg gctgcctgcc tccgttcccg gcggacgtct tcatgattcctcagtacggg 1980 tacctgactc tgaacaacgg cagtcaggcc gtgggccgtt cctccttctactgcctggag 2040 tactttcctt ctcaaatgct gagaacgggc aacaactttg agttcagctaccagtttgag 2100 gacgtgcctt ttcacagcag ctacgcgcac agccaaagcc tggaccggctgacgaacccc 2160 ctcatcgacc agtacctgta ctacctggcc cggacccaga gcactacggggtccacaagg 2220 gggctgcagt tccatcaggc tgggcccaac accatggccg agcaatcaaagaactggctg 2280 cccggaccct gttatcggca gcagagactg tcaaaaaaca tagacagcaacaacaacagt 2340 aactttgcct ggaccggggc cactaaatac catctgaatg gtagaaattcattaaccaac 2400 ccgggcgtag ccatggccac caacaaggac gacgaggacc agttctttcccatcaacgga 2460 gtgctggttt ttggcaaaac gggggctgcc aacaagacaa cgctggaaaacgtgctaatg 2520 accagcgagg aggagatcaa aaccaccaat cccgtggcta cagaagaatacggtgtggtc 2580 tccagcaacc tgcaatcgtc tacggccgga ccccagacac agactgtcaacagccagggg 2640 gctctgcccg gcatggtctg gcagaaccgg gacgtgtacc tgcagggtcccatctgggcc 2700 aaaattcctc acacggacgg caactttcac ccgtctcccc tgatgggcggatttggactc 2760 aaacacccgc ctcctcaaat tctcatcaag tatacttcca actactacaaatctacaaat 2820 gtggactttg ctgtcaatac tgagggtact tattcagagc ctcgccccattggcacccgt 2880 tacctcaccc gtaacctgta attgcctgtt aatcaataaa ccggttaattcgtttcagtt 2940 gaactttggt ctctgcgaag ggcgaattc 2969 59 3129 DNA 44.2 59gaattcgccc tttctacggc tgcgtcaact ggaccaatga gaactttccc ttcaacgatt 60gcgtcgacaa gatggtgatc tggtgggagg agggcaagat gacggccaag gtcgtggagt 120ccgccaaggc cattctcggc ggcagcaaag tgcgcgtgga ccaaaagtgc aagtcgtccg 180cccagatcga ccccaccccc gtgatcgtca cctccaacac caacatgtgc gccgtgattg 240acgggaacag caccaccttc gagcaccagc agccgttgca ggaccggatg ttcaagtttg 300aactcacccg ccgtctggag cacgactttg gcaaggtgac aaagcaggaa gtcagagagt 360tcttccgctg ggcgcaggat cacgtgaccg aggtggcgca cgagttctac gtcagaaagg 420gtggagccaa caagagaccc gcccccgatg acgcggataa aagcgagccc aagcgggcct 480gcccctcagt cgcggatcca tcgacgtcag acgcggaagg agctccggtg gactttgccg 540acaggtacca aaacaaatgt tctcgtcacg cgggcatgct tcagatgctg tttccctgca 600aaacatgcga gagaatgaat cagaatttca acatttgctt cacgcacggg accagagact 660gttcagaatg tttccccggc gtgtcagaat ctcaaccggt cgtcagaaaa aagacgtatc 720ggaaactctg tgcgattcat catctgctgg gggcgggcac ccgagattgc ttgctcggcc 780tgcgatctgg tcaacgtgga cctagatgac tgtgtttctg agcaataaat gacttaaacc 840aggtatggct gccgatggtt atcttccaga ttggctcgag gacaacctct ctgagggcat 900tcgcgagtgg tgggacttga aacctggagc cccgaaaccc aaagccaacc agcaaaagca 960ggacgacggc cggggtctgg tgcttcctgg ctacaagtac ctcggaccct tcaacggact 1020cgacaagggg gagcccgtca acgcggcgga cgcagcggcc ctcgagcacg acaaggccta 1080cgaccagcag ctcaaagcgg gtgacaatcc gtacctgcgg tataaccacg ccgacgccga 1140gtttcaggag cgtctgcaag aagatacgtc ttttgggggc aacctcgggc gagcagtctt 1200ccaggccaag aagcgggttc tcgaacctct cggtctggtt gaggaaggcg ctaagacggc 1260tcctggaaag aagagaccgg tagagccatc accccagcgt tctccagact cctctacggg 1320catcggcaag aaaggccagc agcccgcgaa aaagagactc aactttgggc agactggcga 1380ctcagagtca gtgcccgacc ctcaaccaat cggagaaccc cccgcaggcc cctctggtct 1440gggatctggt acaatggctg caggcggtgg cgctccaatg gcagacaata acgaaggcgc 1500cgacggagtg ggtagttcct caggaaattg gcattgcgat tccacatggc tgggcgacag 1560agtcatcacc accagcaccc gaacctgggc cctccccacc tacaacaacc acctctacaa 1620gcaaatctcc aacgggactt cgggaggaag caccaacgac aacacctact tcggctacag 1680caccccctgg gggtattttg actttaacag attccactgc cacttctcac cacgtgactg 1740gcagcgactc atcaacaaca actggggatt ccggcccaag agactcaact tcaagctctt 1800caacatccag gtcaaggagg tcacgcagaa tgaaggcacc aagaccatcg ccaataacct 1860taccagcacg attcaggtct ttacggactc ggaataccag ctcccgtacg tcctcggctc 1920tgcgcaccag ggctgcctgc ctccgttccc ggcggacgtc ttcatgattc ctcagtacgg 1980gtacctgact ctgaacaatg gcagtcaggc cgtgggccgt tcctccttct actgcctgga 2040gtactttcct tctcaaatgc tgagaacggg caacaacttt gagttcagct accagtttga 2100ggacgtgcct tttcacagca gctacgcgca cagccaaagc ctggaccggc tgatgaaccc 2160cctcatcgac cagtacctgt actacctgtc tcggactcag tccacgggag gtaccgcagg 2220aactcagcag ttgctatttt ctcaggccgg gcctaataac atgtcggctc aggccaaaaa 2280ctggctaccc gggccctgct accggcagca acgcgtctcc acgacactgt cgcaaaataa 2340caacagcaac tttgcctgga ccggtgccac caagtatcat ctgaatggca gagactctct 2400ggtaaatccc ggtgtcgcta tggcaaccca caaggacgac gaagagcgat tttttccgtc 2460cagcggagtc ttaatgtttg ggaaacaggg agctggaaaa gacaacgtgg actatagcag 2520cgttatgcta accagtgagg aagaaattaa aaccaccaac ccagtggcca cagaacagta 2580cggcgtggtg gccgataacc tgcaacagca aaacgccgct cctattgtag gggccgtcaa 2640cagtcaagga gccttacctg gcatggtctg gcagaaccgg gacgtgtacc tgcagggtcc 2700tatctgggcc aagattcctc acacggacgg aaactttcat ccctcgccgc tgatgggagg 2760ctttggactg aaacacccgc ctcctcagat cctgattaag aatacacctg ttcccgcgga 2820tcctccaact accttcagtc aagctaagct ggcgtcgttc atcacgcagt acagcaccgg 2880acaggtcagc gtggaaattg aatgggagct gcagaaagaa aacagcaaac gctggaaccc 2940agagattcaa tacacttcca actactacaa atctacaaat gtggactttg ctgttaacac 3000agatggcact tattctgagc ctcgccccat cggcacccgt tacctcaccc gtaatctgta 3060attgcttgtt aatcaataaa ccggttgatt cgtttcagtt gaactttggt ctctgcgaag 3120ggcgaattc 3129 60 733 PRT capsid protein of AAV serotype, clone C1VP1 60Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 1015 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 20 2530 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 35 4045 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 5560 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 7075 80 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala 8590 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly100 105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu GluPro 115 120 125 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly LysLys Arg 130 135 140 Pro Leu Glu Ser Pro Gln Glu Pro Asp Ser Ser Ser GlyIle Gly Lys 145 150 155 160 Lys Gly Lys Gln Pro Ala Lys Lys Arg Leu AsnPhe Glu Glu Asp Thr 165 170 175 Gly Ala Gly Asp Gly Pro Pro Glu Gly SerAsp Thr Ser Ala Met Ser 180 185 190 Ser Asp Ile Glu Met Arg Ala Ala ProGly Gly Asn Ala Val Asp Ala 195 200 205 Gly Gln Gly Ser Asp Gly Val GlyAsn Ala Ser Gly Asp Trp His Cys 210 215 220 Asp Ser Thr Trp Ser Glu GlyLys Val Thr Thr Thr Ser Thr Arg Thr 225 230 235 240 Trp Val Leu Pro ThrTyr Asn Asn His Leu Tyr Leu Arg Leu Gly Thr 245 250 255 Thr Ser Asn SerAsn Thr Tyr Asn Gly Phe Ser Thr Pro Trp Gly Tyr 260 265 270 Phe Asp PheAsn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln 275 280 285 Arg LeuIle Asn Asn Asn Trp Gly Leu Arg Pro Lys Ala Met Arg Val 290 295 300 LysIle Phe Asn Ile Gln Val Lys Glu Val Thr Thr Ser Asn Gly Glu 305 310 315320 Thr Thr Val Ala Asn Asn Leu Thr Ser Thr Val Gln Ile Phe Ala Asp 325330 335 Ser Ser Tyr Glu Leu Pro Tyr Val Met Asp Ala Gly Gln Glu Gly Ser340 345 350 Leu Ser Pro Phe Pro Asn Asp Val Phe Met Val Pro Gln Tyr GlyTyr 355 360 365 Cys Gly Ile Val Thr Gly Glu Asn Gln Asn Gln Thr Asp ArgAsn Ala 370 375 380 Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu ArgThr Gly Asn 385 390 395 400 Asn Phe Glu Met Ala Tyr Asn Phe Gly Lys ValPro Phe His Ser Met 405 410 415 Tyr Ala Tyr Ser Gln Ser Pro Asp Arg LeuMet Asn Pro Leu Leu Asp 420 425 430 Gln Tyr Leu Trp His Leu Gln Ser ThrThr Ser Gly Glu Thr Leu Asn 435 440 445 Gln Gly Asn Ala Ala Thr Thr PheGly Lys Ile Arg Ser Gly Asp Phe 450 455 460 Ala Phe Tyr Arg Lys Asn TrpLeu Pro Gly Pro Cys Val Lys Gln Gln 465 470 475 480 Arg Leu Ser Lys ThrAla Ser Gln Asn Tyr Lys Ile Pro Ala Ser Gly 485 490 495 Gly Asn Ala LeuLeu Lys Tyr Asp Thr His Tyr Thr Leu Asn Asn Arg 500 505 510 Trp Ser AsnIle Ala Pro Gly Pro Pro Met Ala Thr Ala Gly Pro Ser 515 520 525 Asp GlyAsp Phe Ser Asn Ala Gln Leu Ile Phe Pro Gly Pro Ser Val 530 535 540 ThrGly Asn Thr Thr Thr Ser Ala Asn Asn Leu Leu Phe Thr Ser Glu 545 550 555560 Glu Glu Ile Ala Ala Thr Asn Pro Arg Asp Thr Asp Met Phe Gly Gln 565570 575 Ile Ala Asp Asn Asn Gln Asn Ala Thr Thr Ala Pro Ile Thr Gly Asn580 585 590 Val Thr Ala Met Gly Val Leu Pro Gly Met Val Trp Gln Asn ArgAsp 595 600 605 Ile Tyr Tyr Gln Gly Pro Ile Trp Ala Lys Ile Pro His AlaAsp Gly 610 615 620 His Phe His Pro Ser Pro Leu Ile Gly Gly Phe Gly LeuLys His Pro 625 630 635 640 Pro Pro Gln Ile Phe Ile Lys Asn Thr Pro ValPro Ala Asn Pro Ala 645 650 655 Thr Thr Phe Thr Ala Ala Arg Val Asp SerPhe Ile Thr Gln Tyr Ser 660 665 670 Thr Gly Gln Val Ala Val Gln Ile GluTrp Glu Ile Glu Lys Glu Arg 675 680 685 Ser Lys Arg Trp Asn Pro Glu ValGln Phe Thr Ser Asn Tyr Gly Asn 690 695 700 Gln Ser Ser Met Leu Trp AlaPro Asp Thr Thr Gly Lys Tyr Thr Glu 705 710 715 720 Pro Arg Val Ile GlySer Arg Tyr Leu Thr Asn His Leu 725 730 61 733 PRT capsid protein of AAVserotype, clone C2VP1 61 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu GluAsp Asn Leu Ser 1 5 10 15 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys ProGly Ala Pro Lys Leu 20 25 30 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly ArgGly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Phe His Gly LeuAsp Lys Gly Glu Pro 50 55 60 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu HisAsp Lys Ala Tyr Asp 65 70 75 80 Gln Gln Leu Lys Ala Gly Asp Asn Pro TyrLeu Arg Tyr Asn His Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln GluAsp Thr Ser Phe Gly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe Gln AlaLys Lys Arg Val Leu Glu Pro 115 120 125 Leu Gly Leu Val Glu Glu Gly AlaLys Thr Ala Pro Gly Lys Lys Arg 130 135 140 Pro Leu Glu Ser Pro Gln GluPro Asp Ser Ser Ser Gly Ile Gly Lys 145 150 155 160 Lys Gly Lys Gln ProAla Lys Lys Arg Leu Asn Phe Glu Glu Asp Thr 165 170 175 Gly Ala Gly AspGly Pro Pro Glu Gly Ser Asp Thr Ser Ala Met Ser 180 185 190 Ser Asp IleGlu Met Arg Ala Ala Pro Gly Gly Asn Ala Val Asp Ala 195 200 205 Gly GlnGly Ser Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys 210 215 220 AspSer Thr Trp Ser Glu Gly Lys Val Thr Thr Thr Ser Thr Arg Thr 225 230 235240 Trp Val Leu Pro Thr Tyr Asn Asn His Leu Tyr Leu Arg Leu Gly Thr 245250 255 Thr Ser Asn Ser Asn Thr Tyr Asn Gly Phe Ser Thr Pro Trp Gly Tyr260 265 270 Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp TrpGln 275 280 285 Arg Leu Ile Asn Asn Asn Trp Gly Leu Arg Pro Lys Ala MetArg Val 290 295 300 Lys Ile Phe Asn Ile Gln Val Lys Glu Val Thr Thr SerAsn Gly Glu 305 310 315 320 Thr Thr Val Ala Asn Asn Leu Thr Ser Thr ValGln Ile Phe Ala Asp 325 330 335 Ser Ser Tyr Glu Leu Pro Tyr Val Met AspAla Gly Gln Glu Gly Ser 340 345 350 Leu Pro Pro Phe Pro Asn Asp Val PheMet Val Pro Gln Tyr Gly Tyr 355 360 365 Cys Gly Ile Val Thr Gly Glu AsnGln Asn Gln Thr Asp Arg Asn Ala 370 375 380 Phe Tyr Cys Leu Glu Tyr PhePro Ser Gln Met Leu Arg Thr Gly Asn 385 390 395 400 Asn Phe Glu Met AlaTyr Asn Phe Glu Lys Val Pro Phe His Ser Met 405 410 415 Tyr Ala His SerGln Ser Leu Asp Arg Leu Met Asn Pro Leu Leu Asp 420 425 430 Gln Tyr LeuTrp His Leu Gln Ser Thr Thr Ser Gly Glu Thr Leu Asn 435 440 445 Gln GlyAsn Ala Ala Thr Thr Phe Gly Lys Ile Arg Ser Gly Asp Phe 450 455 460 AlaPhe Tyr Arg Lys Asn Trp Leu Pro Gly Pro Cys Val Lys Gln Gln 465 470 475480 Arg Phe Ser Lys Thr Ala Ser Gln Asn Tyr Lys Ile Pro Ala Ser Gly 485490 495 Gly Asn Ala Leu Leu Lys Tyr Asp Thr His Tyr Thr Leu Asn Asn Arg500 505 510 Trp Ser Asn Ile Ala Pro Gly Pro Pro Met Ala Thr Ala Gly ProSer 515 520 525 Asp Gly Asp Phe Ser Asn Ala Gln Leu Ile Phe Pro Gly ProSer Val 530 535 540 Thr Gly Asn Thr Thr Thr Ser Ala Asn Asn Leu Leu PheThr Ser Glu 545 550 555 560 Gly Glu Ile Ala Ala Thr Asn Pro Arg Asp ThrAsp Met Phe Gly Gln 565 570 575 Ile Ala Asp Asn Asn Gln Asn Ala Thr ThrAla Pro Ile Thr Gly Asn 580 585 590 Val Thr Ala Met Gly Val Leu Pro GlyMet Val Trp Gln Asn Arg Asp 595 600 605 Ile Tyr Tyr Gln Gly Pro Ile TrpAla Lys Ile Pro His Ala Asp Gly 610 615 620 His Phe His Pro Ser Pro LeuIle Gly Gly Phe Gly Leu Lys His Pro 625 630 635 640 Pro Pro Gln Ile PheIle Lys Asn Thr Pro Val Pro Ala Asn Pro Ala 645 650 655 Thr Thr Phe ThrAla Ala Arg Val Asp Ser Phe Ile Thr Gln Tyr Ser 660 665 670 Thr Gly GlnVal Ala Val Gln Ile Glu Trp Glu Ile Glu Lys Glu Arg 675 680 685 Ser LysArg Arg Asn Pro Glu Val Gln Phe Thr Ser Asn Tyr Gly Asn 690 695 700 GlnSer Ser Met Leu Trp Ala Pro Asp Thr Thr Gly Lys Tyr Thr Glu 705 710 715720 Pro Arg Val Ile Gly Ser Arg Tyr Leu Thr Asn His Leu 725 730 62 733PRT capsid protein of AAV serotype, clone C5VP1@2 62 Met Ala Ala Asp GlyTyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile ArgGlu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 20 25 30 Lys Ala Asn GlnGln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Glu TyrLeu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn Ala AlaAsp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 Gln Gln LeuLys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala 85 90 95 Asp Ala GluPhe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110 Asn LeuGly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125 LeuGly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140Pro Leu Glu Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly Lys 145 150155 160 Lys Gly Lys Gln Pro Ala Lys Lys Arg Leu Asn Phe Glu Glu Asp Thr165 170 175 Gly Ala Gly Asp Gly Pro Pro Glu Gly Ser Asp Thr Ser Ala MetSer 180 185 190 Ser Asp Ile Glu Met Arg Ala Ala Pro Gly Gly Asn Ala ValAsp Ala 195 200 205 Gly Gln Gly Ser Asp Gly Val Gly Asn Ala Ser Gly AspTrp His Cys 210 215 220 Asp Ser Thr Trp Ser Glu Gly Lys Val Thr Thr ThrSer Thr Arg Thr 225 230 235 240 Trp Val Leu Pro Thr Tyr Asn Asn His LeuTyr Leu Arg Leu Gly Thr 245 250 255 Thr Ser Asn Ser Asn Thr Tyr Asn GlyPhe Ser Thr Pro Trp Gly Tyr 260 265 270 Phe Asp Phe Asn Arg Phe His CysHis Phe Ser Pro Arg Asp Trp Gln 275 280 285 Arg Leu Ile Asn Asn Asn TrpGly Leu Arg Pro Lys Ala Met Arg Val 290 295 300 Lys Ile Phe Asn Ile GlnVal Lys Glu Val Thr Thr Ser Asn Gly Glu 305 310 315 320 Thr Thr Val AlaAsn Asn Leu Thr Ser Thr Val Gln Ile Phe Ala Asp 325 330 335 Ser Ser TyrGlu Leu Pro Tyr Val Met Asp Ala Gly Gln Glu Gly Ser 340 345 350 Leu ProPro Phe Pro Asn Asp Val Phe Met Val Pro Gln Tyr Gly Tyr 355 360 365 CysGly Ile Val Thr Gly Glu Asn Gln Asn Gln Thr Asp Arg Asn Ala 370 375 380Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg Thr Gly Asn 385 390395 400 Asn Phe Glu Thr Ala Tyr Asn Phe Glu Lys Val Pro Phe His Ser Met405 410 415 Tyr Ala His Ser Gln Ser Leu Asp Gly Leu Met Asn Pro Leu LeuAsp 420 425 430 Gln Tyr Leu Trp His Leu Gln Ser Thr Thr Ser Gly Glu ThrLeu Asn 435 440 445 Gln Gly Asn Ala Ala Thr Thr Phe Gly Lys Ile Arg SerGly Asp Phe 450 455 460 Ala Phe Tyr Arg Lys Asn Trp Leu Pro Gly Pro CysVal Lys Gln Gln 465 470 475 480 Arg Phe Ser Lys Thr Ala Ser Gln Asn TyrLys Ile Pro Ala Ser Gly 485 490 495 Gly Asn Ala Leu Leu Lys Tyr Asp ThrHis Tyr Thr Leu Asn Asn Arg 500 505 510 Trp Ser Asn Ile Ala Pro Gly ProPro Met Ala Thr Ala Gly Pro Ser 515 520 525 Asp Gly Asp Phe Ser Asn AlaGln Leu Ile Phe Pro Gly Pro Ser Val 530 535 540 Thr Gly Asn Thr Thr ThrSer Ala Asn Asn Leu Leu Phe Thr Ser Glu 545 550 555 560 Glu Glu Ile AlaAla Thr Asn Pro Arg Asp Thr Asp Met Phe Gly Gln 565 570 575 Ile Ala AspAsn Asn Gln Asn Ala Thr Thr Ala Pro Ile Thr Gly Asn 580 585 590 Val ThrAla Met Gly Val Leu Pro Gly Met Val Trp Gln Asn Arg Asp 595 600 605 IleTyr Tyr Gln Gly Pro Ile Trp Ala Lys Ile Pro His Ala Asp Gly 610 615 620His Phe His Pro Ser Pro Leu Ile Gly Gly Phe Gly Leu Lys His Pro 625 630635 640 Pro Pro Gln Ile Phe Ile Lys Asn Thr Pro Val Pro Ala Tyr Pro Ala645 650 655 Thr Thr Phe Thr Ala Ala Arg Val Asp Ser Phe Ile Thr Gln TyrSer 660 665 670 Thr Gly Gln Val Ala Val Gln Ile Glu Trp Glu Ile Glu LysGlu Arg 675 680 685 Ser Lys Arg Trp Asn Pro Glu Val Gln Phe Thr Ser AsnCys Gly Asn 690 695 700 Gln Ser Ser Met Leu Trp Ala Pro Asp Thr Thr GlyLys Tyr Thr Glu 705 710 715 720 Pro Arg Val Ile Gly Ser Arg Tyr Leu ThrAsn His Leu 725 730 63 734 PRT capsid protein of AAV serotype, cloneAAV4VP1 63 Met Thr Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu SerGlu 1 5 10 15 Gly Val Arg Glu Trp Trp Ala Leu Gln Pro Gly Ala Pro LysPro Lys 20 25 30 Ala Asn Gln Gln His Gln Asp Asn Ala Arg Gly Leu Val LeuPro Gly 35 40 45 Tyr Lys Tyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly GluPro Val 50 55 60 Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala TyrAsp Gln 65 70 75 80 Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr AsnHis Ala Asp 85 90 95 Ala Glu Phe Gln Gln Arg Leu Gln Gly Asp Thr Ser PheGly Gly Asn 100 105 110 Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg ValLeu Glu Pro Leu 115 120 125 Gly Leu Val Glu Gln Ala Gly Glu Thr Ala ProGly Lys Lys Arg Pro 130 135 140 Leu Ile Glu Ser Pro Gln Gln Pro Asp SerSer Thr Gly Ile Gly Lys 145 150 155 160 Lys Gly Lys Gln Pro Ala Lys LysLys Leu Val Phe Glu Asp Glu Thr 165 170 175 Gly Ala Gly Asp Gly Pro ProGlu Gly Ser Thr Ser Gly Ala Met Ser 180 185 190 Asp Asp Ser Glu Met ArgAla Ala Ala Gly Gly Ala Ala Val Glu Gly 195 200 205 Gly Gln Gly Ala AspGly Val Gly Asn Ala Ser Gly Asp Trp His Cys 210 215 220 Asp Ser Thr TrpSer Glu Gly His Val Thr Thr Thr Ser Thr Arg Thr 225 230 235 240 Trp ValLeu Pro Thr Tyr Asn Asn His Leu Tyr Lys Arg Leu Gly Glu 245 250 255 SerLeu Gln Ser Asn Thr Tyr Asn Gly Phe Ser Thr Pro Trp Gly Tyr 260 265 270Phe Asp Phe Asn Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln 275 280285 Arg Leu Ile Asn Asn Asn Trp Gly Met Arg Pro Lys Ala Met Arg Val 290295 300 Lys Ile Phe Asn Ile Gln Val Lys Glu Val Thr Thr Ser Asn Gly Glu305 310 315 320 Thr Thr Val Ala Asn Asn Leu Thr Ser Thr Val Gln Ile PheAla Asp 325 330 335 Ser Ser Tyr Glu Leu Pro Tyr Val Met Asp Ala Gly GlnGlu Gly Ser 340 345 350 Leu Pro Pro Phe Pro Asn Asp Val Phe Met Val ProGln Tyr Gly Tyr 355 360 365 Cys Gly Leu Val Thr Gly Asn Thr Ser Gln GlnGln Thr Asp Arg Asn 370 375 380 Ala Phe Tyr Cys Leu Glu Tyr Phe Pro SerGln Met Leu Arg Thr Gly 385 390 395 400 Asn Asn Phe Glu Ile Thr Tyr SerPhe Glu Lys Val Pro Phe His Ser 405 410 415 Met Tyr Ala His Ser Gln SerLeu Asp Arg Leu Met Asn Pro Leu Ile 420 425 430 Asp Gln Tyr Leu Trp GlyLeu Gln Ser Thr Thr Thr Gly Thr Thr Leu 435 440 445 Asn Ala Gly Thr AlaThr Thr Asn Phe Thr Lys Leu Arg Pro Thr Asn 450 455 460 Phe Ser Asn PheLys Lys Asn Trp Leu Pro Gly Pro Ser Ile Lys Gln 465 470 475 480 Gln GlyPhe Ser Lys Thr Ala Asn Gln Asn Tyr Lys Ile Pro Ala Thr 485 490 495 GlySer Asp Ser Leu Ile Lys Tyr Glu Thr His Ser Thr Leu Asp Gly 500 505 510Arg Trp Ser Ala Leu Thr Pro Gly Pro Pro Met Ala Thr Ala Gly Pro 515 520525 Ala Asp Ser Lys Phe Ser Asn Ser Gln Leu Ile Phe Ala Gly Pro Lys 530535 540 Gln Asn Gly Asn Thr Ala Thr Val Pro Gly Thr Leu Ile Phe Thr Ser545 550 555 560 Glu Glu Glu Leu Ala Ala Thr Asn Ala Thr Asp Thr Asp MetTrp Gly 565 570 575 Asn Leu Pro Gly Gly Asp Gln Ser Asn Ser Asn Leu ProThr Val Asp 580 585 590 Arg Leu Thr Ala Leu Gly Ala Val Pro Gly Met ValTrp Gln Asn Arg 595 600 605 Asp Ile Tyr Tyr Gln Gly Pro Ile Trp Ala LysIle Pro His Thr Asp 610 615 620 Gly His Phe His Pro Ser Pro Leu Ile GlyGly Phe Gly Leu Lys His 625 630 635 640 Pro Pro Pro Gln Ile Phe Ile LysAsn Thr Pro Val Pro Ala Asn Pro 645 650 655 Ala Thr Thr Phe Ser Ser ThrPro Val Asn Ser Phe Ile Thr Gln Tyr 660 665 670 Ser Thr Gly Gln Val SerVal Gln Ile Asp Trp Glu Ile Gln Lys Glu 675 680 685 Arg Ser Lys Arg TrpAsn Pro Glu Val Gln Phe Thr Ser Asn Tyr Gly 690 695 700 Gln Gln Asn SerLeu Leu Trp Ala Pro Asp Ala Ala Gly Lys Tyr Thr 705 710 715 720 Glu ProArg Ala Ile Gly Thr Arg Tyr Leu Thr His His Leu 725 730 64 736 PRTcapsid protein of AAV serotype, clone AAV1 64 Met Ala Ala Asp Gly TyrLeu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile Arg GluTrp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 20 25 30 Lys Ala Asn Gln GlnLys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr LeuGly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn Ala Ala AspAla Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 Gln Gln Leu LysAla Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala 85 90 95 Asp Ala Glu PheGln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110 Asn Leu GlyArg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125 Leu GlyLeu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140 ProVal Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly 145 150 155160 Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr 165170 175 Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro180 185 190 Ala Thr Pro Ala Ala Val Gly Pro Thr Thr Met Ala Ser Gly GlyGly 195 200 205 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val GlyAsn Ala 210 215 220 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly AspArg Val Ile 225 230 235 240 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro ThrTyr Asn Asn His Leu 245 250 255 Tyr Lys Gln Ile Ser Ser Ala Ser Thr GlyAla Ser Asn Asp Asn His 260 265 270 Tyr Phe Gly Tyr Ser Thr Pro Trp GlyTyr Phe Asp Phe Asn Arg Phe 275 280 285 His Cys His Phe Ser Pro Arg AspTrp Gln Arg Leu Ile Asn Asn Asn 290 295 300 Trp Gly Phe Arg Pro Lys ArgLeu Asn Phe Lys Leu Phe Asn Ile Gln 305 310 315 320 Val Lys Glu Val ThrThr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn 325 330 335 Leu Thr Ser ThrVal Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro 340 345 350 Tyr Val LeuGly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala 355 360 365 Asp ValPhe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly 370 375 380 SerGln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro 385 390 395400 Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe 405410 415 Glu Glu Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp420 425 430 Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu AsnArg 435 440 445 Thr Gln Asn Gln Ser Gly Ser Ala Gln Asn Lys Asp Leu LeuPhe Ser 450 455 460 Arg Gly Ser Pro Ala Gly Met Ser Val Gln Pro Lys AsnTrp Leu Pro 465 470 475 480 Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser LysThr Lys Thr Asp Asn 485 490 495 Asn Asn Ser Asn Phe Thr Trp Thr Gly AlaSer Lys Tyr Asn Leu Asn 500 505 510 Gly Arg Glu Ser Ile Ile Asn Pro GlyThr Ala Met Ala Ser His Lys 515 520 525 Asp Asp Glu Asp Lys Phe Phe ProMet Ser Gly Val Met Ile Phe Gly 530 535 540 Lys Glu Ser Ala Gly Ala SerAsn Thr Ala Leu Asp Asn Val Met Ile 545 550 555 560 Thr Asp Glu Glu GluIle Lys Ala Thr Asn Pro Val Ala Thr Glu Arg 565 570 575 Phe Gly Thr ValAla Val Asn Phe Gln Ser Ser Ser Thr Asp Pro Ala 580 585 590 Thr Gly AspVal His Ala Met Gly Ala Leu Pro Gly Met Val Trp Gln 595 600 605 Asp ArgAsp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His 610 615 620 ThrAsp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu 625 630 635640 Lys Asn Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala 645650 655 Asn Pro Pro Ala Glu Phe Ser Ala Thr Lys Phe Ala Ser Phe Ile Thr660 665 670 Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu LeuGln 675 680 685 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Val Gln Tyr ThrSer Asn 690 695 700 Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr Val Asp AsnAsn Gly Leu 705 710 715 720 Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg TyrLeu Thr Arg Pro Leu 725 730 735 65 736 PRT capsid protein of AAVserotype, clone AAV6VP1 65 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp LeuGlu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile Arg Glu Trp Trp Asp Leu LysPro Gly Ala Pro Lys Pro 20 25 30 Lys Ala Asn Gln Gln Lys Gln Asp Asp GlyArg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn GlyLeu Asp Lys Gly Glu Pro 50 55 60 Val Asn Ala Ala Asp Ala Ala Ala Leu GluHis Asp Lys Ala Tyr Asp 65 70 75 80 Gln Gln Leu Lys Ala Gly Asp Asn ProTyr Leu Arg Tyr Asn His Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu GlnGlu Asp Thr Ser Phe Gly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe GlnAla Lys Lys Arg Val Leu Glu Pro 115 120 125 Phe Gly Leu Val Glu Glu GlyAla Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140 Pro Val Glu Gln Ser ProGln Glu Pro Asp Ser Ser Ser Gly Ile Gly 145 150 155 160 Lys Thr Gly GlnGln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr 165 170 175 Gly Asp SerGlu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro 180 185 190 Ala ThrPro Ala Ala Val Gly Pro Thr Thr Met Ala Ser Gly Gly Gly 195 200 205 AlaPro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala 210 215 220Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile 225 230235 240 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu245 250 255 Tyr Lys Gln Ile Ser Ser Ala Ser Thr Gly Ala Ser Asn Asp AsnHis 260 265 270 Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe AsnArg Phe 275 280 285 His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu IleAsn Asn Asn 290 295 300 Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys LeuPhe Asn Ile Gln 305 310 315 320 Val Lys Glu Val Thr Thr Asn Asp Gly ValThr Thr Ile Ala Asn Asn 325 330 335 Leu Thr Ser Thr Val Gln Val Phe SerAsp Ser Glu Tyr Gln Leu Pro 340 345 350 Tyr Val Leu Gly Ser Ala His GlnGly Cys Leu Pro Pro Phe Pro Ala 355 360 365 Asp Val Phe Met Ile Pro GlnTyr Gly Tyr Leu Thr Leu Asn Asn Gly 370 375 380 Ser Gln Ala Val Gly ArgSer Ser Phe Tyr Cys Leu Glu Tyr Phe Pro 385 390 395 400 Ser Gln Met LeuArg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe 405 410 415 Glu Asp ValPro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp 420 425 430 Arg LeuMet Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Asn Arg 435 440 445 ThrGln Asn Gln Ser Gly Ser Ala Gln Asn Lys Asp Leu Leu Phe Ser 450 455 460Arg Gly Ser Pro Ala Gly Met Ser Val Gln Pro Lys Asn Trp Leu Pro 465 470475 480 Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Lys Thr Lys Thr Asp Asn485 490 495 Asn Asn Ser Asn Phe Thr Trp Thr Gly Ala Ser Lys Tyr Asn LeuAsn 500 505 510 Gly Arg Glu Ser Ile Ile Asn Pro Gly Thr Ala Met Ala SerHis Lys 515 520 525 Asp Asp Lys Asp Lys Phe Phe Pro Met Ser Gly Val MetIle Phe Gly 530 535 540 Lys Glu Ser Ala Gly Ala Ser Asn Thr Ala Leu AspAsn Val Met Ile 545 550 555 560 Thr Asp Glu Glu Glu Ile Lys Ala Thr AsnPro Val Ala Thr Glu Arg 565 570 575 Phe Gly Thr Val Ala Val Asn Leu GlnSer Ser Ser Thr Asp Pro Ala 580 585 590 Thr Gly Asp Val His Val Met GlyAla Leu Pro Gly Met Val Trp Gln 595 600 605 Asp Arg Asp Val Tyr Leu GlnGly Pro Ile Trp Ala Lys Ile Pro His 610 615 620 Thr Asp Gly His Phe HisPro Ser Pro Leu Met Gly Gly Phe Gly Leu 625 630 635 640 Lys His Pro ProPro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala 645 650 655 Asn Pro ProAla Glu Phe Ser Ala Thr Lys Phe Ala Ser Phe Ile Thr 660 665 670 Gln TyrSer Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln 675 680 685 LysGlu Asn Ser Lys Arg Trp Asn Pro Glu Val Gln Tyr Thr Ser Asn 690 695 700Tyr Ala Lys Ser Ala Asn Val Asp Phe Thr Val Asp Asn Asn Gly Leu 705 710715 720 Tyr Thr Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Pro Leu725 730 735 66 735 PRT capsid protein of AAV serotype, clone A3.3 66 MetAla Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Thr Leu Ser 1 5 10 15Glu Gly Ile Arg Gln Trp Trp Lys Leu Lys Pro Gly Pro Pro Pro Pro 20 25 30Lys Pro Asn Gln Gln His Arg Asp Asp Ser Arg Gly Leu Val Leu Pro 35 40 45Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 7580 His Gln Leu Lys Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala 85 9095 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro115 120 125 Leu Gly Leu Val Glu Glu Ala Val Lys Thr Ala Pro Gly Lys LysArg 130 135 140 Pro Ile Glu Gln Ser Pro Ala Glu Pro Asp Ser Ser Ser GlyIle Gly 145 150 155 160 Lys Ser Gly Gln Gln Pro Ala Lys Lys Arg Leu AsnPhe Gly Gln Thr 165 170 175 Gly Asp Thr Glu Ser Val Pro Gly Pro Gln ProIle Gly Glu Pro Pro 180 185 190 Ala Ala Pro Ser Gly Val Gly Ser Asn ThrMet Ala Ser Gly Gly Gly 195 200 205 Ala Pro Met Ala Asp Asn Asn Glu GlyAla Asp Gly Val Gly Asn Ser 210 215 220 Ser Gly Asn Trp His Cys Asp SerThr Trp Met Gly Asp Arg Val Ile 225 230 235 240 Thr Thr Ser Thr Arg ThrTrp Ala Leu Pro Thr Tyr Asn Asn His Leu 245 250 255 Tyr Lys Gln Ile SerSer Glu Ser Gly Ala Thr Asn Asp Asn His Tyr 260 265 270 Phe Gly Tyr SerThr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His 275 280 285 Cys His PheSer Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp 290 295 300 Gly PheArg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn Ile Gln Val 305 310 315 320Lys Glu Val Thr Gln Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn Leu 325 330335 Thr Ser Ala Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr 340345 350 Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp355 360 365 Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn GlySer 370 375 380 Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr PhePro Ser 385 390 395 400 Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe SerTyr Thr Phe Glu 405 410 415 Asp Val Pro Phe His Ser Ser Tyr Ala His SerGln Ser Leu Asp Arg 420 425 430 Leu Met Asn Pro Leu Ile Asp Gln Tyr LeuTyr Tyr Leu Ser Lys Thr 435 440 445 Gln Gly Thr Ser Gly Thr Thr Gln GlnSer Arg Leu Gln Phe Ser Gln 450 455 460 Ala Gly Pro Ser Ser Met Ala GlnGln Ala Lys Asn Trp Leu Pro Gly 465 470 475 480 Pro Ser Tyr Arg Gln GlnArg Met Ser Lys Thr Ala Asn Asp Asn Asn 485 490 495 Asn Ser Glu Phe AlaTrp Thr Ala Ala Thr Lys Tyr Tyr Leu Asn Gly 500 505 510 Arg Asn Ser LeuVal Asn Pro Gly Pro Pro Val Ala Ser His Lys Asp 515 520 525 Asp Glu GluLys Tyr Phe Pro Met His Gly Asn Leu Ile Phe Gly Lys 530 535 540 Gln GlyThr Gly Thr Thr Asn Val Asp Ile Glu Ser Val Leu Ile Thr 545 550 555 560Asp Glu Glu Glu Ile Arg Thr Thr Asn Pro Val Ala Thr Glu Gln Tyr 565 570575 Gly Gln Val Ala Thr Asn His Gln Ser Gln Asn Thr Thr Ala Ser Tyr 580585 590 Gly Ser Val Asp Ser Gln Gly Ile Leu Pro Gly Met Val Trp Gln Asp595 600 605 Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Thr Pro HisThr 610 615 620 Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe GlyLeu Lys 625 630 635 640 His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr ProVal Pro Ala Asn 645 650 655 Pro Ala Thr Thr Phe Thr Pro Gly Lys Phe AlaSer Phe Ile Thr Gln 660 665 670 Tyr Ser Thr Gly Gln Val Ser Val Glu IleGlu Trp Glu Leu Gln Lys 675 680 685 Glu Asn Ser Lys Arg Trp Asn Pro GluIle Gln Tyr Thr Ser Asn Tyr 690 695 700 Asn Lys Ser Val Asn Val Glu PheThr Val Asp Ala Asn Gly Val Tyr 705 710 715 720 Ser Glu Pro Arg Pro IleGly Thr Arg Tyr Leu Thr Arg Asn Leu 725 730 735 67 735 PRT capsidprotein of AAV serotype, clone A3.7 67 Met Ala Ala Asp Gly Tyr Leu ProAsp Trp Leu Glu Asp Thr Leu Ser 1 5 10 15 Glu Gly Ile Arg Gln Trp TrpLys Leu Lys Pro Gly Pro Pro Pro Pro 20 25 30 Lys Pro Asn Gln Gln His ArgAsp Asp Ser Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly ProPhe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn Glu Ala Asp Ala AlaAla Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 His Gln Leu Lys Gln GlyAsp Asn Pro Tyr Leu Lys Tyr Asn His Ala 85 90 95 Asp Ala Glu Phe Gln GluArg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110 Asn Leu Gly Arg AlaVal Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125 Leu Gly Leu ValGlu Glu Ala Val Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140 Pro Ile GluGln Ser Pro Ala Glu Pro Asp Ser Ser Ser Gly Ile Gly 145 150 155 160 LysSer Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr 165 170 175Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro 180 185190 Ala Ala Pro Ser Gly Val Gly Ser Asn Thr Met Ala Ser Gly Gly Gly 195200 205 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ser210 215 220 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Met Gly Asp Arg ValIle 225 230 235 240 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr AsnAsn Arg Leu 245 250 255 Tyr Lys Gln Ile Ser Ser Glu Ser Gly Ala Thr AsnAsp Asn His Tyr 260 265 270 Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe AspPhe Asn Arg Phe His 275 280 285 Cys His Phe Ser Pro Arg Asp Trp Gln ArgLeu Ile Asn Asn Asn Trp 290 295 300 Gly Phe Arg Pro Lys Lys Leu Asn PheLys Leu Phe Asn Ile Gln Val 305 310 315 320 Lys Glu Val Thr Gln Asn AspGly Thr Thr Thr Ile Ala Asn Asn Leu 325 330 335 Thr Ser Thr Val Gln ValPhe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr 340 345 350 Val Leu Gly Ser AlaHis Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp 355 360 365 Val Phe Met IlePro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser 370 375 380 Gln Ala ValGly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser 385 390 395 400 GlnMet Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe Glu 405 410 415Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg 420 425430 Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Lys Thr 435440 445 Gln Gly Thr Ser Gly Thr Thr Gln Gln Ser Arg Leu Gln Phe Ser Gln450 455 460 Ala Gly Pro Ser Ser Met Ala Gln Gln Ala Lys Asn Trp Leu ProGly 465 470 475 480 Pro Ser Tyr Arg Gln Gln Arg Met Ser Lys Thr Ala AsnAsp Asn Asn 485 490 495 Asn Ser Glu Phe Ala Trp Thr Ala Ala Thr Lys TyrTyr Leu Asn Gly 500 505 510 Arg Asn Ser Leu Val Asn Pro Gly Pro Pro MetAla Ser His Lys Asp 515 520 525 Asp Glu Glu Lys Tyr Phe Pro Met His GlyAsn Leu Ile Phe Gly Lys 530 535 540 Gln Gly Thr Gly Thr Thr Asn Val AspIle Glu Ser Val Leu Ile Thr 545 550 555 560 Asp Glu Glu Glu Ile Arg ThrThr Asn Pro Val Ala Thr Glu Gln Tyr 565 570 575 Gly Gln Val Ala Thr AsnHis Gln Ser Gln Asn Thr Thr Ala Ser Tyr 580 585 590 Gly Ser Val Asp SerGln Gly Ile Leu Pro Gly Met Val Trp Gln Asp 595 600 605 Arg Asp Val TyrLeu Gln Gly Pro Ile Trp Ala Lys Thr Pro His Thr 610 615 620 Asp Gly HisPhe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys 625 630 635 640 HisPro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asn 645 650 655Pro Ala Thr Thr Phe Thr Pro Gly Lys Phe Ala Ser Phe Ile Thr Gln 660 665670 Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys 675680 685 Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr690 695 700 Asn Lys Ser Val Asn Val Glu Phe Thr Val Asp Ala Asn Gly ValTyr 705 710 715 720 Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr ArgAsn Leu 725 730 735 68 735 PRT capsid protein of AAV serotype, cloneA3.4 68 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Thr Leu Ser1 5 10 15 Glu Gly Ile Arg Gln Trp Trp Lys Leu Lys Pro Gly Pro Pro ProPro 20 25 30 Lys Pro Asn Gln Gln His Arg Asp Asp Ser Arg Gly Leu Val LeuPro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly GluPro 50 55 60 Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala TyrAsp 65 70 75 80 His Gln Leu Lys Gln Gly Asp Asn Pro Tyr Leu Lys Tyr AsnHis Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser PheGly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg ValLeu Glu Pro 115 120 125 Leu Gly Leu Val Glu Glu Ala Val Lys Thr Ala ProGly Lys Lys Arg 130 135 140 Pro Ile Glu Gln Ser Pro Ala Glu Pro Asp SerSer Ser Gly Ile Gly 145 150 155 160 Glu Ser Gly Gln Gln Pro Ala Lys LysArg Leu Asn Phe Gly Gln Thr 165 170 175 Gly Asp Thr Glu Ser Val Pro AspPro Gln Pro Ile Gly Glu Pro Pro 180 185 190 Ala Ala Pro Ser Gly Val GlySer Asn Thr Met Ala Ser Gly Gly Gly 195 200 205 Ala Pro Met Ala Asp AspAsn Glu Gly Ala Asp Gly Val Gly Asn Ser 210 215 220 Ser Gly Asn Trp HisCys Asp Ser Thr Trp Met Gly Asp Arg Val Ile 225 230 235 240 Thr Thr SerThr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu 245 250 255 Tyr LysGln Ile Ser Ser Glu Ser Gly Ala Thr Asn Asp Asn His Tyr 260 265 270 PheGly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His 275 280 285Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp 290 295300 Gly Phe Arg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn Ile Gln Val 305310 315 320 Lys Glu Val Thr Gln Asn Asp Gly Thr Thr Thr Ile Ala Asn AsnLeu 325 330 335 Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln LeuPro Tyr 340 345 350 Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro PhePro Ala Asp 355 360 365 Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr LeuAsn Asn Gly Ser 370 375 380 Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys LeuGlu Tyr Phe Pro Ser 385 390 395 400 Gln Met Leu Arg Thr Gly Asn Asn PheThr Phe Ser Tyr Thr Phe Glu 405 410 415 Asp Val Pro Phe His Ser Ser TyrAla His Ser Gln Ser Leu Asp Arg 420 425 430 Leu Met Asn Pro Leu Ile AspGln Tyr Leu Tyr Tyr Leu Ser Lys Thr 435 440 445 Gln Gly Thr Ser Gly ThrThr Gln Gln Ser Arg Leu Gln Phe Ser Gln 450 455 460 Ala Gly Pro Ser SerMet Ala Gln Gln Ala Lys Asn Trp Leu Pro Gly 465 470 475 480 Pro Ser TyrArg Gln Gln Arg Met Ser Lys Thr Ala Asn Asp Asn Asn 485 490 495 Asn SerGlu Phe Ala Trp Thr Ala Ala Thr Lys Tyr Tyr Leu Asn Gly 500 505 510 ArgAsn Ser Leu Val Asn Pro Gly Pro Pro Met Ala Ser His Lys Asp 515 520 525Asp Glu Glu Lys Tyr Phe Pro Met His Gly Asn Leu Ile Phe Gly Lys 530 535540 Gln Gly Thr Gly Thr Thr Asn Val Asp Ile Glu Ser Val Leu Ile Thr 545550 555 560 Asp Glu Glu Glu Ile Arg Thr Thr Asn Pro Val Ala Thr Glu GlnTyr 565 570 575 Gly Gln Val Ala Thr Asn His Gln Ser Gln Asp Thr Thr AlaSer Tyr 580 585 590 Gly Ser Val Asp Ser Gln Gly Ile Leu Pro Gly Met ValTrp Gln Asp 595 600 605 Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala LysThr Pro His Thr 610 615 620 Asp Gly His Phe His Pro Ser Pro Leu Met GlyGly Phe Gly Leu Lys 625 630 635 640 His Pro Pro Pro Gln Ile Leu Ile LysAsn Thr Pro Val Pro Ala Asn 645 650 655 Pro Ala Thr Thr Phe Thr Pro GlyLys Phe Ala Ser Phe Ile Thr Gln 660 665 670 Tyr Ser Thr Gly Gln Val SerVal Glu Ile Glu Trp Glu Leu Gln Lys 675 680 685 Glu Asn Ser Lys Arg TrpAsn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr 690 695 700 Asn Lys Ser Val AsnVal Glu Phe Thr Val Asp Ala Asn Gly Val Tyr 705 710 715 720 Ser Glu ProArg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu 725 730 735 69 735 PRTcapsid protein of AAV serotype, clone A3.5 69 Met Ala Ala Asp Gly TyrLeu Pro Asp Trp Leu Glu Asp Thr Leu Ser 1 5 10 15 Glu Gly Ile Arg GlnTrp Trp Lys Leu Lys Pro Gly Pro Pro Pro Pro 20 25 30 Lys Pro Asn Gln GlnHis Arg Asp Asp Ser Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr LeuGly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn Glu Ala AspAla Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 His Gln Leu LysGln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala 85 90 95 Asp Ala Glu PheGln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110 Asn Leu GlyArg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125 Leu GlyLeu Val Glu Glu Ala Val Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140 ProIle Glu Gln Ser Pro Ala Glu Pro Asp Ser Ser Ser Gly Ile Gly 145 150 155160 Lys Ser Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr 165170 175 Gly Asp Thr Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro180 185 190 Ala Ala Pro Ser Gly Val Gly Ser Asn Thr Met Ala Ser Gly GlyGly 195 200 205 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val GlyAsn Ser 210 215 220 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Met Gly AspArg Val Ile 225 230 235 240 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro ThrTyr Asn Asn His Leu 245 250 255 Tyr Lys Gln Ile Ser Ser Glu Ser Gly AlaThr Asn Asp Asn His Tyr 260 265 270 Phe Gly Tyr Ser Thr Pro Trp Gly TyrPhe Asp Phe Asn Arg Phe His 275 280 285 Cys His Phe Ser Pro Arg Asp TrpGln Arg Leu Ile Asn Asn Asn Trp 290 295 300 Gly Phe Arg Pro Lys Lys LeuAsn Phe Lys Leu Phe Asn Ile Gln Val 305 310 315 320 Lys Glu Val Thr GlnAsn Asp Gly Thr Thr Thr Ile Ala Asn Asn Leu 325 330 335 Thr Ser Thr ValGln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr 340 345 350 Val Leu GlySer Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp 355 360 365 Val PheMet Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser 370 375 380 GlnAla Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser 385 390 395400 Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe Glu 405410 415 Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg420 425 430 Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser LysThr 435 440 445 Gln Gly Thr Ser Gly Thr Thr Gln Gln Ser Arg Leu Gln PheAsn Gln 450 455 460 Ala Gly Pro Ser Ser Met Ala Gln Gln Ala Lys Asn TrpLeu Pro Gly 465 470 475 480 Pro Ser Tyr Arg Gln Gln Arg Met Ser Lys ThrAla Asn Asp Asn Asn 485 490 495 Asn Ser Glu Phe Ala Trp Thr Ala Ala ThrLys Tyr Tyr Pro Asn Gly 500 505 510 Arg Asn Ser Leu Val Asn Pro Gly ProPro Met Ala Ser His Lys Asp 515 520 525 Asp Glu Glu Lys Tyr Phe Pro MetHis Gly Asn Leu Ile Phe Gly Lys 530 535 540 Gln Gly Thr Gly Thr Thr AsnVal Asp Ile Glu Ser Val Leu Ile Thr 545 550 555 560 Asp Glu Glu Glu IleArg Thr Thr Asn Pro Val Ala Thr Glu Gln Tyr 565 570 575 Gly Gln Val AlaThr Asn Arg Gln Ser Gln Asn Thr Thr Ala Ser Tyr 580 585 590 Gly Ser ValAsp Ser Gln Gly Ile Leu Pro Gly Met Val Trp Gln Asp 595 600 605 Arg AspVal Tyr Leu Gln Gly Pro Ile Trp Ala Lys Thr Pro His Thr 610 615 620 AspGly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys 625 630 635640 His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asn 645650 655 Pro Ala Thr Thr Phe Thr Pro Gly Lys Phe Ala Ser Phe Ile Thr Gln660 665 670 Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu GlnLys 675 680 685 Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr SerAsn Tyr 690 695 700 Asn Lys Ser Val Asn Val Glu Phe Thr Val Asp Ala AsnGly Val Tyr 705 710 715 720 Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr LeuThr Arg Asn Leu 725 730 735 70 735 PRT capsid protein of AAV serotype,clone AAV2 70 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp ThrLeu Ser 1 5 10 15 Glu Gly Ile Arg Gln Trp Trp Lys Leu Lys Pro Gly ProPro Pro Pro 20 25 30 Lys Pro Ala Glu Arg His Lys Asp Asp Ser Arg Gly LeuVal Leu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp LysGly Glu Pro 50 55 60 Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp LysAla Tyr Asp 65 70 75 80 Arg Gln Leu Asp Ser Gly Asp Asn Pro Tyr Leu LysTyr Asn His Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Lys Glu Asp ThrSer Phe Gly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys LysArg Val Leu Glu Pro 115 120 125 Leu Gly Leu Val Glu Glu Pro Val Lys ThrAla Pro Gly Lys Lys Arg 130 135 140 Pro Val Glu His Ser Pro Val Glu ProAsp Ser Ser Ser Gly Thr Gly 145 150 155 160 Lys Ala Gly Gln Gln Pro AlaArg Lys Arg Leu Asn Phe Gly Gln Thr 165 170 175 Gly Asp Ala Asp Ser ValPro Asp Pro Gln Pro Leu Gly Gln Pro Pro 180 185 190 Ala Ala Pro Ser GlyLeu Gly Thr Asn Thr Met Ala Thr Gly Ser Gly 195 200 205 Ala Pro Met AlaAsp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ser 210 215 220 Ser Gly AsnTrp His Cys Asp Ser Thr Trp Met Gly Asp Arg Val Ile 225 230 235 240 ThrThr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu 245 250 255Tyr Lys Gln Ile Ser Ser Gln Ser Gly Ala Ser Asn Asp Asn His Tyr 260 265270 Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His 275280 285 Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp290 295 300 Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile GlnVal 305 310 315 320 Lys Glu Val Thr Gln Asn Asp Gly Thr Thr Thr Ile AlaAsn Asn Leu 325 330 335 Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu TyrGln Leu Pro Tyr 340 345 350 Val Leu Gly Ser Ala His Gln Gly Cys Leu ProPro Phe Pro Ala Asp 355 360 365 Val Phe Met Val Pro Gln Tyr Gly Tyr LeuThr Leu Asn Asn Gly Ser 370 375 380 Gln Ala Val Gly Arg Ser Ser Phe TyrCys Leu Glu Tyr Phe Pro Ser 385 390 395 400 Gln Met Leu Arg Thr Gly AsnAsn Phe Thr Phe Ser Tyr Thr Phe Glu 405 410 415 Asp Val Pro Phe His SerSer Tyr Ala His Ser Gln Ser Leu Asp Arg 420 425 430 Leu Met Asn Pro LeuIle Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg Thr 435 440 445 Asn Thr Pro SerGly Thr Thr Thr Gln Ser Arg Leu Gln Phe Ser Gln 450 455 460 Ala Gly AlaSer Asp Ile Arg Asp Gln Ser Arg Asn Trp Leu Pro Gly 465 470 475 480 ProCys Tyr Arg Gln Gln Arg Val Ser Lys Thr Ser Ala Asp Asn Asn 485 490 495Asn Ser Glu Tyr Ser Trp Thr Gly Ala Thr Lys Tyr His Leu Asn Gly 500 505510 Arg Asp Ser Leu Val Asn Pro Gly Pro Ala Met Ala Ser His Lys Asp 515520 525 Asp Glu Glu Lys Phe Phe Pro Gln Ser Gly Val Leu Ile Phe Gly Lys530 535 540 Gln Gly Ser Glu Lys Thr Asn Val Asp Ile Glu Lys Val Met IleThr 545 550 555 560 Asp Glu Glu Glu Ile Arg Thr Thr Asn Pro Val Ala ThrGlu Gln Tyr 565 570 575 Gly Ser Val Ser Thr Asn Leu Gln Arg Gly Asn ArgGln Ala Ala Thr 580 585 590 Ala Asp Val Asn Thr Gln Gly Val Leu Pro GlyMet Val Trp Gln Asp 595 600 605 Arg Asp Val Tyr Leu Gln Gly Pro Ile TrpAla Lys Ile Pro His Thr 610 615 620 Asp Gly His Phe His Pro Ser Pro LeuMet Gly Gly Phe Gly Leu Lys 625 630 635 640 His Pro Pro Pro Gln Ile LeuIle Lys Asn Thr Pro Val Pro Ala Asn 645 650 655 Pro Ser Thr Thr Phe SerAla Ala Lys Phe Ala Ser Phe Ile Thr Gln 660 665 670 Tyr Ser Thr Gly GlnVal Ser Val Glu Ile Glu Trp Glu Leu Gln Lys 675 680 685 Glu Asn Ser LysArg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr 690 695 700 Asn Lys SerVal Asn Val Asp Phe Thr Val Asp Thr Asn Gly Val Tyr 705 710 715 720 SerGlu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu 725 730 735 71736 PRT capsid protein of AAV serotype, clone AAV3 71 Met Ala Ala AspGly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15 Glu Gly IleArg Glu Trp Trp Ala Leu Lys Pro Gly Val Pro Gln Pro 20 25 30 Lys Ala AsnGln Gln His Gln Asp Asn Arg Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr LysTyr Leu Gly Pro Gly Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn GluAla Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 Gln GlnLeu Lys Ala Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala 85 90 95 Asp AlaGlu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110 AsnLeu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Ile Leu Glu Pro 115 120 125Leu Gly Leu Val Glu Glu Ala Ala Lys Thr Ala Pro Gly Lys Lys Gly 130 135140 Ala Val Asp Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Val Gly 145150 155 160 Lys Ser Gly Lys Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly GlnThr 165 170 175 Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly GluPro Pro 180 185 190 Ala Ala Pro Thr Ser Leu Gly Ser Asn Thr Met Ala SerGly Gly Gly 195 200 205 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp GlyVal Gly Asn Ser 210 215 220 Ser Gly Asn Trp His Cys Asp Ser Gln Trp LeuGly Asp Arg Val Ile 225 230 235 240 Thr Thr Ser Thr Arg Thr Trp Ala LeuPro Thr Tyr Asn Asn His Leu 245 250 255 Tyr Lys Gln Ile Ser Ser Gln SerGly Ala Ser Asn Asp Asn His Tyr 260 265 270 Phe Gly Tyr Ser Thr Pro TrpGly Tyr Phe Asp Phe Asn Arg Phe His 275 280 285 Cys His Phe Ser Pro ArgAsp Trp Gln Arg Leu Ile Asn Asn Asn Trp 290 295 300 Gly Phe Arg Pro LysLys Leu Ser Phe Lys Leu Phe Asn Ile Gln Val 305 310 315 320 Arg Gly ValThr Gln Asn Asp Gly Thr Thr Thr Ile Ala Asn Asn Leu 325 330 335 Thr SerThr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr 340 345 350 ValLeu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp 355 360 365Val Phe Met Val Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser 370 375380 Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser 385390 395 400 Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Thr PheGlu 405 410 415 Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser LeuAsp Arg 420 425 430 Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr LeuAsn Arg Thr 435 440 445 Gln Gly Thr Thr Ser Gly Thr Thr Asn Gln Ser ArgLeu Leu Phe Ser 450 455 460 Gln Ala Gly Pro Gln Ser Met Ser Leu Gln AlaArg Asn Trp Leu Pro 465 470 475 480 Gly Pro Cys Tyr Arg Gln Gln Arg LeuSer Lys Thr Ala Asn Asp Asn 485 490 495 Asn Asn Ser Asn Phe Pro Trp ThrAla Ala Ser Lys Tyr His Leu Asn 500 505 510 Gly Arg Asp Ser Leu Val AsnPro Gly Pro Ala Met Ala Ser His Lys 515 520 525 Asp Asp Glu Glu Lys PhePhe Pro Met His Gly Asn Leu Ile Phe Gly 530 535 540 Lys Glu Gly Thr ThrAla Ser Asn Ala Glu Leu Asp Asn Val Met Ile 545 550 555 560 Thr Asp GluGlu Glu Ile Arg Thr Thr Asn Pro Val Ala Thr Glu Gln 565 570 575 Tyr GlyThr Val Ala Asn Asn Leu Gln Ser Ser Asn Thr Ala Pro Thr 580 585 590 ThrGly Thr Val Asn His Gln Gly Ala Leu Pro Gly Met Val Trp Gln 595 600 605Asp Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His 610 615620 Thr Asp Gly His Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu 625630 635 640 Lys His Pro Pro Pro Gln Ile Met Ile Lys Asn Thr Pro Val ProAla 645 650 655 Asn Pro Pro Thr Thr Phe Ser Pro Ala Lys Phe Ala Ser PheIle Thr 660 665 670 Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu TrpGlu Leu Gln 675 680 685 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile GlnTyr Thr Ser Asn 690 695 700 Tyr Asn Lys Ser Val Asn Val Asp Phe Thr ValAsp Thr Asn Gly Val 705 710 715 720 Tyr Ser Glu Pro Arg Pro Ile Gly ThrArg Tyr Leu Thr Arg Asn Leu 725 730 735 72 737 PRT capsid protein of AAVserotype, clone 3.3bVP1 72 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp LeuGlu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile Arg Glu Trp Trp Asp Leu LysPro Gly Ala Pro Lys Pro 20 25 30 Lys Ala Asn Gln Gln Lys Gln Asp Asn GlyArg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn GlyLeu Asp Lys Gly Glu Pro 50 55 60 Val Asn Ala Ala Asp Ala Ala Ala Leu GluHis Asp Lys Ala Tyr Asp 65 70 75 80 Gln Gln Leu Asn Ala Gly Asp Asn ProTyr Leu Arg Tyr Asn His Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu GlnGlu Asp Thr Ser Phe Gly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe GlnAla Lys Lys Arg Val Leu Glu Pro 115 120 125 Leu Gly Leu Val Glu Glu GlyAla Lys Thr Ala Pro Ala Lys Lys Arg 130 135 140 Pro Val Glu Pro Ser ProGln Arg Ser Pro Asp Ser Ser Thr Gly Ile 145 150 155 160 Gly Lys Lys GlyGln Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln 165 170 175 Thr Gly AspSer Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro 180 185 190 Pro AlaAla Pro Ser Ser Val Gly Ser Gly Thr Val Ala Ala Gly Gly 195 200 205 GlyAla Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn 210 215 220Ala Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val 225 230235 240 Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His245 250 255 Leu Tyr Glu Gln Ile Ser Ser Glu Thr Ala Gly Ser Thr Asn AspAsn 260 265 270 Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp PheAsn Arg 275 280 285 Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg LeuIle Asn Asn 290 295 300 Asn Trp Gly Phe Arg Pro Lys Lys Leu Arg Phe LysLeu Phe Asn Ile 305 310 315 320 Gln Val Lys Glu Val Thr Thr Asn Asp GlyVal Thr Thr Ile Ala Asn 325 330 335 Asn Leu Thr Ser Thr Ile Gln Val PheSer Asp Ser Glu Tyr Gln Leu 340 345 350 Pro Tyr Val Leu Gly Ser Ala HisGln Gly Cys Leu Pro Pro Phe Pro 355 360 365 Ala Asp Val Phe Met Ile ProGln Tyr Gly Tyr Leu Thr Leu Asn Asn 370 375 380 Gly Ser Gln Ser Val GlyArg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe 385 390 395 400 Pro Ser Gln MetLeu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr Ser 405 410 415 Phe Glu AspVal Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu 420 425 430 Asp ArgLeu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala 435 440 445 ArgThr Gln Ser Asp Pro Gly Gly Thr Ala Gly Asn Arg Glu Leu Gln 450 455 460Phe Tyr Gln Gly Gly Pro Ser Thr Met Ala Glu Gln Ala Lys Asn Trp 465 470475 480 Leu Pro Gly Pro Cys Phe Arg Gln Gln Arg Val Ser Lys Thr Leu Asp485 490 495 Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys TyrHis 500 505 510 Leu Asn Gly Arg Asn Ser Leu Val Asn Pro Gly Val Ala MetAla Thr 515 520 525 His Lys Asp Asp Glu Asp Arg Phe Phe Pro Ser Ser GlyVal Leu Ile 530 535 540 Phe Gly Lys Thr Gly Ala Thr Asn Lys Thr Thr LeuGlu Asn Val Leu 545 550 555 560 Met Thr Asn Glu Glu Glu Ile Arg Pro ThrAsn Pro Val Ala Thr Glu 565 570 575 Glu Tyr Gly Ile Val Ser Ser Asn LeuGln Ala Ala Asn Thr Ala Ala 580 585 590 Gln Thr Gln Val Val Asn Asn GlnGly Ala Leu Pro Gly Met Val Trp 595 600 605 Gln Asn Arg Asp Val Tyr LeuGln Gly Pro Ile Trp Ala Lys Ile Pro 610 615 620 His Thr Asp Gly Asn PheHis Pro Ser Pro Leu Met Gly Gly Phe Gly 625 630 635 640 Leu Lys His ProPro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro 645 650 655 Ala Asn ProPro Glu Val Phe Thr Pro Ala Lys Phe Ala Ser Phe Ile 660 665 670 Thr GlnTyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu 675 680 685 GlnLys Glu Asn Ser Lys Arg Trp Asp Pro Glu Ile Gln Tyr Thr Ser 690 695 700Asn Phe Glu Lys Gln Thr Gly Val Asp Phe Ala Val Asp Ser Gln Gly 705 710715 720 Val Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn725 730 735 Leu 73 644 PRT capsid protein of AAV serotype, clone 223-473 Lys Ala Tyr Asp Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg 1 510 15 Tyr Asn His Ala Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr 2025 30 Ser Phe Gly Gly Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg 3540 45 Val Leu Glu Pro Leu Gly Leu Val Glu Thr Pro Ala Lys Thr Ala Pro 5055 60 Gly Lys Lys Arg Pro Val Asp Ser Pro Asp Ser Thr Ser Gly Ile Gly 6570 75 80 Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr85 90 95 Gly Asp Ser Glu Pro Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro100 105 110 Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly GlyGly 115 120 125 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val GlyAsn Ala 130 135 140 Ser Gly Asn Trp His Cys Asp Ser Thr Arg Leu Gly AspArg Val Ile 145 150 155 160 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro ThrTyr Asn Asn His Leu 165 170 175 Tyr Lys Gln Ile Ser Ser Gln Ser Ala GlySer Thr Asn Asp Asn Val 180 185 190 Tyr Phe Gly Tyr Ser Thr Pro Trp GlyTyr Phe Asp Phe Asn Arg Phe 195 200 205 His Cys His Phe Ser Pro Arg AspTrp Gln Arg Leu Ile Asn Asn Asn 210 215 220 Trp Gly Phe Arg Pro Lys LysLeu Asn Phe Lys Leu Phe Asn Ile Gln 225 230 235 240 Val Lys Glu Val ThrThr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn 245 250 255 Leu Thr Ser ThrVal Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro 260 265 270 Tyr Val LeuGly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala 275 280 285 Asp ValPhe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly 290 295 300 SerGln Ser Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro 305 310 315320 Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe 325330 335 Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Gly340 345 350 Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu AlaArg 355 360 365 Thr Gln Ser Asn Ala Gly Gly Thr Ala Gly Asn Arg Glu LeuGln Phe 370 375 380 Tyr Gln Gly Gly Pro Thr Thr Met Ala Glu Gln Ala LysAsn Trp Leu 385 390 395 400 Pro Gly Pro Cys Phe Arg Gln Gln Arg Val SerLys Thr Leu Asp Gln 405 410 415 Asn Asn Asn Ser Asn Phe Ala Trp Thr GlyAla Thr Lys Tyr His Leu 420 425 430 Asn Gly Arg Asn Ser Leu Val Asn ProGly Val Ala Met Ala Thr His 435 440 445 Lys Asp Asp Glu Glu Arg Phe PhePro Ser Ser Gly Val Leu Ile Phe 450 455 460 Gly Lys Thr Gly Ala Ala AsnLys Thr Thr Leu Glu Asn Val Leu Met 465 470 475 480 Thr Asn Glu Glu GluIle Arg Pro Thr Asn Pro Val Ala Thr Glu Glu 485 490 495 Tyr Gly Ile ValSer Ser Asn Leu Gln Ala Ala Ser Thr Ala Ala Gln 500 505 510 Thr Gln ValVal Asn Asn Gln Gly Ala Leu Pro Gly Met Val Trp Gln 515 520 525 Asn ArgAsp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His 530 535 540 ThrAsp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu 545 550 555560 Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala 565570 575 Asn Pro Pro Glu Val Phe Thr Pro Ala Lys Phe Ala Ser Phe Ile Thr580 585 590 Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu LeuGln 595 600 605 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr ThrSer Asn 610 615 620 Phe Asp Lys Gln Thr Gly Val Asp Phe Ala Val Asp SerGln Gly Val 625 630 635 640 Tyr Ser Glu Pro 74 644 PRT capsid protein ofAAV serotype, clone 223.5 74 Lys Ala Tyr Asp Gln Gln Leu Lys Ala Gly AspAsn Pro Tyr Leu Arg 1 5 10 15 Tyr Asn His Ala Asp Ala Glu Phe Gln GluArg Leu Gln Glu Asp Thr 20 25 30 Ser Phe Gly Gly Asn Leu Gly Arg Ala ValPhe Gln Ala Lys Lys Arg 35 40 45 Val Leu Glu Pro Leu Gly Leu Val Glu ThrPro Ala Lys Thr Ala Pro 50 55 60 Gly Lys Lys Arg Pro Val Asp Ser Pro AspSer Thr Ser Gly Ile Gly 65 70 75 80 Lys Lys Gly Gln Gln Pro Ala Lys LysArg Leu Asn Phe Gly Gln Thr 85 90 95 Gly Asp Ser Glu Pro Val Pro Asp ProGln Pro Ile Gly Glu Pro Pro 100 105 110 Ala Gly Pro Ser Gly Leu Gly SerGly Thr Met Ala Ala Gly Gly Gly 115 120 125 Ala Pro Met Ala Asp Asn AsnGlu Gly Ala Asp Gly Val Gly Asn Ala 130 135 140 Ser Gly Asn Trp His CysAsp Ser Thr Arg Leu Gly Asp Arg Val Ile 145 150 155 160 Thr Thr Ser ThrArg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu 165 170 175 Tyr Lys GlnIle Ser Ser Gln Ser Ala Gly Ser Thr Asn Asp Asn Val 180 185 190 Tyr PheGly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe 195 200 205 HisCys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn 210 215 220Trp Gly Phe Arg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn Ile Gln 225 230235 240 Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn245 250 255 Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser Glu Tyr Gln LeuPro 260 265 270 Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro PhePro Ala 275 280 285 Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr LeuAsn Asn Gly 290 295 300 Ser Gln Ser Val Gly Arg Ser Ser Phe Tyr Cys LeuGlu Tyr Phe Pro 305 310 315 320 Ser Gln Met Leu Arg Thr Gly Asn Asn PheThr Phe Ser Tyr Thr Phe 325 330 335 Glu Asp Val Pro Phe His Ser Ser TyrAla His Ser Gln Ser Leu Gly 340 345 350 Arg Leu Met Asn Pro Leu Ile AspGln Tyr Leu Tyr Tyr Leu Ala Arg 355 360 365 Thr Gln Ser Asn Ala Gly GlyThr Ala Gly Asn Arg Glu Leu Gln Phe 370 375 380 Tyr Gln Gly Gly Pro ThrThr Met Ala Glu Gln Ala Lys Asn Trp Leu 385 390 395 400 Pro Gly Pro CysPhe Arg Gln Gln Arg Val Ser Lys Thr Leu Asp Gln 405 410 415 Asn Asn AsnSer Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu 420 425 430 Asn GlyArg Asn Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr His 435 440 445 LysAsp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Ile Phe 450 455 460Gly Lys Thr Gly Ala Ala Asn Lys Thr Thr Leu Glu Asn Val Leu Met 465 470475 480 Thr Asn Glu Glu Glu Ile Arg Pro Thr Asn Pro Val Ala Thr Glu Glu485 490 495 Tyr Gly Ile Val Ser Ser Asn Leu Gln Ala Ala Ser Thr Ala AlaGln 500 505 510 Thr Gln Val Val Asn Asn Gln Gly Ala Leu Pro Gly Met ValTrp Gln 515 520 525 Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala LysIle Pro His 530 535 540 Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met GlyGly Phe Gly Leu 545 550 555 560 Lys His Pro Pro Pro Gln Ile Leu Ile LysAsn Thr Pro Val Pro Ala 565 570 575 Asn Pro Pro Glu Val Phe Thr Pro AlaLys Phe Ala Ser Phe Ile Thr 580 585 590 Gln Tyr Ser Thr Gly Gln Val SerVal Glu Ile Glu Trp Glu Leu Gln 595 600 605 Lys Glu Asn Ser Lys Arg TrpAsn Pro Glu Ile Gln Tyr Thr Ser Asn 610 615 620 Phe Asp Lys Gln Thr GlyVal Asp Phe Ala Val Asp Ser Gln Gly Val 625 630 635 640 Tyr Ser Glu Pro75 644 PRT capsid protein of AAV serotype, clone 223.10 MISC_FEATURE(434)..(434) can be any amino acid 75 Lys Ala Tyr Asp Gln Gln Leu LysAla Gly Asp Asn Pro Tyr Leu Arg 1 5 10 15 Tyr Asn His Ala Asp Ala GluPhe Gln Glu Arg Leu Gln Glu Asp Thr 20 25 30 Ser Phe Gly Gly Asn Leu GlyArg Ala Val Phe Gln Ala Lys Lys Arg 35 40 45 Val Leu Glu Pro Leu Gly LeuVal Glu Thr Pro Ala Lys Thr Ala Pro 50 55 60 Gly Lys Lys Arg Pro Val AspSer Pro Asp Ser Thr Ser Gly Ile Gly 65 70 75 80 Lys Lys Gly Gln Gln ProAla Lys Lys Arg Leu Asn Phe Gly Gln Thr 85 90 95 Gly Asp Ser Glu Ser ValPro Asp Pro Gln Pro Ile Gly Glu Pro Pro 100 105 110 Ala Gly Pro Ser GlyLeu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly 115 120 125 Ala Pro Met AlaAsp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala 130 135 140 Ser Gly AsnTrp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile 145 150 155 160 ThrThr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu 165 170 175Tyr Lys Gln Ile Ser Ser Gln Ser Ala Gly Ser Thr Asn Asp Asn Val 180 185190 Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe 195200 205 His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn210 215 220 Trp Gly Phe Arg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn IleGln 225 230 235 240 Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr IleAla Asn Asn 245 250 255 Leu Thr Ser Thr Val Gln Val Phe Ser Asp Ser GluTyr Gln Leu Pro 260 265 270 Tyr Val Leu Gly Ser Ala His Gln Gly Cys LeuPro Pro Phe Pro Ala 275 280 285 Asp Val Phe Met Ile Pro Gln Tyr Gly TyrLeu Thr Leu Asn Asn Gly 290 295 300 Ser Gln Ser Val Gly Arg Ser Ser PheTyr Cys Leu Glu Tyr Phe Pro 305 310 315 320 Ser Gln Met Leu Arg Thr GlyAsn Asn Phe Thr Phe Ser Tyr Thr Phe 325 330 335 Glu Asp Val Pro Phe HisSer Ser Tyr Ala His Ser Gln Ser Leu Asp 340 345 350 Arg Leu Met Asn ProLeu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg 355 360 365 Thr Gln Ser AsnAla Gly Gly Thr Ala Gly Asn Arg Glu Leu Gln Phe 370 375 380 Tyr Gln GlyGly Pro Thr Thr Met Ala Glu Gln Ala Lys Asn Trp Leu 385 390 395 400 ProGly Pro Cys Phe Arg Gln Gln Arg Val Ser Lys Thr Leu Asp Gln 405 410 415Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu 420 425430 Asn Xaa Arg Asn Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr His 435440 445 Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Ile Phe450 455 460 Gly Lys Thr Gly Ala Ala Asn Lys Thr Thr Leu Glu Asn Val LeuMet 465 470 475 480 Thr Asn Glu Glu Glu Ile Arg Pro Thr Asn Pro Val AlaThr Glu Glu 485 490 495 Tyr Gly Ile Val Ser Ser Asn Leu Gln Ala Ala SerThr Ala Ala Gln 500 505 510 Thr Gln Val Val Asn Asn Gln Gly Ala Leu ProGly Met Val Trp Gln 515 520 525 Asn Arg Asp Val Tyr Leu Gln Gly Pro IleTrp Ala Lys Ile Pro His 530 535 540 Thr Asp Gly Asn Phe His Pro Ser ProLeu Met Gly Gly Phe Gly Leu 545 550 555 560 Lys His Pro Pro Pro Gln IleLeu Ile Lys Asn Thr Pro Val Pro Ala 565 570 575 Asn Pro Pro Glu Val PheThr Pro Ala Lys Phe Ala Ser Phe Ile Thr 580 585 590 Gln Tyr Ser Thr GlyGln Val Ser Val Glu Ile Glu Trp Glu Leu Gln 595 600 605 Lys Glu Asn SerLys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn 610 615 620 Phe Asp LysGln Thr Gly Val Asp Phe Ala Val Asp Ser Gln Gly Val 625 630 635 640 TyrSer Glu Pro 76 644 PRT capsid protein of AAV serotype, clone 223.2 76Lys Ala Tyr Asp Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg 1 5 1015 Tyr Asn His Ala Asp Ala Glu Phe Gln Glu Cys Leu Gln Glu Asp Thr 20 2530 Ser Phe Gly Gly Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg 35 4045 Val Leu Glu Pro Leu Gly Leu Val Glu Thr Pro Ala Lys Thr Ala Pro 50 5560 Gly Lys Lys Arg Pro Val Asp Ser Pro Asp Ser Thr Ser Gly Ile Gly 65 7075 80 Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr 8590 95 Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro100 105 110 Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Val Ala Gly GlyGly 115 120 125 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val GlyAsn Ala 130 135 140 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly AspArg Val Ile 145 150 155 160 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro ThrTyr Asn Asn His Leu 165 170 175 Tyr Lys Gln Ile Ser Ser Gln Ser Ala GlySer Thr Asn Asp Asn Val 180 185 190 Tyr Phe Gly Tyr Ser Thr Pro Trp GlyTyr Phe Asp Phe Asn Arg Phe 195 200 205 His Cys His Phe Ser Pro Arg AspTrp Gln Arg Leu Ile Asn Asn Asn 210 215 220 Trp Gly Phe Arg Pro Lys LysLeu Asn Phe Lys Leu Phe Asn Ile Gln 225 230 235 240 Val Lys Glu Val ThrThr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn 245 250 255 Leu Thr Ser ThrVal Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro 260 265 270 Tyr Val LeuGly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala 275 280 285 Asp ValPhe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly 290 295 300 SerGln Ser Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro 305 310 315320 Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe 325330 335 Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp340 345 350 Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu AlaArg 355 360 365 Thr Gln Ser Asn Ala Gly Gly Thr Ala Gly Asn Arg Glu LeuGln Phe 370 375 380 Tyr Gln Gly Gly Pro Thr Thr Met Ala Glu Gln Ala LysAsn Trp Leu 385 390 395 400 Pro Gly Pro Cys Phe Arg Gln Gln Arg Val SerLys Thr Leu Asp Gln 405 410 415 Asn Asn Asn Ser Asn Phe Ala Trp Thr GlyAla Thr Lys Tyr His Leu 420 425 430 Asn Gly Arg Asn Ser Leu Val Asn ProGly Val Ala Met Ala Thr His 435 440 445 Lys Asp Asp Glu Glu Arg Phe SerPro Ser Ser Gly Val Leu Ile Phe 450 455 460 Gly Lys Thr Gly Ala Ala AsnLys Thr Thr Leu Glu Asn Val Leu Met 465 470 475 480 Thr Asn Glu Glu GluIle Arg Pro Thr Asn Pro Val Ala Thr Glu Glu 485 490 495 Tyr Gly Ile ValSer Ser Asn Leu Gln Ala Ala Ser Thr Ala Ala Gln 500 505 510 Thr Gln ValVal Asn Asn Gln Gly Ala Leu Pro Gly Met Val Trp Gln 515 520 525 Asn ArgAsp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His 530 535 540 ThrAsp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu 545 550 555560 Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala 565570 575 Asn Pro Pro Glu Val Phe Thr Pro Ala Lys Phe Ala Ser Phe Ile Thr580 585 590 Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu LeuGln 595 600 605 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr ThrSer Asn 610 615 620 Phe Asp Lys Gln Thr Gly Val Asp Phe Ala Val Asp SerGln Gly Val 625 630 635 640 Tyr Ser Glu Pro 77 644 PRT capsid protein ofAAV serotype, clone 223.7 77 Lys Ala Tyr Asp Gln Gln Leu Lys Ala Gly AspAsn Pro Tyr Leu Arg 1 5 10 15 Tyr Asn His Ala Asp Ala Glu Phe Gln GluArg Leu Gln Glu Asp Thr 20 25 30 Ser Phe Gly Gly Asn Leu Gly Arg Ala ValPhe Gln Ala Lys Lys Arg 35 40 45 Val Leu Glu Pro Leu Gly Leu Val Glu ThrPro Ala Lys Thr Ala Pro 50 55 60 Gly Lys Lys Arg Pro Val Asp Ser Pro AspSer Thr Ser Gly Ile Gly 65 70 75 80 Lys Lys Gly Gln Gln Pro Ala Lys LysArg Leu Asn Phe Gly Gln Thr 85 90 95 Gly Asp Ser Glu Ser Val Pro Asp ProGln Pro Ile Gly Glu Pro Pro 100 105 110 Ala Gly Pro Ser Gly Leu Gly SerGly Thr Met Ala Ala Gly Gly Gly 115 120 125 Ala Pro Met Ala Asp Asn AsnGlu Gly Ala Asp Gly Val Gly Asn Ala 130 135 140 Ser Gly Asn Trp His CysAsp Ser Thr Trp Leu Gly Asp Arg Val Ile 145 150 155 160 Thr Thr Ser ThrArg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu 165 170 175 Tyr Lys GlnIle Ser Ser Gln Ser Ala Gly Ser Thr Asn Asp Asn Val 180 185 190 Tyr PheGly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe 195 200 205 HisCys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn 210 215 220Trp Gly Phe Arg Pro Lys Lys Leu Asn Phe Lys Leu Phe Asn Ile Gln 225 230235 240 Val Lys Glu Val Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn245 250 255 Leu Thr Ser Thr Val Gln Val Phe Ser Asp Pro Glu Tyr Gln LeuPro 260 265 270 Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro PhePro Ala 275 280 285 Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr LeuAsn Asn Gly 290 295 300 Ser Gln Ser Val Gly Arg Ser Ser Phe Tyr Cys LeuGlu Tyr Phe Pro 305 310 315 320 Ser Gln Met Leu Arg Thr Gly Asn Asn PheThr Phe Ser Tyr Thr Phe 325 330 335 Glu Asp Val Pro Phe His Ser Ser TyrAla His Ser Gln Ser Leu Asp 340 345 350 Arg Leu Met Asn Pro Leu Ile AspGln Tyr Leu Tyr Tyr Leu Ala Arg 355 360 365 Thr Gln Ser Asn Ala Gly GlyThr Ala Gly Asn Arg Glu Leu Gln Phe 370 375 380 Tyr Gln Gly Gly Pro ThrThr Met Ala Glu Gln Ala Lys Asn Trp Leu 385 390 395 400 Pro Gly Pro CysPhe Arg Gln Gln Arg Val Ser Lys Thr Leu Asp Gln 405 410 415 Asn Asn AsnSer Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu 420 425 430 Asn GlyArg Asn Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr His 435 440 445 LysAsp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Ile Phe 450 455 460Gly Lys Thr Gly Ala Ala Asn Lys Thr Thr Leu Glu Asn Val Leu Met 465 470475 480 Thr Asn Glu Glu Glu Ile Arg Pro Thr Asn Pro Val Ala Thr Glu Glu485 490 495 Tyr Gly Ile Val Ser Ser Asn Leu Gln Ala Ala Ser Thr Ala AlaGln 500 505 510 Thr Gln Val Val Asn Asn Gln Gly Ala Leu Pro Gly Met ValTrp Gln 515 520 525 Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala LysIle Pro His 530 535 540 Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met GlyGly Phe Gly Leu 545 550 555 560 Lys His Pro Pro Pro Gln Ile Leu Ile LysAsn Thr Pro Val Pro Ala 565 570 575 Asn Pro Pro Glu Val Phe Thr Pro AlaLys Ile Ala Ser Phe Ile Thr 580 585 590 Gln Tyr Ser Thr Gly Gln Val SerVal Glu Ile Glu Trp Glu Leu Gln 595 600 605 Lys Glu Asn Ser Lys Arg TrpAsn Pro Glu Ile Gln Tyr Thr Ser Asn 610 615 620 Phe Asp Lys Gln Thr GlyVal Asp Phe Ala Val Asp Ser Gln Gly Val 625 630 635 640 Tyr Ser Glu Pro78 644 PRT capsid protein of AAV serotype, clone 223.6 78 Lys Ala TyrAsp Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg 1 5 10 15 Tyr AsnHis Ala Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr 20 25 30 Ser PheGly Gly Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg 35 40 45 Val LeuGlu Pro Leu Gly Leu Val Glu Thr Pro Ala Lys Thr Ala Pro 50 55 60 Gly LysLys Arg Pro Val Asp Ser Pro Asp Ser Thr Ser Gly Ile Gly 65 70 75 80 LysLys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr 85 90 95 GlyAsp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro 100 105 110Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly 115 120125 Ala Pro Met Ala Asp Asn Ser Glu Gly Ala Asp Gly Val Gly Asn Ala 130135 140 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile145 150 155 160 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn AsnHis Leu 165 170 175 Tyr Lys Gln Ile Ser Ser Gln Ser Ala Gly Ser Thr AsnAsp Asn Val 180 185 190 Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe AspPhe Asn Arg Phe 195 200 205 His Cys His Phe Ser Pro Arg Asp Trp Gln ArgLeu Ile Asn Asn Asn 210 215 220 Trp Gly Phe Arg Pro Lys Lys Leu Asn PheLys Leu Phe Asn Ile Gln 225 230 235 240 Val Lys Glu Val Thr Thr Asn AspGly Val Thr Thr Ile Ala Asn Asn 245 250 255 Leu Thr Ser Thr Val Gln ValPhe Ser Asp Ser Glu Tyr Gln Leu Pro 260 265 270 Tyr Val Leu Gly Ser AlaHis Gln Gly Cys Leu Pro Pro Phe Pro Ala 275 280 285 Asp Val Phe Met IlePro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly 290 295 300 Ser Gln Ser ValGly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro 305 310 315 320 Ser GlnMet Leu Arg Thr Gly Asn Asn Phe Thr Phe Ser Tyr Thr Phe 325 330 335 GluAsp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp 340 345 350Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg 355 360365 Thr Gln Ser Asn Ala Gly Gly Thr Ala Gly Asn Arg Glu Leu Gln Phe 370375 380 Tyr Gln Gly Gly Pro Thr Thr Met Ala Glu Gln Ala Lys Asn Trp Leu385 390 395 400 Pro Gly Pro Cys Phe Arg Gln Gln Arg Val Ser Lys Thr LeuAsp Gln 405 410 415 Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr LysTyr His Leu 420 425 430 Asn Gly Arg Asn Ser Leu Val Asn Pro Gly Val AlaMet Ala Thr His 435 440 445 Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser SerGly Val Leu Ile Phe 450 455 460 Gly Lys Thr Gly Ala Ala Asn Lys Thr ThrLeu Glu Asn Val Leu Met 465 470 475 480 Thr Asn Glu Glu Glu Ile Arg ProThr Asn Pro Val Ala Thr Glu Glu 485 490 495 Tyr Gly Ile Val Ser Ser AsnLeu Gln Ala Ala Ser Thr Ala Ala Gln 500 505 510 Thr Gln Val Val Asn AsnGln Gly Ala Leu Pro Gly Met Val Trp Gln 515 520 525 Asn Arg Asp Val TyrLeu Gln Gly Pro Ile Trp Ala Lys Ile Pro His 530 535 540 Thr Asp Gly AsnPhe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu 545 550 555 560 Lys HisPro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala 565 570 575 AsnPro Pro Glu Val Phe Thr Pro Ala Lys Leu Ala Ser Phe Ile Thr 580 585 590Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln 595 600605 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn 610615 620 Phe Asp Lys Gln Thr Gly Val Asp Phe Ala Val Asp Ser Gln Gly Val625 630 635 640 Tyr Ser Glu Pro 79 738 PRT capsid protein of AAVserotype, clone 44.1 79 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu GluAsp Asn Leu Ser 1 5 10 15 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys ProGly Ala Pro Lys Pro 20 25 30 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly ArgGly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly LeuAsp Lys Gly Glu Pro 50 55 60 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu HisAsp Lys Ala Tyr Asp 65 70 75 80 Gln Gln Leu Lys Ala Gly Asp Asn Pro TyrLeu Arg Tyr Asn His Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln GluAsp Thr Ser Phe Gly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe Gln AlaLys Lys Arg Val Leu Glu Pro 115 120 125 Leu Gly Leu Val Glu Glu Gly AlaLys Thr Ala Pro Gly Lys Lys Arg 130 135 140 Pro Val Glu Pro Ser Pro GlnArg Ser Pro Asp Ser Ser Thr Gly Ile 145 150 155 160 Gly Lys Lys Gly GlnGln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln 165 170 175 Thr Gly Asp SerGlu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro 180 185 190 Pro Ala GlyPro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly 195 200 205 Gly AlaPro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser 210 215 220 SerSer Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val 225 230 235240 Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His 245250 255 Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp260 265 270 Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp PheAsn 275 280 285 Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg LeuIle Asn 290 295 300 Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe LysLeu Phe Asn 305 310 315 320 Ile Gln Val Lys Glu Val Thr Gln Asn Glu GlyThr Lys Thr Ile Ala 325 330 335 Asn Asn Leu Thr Ser Thr Ile Gln Val PheThr Asp Ser Glu Tyr Gln 340 345 350 Leu Pro Tyr Val Leu Gly Ser Ala HisGln Gly Cys Leu Pro Pro Phe 355 360 365 Pro Ala Asp Val Phe Met Ile ProGln Tyr Gly Tyr Leu Thr Leu Asn 370 375 380 Asn Gly Ser Gln Ala Val GlyArg Ser Ser Phe Tyr Cys Leu Glu Tyr 385 390 395 400 Phe Pro Ser Gln MetLeu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr 405 410 415 Gln Phe Glu AspVal Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser 420 425 430 Leu Asp ArgLeu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu 435 440 445 Ser ArgThr Gln Ser Thr Gly Gly Thr Ala Gly Thr Gln Gln Leu Leu 450 455 460 PheSer Gln Ala Gly Pro Asn Asn Met Ser Ala Gln Ala Lys Asn Trp 465 470 475480 Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser 485490 495 Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His500 505 510 Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Val Ala Met AlaThr 515 520 525 His Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly ValLeu Met 530 535 540 Phe Gly Lys Gln Gly Ala Gly Lys Asp Asn Val Asp TyrSer Ser Val 545 550 555 560 Met Leu Thr Ser Glu Glu Glu Ile Lys Thr ThrAsn Pro Val Ala Thr 565 570 575 Glu Gln Tyr Gly Val Val Ala Asp Asn LeuGln Gln Gln Asn Ala Ala 580 585 590 Pro Ile Val Gly Ala Val Asn Ser GlnGly Ala Leu Pro Gly Met Val 595 600 605 Trp Gln Asn Arg Asp Val Tyr LeuGln Gly Pro Ile Trp Ala Lys Ile 610 615 620 Pro His Thr Asp Gly Asn PheHis Pro Ser Pro Leu Met Gly Gly Phe 625 630 635 640 Gly Leu Lys His ProPro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val 645 650 655 Pro Ala Asp ProPro Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe 660 665 670 Ile Thr GlnTyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu 675 680 685 Leu GlnLys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr 690 695 700 SerAsn Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Asp 705 710 715720 Gly Thr Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg 725730 735 Asn Leu 80 738 PRT capsid protein of AAV serotype, clone 44.5 80Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 1015 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 20 2530 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 35 4045 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 5560 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 7075 80 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala 8590 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly100 105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu GluPro 115 120 125 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly LysLys Arg 130 135 140 Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser SerThr Gly Ile 145 150 155 160 Gly Lys Lys Gly Gln Gln Pro Ala Lys Lys ArgLeu Asn Phe Gly Gln 165 170 175 Thr Gly Asp Ser Glu Ser Val Pro Asp ProGln Pro Ile Gly Glu Pro 180 185 190 Pro Ala Gly Pro Ser Gly Leu Gly SerGly Thr Met Ala Ala Gly Gly 195 200 205 Gly Ala Pro Met Ala Asp Asn AsnGlu Gly Ala Asp Gly Val Gly Ser 210 215 220 Ser Ser Gly Asn Trp His CysAsp Ser Thr Trp Leu Gly Asp Arg Val 225 230 235 240 Ile Thr Thr Ser ThrArg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His 245 250 255 Leu Tyr Lys GlnIle Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp 260 265 270 Asn Thr TyrPhe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn 275 280 285 Arg PheHis Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn 290 295 300 AsnAsn Trp Gly Phe Arg Pro Lys Arg Pro Asn Phe Lys Leu Phe Asn 305 310 315320 Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala 325330 335 Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln340 345 350 Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro ProPhe 355 360 365 Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu ThrLeu Asn 370 375 380 Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr CysLeu Glu Tyr 385 390 395 400 Phe Pro Ser Gln Met Leu Arg Thr Gly Asn AsnPhe Glu Phe Ser Tyr 405 410 415 Gln Phe Glu Asp Val Pro Phe His Ser SerTyr Ala His Ser Gln Ser 420 425 430 Leu Asp Arg Leu Met Asn Pro Leu IleAsp Gln Tyr Leu Tyr Tyr Leu 435 440 445 Ser Arg Thr Gln Ser Thr Gly GlyThr Ala Gly Thr Gln Gln Leu Leu 450 455 460 Phe Ser Gln Ala Gly Pro AsnAsn Met Ser Ala Gln Ala Lys Asn Trp 465 470 475 480 Leu Pro Gly Pro CysTyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser 485 490 495 Gln Asn Asn AsnSer Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His 500 505 510 Leu Asn GlyArg Asp Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr 515 520 525 His LysAsp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met 530 535 540 PheGly Lys Gln Gly Ala Gly Lys Asp Asn Val Asp Tyr Ser Ser Val 545 550 555560 Met Leu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr 565570 575 Glu Gln Tyr Gly Val Val Ala Asp Asn Leu Gln Gln Gln Asn Ala Ala580 585 590 Pro Ile Val Gly Ala Val Asn Ser Gln Gly Ala Leu Pro Gly MetVal 595 600 605 Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp AlaLys Ile 610 615 620 Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu MetGly Gly Phe 625 630 635 640 Gly Leu Lys His Pro Pro Pro Gln Ile Leu IleLys Asn Thr Pro Val 645 650 655 Pro Ala Asp Pro Pro Thr Thr Phe Ser GlnAla Lys Leu Ala Ser Phe 660 665 670 Ile Thr Gln Tyr Ser Thr Gly Gln ValSer Val Glu Ile Glu Trp Glu 675 680 685 Leu Gln Lys Glu Asn Ser Lys ArgTrp Asn Pro Glu Ile Gln Tyr Thr 690 695 700 Ser Asn Tyr Tyr Lys Ser ThrAsn Val Asp Phe Ala Val Asn Thr Asp 705 710 715 720 Gly Thr Tyr Ser GluPro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg 725 730 735 Asn Leu 81 738PRT capsid protein of AAV serotype, clone 44.2 81 Met Ala Ala Asp GlyTyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile ArgGlu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 20 25 30 Lys Ala Asn GlnGln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys TyrLeu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn Ala AlaAsp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 Gln Gln LeuLys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala 85 90 95 Asp Ala GluPhe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110 Asn LeuGly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125 LeuGly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile 145 150155 160 Gly Lys Lys Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln165 170 175 Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly GluPro 180 185 190 Pro Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala AlaGly Gly 195 200 205 Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp GlyVal Gly Ser 210 215 220 Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp LeuGly Asp Arg Val 225 230 235 240 Ile Thr Thr Ser Thr Arg Thr Trp Ala LeuPro Thr Tyr Asn Asn His 245 250 255 Leu Tyr Lys Gln Ile Ser Asn Gly ThrSer Gly Gly Ser Thr Asn Asp 260 265 270 Asn Thr Tyr Phe Gly Tyr Ser ThrPro Trp Gly Tyr Phe Asp Phe Asn 275 280 285 Arg Phe His Cys His Phe SerPro Arg Asp Trp Gln Arg Leu Ile Asn 290 295 300 Asn Asn Trp Gly Phe ArgPro Lys Arg Leu Asn Phe Lys Leu Phe Asn 305 310 315 320 Ile Gln Val LysGlu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala 325 330 335 Asn Asn LeuThr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln 340 345 350 Leu ProTyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe 355 360 365 ProAla Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn 370 375 380Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr 385 390395 400 Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr405 410 415 Gln Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser GlnSer 420 425 430 Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu TyrTyr Leu 435 440 445 Ser Arg Thr Gln Ser Thr Gly Gly Thr Ala Gly Thr GlnGln Leu Leu 450 455 460 Phe Ser Gln Ala Gly Pro Asn Asn Met Ser Ala GlnAla Lys Asn Trp 465 470 475 480 Leu Pro Gly Pro Cys Tyr Arg Gln Gln ArgVal Ser Thr Thr Leu Ser 485 490 495 Gln Asn Asn Asn Ser Asn Phe Ala TrpThr Gly Ala Thr Lys Tyr His 500 505 510 Leu Asn Gly Arg Asp Ser Leu ValAsn Pro Gly Val Ala Met Ala Thr 515 520 525 His Lys Asp Asp Glu Glu ArgPhe Phe Pro Ser Ser Gly Val Leu Met 530 535 540 Phe Gly Lys Gln Gly AlaGly Lys Asp Asn Val Asp Tyr Ser Ser Val 545 550 555 560 Met Leu Thr SerGlu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr 565 570 575 Glu Gln TyrGly Val Val Ala Asp Asn Leu Gln Gln Gln Asn Ala Ala 580 585 590 Pro IleVal Gly Ala Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val 595 600 605 TrpGln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile 610 615 620Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe 625 630635 640 Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val645 650 655 Pro Ala Asp Pro Pro Thr Thr Phe Ser Gln Ala Lys Leu Ala SerPhe 660 665 670 Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile GluTrp Glu 675 680 685 Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu IleGln Tyr Thr 690 695 700 Ser Asn Tyr Tyr Lys Ser Thr Asn Val Asp Phe AlaVal Asn Thr Asp 705 710 715 720 Gly Thr Tyr Ser Glu Pro Arg Pro Ile GlyThr Arg Tyr Leu Thr Arg 725 730 735 Asn Leu 82 738 PRT capsid protein ofAAV serotype, clone 29.3VP1 82 Met Ala Ala Asp Gly Tyr Leu Pro Asp TrpLeu Glu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile Arg Glu Trp Trp Ala LeuLys Pro Gly Ala Pro Lys Pro 20 25 30 Lys Ala Asn Gln Gln Lys Gln Asp AspGly Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Phe AsnGly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn Ala Ala Asp Ala Ala Ala LeuGlu His Asp Lys Ala Tyr Asp 65 70 75 80 Gln Gln Leu Lys Ala Gly Asp AsnPro Tyr Leu Arg Tyr Asn His Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg LeuGln Glu Asp Thr Ser Phe Gly Gly 100 105 110 Asn Leu Gly Arg Ala Val PheGln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125 Leu Gly Leu Val Glu GluGly Ala Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140 Pro Val Glu Pro SerPro Gln Arg Ser Pro Asp Ser Thr Thr Gly Ile 145 150 155 160 Gly Lys LysGly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln 165 170 175 Thr GlyAsp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro 180 185 190 ProAla Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly 195 200 205Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser 210 215220 Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val 225230 235 240 Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn AsnHis 245 250 255 Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser ThrAsn Asp 260 265 270 Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr PheAsp Phe Asn 275 280 285 Arg Phe His Cys His Phe Ser Pro Arg Asp Trp GlnArg Leu Ile Asn 290 295 300 Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu AsnPhe Lys Leu Phe Asn 305 310 315 320 Ile Gln Val Lys Glu Val Thr Gln AsnGlu Gly Thr Lys Thr Ile Ala 325 330 335 Asn Asn Leu Thr Ser Thr Ile GlnVal Phe Thr Asp Ser Glu Tyr Gln 340 345 350 Leu Pro Tyr Val Leu Gly SerAla Arg Gln Gly Cys Leu Pro Pro Phe 355 360 365 Pro Ala Asp Val Phe MetIle Pro Gln Tyr Gly Tyr Leu Thr Leu Asn 370 375 380 Asn Gly Ser Gln AlaVal Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr 385 390 395 400 Phe Pro SerGln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr 405 410 415 Gln PheGlu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser 420 425 430 LeuAsp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu 435 440 445Ser Arg Thr Gln Ser Thr Gly Gly Thr Ala Gly Thr Gln Gln Leu Leu 450 455460 Phe Ser Gln Ala Gly Pro Asn Asn Met Ser Ala Gln Ala Lys Asn Trp 465470 475 480 Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr LeuSer 485 490 495 Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr LysTyr His 500 505 510 Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Val AlaMet Ala Thr 515 520 525 His Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser SerGly Val Leu Met 530 535 540 Phe Gly Lys Gln Gly Ala Gly Lys Gly Asn ValAsp Tyr Ser Ser Val 545 550 555 560 Met Leu Thr Ser Glu Glu Glu Ile LysThr Thr Asn Pro Val Ala Thr 565 570 575 Glu Gln Tyr Gly Val Val Ala AspAsn Leu Gln Gln Gln Asn Ala Ala 580 585 590 Pro Ile Val Gly Ala Val AsnSer Gln Gly Ala Leu Pro Gly Met Val 595 600 605 Trp Gln Asn Arg Asp ValTyr Leu Gln Gly Pro Ile Trp Ala Lys Ile 610 615 620 Pro His Thr Asp GlyAsn Phe His Pro Ser Pro Leu Met Gly Gly Phe 625 630 635 640 Gly Leu LysHis Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val 645 650 655 Pro AlaAsp Pro Pro Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe 660 665 670 IleThr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu 675 680 685Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr 690 695700 Ser Asn Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Asp 705710 715 720 Gly Thr Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu ThrArg 725 730 735 Asn Leu 83 738 PRT capsid protein of AAV serotype, clone29.5VP1 83 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn LeuSer 1 5 10 15 Glu Gly Ile Arg Glu Trp Trp Ala Leu Lys Pro Gly Ala ProLys Pro 20 25 30 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu ValLeu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys GlyGlu Pro 50 55 60 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys AlaTyr Asp 65 70 75 80 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg TyrAsn His Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr SerPhe Gly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys ArgVal Leu Glu Pro 115 120 125 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr AlaPro Gly Lys Lys Arg 130 135 140 Pro Val Glu Pro Ser Pro Gln Arg Ser ProAsp Ser Ser Thr Gly Ile 145 150 155 160 Gly Lys Lys Gly Gln Gln Pro AlaLys Lys Arg Leu Asn Phe Gly Gln 165 170 175 Thr Gly Asp Ser Glu Ser ValPro Asp Pro Gln Pro Ile Gly Glu Pro 180 185 190 Pro Ala Gly Pro Ser GlyLeu Gly Ser Gly Thr Met Ala Ala Gly Gly 195 200 205 Gly Ala Pro Met AlaAsp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser 210 215 220 Ser Ser Gly AsnTrp His Cys Asp Ser Thr Trp Leu Gly Asp Gly Val 225 230 235 240 Ile ThrThr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His 245 250 255 LeuTyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp 260 265 270Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn 275 280285 Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn 290295 300 Asn Asn Trp Gly Phe Arg Pro Lys Ser Leu Asn Phe Lys Leu Phe Asn305 310 315 320 Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys ThrIle Ala 325 330 335 Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp SerGlu Tyr Gln 340 345 350 Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly CysLeu Pro Pro Phe 355 360 365 Pro Ala Asp Val Phe Met Ile Pro Gln Tyr GlyTyr Leu Thr Leu Asn 370 375 380 Asn Gly Ser Gln Ala Val Gly Arg Ser SerPhe Tyr Cys Leu Glu Tyr 385 390 395 400 Phe Pro Ser Gln Met Leu Arg ThrGly Asn Asn Phe Glu Phe Ser Tyr 405 410 415 Gln Phe Glu Asp Val Pro PheHis Ser Ser Tyr Ala His Ser Gln Ser 420 425 430 Leu Asp Arg Leu Met AsnPro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu 435 440 445 Ser Arg Thr Gln SerThr Gly Gly Thr Ala Gly Thr Gln Gln Leu Leu 450 455 460 Phe Ser Gln AlaGly Pro Asn Asn Met Ser Ala Gln Ala Lys Asn Trp 465 470 475 480 Leu ProGly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser 485 490 495 GlnAsn Asp Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His 500 505 510Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr 515 520525 His Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met 530535 540 Phe Gly Lys Gln Gly Ala Gly Lys Asp Asn Val Asp Tyr Ser Ser Val545 550 555 560 Met Leu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro ValAla Thr 565 570 575 Glu Gln Tyr Gly Val Val Ala Asp Asn Leu Gln Gln GlnAsn Ala Ala 580 585 590 Pro Ile Val Gly Ala Val Asn Ser Gln Gly Ala LeuPro Gly Met Val 595 600 605 Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly ProIle Trp Ala Lys Ile 610 615 620 Pro His Thr Asp Gly Asn Phe His Pro SerPro Leu Met Gly Gly Phe 625 630 635 640 Gly Leu Lys His Pro Pro Pro GlnIle Leu Ile Lys Asn Thr Pro Val 645 650 655 Pro Ala Asp Pro Pro Thr ThrPhe Ser Gln Ala Lys Leu Ala Ser Phe 660 665 670 Ile Thr Gln Tyr Ser ThrGly Gln Val Ser Val Glu Ile Glu Trp Glu 675 680 685 Leu Gln Lys Glu AsnSer Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr 690 695 700 Ser Asn Tyr TyrLys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Asp 705 710 715 720 Gly ThrTyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg 725 730 735 AsnLeu 84 738 PRT capsid protein of AAV serotype, clone 42.15 84 Met AlaAla Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15 GluGly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 20 25 30 LysAla Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 35 40 45 GlyTyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 ValAsn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala 85 90 95Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115120 125 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg130 135 140 Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr GlyIle 145 150 155 160 Gly Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu AsnPhe Gly Gln 165 170 175 Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln ProIle Gly Glu Pro 180 185 190 Pro Ala Gly Pro Ser Gly Leu Gly Ser Gly ThrMet Ala Ala Gly Gly 195 200 205 Gly Ala Pro Met Ala Asp Asn Asn Glu GlyAla Asp Gly Val Gly Ser 210 215 220 Ser Ser Gly Asn Trp His Cys Asp SerThr Trp Leu Gly Asp Arg Val 225 230 235 240 Ile Thr Thr Ser Thr Arg ThrTrp Ala Leu Pro Thr Tyr Asn Asn His 245 250 255 Leu Tyr Lys Gln Ile SerAsn Gly Thr Ser Gly Gly Ser Thr Asn Asp 260 265 270 Asn Thr Tyr Phe GlyTyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn 275 280 285 Arg Phe His CysHis Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn 290 295 300 Asn Asn TrpGly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn 305 310 315 320 IleGln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala 325 330 335Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln 340 345350 Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Pro Pro Pro Phe 355360 365 Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn370 375 380 Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu GluTyr 385 390 395 400 Phe Pro Ser Gln Met Arg Arg Thr Gly Asn Asn Phe GluPhe Ser Tyr 405 410 415 Gln Phe Glu Asp Val Pro Phe His Ser Ser Tyr AlaHis Ser Gln Ser 420 425 430 Leu Asp Arg Leu Met Asn Pro Leu Ile Asp GlnTyr Leu Tyr Tyr Leu 435 440 445 Ser Arg Thr Gln Ser Thr Gly Gly Thr AlaGly Thr Gln Gln Leu Leu 450 455 460 Phe Ser Gln Ala Gly Pro Asn Asn MetSer Ala Gln Ala Lys Asn Trp 465 470 475 480 Leu Pro Gly Pro Cys Tyr ArgGln Gln Arg Val Ser Thr Thr Leu Ser 485 490 495 Gln Asn Asn Asn Ser AsnPhe Ala Trp Thr Gly Ala Thr Lys Tyr His 500 505 510 Leu Asn Gly Arg AspSer Leu Val Asn Pro Gly Val Ala Met Ala Thr 515 520 525 His Lys Asp AspGlu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met 530 535 540 Phe Gly LysGln Gly Ala Gly Lys Asp Asn Val Asp Tyr Ser Ser Val 545 550 555 560 MetLeu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr 565 570 575Glu Gln Tyr Gly Val Val Ala Asp Asn Leu Gln Gln Gln Asn Ala Ala 580 585590 Pro Ile Val Gly Ala Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val 595600 605 Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile610 615 620 Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly GlyPhe 625 630 635 640 Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys AsnThr Pro Val 645 650 655 Pro Ala Asp Pro Pro Thr Thr Phe Ser Gln Ala LysLeu Ala Ser Phe 660 665 670 Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser ValGlu Ile Glu Trp Glu 675 680 685 Leu Gln Lys Glu Asn Ser Lys Arg Trp AsnPro Glu Ile Gln Tyr Thr 690 695 700 Ser Asn Tyr Tyr Lys Ser Thr Asn ValAsp Phe Ala Val Asn Thr Glu 705 710 715 720 Gly Thr Tyr Ser Glu Pro ArgPro Ile Gly Thr Arg Tyr Leu Thr Arg 725 730 735 Asn Leu 85 738 PRTcapsid protein of AAV serotype, clone 42.8 85 Met Ala Ala Asp Gly TyrLeu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile Arg GluTrp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 20 25 30 Lys Ala Asn Gln GlnLys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr LeuGly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn Ala Ala AspAla Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 Gln Gln Leu LysAla Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala 85 90 95 Asp Ala Glu PheGln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110 Asn Leu GlyArg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125 Leu GlyLeu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140 ProVal Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile 145 150 155160 Gly Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln 165170 175 Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro180 185 190 Pro Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala GlyGly 195 200 205 Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly ValGly Ser 210 215 220 Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu GlyAsp Arg Val 225 230 235 240 Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu ProThr Tyr Asn Asn His 245 250 255 Leu Tyr Lys Gln Ile Ser Asn Gly Thr SerGly Gly Ser Thr Asn Asp 260 265 270 Asn Thr Tyr Phe Gly Tyr Ser Thr ProTrp Gly Tyr Phe Asp Phe Asn 275 280 285 Arg Phe His Cys His Phe Ser ProArg Asp Trp Gln Arg Leu Ile Asn 290 295 300 Asn Asn Trp Gly Phe Arg ProLys Arg Leu Asn Phe Lys Leu Phe Asn 305 310 315 320 Ile Gln Val Lys GluVal Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala 325 330 335 Asn Asn Leu ThrSer Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln 340 345 350 Leu Pro TyrVal Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe 355 360 365 Pro AlaAsp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn 370 375 380 AsnGly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr 385 390 395400 Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr 405410 415 Gln Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser420 425 430 Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr TyrLeu 435 440 445 Ser Arg Thr Gln Ser Thr Gly Gly Thr Ala Gly Thr Gln GlnLeu Leu 450 455 460 Phe Ser Gln Ala Gly Pro Asn Asn Met Ser Ala Gln AlaLys Asn Trp 465 470 475 480 Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg ValSer Thr Thr Leu Ser 485 490 495 Gln Asn Asn Asn Ser Asn Phe Ala Trp ThrGly Ala Thr Lys Tyr His 500 505 510 Leu Asn Gly Arg Asp Ser Leu Val AsnPro Gly Val Ala Met Ala Thr 515 520 525 His Lys Asp Asp Glu Glu Arg PhePhe Pro Ser Ser Gly Val Leu Met 530 535 540 Phe Gly Lys Gln Gly Ala GlyLys Asp Asn Val Asp Tyr Ser Ser Val 545 550 555 560 Met Leu Thr Ser GluGlu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr 565 570 575 Glu Gln Tyr GlyVal Val Ala Asp Asn Leu Gln Gln Gln Asn Ala Ala 580 585 590 Pro Ile ValGly Ala Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val 595 600 605 Trp GlnAsn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile 610 615 620 ProHis Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe 625 630 635640 Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val 645650 655 Pro Ala Asp Pro Pro Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe660 665 670 Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu TrpGlu 675 680 685 Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile GlnTyr Thr 690 695 700 Ser Asn Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala ValAsn Thr Glu 705 710 715 720 Gly Thr Tyr Ser Glu Pro Arg Pro Ile Gly ThrArg Tyr Leu Thr Arg 725 730 735 Asn Leu 86 733 PRT amino acid of AAVserotype, clone 42.13 86 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu GluAsp Asn Leu Ser 1 5 10 15 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys ProGly Ala Pro Lys Pro 20 25 30 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly ArgGly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly LeuAsp Lys Gly Glu Pro 50 55 60 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu HisAsp Lys Ala Tyr Asp 65 70 75 80 Gln Gln Leu Lys Ala Gly Asp Asn Pro TyrLeu Arg Tyr Asn His Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln GluAsp Thr Ser Phe Gly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe Gln AlaLys Lys Arg Val Leu Glu Pro 115 120 125 Leu Gly Leu Val Glu Glu Gly AlaLys Thr Ala Pro Gly Lys Lys Arg 130 135 140 Pro Ile Glu Ser Pro Asp SerSer Thr Gly Ile Gly Lys Lys Gly Gln 145 150 155 160 Gln Pro Ala Lys LysLys Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu 165 170 175 Ser Val Pro AspPro Gln Pro Ile Gly Glu Pro Pro Ala Gly Pro Ser 180 185 190 Gly Leu GlySer Gly Thr Met Ala Ala Gly Gly Gly Ala Pro Met Ala 195 200 205 Asp AsnAsn Glu Gly Ala Asp Gly Val Gly Ser Ser Ser Gly Asn Trp 210 215 220 HisCys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr 225 230 235240 Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile 245250 255 Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp Asn Thr Tyr Phe Gly260 265 270 Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His CysHis 275 280 285 Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn TrpGly Phe 290 295 300 Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile GlnVal Lys Glu 305 310 315 320 Val Thr Gln Asn Glu Gly Thr Lys Thr Ile AlaAsn Asn Leu Thr Ser 325 330 335 Thr Ile Gln Val Phe Thr Asp Ser Glu TyrGln Leu Pro Tyr Val Leu 340 345 350 Gly Ser Ala His Gln Gly Cys Leu ProPro Phe Pro Ala Asp Val Phe 355 360 365 Met Ile Pro Gln Tyr Gly Tyr LeuThr Leu Asn Asn Gly Ser Gln Ala 370 375 380 Val Gly Arg Ser Ser Phe TyrCys Leu Glu Tyr Phe Pro Ser Gln Met 385 390 395 400 Leu Arg Thr Gly AsnAsn Phe Glu Phe Ser Tyr Gln Phe Glu Asp Val 405 410 415 Pro Phe His SerSer Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met 420 425 430 Asn Pro LeuIle Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg Thr Gln Ser 435 440 445 Thr GlyGly Thr Ala Gly Thr Gln Gln Leu Leu Phe Ser Gln Ala Gly 450 455 460 ProAsn Asn Met Ser Ala Gln Ala Lys Asn Trp Leu Pro Gly Pro Cys 465 470 475480 Tyr Arg Gln Gln Arg Val Ser Thr Thr Val Ser Gln Asn Asn Asn Ser 485490 495 Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn Gly Arg Asp500 505 510 Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr His Lys Gly AspGlu 515 520 525 Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met Phe Gly LysGln Gly 530 535 540 Ala Gly Lys Asp Asn Val Asp Tyr Ser Ser Val Met LeuThr Ser Glu 545 550 555 560 Glu Glu Ile Lys Thr Thr Asn Pro Val Ala ThrGlu Gln Tyr Gly Val 565 570 575 Val Ala Asp Asn Leu Gln Gln Gln Asn AlaAla Pro Ile Val Gly Ala 580 585 590 Val Asn Ser Gln Gly Ala Leu Pro GlyMet Val Trp Gln Asn Arg Asp 595 600 605 Val Tyr Leu Gln Gly Pro Ile TrpAla Lys Ile Pro His Thr Asp Gly 610 615 620 Asn Phe His Pro Ser Pro LeuMet Gly Gly Phe Gly Leu Lys His Pro 625 630 635 640 Pro Pro Gln Ile LeuIle Lys Asn Thr Pro Val Pro Ala Asp Pro Pro 645 650 655 Thr Thr Phe SerGln Ala Lys Leu Ala Ser Phe Ile Thr Gln Tyr Ser 660 665 670 Thr Gly GlnVal Ser Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn 675 680 685 Ser LysArg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys 690 695 700 SerThr Asn Val Asp Phe Ala Val Asn Thr Glu Gly Thr Tyr Ser Glu 705 710 715720 Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Ser Leu 725 730 87 733PRT capsid protein of AAV serotype, clone 42.3A 87 Met Ala Ala Asp GlyHis Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile ArgGlu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 20 25 30 Lys Ala Asn GlnGln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys TyrLeu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn Ala AlaAsp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 Gln Gln LeuLys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala 85 90 95 Asp Ala GluPhe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110 Asn LeuGly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125 LeuGly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly Lys Lys Gly Gln 145 150155 160 Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu165 170 175 Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro Ala Gly ProSer 180 185 190 Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly Ala ProMet Ala 195 200 205 Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser SerGly Asn Trp 210 215 220 His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val IleThr Thr Ser Thr 225 230 235 240 Arg Thr Trp Ala Leu Pro Thr Tyr Asn AsnHis Leu Tyr Lys Gln Ile 245 250 255 Ser Asn Gly Thr Ser Gly Gly Ser ThrAsn Asp Asn Thr Tyr Phe Gly 260 265 270 Tyr Ser Thr Pro Trp Gly Tyr PheAsp Phe Asn Arg Phe His Cys His 275 280 285 Phe Ser Pro Arg Asp Trp GlnArg Leu Ile Asn Asn Ser Trp Gly Phe 290 295 300 Arg Pro Lys Arg Leu AsnPhe Lys Leu Phe Asn Ile Gln Val Lys Glu 305 310 315 320 Val Thr Gln AsnGlu Gly Thr Lys Thr Ile Ala Asn Asn Leu Thr Ser 325 330 335 Thr Ile GlnVal Phe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu 340 345 350 Gly SerAla His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe 355 360 365 MetIle Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ala 370 375 380Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met 385 390395 400 Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr Gln Phe Glu Asp Val405 410 415 Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg LeuMet 420 425 430 Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg ThrGln Ser 435 440 445 Thr Gly Gly Thr Ala Gly Thr Gln Gln Leu Leu Phe SerGln Ala Gly 450 455 460 Pro Asn Asn Met Ser Ala Gln Ala Lys Asn Trp LeuPro Gly Pro Cys 465 470 475 480 Tyr Arg Gln Gln Arg Val Ser Thr Thr LeuSer Gln Asn Asn Asn Ser 485 490 495 Asn Phe Ala Trp Thr Gly Ala Thr LysTyr His Leu Asn Gly Arg Asp 500 505 510 Ser Leu Val Asn Pro Gly Val AlaMet Ala Thr His Lys Asp Asp Glu 515 520 525 Glu Arg Phe Phe Pro Ser SerGly Val Leu Met Phe Gly Lys Gln Gly 530 535 540 Ala Gly Lys Asp Asn ValAsp Tyr Ser Ser Val Met Leu Thr Ser Glu 545 550 555 560 Glu Glu Ile LysThr Thr Asn Pro Val Ala Thr Glu Gln Tyr Gly Val 565 570 575 Val Ala AspAsn Leu Gln Gln Gln Asn Ala Ala Pro Ile Val Gly Ala 580 585 590 Val AsnSer Gln Gly Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp 595 600 605 ValTyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly 610 615 620Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro 625 630635 640 Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asp Pro Pro645 650 655 Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe Ile Thr Gln TyrSer 660 665 670 Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln LysGlu Asn 675 680 685 Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser AsnTyr Tyr Lys 690 695 700 Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu GlyThr Tyr Ser Glu 705 710 715 720 Pro Arg Pro Ile Gly Thr Arg Tyr Leu ThrArg Asn Leu 725 730 88 731 PRT capsid protein of AAV serotype, clone42.4 88 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser1 5 10 15 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro LysPro 20 25 30 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val LeuPro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly GluPro 50 55 60 Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala TyrAsp 65 70 75 80 Lys Gln Leu Glu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr AsnHis Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser PheGly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg ValLeu Glu Pro 115 120 125 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala ProGly Lys Lys Arg 130 135 140 Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly IleGly Lys Lys Gly Gln 145 150 155 160 Gln Pro Ala Lys Lys Lys Leu Asn PheGly Gln Thr Gly Asp Ser Glu 165 170 175 Ser Val Pro Asp Pro Gln Pro IleGly Glu Pro Pro Ala Gly Pro Ser 180 185 190 Gly Leu Gly Ser Gly Thr MetAla Ala Gly Gly Gly Ala Pro Met Ala 195 200 205 Asp Asn Asn Glu Gly AlaAsp Gly Val Gly Asn Ala Ser Gly Asn Trp 210 215 220 His Cys Asp Ser ThrTrp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr 225 230 235 240 Arg Thr TrpAla Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile 245 250 255 Ser SerGln Ser Gly Ala Thr Asn Asp Asn His Phe Phe Gly Tyr Ser 260 265 270 ThrPro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser 275 280 285Ser Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro 290 295300 Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr 305310 315 320 Gln Asn Glu Gly Thr Lys Thr Ile Ala Asn Asn Leu Thr Ser ThrIle 325 330 335 Gln Val Phe Thr Asp Ser Glu Tyr Arg Leu Pro Tyr Val LeuGly Ser 340 345 350 Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp ValPhe Met Ile 355 360 365 Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly SerGln Ala Val Gly 370 375 380 Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe ProSer Gln Met Leu Arg 385 390 395 400 Thr Gly Asn Asn Phe Glu Phe Ser TyrGln Phe Glu Asp Val Pro Phe 405 410 415 His Ser Ser Tyr Ala His Ser GlnSer Leu Asp Arg Leu Met Asn Pro 420 425 430 Leu Ile Asp Gln Tyr Leu TyrTyr Leu Ser Arg Thr Gln Ser Thr Gly 435 440 445 Gly Thr Ala Gly Thr GlnGln Leu Leu Phe Ser Gln Ala Gly Pro Asn 450 455 460 Asn Met Ser Ala GlnAla Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg 465 470 475 480 Gln Gln ArgVal Ser Thr Thr Leu Ser Gln Asn Asn Asn Ser Asn Phe 485 490 495 Ala TrpThr Gly Ala Thr Lys Tyr His Leu Asn Gly Arg Asp Ser Leu 500 505 510 ValAsn Pro Gly Val Ala Met Ala Thr His Lys Asp Asp Glu Glu Arg 515 520 525Phe Phe Pro Ser Ser Gly Val Leu Met Phe Gly Lys Gln Gly Ala Gly 530 535540 Lys Asp Asn Val Asp Tyr Ser Ser Val Met Leu Thr Ser Glu Glu Glu 545550 555 560 Ile Lys Thr Thr Asn Pro Val Ala Thr Glu Gln Tyr Gly Val ValAla 565 570 575 Asp Asn Leu Gln Gln Gln Asn Ala Ala Pro Ile Val Gly AlaVal Asn 580 585 590 Ser Gln Gly Ala Leu Pro Gly Met Val Trp Gln Asn ArgAsp Val Tyr 595 600 605 Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His ThrAsp Gly Asn Phe 610 615 620 His Pro Ser Pro Leu Met Gly Gly Phe Gly LeuLys His Pro Pro Pro 625 630 635 640 Gln Ile Leu Ile Lys Asn Thr Pro ValPro Ala Asp Pro Pro Thr Thr 645 650 655 Phe Ser Gln Ala Lys Pro Ala SerPhe Ile Thr Gln Tyr Ser Thr Gly 660 665 670 Gln Val Ser Val Glu Ile GluTrp Glu Leu Gln Lys Glu Asn Ser Lys 675 680 685 Arg Trp Asn Pro Glu IleGln Tyr Thr Ser Asn Tyr Tyr Lys Ser Thr 690 695 700 Asn Val Asp Phe AlaVal Asn Thr Glu Gly Thr Tyr Ser Glu Pro Arg 705 710 715 720 Pro Ile GlyThr Arg Tyr Leu Thr Arg Asn Leu 725 730 89 731 PRT capsid protein of AAVserotype, clone 42.5A 89 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu GluAsp Asn Leu Ser 1 5 10 15 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys ProGly Ala Pro Lys Pro 20 25 30 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly ArgGly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly LeuAsp Lys Gly Glu Pro 50 55 60 Val Asn Glu Ala Asp Ala Ala Ala Leu Glu HisAsp Lys Ala Tyr Asp 65 70 75 80 Lys Gln Leu Glu Gln Gly Asp Asn Pro TyrLeu Lys Tyr Asn His Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln GluAsp Thr Ser Phe Gly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe Arg AlaLys Lys Arg Val Leu Glu Pro 115 120 125 Leu Gly Leu Val Glu Glu Gly AlaLys Thr Ala Pro Gly Lys Lys Arg 130 135 140 Pro Ile Glu Ser Pro Asp SerSer Thr Gly Ile Gly Lys Lys Gly Gln 145 150 155 160 Gln Pro Ala Lys LysLys Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu 165 170 175 Ser Val Pro AspPro Gln Pro Leu Gly Glu Pro Pro Ala Ala Pro Ser 180 185 190 Gly Leu GlySer Gly Thr Met Ala Ala Gly Gly Gly Ala Pro Met Ala 195 200 205 Asp AsnAsn Glu Gly Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp 210 215 220 HisCys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr 225 230 235240 Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile 245250 255 Ser Ser Gln Ser Gly Ala Thr Asn Asp Asn His Phe Phe Gly Tyr Ser260 265 270 Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His PheSer 275 280 285 Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Arg Gly PheArg Pro 290 295 300 Arg Lys Leu Arg Phe Lys Leu Phe Asn Ile Gln Val LysGlu Val Thr 305 310 315 320 Thr Asn Asp Gly Val Thr Thr Ile Ala Asn AsnLeu Thr Ser Thr Ile 325 330 335 Gln Val Phe Ser Asp Ser Glu Tyr Gln LeuPro Tyr Val Leu Gly Ser 340 345 350 Ala His Gln Gly Cys Leu Pro Pro PhePro Ala Asp Val Phe Met Ile 355 360 365 Pro Gln Tyr Gly Tyr Leu Thr LeuAsn Asn Gly Ser Gln Ser Val Gly 370 375 380 Arg Ser Ser Phe Tyr Cys LeuGlu Tyr Phe Pro Ser Gln Met Leu Arg 385 390 395 400 Thr Gly Asn Asn PheGlu Phe Ser Tyr Gln Phe Glu Asp Val Pro Phe 405 410 415 His Ser Ser TyrAla His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro 420 425 430 Leu Ile AspGln Tyr Leu Tyr Tyr Leu Ser Arg Thr Gln Ser Thr Gly 435 440 445 Gly ThrAla Gly Thr Gln Gln Leu Leu Phe Ser Gln Ala Gly Pro Asn 450 455 460 AsnMet Ser Ala Gln Ala Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg 465 470 475480 Gln Gln Arg Val Ser Thr Thr Leu Ser Gln Asn Asn Asn Ser Asn Phe 485490 495 Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn Gly Arg Asp Ser Leu500 505 510 Val Asn Pro Gly Val Ala Met Ala Thr His Lys Asp Asp Glu GluArg 515 520 525 Phe Phe Pro Ser Ser Gly Val Leu Met Phe Gly Lys Gln GlyAla Gly 530 535 540 Lys Asp Asn Val Asp Tyr Ser Ser Val Met Leu Thr SerGlu Glu Glu 545 550 555 560 Ile Lys Thr Thr Asn Pro Val Ala Thr Glu GlnTyr Gly Val Val Ala 565 570 575 Asp Asn Leu Gln Gln Gln Asn Ala Ala ProIle Val Gly Ala Val Asn 580 585 590 Ser Gln Gly Ala Leu Pro Gly Met AlaTrp Gln Asn Arg Asp Val Tyr 595 600 605 Leu Gln Gly Pro Ile Trp Ala LysIle Pro His Thr Asp Gly Asn Phe 610 615 620 His Pro Ser Pro Leu Met GlyGly Phe Gly Leu Lys His Pro Pro Pro 625 630 635 640 Gln Ile Leu Ile LysAsn Thr Pro Val Pro Ala Asp Pro Pro Thr Thr 645 650 655 Phe Ser Gln AlaLys Leu Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly 660 665 670 Gln Val SerVal Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys 675 680 685 Arg TrpAsn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Tyr Lys Ser Thr 690 695 700 AsnVal Asp Phe Ala Val Asn Thr Glu Gly Thr Tyr Ser Glu Pro Arg 705 710 715720 Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu 725 730 90 733 PRTcapsid protein of AAV serotype, clone 42.1B 90 Met Ala Ala Asp Gly TyrLeu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile Arg GluTrp Trp Asp Leu Arg Pro Gly Ala Pro Lys Pro 20 25 30 Lys Ala Asn Gln GlnLys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr LeuGly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn Glu Ala AspAla Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 Lys Gln Leu GluGln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala 85 90 95 Asp Ala Glu PheGln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110 Asn Leu GlyArg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125 Leu GlyLeu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140 ProIle Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly Lys Lys Gly Gln 145 150 155160 Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu 165170 175 Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro Pro Ala Gly Pro Ser180 185 190 Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly Ala Pro MetAla 195 200 205 Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser Ser Ser GlyAsn Trp 210 215 220 His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile ThrThr Ser Thr 225 230 235 240 Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn HisLeu Tyr Lys Gln Ile 245 250 255 Ser Asn Gly Thr Ser Gly Gly Ser Thr AsnAsp Asn Thr Tyr Phe Gly 260 265 270 Tyr Ser Thr Pro Trp Gly Tyr Phe AspPhe Asn Arg Phe His Cys His 275 280 285 Phe Ser Pro Arg Asp Trp Gln ArgLeu Ile Asn Asn Asn Trp Gly Phe 290 295 300 Arg Pro Lys Arg Leu Asn PheLys Leu Phe Asn Ile Gln Val Lys Glu 305 310 315 320 Val Thr Gln Asn GluGly Thr Lys Thr Ile Ala Asn Asn Leu Thr Ser 325 330 335 Thr Ile Gln ValPhe Thr Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu 340 345 350 Gly Ser AlaHis Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe 355 360 365 Met IlePro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ala 370 375 380 ValGly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met 385 390 395400 Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr Gln Phe Glu Asp Val 405410 415 Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met420 425 430 Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ser Arg Thr GlnSer 435 440 445 Thr Gly Gly Thr Ala Gly Thr Gln Gln Leu Leu Phe Ser GlnAla Gly 450 455 460 Pro Asn Asn Met Ser Ala Gln Ala Lys Asn Trp Leu ProGly Pro Cys 465 470 475 480 Tyr Arg Gln Gln Arg Val Ser Thr Thr Val SerGln Asn Asn Asn Ser 485 490 495 Asn Phe Ala Trp Thr Gly Ala Thr Lys TyrHis Leu Asn Gly Arg Asp 500 505 510 Ser Leu Val Asn Pro Gly Val Ala MetAla Thr His Lys Gly Asp Glu 515 520 525 Glu Arg Phe Phe Pro Ser Ser GlyVal Leu Met Phe Gly Lys Gln Gly 530 535 540 Ala Gly Lys Asp Asn Val AspTyr Ser Ser Val Met Leu Thr Ser Glu 545 550 555 560 Glu Glu Ile Lys ThrThr Asn Pro Val Ala Thr Glu Gln Tyr Gly Val 565 570 575 Val Ala Asp AsnLeu Gln Gln Gln Asn Ala Ala Pro Ile Val Gly Ala 580 585 590 Val Asn SerGln Gly Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp 595 600 605 Val TyrLeu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly 610 615 620 AsnPhe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro 625 630 635640 Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asp Pro Pro 645650 655 Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe Ile Thr Gln Tyr Ser660 665 670 Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys GluAsn 675 680 685 Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn TyrTyr Lys 690 695 700 Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu Gly ThrTyr Ser Glu 705 710 715 720 Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr ArgAsn Leu 725 730 91 738 PRT capsid protein of AAV serotype, clone 42.5B91 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 510 15 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 2025 30 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 3540 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 5055 60 Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 6570 75 80 Lys Gln Leu Glu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly100 105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu GluPro 115 120 125 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly LysLys Arg 130 135 140 Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser SerThr Gly Ile 145 150 155 160 Gly Lys Thr Gly Gln Gln Pro Ala Lys Lys ArgLeu Asn Phe Gly Gln 165 170 175 Thr Gly Asp Ser Glu Ser Val Pro Asp ProGln Pro Ile Gly Glu Pro 180 185 190 Pro Ala Gly Pro Ser Gly Leu Gly SerGly Thr Met Ala Ala Gly Gly 195 200 205 Gly Ala Pro Met Ala Asp Asn AsnGlu Gly Ala Asp Gly Val Gly Ser 210 215 220 Ser Ser Gly Asn Trp His CysAsp Ser Thr Trp Leu Gly Asp Arg Val 225 230 235 240 Ile Thr Thr Ser ThrArg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His 245 250 255 Leu Tyr Lys GlnIle Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp 260 265 270 Asn Thr TyrPhe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn 275 280 285 Arg PheHis Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn 290 295 300 AsnAsn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn 305 310 315320 Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala 325330 335 Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln340 345 350 Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro ProPhe 355 360 365 Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu ThrLeu Asn 370 375 380 Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr CysLeu Glu Tyr 385 390 395 400 Phe Pro Ser Gln Met Leu Arg Thr Gly Asn AsnPhe Glu Phe Ser Tyr 405 410 415 Gln Phe Glu Asp Val Pro Phe His Ser SerTyr Ala His Ser Gln Ser 420 425 430 Leu Asp Arg Leu Met Asn Pro Leu IleAsp Gln Tyr Leu Tyr Tyr Leu 435 440 445 Ser Arg Thr Gln Ser Thr Gly GlyThr Ala Gly Thr Gln Gln Leu Leu 450 455 460 Phe Ser Gln Ala Gly Pro AsnAsn Met Ser Ala Gln Ala Lys Asn Trp 465 470 475 480 Leu Pro Gly Pro CysTyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser 485 490 495 Gln Asn Asn AsnSer Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His 500 505 510 Leu Asn GlyArg Asp Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr 515 520 525 His LysAsp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met 530 535 540 PheGly Lys Gln Gly Ala Gly Lys Asp Asn Val Asp Tyr Ser Ser Val 545 550 555560 Met Leu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr 565570 575 Glu Gln Tyr Gly Val Val Ala Asp Asn Leu Gln Gln Gln Asn Ala Ala580 585 590 Pro Ile Val Gly Ala Val Asn Ser Gln Gly Ala Leu Pro Gly MetVal 595 600 605 Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp AlaLys Ile 610 615 620 Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu MetGly Gly Phe 625 630 635 640 Gly Leu Lys His Pro Pro Pro Gln Ile Leu IleLys Asn Thr Pro Val 645 650 655 Pro Ala Asp Pro Pro Thr Thr Phe Ser GlnAla Lys Leu Ala Ser Phe 660 665 670 Ile Thr Gln Tyr Ser Thr Gly Gln ValSer Val Glu Ile Glu Trp Glu 675 680 685 Leu Gln Lys Glu Asn Ser Lys ArgTrp Asn Pro Glu Ile Gln Tyr Thr 690 695 700 Ser Asn Tyr Tyr Lys Ser ThrAsn Val Asp Phe Ala Val Asn Thr Glu 705 710 715 720 Gly Thr Tyr Ser GluPro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg 725 730 735 Asn Leu 92 738PRT capsid protein of AAV serotype, clone 43.1 92 Met Ala Ala Asp GlyTyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile ArgGlu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 20 25 30 Lys Ala Asn GlnGln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys TyrLeu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn Ala AlaAsp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 Gln Gln LeuLys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala 85 90 95 Asp Ala GluPhe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110 Asn LeuGly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125 LeuGly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile 145 150155 160 Gly Lys Lys Gly His Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln165 170 175 Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly GluPro 180 185 190 Pro Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala AlaGly Gly 195 200 205 Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp GlyVal Gly Ser 210 215 220 Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp LeuGly Asp Arg Val 225 230 235 240 Ile Thr Thr Ser Thr Arg Thr Trp Ala LeuPro Thr Tyr Asn Asn His 245 250 255 Leu Tyr Lys Gln Ile Ser Asn Gly ThrSer Gly Gly Ser Thr Asn Asp 260 265 270 Asn Thr Tyr Phe Gly Tyr Ser ThrPro Trp Gly Tyr Phe Asp Phe Asn 275 280 285 Arg Phe His Cys His Phe SerPro Arg Asp Trp Gln Arg Leu Ile Asn 290 295 300 Asn Asn Trp Gly Phe ArgPro Lys Arg Leu Asn Phe Lys Leu Phe Asn 305 310 315 320 Ile Gln Val LysGlu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala 325 330 335 Asn Asn LeuThr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln 340 345 350 Leu ProTyr Val Pro Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe 355 360 365 ProAla Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn 370 375 380Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr 385 390395 400 Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr405 410 415 Thr Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser GlnSer 420 425 430 Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu TyrTyr Leu 435 440 445 Ser Arg Thr Gln Ser Thr Gly Gly Thr Gln Gly Thr GlnGln Leu Leu 450 455 460 Phe Ser Gln Ala Gly Pro Ala Asn Met Ser Ala GlnAla Lys Asn Trp 465 470 475 480 Leu Pro Gly Pro Cys Tyr Arg Gln Gln ArgVal Ser Thr Thr Leu Ser 485 490 495 Gln Asn Asn Asn Ser Asn Phe Ala TrpThr Gly Ala Thr Lys Tyr His 500 505 510 Leu Asn Gly Arg Asp Ser Leu ValAsn Pro Gly Val Ala Met Ala Thr 515 520 525 His Lys Asp Asp Glu Glu ArgPhe Phe Pro Ser Ser Gly Val Leu Met 530 535 540 Phe Gly Lys Gln Gly AlaGly Lys Asp Asn Val Asp Tyr Ser Ser Val 545 550 555 560 Met Leu Thr SerGlu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr 565 570 575 Glu Gln TyrGly Val Val Ala Asp Asn Leu Gln Gln Thr Asn Gly Ala 580 585 590 Pro IleVal Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val 595 600 605 TrpGln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile 610 615 620Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe 625 630635 640 Gly Leu Lys His Pro Pro Pro Gln Ile Leu Val Lys Asn Thr Pro Val645 650 655 Pro Ala Asp Pro Pro Thr Thr Phe Ser Gln Ala Lys Leu Ala SerPhe 660 665 670 Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile GluTrp Glu 675 680 685 Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu IleGln Tyr Thr 690 695 700 Ser Asn Tyr Tyr Lys Ser Thr Asn Val Asp Phe AlaVal Asn Thr Glu 705 710 715 720 Gly Thr Tyr Ser Glu Pro Arg Pro Ile GlyThr Arg Tyr Leu Thr Arg 725 730 735 Asn Leu 93 738 PRT capsid protein ofAAV serotype, clone 43.12 93 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp LeuGlu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile Arg Glu Trp Trp Asp Leu LysPro Gly Ala Pro Lys Pro 20 25 30 Lys Ala Asn Gln Gln Lys Gln Asp Asp GlyArg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn GlyLeu Asp Lys Gly Glu Pro 50 55 60 Val Asn Ala Ala Asp Ala Ala Ala Leu GluHis Asp Lys Ala Tyr Asp 65 70 75 80 Gln Gln Leu Lys Ala Gly Asp Asn ProTyr Leu Arg Tyr Asn His Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu GlnGlu Asp Thr Ser Phe Gly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe GlnAla Lys Lys Arg Val Leu Glu Pro 115 120 125 Leu Gly Leu Val Glu Glu GlyAla Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140 Pro Val Glu Pro Ser ProGln Arg Ser Pro Asp Ser Ser Thr Gly Ile 145 150 155 160 Gly Lys Lys GlyHis Gln Pro Ala Arg Lys Arg Leu Asn Phe Gly Gln 165 170 175 Thr Gly AspSer Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro 180 185 190 Pro AlaGly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly 195 200 205 GlyAla Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser 210 215 220Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val 225 230235 240 Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His245 250 255 Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr AsnAsp 260 265 270 Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe AspPhe Asn 275 280 285 Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln ArgLeu Ile Asn 290 295 300 Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn PheLys Leu Phe Asn 305 310 315 320 Ile Gln Val Lys Glu Val Thr Gln Asn GluGly Thr Lys Thr Ile Ala 325 330 335 Asn Asn Leu Thr Ser Thr Ile Gln ValPhe Thr Asp Ser Glu Tyr Gln 340 345 350 Leu Pro Tyr Val Leu Gly Ser AlaHis Gln Gly Cys Leu Pro Pro Phe 355 360 365 Pro Ala Asp Val Phe Met IlePro Gln Tyr Gly Tyr Leu Thr Leu Asn 370 375 380 Asn Gly Ser Gln Ala ValGly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr 385 390 395 400 Phe Pro Ser GlnMet Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr 405 410 415 Thr Phe GluAsp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser 420 425 430 Leu AspArg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu 435 440 445 SerArg Thr Gln Ser Thr Gly Gly Thr Gln Gly Thr Gln Gln Leu Leu 450 455 460Phe Ser Gln Ala Gly Pro Ala Asn Met Ser Ala Gln Ala Lys Asn Trp 465 470475 480 Leu Pro Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser485 490 495 Gln Asn Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys TyrHis 500 505 510 Leu Asn Gly Arg Asp Ser Leu Val Asn Pro Gly Val Ala MetAla Thr 515 520 525 His Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser GlyVal Leu Met 530 535 540 Phe Gly Lys Gln Gly Ala Gly Lys Asp Asn Val AspTyr Ser Ser Val 545 550 555 560 Met Leu Thr Ser Glu Glu Glu Ile Lys ThrThr Asn Pro Val Ala Thr 565 570 575 Glu Gln Tyr Gly Val Val Ala Asp AsnLeu Gln Gln Thr Asn Gly Ala 580 585 590 Pro Ile Val Gly Thr Val Asn SerGln Gly Ala Leu Pro Gly Met Val 595 600 605 Trp Gln Asn Arg Asp Val TyrLeu Gln Gly Pro Ile Trp Ala Lys Ile 610 615 620 Pro His Thr Asp Gly AsnPhe His Pro Ser Pro Leu Met Gly Gly Phe 625 630 635 640 Gly Leu Lys HisPro Pro Pro Gln Ile Leu Val Lys Asn Thr Pro Val 645 650 655 Pro Ala AspPro Pro Thr Thr Phe Ser Gln Ala Lys Leu Ala Ser Phe 660 665 670 Ile ThrGln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu 675 680 685 LeuGln Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr 690 695 700Ser Asn Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu 705 710715 720 Gly Thr Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg725 730 735 Asn Leu 94 738 PRT capsid protein of AAV serotype, clone43.5 94 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser1 5 10 15 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro LysPro 20 25 30 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val LeuPro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly GluPro 50 55 60 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala TyrAsp 65 70 75 80 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr AsnHis Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser PheGly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg ValLeu Glu Pro 115 120 125 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala ProGly Lys Lys Arg 130 135 140 Pro Val Glu Pro Ser Pro Gln Arg Ser Pro AspSer Ser Thr Gly Ile 145 150 155 160 Gly Lys Lys Gly His Gln Pro Ala ArgLys Arg Leu Asn Phe Gly Gln 165 170 175 Thr Gly Asp Ser Glu Ser Val ProAsp Pro Gln Pro Ile Gly Glu Pro 180 185 190 Pro Ala Gly Pro Ser Gly LeuGly Ser Gly Thr Met Ala Ala Gly Gly 195 200 205 Gly Ala Pro Met Ala AspAsn Asn Glu Gly Ala Asp Gly Val Gly Ser 210 215 220 Ser Ser Gly Asn TrpHis Cys Asp Ser Thr Trp Leu Gly Asp Arg Val 225 230 235 240 Ile Thr ThrSer Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His 245 250 255 Leu TyrLys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp 260 265 270 AsnThr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn 275 280 285Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn 290 295300 Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn 305310 315 320 Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr IleAla 325 330 335 Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser GluTyr Gln 340 345 350 Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys LeuPro Pro Phe 355 360 365 Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly TyrLeu Thr Leu Asn 370 375 380 Asn Gly Ser Gln Ala Val Gly Arg Ser Ser PheTyr Cys Leu Glu Tyr 385 390 395 400 Phe Pro Ser Gln Met Leu Arg Thr GlyAsn Asn Phe Glu Phe Ser Tyr 405 410 415 Thr Phe Glu Asp Val Pro Phe HisSer Ser Tyr Ala His Ser Gln Ser 420 425 430 Leu Asp Arg Leu Met Asn ProLeu Ile Asp Gln Tyr Leu Tyr Tyr Leu 435 440 445 Ser Arg Thr Gln Ser ThrGly Gly Thr Gln Gly Thr Gln Gln Leu Leu 450 455 460 Phe Ser Gln Ala GlyPro Ala Asn Met Ser Ala Gln Ala Lys Asn Trp 465 470 475 480 Leu Pro GlyPro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Leu Ser 485 490 495 Gln AsnAsn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His 500 505 510 LeuAsn Gly Arg Asp Ser Leu Val Asn Pro Gly Val Ala Met Ala Thr 515 520 525His Lys Asp Asp Glu Glu Arg Phe Phe Pro Ser Ser Gly Val Leu Met 530 535540 Phe Gly Lys Gln Gly Ala Gly Lys Asp Asn Val Asp Tyr Ser Ser Val 545550 555 560 Met Leu Thr Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val AlaThr 565 570 575 Glu Gln Tyr Gly Val Val Ala Asp Asn Leu Gln Gln Thr AsnGly Ala 580 585 590 Pro Ile Val Gly Thr Val Asn Ser Gln Gly Ala Leu ProGly Met Val 595 600 605 Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro IleTrp Ala Lys Ile 610 615 620 Pro His Thr Asp Gly Asn Phe His Pro Ser ProLeu Met Gly Gly Phe 625 630 635 640 Gly Leu Lys His Pro Pro Pro Gln IleLeu Val Lys Asn Thr Pro Val 645 650 655 Pro Ala Asp Pro Pro Thr Thr PheSer Gln Ala Lys Leu Ala Ser Phe 660 665 670 Ile Thr Gln Tyr Ser Thr GlyGln Val Ser Val Glu Ile Glu Trp Glu 675 680 685 Leu Gln Lys Glu Asn SerLys Arg Trp Asn Pro Glu Ile Gln Tyr Thr 690 695 700 Ser Asn Tyr Tyr LysSer Thr Asn Val Asp Phe Ala Val Asn Thr Glu 705 710 715 720 Gly Thr TyrSer Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg 725 730 735 Asn Leu95 738 PRT capsid protein of AAV serotype, clone AAV8 95 Met Ala Ala AspGly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15 Glu Gly IleArg Glu Trp Trp Ala Leu Lys Pro Gly Ala Pro Lys Pro 20 25 30 Lys Ala AsnGln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr LysTyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn AlaAla Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 Gln GlnLeu Gln Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala 85 90 95 Asp AlaGlu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110 AsnLeu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg 130 135140 Pro Val Glu Pro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile 145150 155 160 Gly Lys Lys Gly Gln Gln Pro Ala Arg Lys Arg Leu Asn Phe GlyGln 165 170 175 Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu GlyGlu Pro 180 185 190 Pro Ala Ala Pro Ser Gly Val Gly Pro Asn Thr Met AlaAla Gly Gly 195 200 205 Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala AspGly Val Gly Ser 210 215 220 Ser Ser Gly Asn Trp His Cys Asp Ser Thr TrpLeu Gly Asp Arg Val 225 230 235 240 Ile Thr Thr Ser Thr Arg Thr Trp AlaLeu Pro Thr Tyr Asn Asn His 245 250 255 Leu Tyr Lys Gln Ile Ser Asn GlyThr Ser Gly Gly Ala Thr Asn Asp 260 265 270 Asn Thr Tyr Phe Gly Tyr SerThr Pro Trp Gly Tyr Phe Asp Phe Asn 275 280 285 Arg Phe His Cys His PheSer Pro Arg Asp Trp Gln Arg Leu Ile Asn 290 295 300 Asn Asn Trp Gly PheArg Pro Lys Arg Leu Ser Phe Lys Leu Phe Asn 305 310 315 320 Ile Gln ValLys Glu Val Thr Gln Asn Glu Gly Thr Lys Thr Ile Ala 325 330 335 Asn AsnLeu Thr Ser Thr Ile Gln Val Phe Thr Asp Ser Glu Tyr Gln 340 345 350 LeuPro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe 355 360 365Pro Ala Asp Val Phe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn 370 375380 Asn Gly Ser Gln Ala Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr 385390 395 400 Phe Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe ThrTyr 405 410 415 Thr Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His SerGln Ser 420 425 430 Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr LeuTyr Tyr Leu 435 440 445 Ser Arg Thr Gln Thr Thr Gly Gly Thr Ala Asn ThrGln Thr Leu Gly 450 455 460 Phe Ser Gln Gly Gly Pro Asn Thr Met Ala AsnGln Ala Lys Asn Trp 465 470 475 480 Leu Pro Gly Pro Cys Tyr Arg Gln GlnArg Val Ser Thr Thr Thr Gly 485 490 495 Gln Asn Asn Asn Ser Asn Phe AlaTrp Thr Ala Gly Thr Lys Tyr His 500 505 510 Leu Asn Gly Arg Asn Ser LeuAla Asn Pro Gly Ile Ala Met Ala Thr 515 520 525 His Lys Asp Asp Glu GluArg Phe Phe Pro Ser Asn Gly Ile Leu Ile 530 535 540 Phe Gly Lys Gln AsnAla Ala Arg Asp Asn Ala Asp Tyr Ser Asp Val 545 550 555 560 Met Leu ThrSer Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr 565 570 575 Glu GluTyr Gly Ile Val Ala Asp Asn Leu Gln Gln Gln Asn Thr Ala 580 585 590 ProGln Ile Gly Thr Val Asn Ser Gln Gly Ala Leu Pro Gly Met Val 595 600 605Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile 610 615620 Pro His Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe 625630 635 640 Gly Leu Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr ProVal 645 650 655 Pro Ala Asp Pro Pro Thr Thr Phe Asn Gln Ser Lys Leu AsnSer Phe 660 665 670 Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser Val Glu IleGlu Trp Glu 675 680 685 Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn Pro GluIle Gln Tyr Thr 690 695 700 Ser Asn Tyr Tyr Lys Ser Thr Ser Val Asp PheAla Val Asn Thr Glu 705 710 715 720 Gly Val Tyr Ser Glu Pro Arg Pro IleGly Thr Arg Tyr Leu Thr Arg 725 730 735 Asn Leu 96 736 PRT capsidprotein of AAV serotype, clone 43.21 96 Met Ala Ala Asp Gly Tyr Leu ProAsp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile Arg Glu Trp TrpAsp Leu Lys Pro Gly Ala Pro Lys Pro 20 25 30 Lys Ala Asn Gln Gln Lys GlnAsp Asp Gly Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly ProPhe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn Ala Ala Asp Ala AlaAla Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 Gln Gln Leu Lys Ala GlyAsp Asn Pro Tyr Leu Arg Tyr Asn His Ala 85 90 95 Asp Ala Glu Phe Gln GluArg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110 Asn Leu Gly Arg AlaVal Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125 Leu Gly Leu ValGlu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140 Pro Val GluGln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly 145 150 155 160 LysThr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr 165 170 175Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro 180 185190 Ala Ala Pro Ser Gly Leu Gly Pro Asn Thr Met Ala Ser Gly Gly Gly 195200 205 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ser210 215 220 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg ValIle 225 230 235 240 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr AsnAsn His Leu 245 250 255 Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly SerThr Asn Asp Asn 260 265 270 Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly TyrPhe Asp Phe Asn Arg 275 280 285 Phe His Cys His Phe Ser Pro Arg Asp TrpGln Arg Leu Ile Asn Asn 290 295 300 Asn Trp Gly Phe Arg Pro Lys Arg LeuAsn Phe Lys Leu Phe Asn Ile 305 310 315 320 Gln Val Lys Glu Val Thr ThrAsn Glu Gly Thr Lys Thr Ile Ala Asn 325 330 335 Asn Leu Thr Ser Thr ValArg Val Phe Thr Asp Ser Glu Tyr Gln Leu 340 345 350 Pro Tyr Val Leu GlySer Ala His Gln Gly Cys Leu Pro Pro Phe Pro 355 360 365 Ala Asp Val PheMet Val Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn 370 375 380 Gly Ser GlnAla Leu Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe 385 390 395 400 ProSer Gln Met Leu Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Thr 405 410 415Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu 420 425430 Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Val 435440 445 Arg Thr Gln Thr Thr Gly Thr Gly Gly Thr Gln Thr Leu Ala Phe Ser450 455 460 Gln Ala Gly Pro Ser Ser Met Ala Asn Gln Ala Arg Asn Trp ValPro 465 470 475 480 Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr ThrAsn Gln Ser 485 490 495 Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Ala LysPhe Lys Leu Asn 500 505 510 Gly Arg Asp Ser Leu Met Asn Pro Gly Val AlaMet Ala Ser His Lys 515 520 525 Asp Asp Asp Asp Arg Phe Phe Pro Ser SerGly Val Leu Ile Phe Gly 530 535 540 Lys Gln Gly Ala Gly Asn Asp Gly ValAsp Tyr Ser Gln Val Leu Ile 545 550 555 560 Thr Asp Glu Glu Glu Ile LysAla Thr Asn Pro Val Ala Thr Glu Glu 565 570 575 Tyr Gly Ala Val Ala IleAsn Asn Gln Ala Ala Asn Thr Gln Ala Gln 580 585 590 Thr Gly Leu Val HisAsn Gln Gly Val Ile Pro Gly Met Val Trp Gln 595 600 605 Asn Arg Asp ValTyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His 610 615 620 Thr Asp GlyAsn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu 625 630 635 640 LysHis Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala 645 650 655Asp Pro Pro Leu Thr Phe Asn Gln Ala Lys Leu Asn Ser Phe Ile Thr 660 665670 Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln 675680 685 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn690 695 700 Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu GlyVal 705 710 715 720 Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu ThrArg Asn Leu 725 730 735 97 736 PRT capsid protein of AAV serotype, clone43.25 97 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser1 5 10 15 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro LysPro 20 25 30 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val LeuPro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly GluPro 50 55 60 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala TyrAsp 65 70 75 80 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr AsnHis Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser PheGly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg ValLeu Glu Pro 115 120 125 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala ProGly Lys Lys Arg 130 135 140 Pro Val Glu Gln Ser Pro Gln Glu Pro Asp SerSer Ser Gly Ile Gly 145 150 155 160 Lys Thr Gly Gln Gln Pro Ala Lys LysArg Leu Asn Phe Gly Gln Thr 165 170 175 Gly Asp Ser Glu Ser Val Pro AspPro Gln Pro Leu Gly Glu Pro Pro 180 185 190 Ala Ala Pro Ser Gly Leu GlyPro Asn Thr Met Ala Ser Gly Gly Gly 195 200 205 Ala Pro Met Ala Asp AsnAsn Glu Gly Ala Asp Gly Val Gly Asn Ser 210 215 220 Ser Gly Asn Trp HisCys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile 225 230 235 240 Thr Thr SerThr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu 245 250 255 Tyr LysGln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp Asn 260 265 270 ThrTyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg 275 280 285Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn 290 295300 Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile 305310 315 320 Gln Val Lys Glu Val Thr Thr Asn Glu Gly Thr Lys Thr Ile AlaAsn 325 330 335 Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu TyrGln Leu 340 345 350 Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu ProPro Phe Pro 355 360 365 Ala Asp Val Phe Met Val Pro Gln Tyr Gly Tyr LeuThr Leu Asn Asn 370 375 380 Gly Ser Gln Ala Leu Gly Arg Ser Ser Phe TyrCys Leu Glu Tyr Phe 385 390 395 400 Pro Ser Gln Met Leu Arg Thr Gly AsnAsn Phe Gln Phe Ser Tyr Thr 405 410 415 Phe Glu Asp Val Pro Phe His SerSer Tyr Ala His Ser Gln Ser Leu 420 425 430 Asp Arg Leu Met Asn Pro LeuIle Asp Gln Tyr Leu Tyr Tyr Leu Val 435 440 445 Arg Thr Gln Thr Thr GlyThr Gly Gly Thr Gln Thr Leu Ala Phe Ser 450 455 460 Gln Ala Gly Pro SerSer Met Ala Asn Gln Ala Arg Asn Trp Val Pro 465 470 475 480 Gly Pro CysTyr Arg Gln Gln Arg Val Ser Thr Thr Thr Asn Gln Asn 485 490 495 Asn AsnSer Asn Phe Ala Trp Thr Gly Ala Ala Lys Phe Lys Leu Asn 500 505 510 GlyArg Asp Ser Leu Met Asn Pro Gly Val Ala Met Ala Ser His Lys 515 520 525Asp Asp Asp Asp Arg Phe Phe Pro Ser Ser Gly Val Leu Ile Phe Gly 530 535540 Lys Gln Gly Ala Gly Asn Asp Gly Val Asp Tyr Ser Gln Val Leu Ile 545550 555 560 Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr GluGlu 565 570 575 Tyr Gly Ala Val Ala Ile Asn Asn Gln Ala Ala Asn Thr GlnAla Gln 580 585 590 Thr Gly Leu Val His Asn Gln Gly Val Ile Pro Gly MetVal Trp Gln 595 600 605 Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp AlaLys Ile Pro His 610 615 620 Thr Asp Gly Asn Phe His Pro Ser Pro Leu MetGly Gly Phe Gly Leu 625 630 635 640 Lys His Pro Pro Pro Gln Ile Leu IleLys Asn Thr Pro Val Pro Ala 645 650 655 Asp Pro Pro Leu Thr Phe Asn GlnAla Lys Leu Asn Ser Phe Ile Thr 660 665 670 Gln Tyr Ser Thr Gly Gln ValSer Val Glu Ile Glu Trp Glu Leu Gln 675 680 685 Lys Glu Asn Ser Lys ArgTrp Asn Pro Glu Ile Gln Tyr Thr Ser Asn 690 695 700 Tyr Tyr Lys Ser ThrAsn Val Asp Phe Ala Val Asn Thr Glu Gly Val 705 710 715 720 Tyr Ser GluPro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu 725 730 735 98 736PRT capsid protein of AAV serotype, clone 43.23 98 Met Ala Ala Asp GlyTyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile ArgGlu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 20 25 30 Lys Ala Asn GlnGln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys TyrLeu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn Ala AlaAsp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 Gln Gln LeuLys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala 85 90 95 Asp Ala GluPhe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110 Asn LeuGly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125 LeuGly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser Gly Ile Gly 145 150155 160 Lys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr165 170 175 Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Leu Gly Glu ProPro 180 185 190 Ala Ala Pro Ser Gly Leu Gly Pro Asn Thr Met Ala Ser GlyGly Gly 195 200 205 Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly ValGly Asn Ser 210 215 220 Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu GlyAsp Arg Val Ile 225 230 235 240 Thr Thr Ser Thr Arg Thr Trp Ala Leu ProThr Tyr Asn Asn His Leu 245 250 255 Tyr Lys Gln Ile Ser Asn Gly Thr SerGly Gly Ser Thr Asn Asp Asn 260 265 270 Thr Tyr Phe Gly Tyr Ser Thr ProTrp Gly Tyr Phe Asp Phe Asn Arg 275 280 285 Phe His Cys His Phe Ser ProArg Asp Trp Gln Arg Leu Ile Asn Asn 290 295 300 Asn Trp Gly Phe Arg ProLys Arg Leu Asn Phe Lys Leu Phe Asn Ile 305 310 315 320 Gln Val Lys GluVal Thr Thr Asn Glu Gly Thr Lys Thr Ile Ala Asn 325 330 335 Asn Leu ThrSer Thr Val Gln Val Phe Thr Asp Leu Glu Tyr Gln Leu 340 345 350 Pro TyrVal Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro 355 360 365 AlaAsp Val Phe Met Val Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn 370 375 380Gly Ser Gln Ala Leu Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe 385 390395 400 Pro Ser Gln Met Pro Arg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Thr405 410 415 Phe Glu Asp Val Pro Phe His Ser Ser Tyr Ala His Ser Gln SerLeu 420 425 430 Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr TyrLeu Val 435 440 445 Arg Thr Gln Thr Thr Gly Thr Gly Gly Thr Gln Thr LeuAla Phe Ser 450 455 460 Gln Ala Gly Pro Ser Ser Met Ala Asn Gln Ala ArgAsn Trp Val Pro 465 470 475 480 Gly Pro Cys Tyr Arg Gln Gln Arg Val SerThr Thr Thr Asn Gln Asn 485 490 495 Asn Asn Ser Asn Phe Ala Trp Thr GlyAla Ala Lys Phe Lys Leu Asn 500 505 510 Gly Arg Asp Ser Leu Met Asn ProGly Val Ala Met Ala Ser His Lys 515 520 525 Asp Asp Asp Asp Arg Phe PhePro Ser Ser Gly Val Leu Ile Phe Gly 530 535 540 Lys Gln Gly Ala Gly AsnAsp Gly Val Asp Tyr Ser Gln Val Leu Ile 545 550 555 560 Thr Asp Glu GluGlu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Glu 565 570 575 Tyr Gly AlaVal Ala Ile Asn Asn Gln Ala Ala Asn Thr Gln Ala Gln 580 585 590 Thr GlyLeu Val His Asn Gln Gly Val Ile Pro Gly Met Val Trp Gln 595 600 605 AsnArg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile Pro His 610 615 620Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly Phe Gly Leu 625 630635 640 Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala645 650 655 Asp Pro Pro Leu Thr Phe Asn Gln Ala Lys Leu Asn Ser Phe IleThr 660 665 670 Gln Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp GluLeu Gln 675 680 685 Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln TyrThr Ser Asn 690 695 700 Tyr Tyr Lys Ser Thr Asn Val Asp Phe Ala Val AsnThr Glu Gly Val 705 710 715 720 Tyr Ser Glu Pro Arg Pro Ile Gly Thr ArgTyr Leu Thr Arg Asn Leu 725 730 735 99 736 PRT capsid protein of AAVserotype, clone 43.20 99 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu GluAsp Asn Leu Ser 1 5 10 15 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys ProGly Ala Pro Lys Pro 20 25 30 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly ArgGly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly LeuAsp Lys Gly Glu Pro 50 55 60 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu HisAsp Lys Ala Tyr Asp 65 70 75 80 Gln Gln Leu Lys Ala Gly Asp Asn Pro TyrLeu Arg Tyr Asn His Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln GluAsp Thr Ser Phe Gly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe Gln AlaLys Lys Arg Val Leu Glu Pro 115 120 125 Leu Gly Leu Val Glu Glu Gly AlaLys Thr Ala Pro Gly Lys Lys Arg 130 135 140 Leu Val Glu Gln Ser Pro GlnGlu Pro Asp Ser Ser Ser Gly Ile Gly 145 150 155 160 Lys Thr Gly Gln GlnPro Ala Lys Lys Arg Leu Asn Phe Gly Gln Thr 165 170 175 Gly Asp Ser GluSer Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro 180 185 190 Ala Ala ProSer Gly Leu Gly Pro Asn Thr Met Ala Ser Gly Gly Gly 195 200 205 Ala ProMet Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ser 210 215 220 SerGly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile 225 230 235240 Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu 245250 255 Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp Asn260 265 270 Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe AsnArg 275 280 285 Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu IleAsn Asn 290 295 300 Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys LeuPhe Asn Ile 305 310 315 320 Gln Val Lys Glu Val Thr Thr Asn Glu Gly ThrLys Thr Ile Ala Asn 325 330 335 Asn Leu Thr Ser Thr Val Gln Val Phe ThrAsp Ser Glu Tyr Gln Leu 340 345 350 Pro Tyr Val Leu Gly Ser Ala His GlnGly Cys Leu Pro Pro Phe Pro 355 360 365 Ala Asp Val Phe Thr Val Pro GlnTyr Gly Tyr Leu Thr Leu Asn Asn 370 375 380 Gly Ser Gln Ala Leu Gly ArgSer Ser Phe Tyr Cys Leu Glu Tyr Phe 385 390 395 400 Pro Ser Gln Met LeuArg Thr Gly Asn Asn Phe Gln Phe Ser Tyr Thr 405 410 415 Phe Glu Asp ValPro Phe His Ser Ser Tyr Ala His Ser Gln Ser Leu 420 425 430 Asp Arg LeuMet Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Val 435 440 445 Arg ThrGln Thr Thr Gly Thr Gly Gly Thr Gln Thr Leu Ala Phe Ser 450 455 460 GlnAla Gly Pro Ser Ser Met Ala Asn Gln Ala Arg Asn Trp Val Pro 465 470 475480 Gly Pro Cys Tyr Arg Gln Gln Arg Val Ser Thr Thr Thr Asn Gln Asn 485490 495 Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Ala Lys Phe Lys Leu Asn500 505 510 Gly Arg Asp Ser Leu Met Asn Pro Gly Val Ala Met Ala Ser HisLys 515 520 525 Asp Asp Asp Asp Arg Phe Phe Pro Ser Ser Gly Val Leu IlePhe Gly 530 535 540 Lys Gln Gly Ala Gly Asn Asp Gly Val Asp Tyr Ser GlnVal Leu Ile 545 550 555 560 Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn ProVal Ala Thr Glu Glu 565 570 575 Tyr Gly Ala Val Ala Ile Asn Asn Gln AlaAla Asn Thr Gln Ala Gln 580 585 590 Thr Gly Leu Val His Asn Gln Gly ValIle Pro Gly Met Val Trp Gln 595 600 605 Asn Arg Asp Val Tyr Leu Gln GlyPro Ile Trp Ala Lys Ile Pro His 610 615 620 Thr Asp Gly Asn Phe His ProSer Pro Leu Met Gly Gly Phe Gly Leu 625 630 635 640 Lys His Pro Pro ProGln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala 645 650 655 Asp Pro Pro LeuThr Phe Asn Gln Ala Lys Leu Asn Ser Phe Ile Thr 660 665 670 Gln Tyr SerThr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln 675 680 685 Lys GluAsn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn 690 695 700 TyrTyr Lys Ser Thr Asn Val Asp Phe Ala Val Asn Thr Glu Gly Val 705 710 715720 Tyr Ser Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr Arg Asn Leu 725730 735 100 736 PRT capsid protein of AAV serotype, clone AAV9 100 MetAla Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 20 25 30Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 35 40 45Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 7580 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala 85 9095 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro115 120 125 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys LysArg 130 135 140 Pro Val Glu Gln Ser Pro Gln Glu Pro Asp Ser Ser Ser GlyIle Gly 145 150 155 160 Lys Ser Gly Gln Gln Pro Ala Lys Lys Arg Leu AsnPhe Gly Gln Thr 165 170 175 Gly Asp Ser Glu Ser Val Pro Asp Pro Gln ProLeu Gly Glu Pro Pro 180 185 190 Glu Ala Pro Ser Gly Leu Gly Pro Asn ThrMet Ala Ser Gly Gly Gly 195 200 205 Ala Pro Met Ala Asp Asn Asn Glu GlyAla Asp Gly Val Gly Asn Ser 210 215 220 Ser Gly Asn Trp His Cys Asp SerThr Trp Leu Gly Asp Arg Val Ile 225 230 235 240 Thr Thr Ser Thr Arg ThrTrp Ala Leu Pro Thr Tyr Asn Asn His Leu 245 250 255 Tyr Lys Gln Ile SerAsn Gly Thr Ser Gly Gly Ser Thr Asn Asp Asn 260 265 270 Thr Tyr Phe GlyTyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg 275 280 285 Phe His CysHis Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn 290 295 300 Asn TrpGly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn Ile 305 310 315 320Gln Val Lys Glu Val Thr Thr Asn Glu Gly Thr Lys Thr Ile Ala Asn 325 330335 Asn Leu Thr Ser Thr Val Gln Val Phe Thr Asp Ser Glu Tyr Gln Leu 340345 350 Pro Tyr Val Leu Gly Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro355 360 365 Ala Asp Val Phe Met Val Pro Gln Tyr Gly Tyr Leu Thr Leu AsnAsn 370 375 380 Gly Ser Gln Ala Leu Gly Arg Ser Ser Phe Tyr Cys Leu GluTyr Phe 385 390 395 400 Pro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe GlnPhe Ser Tyr Thr 405 410 415 Phe Glu Asp Val Pro Phe His Ser Ser Tyr AlaHis Ser Gln Ser Leu 420 425 430 Asp Arg Leu Met Asn Pro Leu Ile Asp GlnTyr Leu Tyr Tyr Leu Val 435 440 445 Arg Thr Gln Thr Thr Gly Thr Gly GlyThr Gln Thr Leu Ala Phe Ser 450 455 460 Gln Ala Gly Pro Ser Ser Met AlaAsn Gln Ala Arg Asn Trp Val Pro 465 470 475 480 Gly Pro Cys Tyr Arg GlnGln Arg Val Ser Thr Thr Thr Asn Gln Asn 485 490 495 Asn Asn Ser Asn PheAla Trp Thr Gly Ala Ala Lys Phe Lys Leu Asn 500 505 510 Gly Arg Asp SerLeu Met Asn Pro Gly Val Ala Met Ala Ser His Lys 515 520 525 Asp Asp GluAsp Arg Phe Phe Pro Ser Ser Gly Val Leu Ile Phe Gly 530 535 540 Lys GlnGly Ala Gly Asn Asp Gly Val Asp Tyr Ser Gln Val Leu Ile 545 550 555 560Thr Asp Glu Glu Glu Ile Lys Ala Thr Asn Pro Val Ala Thr Glu Glu 565 570575 Tyr Gly Ala Val Ala Ile Asn Asn Gln Ala Ala Asn Thr Gln Ala Gln 580585 590 Thr Gly Leu Val His Asn Gln Gly Val Ile Pro Gly Met Val Trp Gln595 600 605 Asn Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp Ala Lys Ile ProHis 610 615 620 Thr Asp Gly Asn Phe His Pro Ser Pro Leu Met Gly Gly PheGly Leu 625 630 635 640 Lys His Pro Pro Pro Gln Ile Leu Ile Lys Asn ThrPro Val Pro Ala 645 650 655 Asp Pro Pro Leu Thr Phe Asn Gln Ala Lys LeuAsn Ser Phe Ile Thr 660 665 670 Gln Tyr Ser Thr Gly Gln Val Ser Val GluIle Glu Trp Glu Leu Gln 675 680 685 Lys Glu Asn Ser Lys Arg Trp Asn ProGlu Ile Gln Tyr Thr Ser Asn 690 695 700 Tyr Tyr Lys Ser Thr Asn Val AspPhe Ala Val Asn Thr Glu Gly Val 705 710 715 720 Tyr Ser Glu Pro Arg ProIle Gly Thr Arg Tyr Leu Thr Arg Asn Leu 725 730 735 101 728 PRT capsidprotein of AAV serotype, clone 24.1 101 Met Ala Ala Asp Gly Tyr Leu ProAsp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile Arg Glu Trp TrpAsp Leu Lys Pro Gly Ala Pro Lys Pro 20 25 30 Lys Ala Asn Gln Gln Lys GlnAsp Asp Gly Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr Leu Arg ProPhe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn Glu Ala Asp Ala AlaAla Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 Lys Gln Leu Glu Gln GlyAsp Asn Pro Tyr Leu Lys Tyr Asn His Ala 85 90 95 Asp Ala Glu Phe Gln GluArg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110 Asn Leu Gly Arg AlaVal Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125 Leu Gly Leu ValGlu Glu Val Ala Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140 Pro Ile GluSer Pro Asp Ser Ser Thr Gly Ile Gly Lys Lys Gly Gln 145 150 155 160 GlnPro Ala Lys Lys Lys Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu 165 170 175Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro Ala Ala Pro Ser 180 185190 Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly Ala Pro Met Ala 195200 205 Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp210 215 220 His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr SerThr 225 230 235 240 Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu TyrLys Gln Ile 245 250 255 Ser Ser Gln Ser Gly Ala Thr Asn Asp Asn His PhePhe Ser Tyr Ser 260 265 270 Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg PheHis Cys His Phe Ser 275 280 285 Pro Arg Asp Trp Gln Arg Leu Ile Asn AsnAsn Trp Gly Phe Arg Pro 290 295 300 Arg Lys Leu Arg Phe Lys Leu Phe AsnIle Gln Val Lys Glu Val Thr 305 310 315 320 Thr Asn Asp Gly Val Thr ThrIle Ala Asn Asn Leu Thr Ser Thr Ile 325 330 335 Gln Val Phe Ser Asp SerGlu Tyr Gln Leu Pro Tyr Val Leu Gly Ser 340 345 350 Ala His Gln Gly CysLeu Pro Pro Phe Pro Ala Asp Val Phe Met Ile 355 360 365 Pro Gln Tyr GlyTyr Leu Thr Leu Asn Asn Gly Ser Gln Ser Val Gly 370 375 380 Arg Ser SerPhe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg 385 390 395 400 ThrGly Asn Asn Phe Glu Phe Ser Tyr Thr Phe Glu Glu Val Pro Phe 405 410 415His Ser Ser Tyr Val His Ser Gln Ser Leu Asp Arg Leu Met Asn Pro 420 425430 Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg Thr Gln Ser Thr Thr 435440 445 Gly Ser Thr Arg Glu Leu Gln Phe His Gln Ala Gly Pro Asn Thr Met450 455 460 Ala Glu Gln Ser Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg GlnGln 465 470 475 480 Arg Leu Ser Lys Asn Ile Asp Ser Asn Asn Asn Ser AsnPhe Ala Trp 485 490 495 Thr Gly Ala Thr Lys Tyr His Leu Asn Gly Arg AsnSer Leu Thr Asn 500 505 510 Pro Gly Val Ala Met Ala Thr Asn Lys Asp AspGlu Asp Gln Phe Phe 515 520 525 Pro Ile Asn Gly Val Leu Val Phe Gly LysThr Gly Ala Ala Asn Lys 530 535 540 Thr Thr Leu Glu Asn Val Leu Met ThrSer Glu Glu Glu Ile Lys Thr 545 550 555 560 Thr Asn Pro Val Ala Thr GluGlu Tyr Gly Val Val Ser Ser Asn Leu 565 570 575 Gln Ser Ser Thr Ala GlyPro Gln Thr Gln Thr Val Asn Ser Gln Gly 580 585 590 Ala Leu Pro Gly MetVal Trp Gln Asn Arg Asp Val Cys Leu Gln Gly 595 600 605 Pro Ile Trp AlaLys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser 610 615 620 Pro Leu MetGly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile Leu 625 630 635 640 IleLys Asn Thr Pro Val Pro Ala Asn Pro Pro Glu Val Phe Thr Pro 645 650 655Ala Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val Ser 660 665670 Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp Asn 675680 685 Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Asn Asn Val Glu690 695 700 Phe Ala Val Asn Asn Glu Gly Val Tyr Thr Glu Pro Arg Pro IleGly 705 710 715 720 Thr Arg Tyr Leu Thr Arg Asn Leu 725 102 728 PRTcapsid protein of AAV serotype, clone 42.2REAL 102 Met Ala Ala Asp GlyTyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile ArgGlu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 20 25 30 Lys Ala Asn GlnGln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys TyrLeu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn Glu AlaAsp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 Lys Gln LeuGlu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala 85 90 95 Asp Ala GluPhe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110 Asn LeuGly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125 LeuGly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly Lys Lys Gly Gln 145 150155 160 Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu165 170 175 Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro Ala Ala ProSer 180 185 190 Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly Ala ProMet Ala 195 200 205 Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala SerGly Asn Trp 210 215 220 His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val IleThr Thr Ser Thr 225 230 235 240 Arg Thr Trp Ala Leu Pro Thr Tyr Asn AsnHis Leu Tyr Lys Gln Ile 245 250 255 Ser Ser Gln Ser Gly Ala Thr Asn AspAsn His Phe Phe Gly Tyr Ser 260 265 270 Thr Pro Trp Gly Tyr Phe Asp PheAsn Arg Phe His Cys His Phe Ser 275 280 285 Pro Arg Asp Trp Gln Arg LeuIle Asn Asn Asn Trp Gly Phe Arg Pro 290 295 300 Arg Lys Leu Arg Phe LysLeu Phe Asn Ile Gln Val Lys Glu Val Thr 305 310 315 320 Thr Asn Asp GlyVal Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Ile 325 330 335 Gln Val PheSer Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser 340 345 350 Ala HisGln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile 355 360 365 ProGln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ser Val Gly 370 375 380Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg 385 390395 400 Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr Phe Glu Glu Val Pro Phe405 410 415 His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met AsnPro 420 425 430 Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg Thr Gln SerThr Thr 435 440 445 Gly Ser Thr Arg Glu Leu Gln Phe His Gln Ala Gly ProAsn Thr Met 450 455 460 Ala Glu Gln Ser Lys Asn Trp Leu Pro Gly Pro CysTyr Arg Gln Gln 465 470 475 480 Arg Leu Ser Lys Asn Ile Asp Ser Asn AsnAsn Ser Asn Phe Ala Trp 485 490 495 Thr Gly Ala Thr Lys Tyr His Leu AsnGly Arg Asn Ser Leu Thr Asn 500 505 510 Pro Gly Val Ala Met Ala Thr AsnLys Asp Asp Glu Asp Gln Phe Phe 515 520 525 Pro Ile Asn Gly Val Leu ValPhe Gly Glu Thr Gly Ala Ala Asn Lys 530 535 540 Thr Thr Leu Glu Asn ValLeu Met Thr Ser Glu Glu Glu Ile Lys Thr 545 550 555 560 Thr Asn Pro ValAla Thr Glu Glu Tyr Gly Val Val Ser Ser Asn Leu 565 570 575 Gln Ser SerThr Ala Gly Pro Gln Thr Gln Thr Val Asn Ser Gln Gly 580 585 590 Ala LeuPro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly 595 600 605 ProIle Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser 610 615 620Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile Leu 625 630635 640 Ile Lys Asn Thr Pro Val Pro Ala Asn Pro Pro Glu Val Phe Thr Pro645 650 655 Ala Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln ValSer 660 665 670 Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys ArgTrp Asn 675 680 685 Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Ala Lys Ser AsnAsn Val Glu 690 695 700 Phe Ala Val Asn Asn Glu Gly Val Tyr Thr Glu ProArg Pro Ile Gly 705 710 715 720 Thr Arg Tyr Leu Thr Arg Asn Leu 725 103728 PRT capsid protein of AAV serotype, clone 7.2VP1 103 Met Ala Ala AspGly Tyr Leu Pro Asp Trp Leu Glu Gly Asn Leu Ser 1 5 10 15 Glu Gly IleArg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 20 25 30 Lys Ala AsnGln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr ArgTyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn GluAla Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 Lys GlnLeu Glu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala 85 90 95 Asp AlaGlu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110 AsnLeu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg 130 135140 Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly Lys Asn Gly Gln 145150 155 160 Pro Pro Ala Lys Lys Lys Leu Asn Phe Gly Gln Thr Gly Asp SerGlu 165 170 175 Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro Pro Ala AlaPro Ser 180 185 190 Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly Gly AlaPro Met Ala 195 200 205 Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Asn AlaSer Gly Asn Trp 210 215 220 His Cys Asp Ser Thr Trp Leu Gly Asp Arg ValIle Thr Thr Ser Thr 225 230 235 240 Arg Thr Trp Ala Leu Pro Thr Tyr AsnAsn His Leu Tyr Lys Gln Ile 245 250 255 Ser Ser Gln Ser Gly Ala Thr AsnAsp Asn His Phe Phe Gly Tyr Ser 260 265 270 Thr Pro Trp Gly Tyr Phe AspPhe Asn Arg Phe His Cys His Phe Ser 275 280 285 Pro Arg Asp Trp Gln ArgLeu Ile Asn Asn Asn Trp Gly Phe Arg Pro 290 295 300 Arg Lys Leu Arg PheLys Leu Phe Asn Ile Gln Val Lys Glu Val Thr 305 310 315 320 Thr Asn AspGly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Ile 325 330 335 Gln ValPhe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser 340 345 350 AlaHis Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile 355 360 365Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ser Val Gly 370 375380 Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser Gln Met Leu Arg 385390 395 400 Thr Gly Asp Asn Phe Glu Phe Ser Tyr Thr Phe Glu Glu Val ProPhe 405 410 415 His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp Arg Leu MetAsn Pro 420 425 430 Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg Thr GlnSer Thr Thr 435 440 445 Gly Ser Thr Arg Glu Leu Gln Phe His Gln Ala GlyPro Asn Thr Met 450 455 460 Ala Glu Gln Ser Lys Asn Trp Leu Pro Gly ProCys Tyr Arg Gln Gln 465 470 475 480 Arg Leu Ser Lys Asn Ile Asp Ser AsnAsn Asn Ser Asn Phe Ala Trp 485 490 495 Thr Gly Ala Thr Lys Tyr His LeuAsn Gly Arg Asn Ser Leu Thr Asn 500 505 510 Pro Gly Val Ala Met Ala ThrAsn Lys Asp Asp Glu Asp Gln Phe Phe 515 520 525 Pro Ile Asn Gly Val LeuVal Phe Gly Lys Thr Gly Ala Ala Asn Lys 530 535 540 Thr Thr Leu Glu AsnVal Leu Met Thr Ser Glu Glu Glu Ile Lys Thr 545 550 555 560 Thr Asn ProVal Ala Thr Glu Glu Tyr Gly Val Val Ser Ser Asn Leu 565 570 575 Gln SerSer Thr Ala Gly Pro Gln Thr Gln Thr Val Asn Ser Gln Gly 580 585 590 AlaLeu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly 595 600 605Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe His Pro Ser 610 615620 Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln Ile Leu 625630 635 640 Ile Lys Asn Thr Pro Val Pro Ala Asn Pro Pro Glu Val Phe ThrPro 645 650 655 Ala Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly GlnVal Ser 660 665 670 Val Glu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser LysArg Trp Asn 675 680 685 Pro Glu Ile Gln Tyr Thr Ser Asn Tyr Ala Lys SerAsn Asn Val Glu 690 695 700 Phe Ala Val Asn Asn Glu Gly Val Tyr Thr GluPro Arg Pro Ile Gly 705 710 715 720 Thr Arg Tyr Leu Thr Arg Asn Leu 725104 728 PRT capsid protein of AAV serotype, clone 27.3VP1 104 Met AlaAla Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15 GluGly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 20 25 30 LysAla Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 35 40 45 GlyTyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 ValAsn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80Lys Gln Leu Glu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala 85 90 95Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115120 125 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Ser Gly Lys Lys Arg130 135 140 Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly Lys Lys GlyGln 145 150 155 160 Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly Gln Thr GlyAsp Ser Glu 165 170 175 Ser Val Pro Asp Pro Gln Pro Leu Gly Glu Pro ProAla Ala Pro Ser 180 185 190 Gly Leu Gly Ser Gly Thr Met Ala Ala Gly GlyGly Ala Pro Met Ala 195 200 205 Asp Asn Asn Glu Gly Ala Asp Gly Val GlyAsn Ala Ser Gly Asn Trp 210 215 220 His Cys Asp Ser Thr Trp Leu Gly AspArg Val Ile Thr Thr Ser Thr 225 230 235 240 Arg Thr Trp Ala Leu Pro ThrTyr Asn Asn His Leu Tyr Lys Gln Ile 245 250 255 Ser Ser Gln Ser Gly AlaThr Asn Asp Asn His Phe Phe Gly Tyr Ser 260 265 270 Thr Pro Trp Gly TyrPhe Asp Phe Asn Arg Phe His Cys His Phe Ser 275 280 285 Pro Arg Asp TrpGln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro 290 295 300 Arg Lys LeuArg Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr 305 310 315 320 ThrAsn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Ile 325 330 335Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser 340 345350 Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe Met Ile 355360 365 Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln Ser Val Gly370 375 380 Arg Ser Ser Phe Cys Cys Leu Glu Tyr Phe Pro Ser Gln Met LeuArg 385 390 395 400 Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr Phe Glu GluVal Pro Phe 405 410 415 His Ser Ser Tyr Ala His Ser Gln Ser Leu Asp ArgLeu Met Asn Pro 420 425 430 Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu Ala ArgThr Gln Ser Thr Thr 435 440 445 Gly Ser Thr Arg Glu Leu Gln Phe His GlnAla Gly Pro Asn Thr Val 450 455 460 Ala Glu Gln Ser Lys Asn Trp Leu ProGly Pro Cys Tyr Arg Gln Gln 465 470 475 480 Arg Leu Ser Lys Asn Ile AspSer Asn Asn Asn Ser Asn Phe Ala Trp 485 490 495 Thr Gly Ala Thr Lys TyrHis Leu Asn Gly Arg Asn Ser Leu Thr Asn 500 505 510 Pro Gly Val Ala MetAla Thr Asn Lys Asp Asp Glu Asp Gln Phe Leu 515 520 525 Pro Ile Asn GlyVal Leu Val Phe Gly Lys Thr Gly Ala Ala Asn Lys 530 535 540 Thr Thr LeuGlu Asn Val Leu Met Thr Ser Glu Glu Glu Ile Lys Thr 545 550 555 560 ThrAsn Pro Val Ala Thr Glu Glu Tyr Gly Val Val Ser Ser Asn Leu 565 570 575Gln Ser Ser Thr Ala Gly Pro Arg Thr Gln Thr Val Asn Ser Gln Gly 580 585590 Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu Gln Gly 595600 605 Pro Ile Trp Ala Glu Ile Pro His Thr Asp Gly Asn Phe His Pro Ser610 615 620 Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro Pro Gln IleLeu 625 630 635 640 Ile Lys Asn Thr Pro Val Pro Ala Asn Pro Pro Glu ValPhe Thr Pro 645 650 655 Ala Lys Phe Ala Ser Phe Ile Thr Gln Tyr Ser ThrGly Gln Val Ser 660 665 670 Val Glu Ile Glu Trp Glu Leu Gln Lys Glu AsnSer Lys Arg Trp Asn 675 680 685 Pro Glu Ile Gln Tyr Thr Ser Asn Tyr AlaLys Ser Asn Asn Val Glu 690 695 700 Phe Ala Val Asn Asn Glu Gly Val TyrThr Glu Pro Arg Pro Ile Gly 705 710 715 720 Thr Arg Tyr Leu Thr Arg AsnLeu 725 105 728 PRT capsid protein of AAV serotype, clone 16.3VP1 105Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 5 1015 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 20 2530 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 35 4045 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 50 5560 Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 65 7075 80 Lys Gln Leu Glu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala 8590 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly100 105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu GluPro 115 120 125 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly LysLys Arg 130 135 140 Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly LysLys Gly Gln 145 150 155 160 Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly GlnThr Gly Asp Ser Glu 165 170 175 Ser Val Pro Asp Pro Gln Pro Leu Gly GluPro Pro Ala Ala Pro Ser 180 185 190 Gly Leu Gly Ser Gly Thr Met Ala AlaGly Gly Gly Ala Pro Met Ala 195 200 205 Asp Asn Asn Glu Gly Ala Asp GlyVal Gly Asn Ala Ser Gly Asn Trp 210 215 220 His Cys Asp Ser Thr Trp LeuGly Asp Arg Val Ile Thr Thr Ser Thr 225 230 235 240 Arg Thr Trp Ala LeuPro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile 245 250 255 Ser Ser Gln SerGly Ala Thr Asn Asp Asn His Phe Phe Gly Tyr Ser 260 265 270 Thr Pro TrpGly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser 275 280 285 Pro ArgAsp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro 290 295 300 ArgLys Leu Arg Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr 305 310 315320 Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Ile 325330 335 Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser340 345 350 Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe MetIle 355 360 365 Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln SerMet Gly 370 375 380 Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser GlnMet Leu Arg 385 390 395 400 Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr PheGlu Glu Val Pro Phe 405 410 415 His Ser Ser Tyr Ala His Ser Gln Ser LeuAsp Arg Leu Met Asn Pro 420 425 430 Leu Ile Asp Gln Tyr Leu Tyr Tyr LeuAla Arg Thr Gln Ser Thr Thr 435 440 445 Gly Ser Thr Arg Glu Leu Gln PheHis Gln Ala Gly Pro Asn Thr Met 450 455 460 Ala Glu Gln Ser Lys Asn TrpLeu Pro Gly Pro Cys Tyr Arg Gln Gln 465 470 475 480 Arg Leu Ser Lys AsnIle Asp Ser Asn Asn Asn Ser Asn Phe Ala Trp 485 490 495 Thr Gly Ala ThrLys Tyr His Leu Asn Gly Arg Asn Ser Leu Thr Asn 500 505 510 Pro Gly ValAla Met Ala Thr Asn Lys Asp Asp Glu Gly Gln Phe Phe 515 520 525 Pro IleAsn Gly Val Leu Val Phe Gly Lys Thr Gly Ala Ala Asn Lys 530 535 540 ThrThr Leu Glu Asn Val Leu Met Thr Ser Glu Glu Glu Ile Lys Thr 545 550 555560 Thr Asn Pro Val Ala Thr Glu Glu Tyr Gly Val Val Ser Ser Asn Leu 565570 575 Gln Ser Ser Thr Ala Gly Pro Gln Thr Gln Thr Val Asn Ser Gln Gly580 585 590 Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu GlnGly 595 600 605 Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe HisPro Ser 610 615 620 Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro ProGln Ile Leu 625 630 635 640 Ile Lys Asn Thr Pro Val Pro Ala Asn Pro ProGly Val Phe Thr Pro 645 650 655 Ala Leu Phe Ala Ser Phe Ile Thr Gln TyrSer Thr Gly Gln Val Ser 660 665 670 Val Glu Ile Glu Trp Glu Leu Gln LysGlu Asn Ser Lys Arg Trp Asn 675 680 685 Pro Glu Ile Gln Tyr Thr Ser AsnTyr Ala Lys Ser Asn Asn Val Glu 690 695 700 Phe Ala Val Asn Asn Glu GlyVal Tyr Thr Glu Pro Arg Pro Ile Gly 705 710 715 720 Thr Arg Tyr Leu ThrArg Asn Leu 725 106 728 PRT capsid protein of AAV serotype, clone 42.10106 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 510 15 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 2025 30 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 3540 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 5055 60 Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 6570 75 80 Lys Gln Leu Glu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly100 105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu GluPro 115 120 125 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly LysLys Arg 130 135 140 Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly ArgLys Gly Gln 145 150 155 160 Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly GlnThr Gly Asp Ser Glu 165 170 175 Ser Val Pro Asp Pro Gln Pro Ile Gly GluPro Pro Ala Gly Pro Ser 180 185 190 Gly Leu Gly Ser Gly Thr Met Ala AlaGly Gly Gly Ala Pro Met Ala 195 200 205 Asp Asn Asn Glu Gly Ala Asp GlyVal Gly Asn Ala Ser Gly Asn Trp 210 215 220 His Cys Asp Ser Thr Trp LeuGly Asp Arg Val Ile Thr Thr Ser Thr 225 230 235 240 Arg Thr Trp Ala LeuPro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile 245 250 255 Ser Ser Gln SerGly Ala Thr Asn Asp Asn His Phe Phe Gly Tyr Ser 260 265 270 Thr Pro TrpGly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser 275 280 285 Pro ArgAsp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro 290 295 300 ArgLys Leu Arg Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr 305 310 315320 Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Ile 325330 335 Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser340 345 350 Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe MetIle 355 360 365 Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln SerVal Gly 370 375 380 Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser GlnMet Leu Arg 385 390 395 400 Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr PheGlu Glu Val Pro Phe 405 410 415 His Ser Ser Tyr Ala His Ser Gln Ser LeuAsp Arg Leu Met Asn Pro 420 425 430 Leu Ile Asp Gln Tyr Leu Tyr Tyr LeuAla Arg Thr Gln Ser Thr Thr 435 440 445 Gly Ser Thr Arg Glu Leu Gln PheHis Gln Ala Gly Pro Asn Thr Met 450 455 460 Ala Glu Gln Ser Lys Asn TrpLeu Pro Gly Pro Cys Tyr Arg Gln Gln 465 470 475 480 Arg Leu Ser Lys AsnIle Asp Ser Asn Asn Asn Ser Asn Phe Ala Trp 485 490 495 Thr Gly Ala ThrLys Tyr His Leu Asn Gly Arg Asn Ser Leu Thr Asn 500 505 510 Pro Gly ValAla Met Ala Thr Asn Lys Asp Asp Glu Asp Gln Phe Phe 515 520 525 Pro IleAsn Gly Val Leu Val Phe Gly Lys Thr Gly Ala Ala Asn Lys 530 535 540 ThrThr Leu Glu Asn Val Leu Met Thr Ser Glu Glu Glu Ile Lys Thr 545 550 555560 Thr Asn Pro Val Ala Thr Glu Glu Tyr Gly Val Val Ser Ser Asn Leu 565570 575 Gln Ser Ser Thr Ala Gly Pro Gln Thr Gln Thr Val Asn Ser Gln Gly580 585 590 Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu GlnGly 595 600 605 Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe HisPro Ser 610 615 620 Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro ProGln Ile Leu 625 630 635 640 Ile Lys Asn Thr Pro Val Pro Ala Asn Pro ProGlu Val Phe Thr Pro 645 650 655 Ala Lys Phe Ala Ser Phe Ile Thr Gln TyrSer Thr Gly Gln Val Ser 660 665 670 Val Glu Ile Glu Trp Glu Leu Gln LysGlu Asn Ser Lys Arg Trp Asn 675 680 685 Pro Glu Ile Gln Tyr Thr Ser AsnTyr Ala Lys Ser Asn Asn Val Glu 690 695 700 Phe Ala Val Asn Asn Glu GlyVal Tyr Thr Glu Pro Arg Pro Ile Gly 705 710 715 720 Thr Arg Tyr Leu ThrArg Asn Leu 725 107 728 PRT capsid protein of AAV serotype, clone 42.3B107 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 510 15 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 2025 30 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 3540 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 5055 60 Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 6570 75 80 Lys Gln Leu Glu Gln Gly Asp Asn Pro Tyr Leu Lys Tyr Asn His Ala85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly100 105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu GluPro 115 120 125 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly LysLys Arg 130 135 140 Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly LysLys Gly Gln 145 150 155 160 Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly GlnThr Gly Asp Ser Glu 165 170 175 Ser Val Pro Asp Pro Gln Pro Ile Gly GluPro Pro Ala Gly Pro Ser 180 185 190 Gly Leu Gly Ser Gly Thr Met Ala AlaGly Gly Gly Ala Pro Met Ala 195 200 205 Asp Asn Asn Glu Gly Ala Asp GlyVal Gly Asn Ala Ser Gly Asn Trp 210 215 220 His Cys Asp Ser Thr Trp LeuGly Asp Arg Val Ile Thr Thr Ser Thr 225 230 235 240 Arg Thr Trp Ala LeuPro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile 245 250 255 Ser Ser Gln SerGly Ala Thr Asn Asp Asn His Phe Phe Gly Tyr Ser 260 265 270 Thr Pro TrpGly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser 275 280 285 Pro ArgAsp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro 290 295 300 ArgLys Leu Arg Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr 305 310 315320 Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Ile 325330 335 Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser340 345 350 Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe MetIle 355 360 365 Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln SerVal Gly 370 375 380 Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser GlnMet Leu Arg 385 390 395 400 Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr PheGlu Glu Val Pro Phe 405 410 415 His Ser Ser Tyr Ala His Ser Gln Ser LeuAsp Arg Leu Met Asn Pro 420 425 430 Leu Ile Asp Gln Tyr Leu Tyr Tyr LeuAla Arg Thr Gln Ser Thr Thr 435 440 445 Gly Ser Thr Arg Glu Leu Gln PheHis Gln Ala Gly Pro Asn Thr Met 450 455 460 Ala Glu Gln Ser Lys Asn TrpLeu Pro Gly Pro Cys Tyr Arg Gln Gln 465 470 475 480 Arg Leu Ser Lys AsnIle Asp Ser Asn Asn Thr Ser Asn Phe Ala Trp 485 490 495 Thr Gly Ala ThrLys Tyr His Leu Asn Gly Arg Asn Ser Leu Thr Asn 500 505 510 Pro Gly ValAla Met Ala Thr Asn Lys Asp Asp Glu Asp Gln Phe Phe 515 520 525 Pro IleAsn Gly Val Leu Val Phe Gly Lys Thr Gly Ala Ala Asn Lys 530 535 540 ThrThr Leu Glu Asn Val Leu Met Thr Ser Glu Glu Glu Ile Lys Thr 545 550 555560 Thr Asn Pro Val Ala Thr Glu Gln Tyr Gly Val Val Ser Ser Asn Leu 565570 575 Gln Ser Ser Thr Ala Gly Pro Gln Thr Gln Thr Val Asn Ser Gln Gly580 585 590 Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu GlnGly 595 600 605 Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe HisPro Ser 610 615 620 Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro ProGln Ile Leu 625 630 635 640 Ile Lys Asn Thr Pro Val Pro Ala Asn Pro ProGlu Val Phe Thr Pro 645 650 655 Ala Lys Phe Ala Ser Phe Ile Thr Gln TyrSer Thr Gly Gln Val Ser 660 665 670 Val Glu Ile Glu Trp Glu Leu Gln LysGlu Asn Ser Lys Arg Trp Asn 675 680 685 Pro Glu Ile Gln Tyr Thr Ser AsnTyr Ala Lys Ser Asn Asn Val Glu 690 695 700 Phe Ala Val Asn Asn Glu GlyVal Tyr Thr Glu Pro Arg Pro Ile Gly 705 710 715 720 Thr Arg Tyr Leu ThrArg Asn Leu 725 108 728 PRT capsid protein of AAV serotype, clone 42.11108 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 510 15 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 2025 30 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 3540 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 5055 60 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 6570 75 80 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly100 105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu GluPro 115 120 125 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly LysLys Arg 130 135 140 Pro Ile Glu Ser Pro Asp Ser Ser Thr Gly Ile Gly LysLys Gly Gln 145 150 155 160 Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly GlnThr Gly Asp Ser Glu 165 170 175 Ser Val Pro Asp Pro Gln Pro Ile Gly GluPro Pro Ala Gly Pro Ser 180 185 190 Gly Leu Gly Ser Gly Thr Met Ala AlaGly Gly Gly Ala Pro Met Ala 195 200 205 Asp Asn Asn Glu Gly Ala Asp GlyVal Gly Asn Ala Ser Gly Asn Trp 210 215 220 His Cys Asp Ser Thr Trp LeuGly Asp Arg Val Ile Thr Thr Ser Thr 225 230 235 240 Arg Thr Trp Ala LeuPro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile 245 250 255 Ser Ser Gln SerGly Ala Thr Asn Asp Asn His Phe Phe Gly Tyr Ser 260 265 270 Thr Pro TrpGly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe Ser 275 280 285 Pro ArgAsp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg Pro 290 295 300 ArgLys Leu Arg Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val Thr 305 310 315320 Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr Ile 325330 335 Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly Ser340 345 350 Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val Phe MetIle 355 360 365 Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser Gln SerVal Gly 370 375 380 Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro Ser GlnMet Leu Arg 385 390 395 400 Thr Gly Asn Asn Phe Glu Phe Ser Tyr Thr PheGlu Glu Val Pro Phe 405 410 415 His Ser Ser Tyr Ala His Ser Gln Ser LeuAsp Arg Leu Met Asn Pro 420 425 430 Leu Ile Asp Gln Tyr Leu Tyr Tyr LeuAla Arg Thr Gln Ser Thr Thr 435 440 445 Gly Ser Thr Arg Glu Leu Gln PheHis Gln Ala Gly Pro Asn Thr Met 450 455 460 Ala Glu Gln Ser Lys Asn TrpLeu Pro Gly Pro Cys Tyr Arg Arg Gln 465 470 475 480 Arg Leu Ser Lys AspIle Asp Ser Asn Asn Asn Ser Asn Phe Ala Trp 485 490 495 Thr Gly Ala ThrLys Tyr His Leu Asn Gly Arg Asn Ser Leu Thr Asn 500 505 510 Pro Gly ValAla Met Ala Thr Asn Lys Asp Asp Glu Asp Gln Phe Phe 515 520 525 Pro IleAsn Gly Val Leu Val Phe Gly Lys Thr Gly Ala Ala Asn Lys 530 535 540 ThrThr Leu Glu Asn Val Leu Met Thr Ser Glu Glu Glu Ile Lys Thr 545 550 555560 Thr Asn Pro Val Ala Thr Glu Glu Tyr Gly Val Val Ser Ser Asn Leu 565570 575 Gln Ser Ser Thr Ala Gly Pro Gln Thr Gln Thr Val Asn Ser Gln Gly580 585 590 Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr Leu GlnGly 595 600 605 Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn Phe HisPro Ser 610 615 620 Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro Pro ProGln Ile Leu 625 630 635 640 Ile Lys Asn Thr Pro Val Pro Ala Asn Pro ProGlu Val Phe Thr Pro 645 650 655 Ala Lys Phe Ala Ser Phe Ile Thr Gln TyrSer Thr Gly Gln Val Ser 660 665 670 Val Glu Ile Glu Trp Glu Leu Gln LysGlu Asn Ser Lys Arg Trp Asn 675 680 685 Pro Glu Ile Gln Tyr Thr Ser AsnTyr Ala Lys Ser Asn Asn Val Glu 690 695 700 Phe Ala Val Asn Asn Glu GlyVal Tyr Thr Glu Pro Arg Pro Ile Gly 705 710 715 720 Thr Arg Tyr Leu ThrArg Asn Leu 725 109 729 PRT capsid protein of AAV serotype, clone F1VP1109 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn Leu Ser 1 510 15 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala Pro Lys Pro 2025 30 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu Val Leu Pro 3540 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys Gly Glu Pro 5055 60 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys Ala Tyr Asp 6570 75 80 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg Tyr Asn His Ala85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr Ser Phe Gly Gly100 105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys Arg Val Leu GluPro 115 120 125 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr Ala Pro Gly LysLys Arg 130 135 140 Pro Ile Asp Ser Pro Asp Ser Ser Thr Gly Ile Gly LysLys Gly Gln 145 150 155 160 Gln Pro Ala Lys Lys Lys Leu Asn Phe Gly GlnThr Gly Asp Ser Glu 165 170 175 Ser Val Pro Asp Pro Gln Pro Leu Gly GluPro Pro Ala Ala Pro Ser 180 185 190 Ser Val Gly Ser Gly Thr Met Ala AlaGly Gly Gly Ala Pro Met Ala 195 200 205 Asp Asn Asn Glu Gly Ala Asp GlyVal Gly Asn Ala Ser Gly Asn Trp 210 215 220 His Cys Asp Ser Thr Trp LeuGly Asp Arg Val Ile Thr Thr Ser Thr 225 230 235 240 Arg Thr Trp Ala LeuPro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile 245 250 255 Ser Ser Ser SerSer Gly Ala Thr Asn Asp Asn His Tyr Phe Gly Tyr 260 265 270 Ser Thr ProTrp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe 275 280 285 Ser ProArg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg 290 295 300 ProLys Lys Leu Arg Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val 305 310 315320 Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu Thr Ser Thr 325330 335 Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro Tyr Val Leu Gly340 345 350 Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro Ala Asp Val PheMet 355 360 365 Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn Asn Gly Ser GlnSer Val 370 375 380 Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr Phe Pro SerGln Met Leu 385 390 395 400 Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr SerPhe Glu Asp Val Pro 405 410 415 Phe His Ser Ser Tyr Ala His Ser Gln SerLeu Asp Arg Leu Met Asn 420 425 430 Pro Leu Ile Asp Gln Tyr Leu Tyr TyrLeu Ala Arg Thr Gln Ser Thr 435 440 445 Thr Gly Ser Thr Arg Glu Leu GlnPhe His Gln Ala Gly Pro Asn Thr 450 455 460 Met Ala Glu Gln Ser Lys AsnTrp Leu Pro Gly Pro Cys Tyr Arg Gln 465 470 475 480 Gln Gly Leu Ser LysAsn Leu Asp Phe Asn Asn Asn Ser Asn Phe Ala 485 490 495 Trp Thr Ala AlaThr Lys Tyr His Leu Asn Gly Arg Asn Ser Leu Thr 500 505 510 Asn Pro GlyIle Pro Met Ala Thr Asn Lys Asp Asp Glu Asp Gln Phe 515 520 525 Phe ProIle Asn Gly Val Leu Val Phe Gly Lys Thr Gly Ala Ala Asn 530 535 540 LysThr Thr Leu Glu Asn Val Leu Met Thr Ser Glu Glu Glu Ile Lys 545 550 555560 Thr Thr Asn Pro Val Ala Thr Glu Glu Tyr Gly Val Val Ser Ser Asn 565570 575 Leu Gln Pro Ser Thr Ala Gly Pro Gln Ser Gln Thr Ile Asn Ser Gln580 585 590 Gly Ala Leu Pro Gly Met Val Trp Gln Asn Arg Asp Val Tyr LeuGln 595 600 605 Gly Pro Ile Trp Ala Lys Ile Pro His Thr Asp Gly Asn PheHis Pro 610 615 620 Ser Pro Leu Met Gly Gly Phe Gly Leu Lys His Pro ProPro Gln Ile 625 630 635 640 Leu Ile Lys Asn Thr Pro Val Pro Ala Asn ProPro Glu Val Phe Thr 645 650 655 Pro Ala Lys Phe Ala Ser Phe Ile Thr GlnTyr Ser Thr Gly Gln Val 660 665 670 Ser Val Glu Ile Glu Trp Glu Leu GlnLys Glu Asn Ser Lys Arg Trp 675 680 685 Asn Pro Glu Ile Gln Tyr Thr SerAsn Tyr Ala Lys Ser Asn Asn Val 690 695 700 Glu Phe Ala Val Asn Pro AspGly Val Tyr Thr Glu Pro Arg Pro Ile 705 710 715 720 Gly Thr Arg Tyr LeuPro Arg Asn Leu 725 110 729 PRT capsid protein of AAV serotype, cloneF5VP1@3 110 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn LeuSer 1 5 10 15 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala ProLys Pro 20 25 30 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu ValLeu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys GlyGlu Pro 50 55 60 Val Asn Ala Ala Asp Ala Ala Ala Leu Glu His Asp Lys AlaTyr Asp 65 70 75 80 Gln Gln Leu Lys Ala Gly Asp Asn Pro Tyr Leu Arg TyrAsn His Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr SerPhe Gly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys ArgVal Leu Glu Pro 115 120 125 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr AlaPro Gly Lys Lys Arg 130 135 140 Pro Ile Asp Ser Pro Asp Ser Ser Thr GlyIle Gly Lys Lys Gly Gln 145 150 155 160 Gln Pro Ala Lys Lys Lys Leu AsnPhe Gly Gln Thr Gly Asp Ser Glu 165 170 175 Ser Val Pro Asp Pro Gln ProLeu Gly Glu Pro Pro Ala Ala Pro Ser 180 185 190 Ser Val Gly Ser Gly ThrMet Ala Ala Gly Gly Gly Ala Pro Thr Ala 195 200 205 Asp Asn Asn Glu GlyAla Asp Gly Val Gly Asn Ala Ser Gly Asn Trp 210 215 220 His Cys Asp SerThr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr 225 230 235 240 Arg ThrTrp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile 245 250 255 SerSer Ser Ser Ser Gly Ala Thr Asn Asp Asn His Tyr Phe Gly Tyr 260 265 270Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His Cys His Phe 275 280285 Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn Trp Gly Phe Arg 290295 300 Pro Lys Lys Leu Arg Phe Lys Leu Phe Asn Ile Gln Val Lys Glu Val305 310 315 320 Thr Thr Asn Asp Gly Val Thr Thr Ile Ala Asn Asn Leu ThrSer Thr 325 330 335 Val Gln Val Phe Ser Asp Ser Glu Tyr Gln Leu Pro TyrVal Leu Gly 340 345 350 Ser Ala His Gln Gly Cys Leu Pro Pro Phe Pro AlaAsp Val Phe Met 355 360 365 Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn AsnGly Ser Gln Ser Val 370 375 380 Gly Arg Ser Ser Phe Tyr Cys Leu Glu TyrPhe Pro Ser Gln Met Leu 385 390 395 400 Arg Thr Gly Asn Asn Phe Glu PheSer Tyr Ser Phe Glu Asp Val Pro 405 410 415 Phe His Ser Ser Tyr Ala HisSer Gln Ser Leu Asp Arg Leu Met Asn 420 425 430 Pro Leu Ile Asp Gln TyrLeu Tyr Tyr Leu Ala Arg Thr Gln Ser Thr 435 440 445 Thr Gly Ser Thr ArgGlu Leu Gln Phe His Gln Ala Gly Pro Asn Thr 450 455 460 Met Ala Glu GlnSer Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln 465 470 475 480 Gln ArgLeu Ser Lys Asn Leu Asp Phe Asn Asn Asn Ser Asn Phe Ala 485 490 495 TrpThr Ala Ala Thr Lys Tyr His Leu Asn Gly Arg Asn Ser Leu Thr 500 505 510Asn Pro Gly Ile Pro Met Ala Thr Asn Lys Asp Asp Glu Asp Gln Phe 515 520525 Phe Pro Ile Asn Gly Val Leu Val Phe Gly Lys Thr Gly Ala Ala Asn 530535 540 Lys Thr Thr Leu Glu Asn Val Leu Met Thr Ser Glu Glu Glu Ile Lys545 550 555 560 Thr Thr Asn Pro Val Ala Thr Glu Glu Tyr Gly Val Val SerSer Asn 565 570 575 Leu Gln Ser Ser Thr Ala Gly Pro Gln Ser Gln Thr IleAsn Ser Gln 580 585 590 Gly Ala Leu Pro Gly Met Val Trp Gln Asn Arg AspVal Tyr Leu Gln 595 600 605 Gly Pro Ile Trp Ala Lys Ile Pro His Thr AspGly Asn Phe His Pro 610 615 620 Ser Pro Leu Met Gly Gly Phe Gly Leu GluHis Pro Pro Pro Gln Ile 625 630 635 640 Leu Ile Lys Asn Thr Pro Val ProAla Asn Pro Pro Glu Val Phe Thr 645 650 655 Pro Ala Lys Phe Ala Ser PheIle Thr Gln Tyr Ser Thr Gly Gln Val 660 665 670 Ser Val Glu Ile Glu TrpGlu Leu Gln Lys Glu Asn Ser Lys Arg Trp 675 680 685 Asn Pro Glu Ile GlnTyr Thr Ser Asn Tyr Ala Lys Ser Asn Asn Val 690 695 700 Glu Phe Ala ValAsn Pro Asp Gly Val Tyr Thr Glu Pro Arg Pro Ile 705 710 715 720 Gly ThrArg Tyr Leu Thr Arg Asn Leu 725 111 729 PRT capsid protein of AAVserotype, clone F3VP1 111 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp LeuGlu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile Arg Glu Trp Trp Asp Leu LysPro Gly Ala Pro Lys Pro 20 25 30 Lys Ala Asn Gln Gln Lys Gln Asp Asp GlyArg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn GlyLeu Asp Lys Gly Glu Pro 50 55 60 Val Asn Ala Ala Asp Ala Ala Ala Leu GluHis Asp Lys Ala Tyr Asp 65 70 75 80 Gln Gln Leu Lys Ala Gly Asp Asn ProTyr Leu Arg Tyr Asn His Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu GlnGlu Asp Thr Ser Phe Gly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe GlnAla Lys Lys Arg Val Leu Glu Pro 115 120 125 Leu Gly Leu Val Glu Glu GlyAla Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140 Pro Ile Gly Ser Pro AspSer Ser Thr Gly Ile Gly Lys Lys Gly Gln 145 150 155 160 Gln Pro Ala LysLys Lys Leu Asn Phe Gly Gln Thr Gly Asp Ser Glu 165 170 175 Ser Val ProAsp Pro Gln Pro Leu Gly Glu Pro Pro Ala Ala Pro Ser 180 185 190 Ser ValGly Ser Gly Thr Met Ala Ala Gly Gly Gly Ala Pro Met Ala 195 200 205 AspAsn Asn Glu Gly Ala Asp Gly Val Gly Asn Ala Ser Gly Asn Trp 210 215 220His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val Ile Thr Thr Ser Thr 225 230235 240 Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His Leu Tyr Lys Gln Ile245 250 255 Ser Ser Ser Ser Ser Gly Ala Thr Asn Asp Asn His Tyr Phe GlyTyr 260 265 270 Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn Arg Phe His CysHis Phe 275 280 285 Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn Asn Asn TrpGly Phe Arg 290 295 300 Pro Lys Lys Leu Arg Phe Lys Leu Leu Asn Ile GlnVal Lys Glu Val 305 310 315 320 Thr Thr Asn Asp Gly Val Thr Thr Ile AlaAsn Asn Leu Thr Ser Thr 325 330 335 Val Gln Val Phe Ser Asp Ser Glu TyrGln Leu Pro Tyr Val Leu Gly 340 345 350 Ser Ala His Gln Gly Cys Leu ProPro Phe Pro Ala Asp Val Phe Met 355 360 365 Ile Pro Gln Tyr Gly Tyr LeuThr Leu Asp Asn Gly Ser Gln Ser Val 370 375 380 Gly Arg Ser Ser Phe TyrCys Leu Glu Tyr Phe Pro Ser Gln Met Leu 385 390 395 400 Arg Thr Gly AsnAsn Phe Glu Phe Ser Tyr Ser Phe Glu Asp Val Pro 405 410 415 Phe His SerSer Tyr Ala His Ser Gln Ser Leu Asp Arg Leu Met Asn 420 425 430 Pro LeuIle Asp Gln Tyr Leu Tyr Tyr Leu Ala Arg Thr Gln Ser Thr 435 440 445 ThrGly Ser Thr Arg Glu Leu Gln Phe His Gln Ala Gly Pro Asn Thr 450 455 460Met Ala Glu Gln Ser Lys Asn Trp Leu Pro Gly Pro Cys Tyr Arg Gln 465 470475 480 Gln Arg Leu Ser Lys Asn Leu Asp Phe Asn Asn Asn Ser Asn Phe Ala485 490 495 Trp Thr Ala Ala Thr Lys Tyr His Leu Asn Gly Arg Asn Ser LeuThr 500 505 510 Asn Pro Gly Ile Pro Met Ala Thr Asn Lys Asp Asp Glu AspGln Phe 515 520 525 Phe Pro Ile Asn Gly Val Leu Val Phe Gly Lys Thr GlyAla Ala Asn 530 535 540 Lys Thr Thr Leu Glu Asn Val Leu Met Thr Ser GluGlu Glu Ile Lys 545 550 555 560 Thr Thr Asn Pro Val Ala Thr Glu Glu TyrGly Val Val Ser Ser Asn 565 570 575 Leu Gln Ser Ser Thr Ala Gly Pro GlnSer Gln Thr Ile Asn Ser Gln 580 585 590 Gly Ala Leu Pro Gly Met Val TrpGln Asn Arg Asp Val Tyr Leu Gln 595 600 605 Gly Pro Ile Trp Ala Lys IlePro His Thr Asp Gly Asn Phe His Pro 610 615 620 Ser Pro Leu Met Gly GlyPhe Gly Leu Lys His Pro Pro Pro Gln Ile 625 630 635 640 Leu Ile Lys AsnThr Pro Val Pro Ala Asn Pro Pro Glu Val Phe Thr 645 650 655 Pro Ala LysPhe Ala Ser Phe Ile Thr Gln Tyr Ser Thr Gly Gln Val 660 665 670 Ser ValGlu Ile Glu Trp Glu Leu Gln Lys Glu Asn Ser Lys Arg Trp 675 680 685 AsnPro Glu Ile Gln Tyr Thr Ser Asn Tyr Ala Lys Ser Asn Asn Val 690 695 700Glu Phe Ala Val Asn Pro Asp Gly Val Tyr Thr Glu Pro Arg Pro Ile 705 710715 720 Gly Thr Arg Tyr Leu Thr Arg Asn Leu 725 112 735 PRT capsidprotein of AAV serotype, clone 42.6B 112 Met Ala Ala Asp Gly Tyr Leu ProAsp Trp Leu Glu Asp Asn Leu Ser 1 5 10 15 Glu Gly Ile Arg Glu Trp TrpAsp Leu Lys Pro Gly Ala Pro Lys Pro 20 25 30 Lys Ala Asn Gln Gln Lys GlnAsp Asp Gly Arg Gly Leu Val Leu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly ProPhe Asn Gly Leu Asp Lys Gly Glu Pro 50 55 60 Val Asn Glu Ala Asp Ala AlaAla Leu Glu His Asp Lys Ala Tyr Asp 65 70 75 80 Lys Gln Leu Glu Gln GlyAsp Asn Pro Tyr Leu Lys Tyr Asn His Ala 85 90 95 Asp Ala Glu Phe Gln GluArg Leu Gln Glu Asp Thr Ser Phe Gly Gly 100 105 110 Asn Leu Gly Arg AlaVal Phe Gln Ala Lys Lys Arg Val Leu Glu Pro 115 120 125 Leu Gly Leu ValGlu Glu Gly Ala Lys Thr Ala Pro Gly Lys Lys Arg 130 135 140 Pro Val GluPro Ser Pro Gln Arg Ser Pro Asp Ser Ser Thr Gly Ile 145 150 155 160 GlyLys Thr Gly Gln Gln Pro Ala Lys Lys Arg Leu Asn Phe Gly Gln 165 170 175Thr Gly Asp Ser Glu Ser Val Pro Asp Pro Gln Pro Ile Gly Glu Pro 180 185190 Pro Ala Gly Pro Ser Gly Leu Gly Ser Gly Thr Met Ala Ala Gly Gly 195200 205 Gly Ala Pro Met Ala Asp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser210 215 220 Ser Ser Gly Asn Trp His Cys Asp Ser Thr Trp Leu Gly Asp ArgVal 225 230 235 240 Ile Thr Thr Ser Thr Arg Thr Trp Ala Leu Pro Thr TyrAsn Asn His 245 250 255 Leu Tyr Lys Gln Ile Ser Asn Gly Thr Ser Gly GlySer Thr Asn Asp 260 265 270 Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp GlyTyr Phe Asp Phe Asn 275 280 285 Arg Phe His Cys His Phe Ser Pro Arg AspTrp Gln Arg Leu Ile Asn 290 295 300 Asn Asn Trp Gly Phe Arg Pro Arg LysLeu Arg Phe Lys Leu Phe Asn 305 310 315 320 Ile Gln Val Lys Glu Val ThrThr Asp Asp Gly Val Thr Thr Ile Ala 325 330 335 Asn Asn Leu Thr Ser ThrIle Gln Val Phe Ser Asp Ser Glu Tyr Gln 340 345 350 Leu Pro Tyr Val LeuGly Ser Ala His Gln Gly Cys Leu Pro Pro Phe 355 360 365 Pro Ala Asp ValPhe Met Ile Pro Gln Tyr Gly Tyr Leu Thr Leu Asn 370 375 380 Asn Gly SerGln Ser Val Gly Arg Ser Ser Phe Tyr Cys Leu Glu Tyr 385 390 395 400 PhePro Ser Gln Met Leu Arg Thr Gly Asn Asn Phe Glu Phe Ser Tyr 405 410 415Thr Phe Glu Glu Val Pro Phe His Ser Ser Tyr Ala His Ser Gln Ser 420 425430 Leu Asp Arg Leu Met Asn Pro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu 435440 445 Ala Arg Thr Gln Ser Thr Thr Gly Ser Thr Arg Glu Leu Gln Phe His450 455 460 Gln Ala Gly Pro Asn Thr Met Ala Glu Gln Ser Lys Asn Trp LeuPro 465 470 475 480 Gly Pro Cys Tyr Arg Gln Gln Arg Leu Ser Lys Asn IleAsp Ser Asn 485 490 495 Asn Asn Ser Asn Phe Ala Trp Thr Gly Ala Thr LysTyr His Leu Asn 500 505 510 Gly Arg Asn Ser Leu Thr Asn Pro Gly Val AlaMet Ala Thr Asn Lys 515 520 525 Asp Asp Glu Asp Gln Phe Phe Pro Ile AsnGly Val Leu Val Phe Gly 530 535 540 Lys Thr Gly Ala Ala Asn Lys Thr ThrLeu Glu Asn Val Leu Met Thr 545 550 555 560 Ser Glu Glu Glu Ile Lys ThrThr Asn Pro Val Ala Thr Glu Glu Tyr 565 570 575 Gly Val Val Ser Ser AsnLeu Gln Ser Ser Thr Ala Gly Pro Gln Thr 580 585 590 Gln Thr Val Asn SerGln Gly Ala Leu Pro Gly Met Val Trp Gln Asn 595 600 605 Arg Asp Val TyrLeu Gln Gly Pro Ile Trp Ala Lys Ile Pro His Thr 610 615 620 Asp Gly AsnPhe His Pro Ser Pro Leu Met Asp Gly Phe Gly Leu Lys 625 630 635 640 HisPro Pro Pro Gln Ile Leu Ile Lys Asn Thr Pro Val Pro Ala Asn 645 650 655Pro Pro Glu Val Phe Thr Pro Ala Lys Phe Ala Ser Phe Ile Thr Gln 660 665670 Tyr Ser Thr Gly Gln Val Ser Val Glu Ile Glu Trp Glu Leu Gln Lys 675680 685 Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln Tyr Thr Ser Asn Tyr690 695 700 Ala Lys Ser Asn Asn Val Glu Phe Ala Val Asn Asn Glu Gly ValTyr 705 710 715 720 Thr Glu Pro Arg Pro Ile Gly Thr Arg Tyr Leu Thr ArgAsn Leu 725 730 735 113 685 PRT capsid protein of AAV serotype, clone42.12 113 Met Ala Ala Asp Gly Tyr Leu Pro Asp Trp Leu Glu Asp Asn LeuSer 1 5 10 15 Glu Gly Ile Arg Glu Trp Trp Asp Leu Lys Pro Gly Ala ProLys Pro 20 25 30 Lys Ala Asn Gln Gln Lys Gln Asp Asp Gly Arg Gly Leu ValLeu Pro 35 40 45 Gly Tyr Lys Tyr Leu Gly Pro Phe Asn Gly Leu Asp Lys GlyGlu Pro 50 55 60 Val Asn Glu Ala Asp Ala Ala Ala Leu Glu His Asp Lys AlaTyr Asp 65 70 75 80 Lys Gln Leu Glu Gln Gly Asp Asn Pro Tyr Leu Lys TyrAsn His Ala 85 90 95 Asp Ala Glu Phe Gln Glu Arg Leu Gln Glu Asp Thr SerPhe Gly Gly 100 105 110 Asn Leu Gly Arg Ala Val Phe Gln Ala Lys Lys ArgVal Leu Glu Pro 115 120 125 Leu Gly Leu Val Glu Glu Gly Ala Lys Thr AlaPro Gly Lys Lys Arg 130 135 140 Pro Val Glu Pro Ser Pro Gln Arg Ser ProAsp Ser Ser Thr Gly Ile 145 150 155 160 Gly Lys Thr Gly Gln Gln Pro AlaLys Lys Arg Leu Asn Phe Gly Gln 165 170 175 Thr Gly Asp Ser Glu Ser ValPro Asp Pro Gln Pro Ile Gly Glu Pro 180 185 190 Pro Ala Gly Pro Ser GlyLeu Gly Ser Gly Thr Met Ala Ala Gly Gly 195 200 205 Gly Ala Pro Met AlaAsp Asn Asn Glu Gly Ala Asp Gly Val Gly Ser 210 215 220 Ser Ser Gly AsnTrp His Cys Asp Ser Thr Trp Leu Gly Asp Arg Val 225 230 235 240 Ile ThrThr Ser Thr Arg Thr Trp Ala Leu Pro Thr Tyr Asn Asn His 245 250 255 LeuTyr Lys Gln Ile Ser Asn Gly Thr Ser Gly Gly Ser Thr Asn Asp 260 265 270Asn Thr Tyr Phe Gly Tyr Ser Thr Pro Trp Gly Tyr Phe Asp Phe Asn 275 280285 Arg Phe His Cys His Phe Ser Pro Arg Asp Trp Gln Arg Leu Ile Asn 290295 300 Asn Asn Trp Gly Phe Arg Pro Lys Arg Leu Asn Phe Lys Leu Phe Asn305 310 315 320 Ile Gln Val Lys Glu Val Thr Gln Asn Glu Gly Thr Lys ThrIle Ala 325 330 335 Asn Asn Leu Thr Ser Thr Ile Gln Val Phe Thr Asp SerGlu Tyr Gln 340 345 350 Leu Pro Tyr Val Leu Gly Ser Ala His Gln Gly CysLeu Pro Pro Phe 355 360 365 Pro Ala Asp Val Phe Met Ile Pro Gln Tyr GlyTyr Leu Thr Leu Asn 370 375 380 Asn Gly Ser Gln Ala Val Gly Arg Ser SerPhe Tyr Cys Leu Glu Tyr 385 390 395 400 Phe Pro Ser Gln Met Leu Arg ThrGly Asn Asn Phe Glu Phe Ser Tyr 405 410 415 Gln Phe Glu Asp Val Pro PheHis Ser Ser Tyr Ala His Ser Gln Ser 420 425 430 Leu Asp Arg Leu Thr AsnPro Leu Ile Asp Gln Tyr Leu Tyr Tyr Leu 435 440 445 Ala Arg Thr Gln SerThr Thr Gly Ser Thr Arg Gly Leu Gln Phe His 450 455 460 Gln Ala Gly ProAsn Thr Met Ala Glu Gln Ser Lys Asn Trp Leu Pro 465 470 475 480 Gly ProCys Tyr Arg Gln Gln Arg Leu Ser Lys Asn Ile Asp Ser Asn 485 490 495 AsnAsn Ser Asn Phe Ala Trp Thr Gly Ala Thr Lys Tyr His Leu Asn 500 505 510Gly Arg Asn Ser Leu Thr Asn Pro Gly Val Ala Met Ala Thr Asn Lys 515 520525 Asp Asp Glu Asp Gln Phe Phe Pro Ile Asn Gly Val Leu Val Phe Gly 530535 540 Lys Thr Gly Ala Ala Asn Lys Thr Thr Leu Glu Asn Val Leu Met Thr545 550 555 560 Ser Glu Glu Glu Ile Lys Thr Thr Asn Pro Val Ala Thr GluGlu Tyr 565 570 575 Gly Val Val Ser Ser Asn Leu Gln Ser Ser Thr Ala GlyPro Gln Thr 580 585 590 Gln Thr Val Asn Ser Gln Gly Ala Leu Pro Gly MetVal Trp Gln Asn 595 600 605 Arg Asp Val Tyr Leu Gln Gly Pro Ile Trp AlaLys Ile Pro His Thr 610 615 620 Asp Gly Asn Phe His Pro Ser Pro Leu MetGly Gly Phe Gly Leu Lys 625 630 635 640 His Pro Pro Pro Gln Ile Leu IleLys Tyr Thr Ser Asn Tyr Tyr Lys 645 650 655 Ser Thr Asn Val Asp Phe AlaVal Asn Thr Glu Gly Thr Tyr Ser Glu 660 665 670 Pro Arg Pro Ile Gly ThrArg Tyr Leu Thr Arg Asn Leu 675 680 685 114 724 PRT capsid protein ofAAV serotype, clone AAV5CAP 114 Met Ser Phe Val Asp His Pro Pro Asp TrpLeu Glu Glu Val Gly Glu 1 5 10 15 Gly Leu Arg Glu Phe Leu Gly Leu GluAla Gly Pro Pro Lys Pro Lys 20 25 30 Pro Asn Gln Gln His Gln Asp Gln AlaArg Gly Leu Val Leu Pro Gly 35 40 45 Tyr Asn Tyr Leu Gly Pro Gly Asn GlyLeu Asp Arg Gly Glu Pro Val 50 55 60 Asn Arg Ala Asp Glu Val Ala Arg GluHis Asp Ile Ser Tyr Asn Glu 65 70 75 80 Gln Leu Glu Ala Gly Asp Asn ProTyr Leu Lys Tyr Asn His Ala Asp 85 90 95 Ala Glu Phe Gln Glu Lys Leu AlaAsp Asp Thr Ser Phe Gly Gly Asn 100 105 110 Leu Gly Lys Ala Val Phe GlnAla Lys Lys Arg Val Leu Glu Pro Phe 115 120 125 Gly Leu Val Glu Glu GlyAla Lys Thr Ala Pro Thr Gly Lys Arg Ile 130 135 140 Asp Asp His Phe ProLys Arg Lys Lys Ala Arg Thr Glu Glu Asp Ser 145 150 155 160 Lys Pro SerThr Ser Ser Asp Ala Glu Ala Gly Pro Ser Gly Ser Gln 165 170 175 Gln LeuGln Ile Pro Ala Gln Pro Ala Ser Ser Leu Gly Ala Asp Thr 180 185 190 MetSer Ala Gly Gly Gly Gly Pro Leu Gly Asp Asn Asn Gln Gly Ala 195 200 205Asp Gly Val Gly Asn Ala Ser Gly Asp Trp His Cys Asp Ser Thr Trp 210 215220 Met Gly Asp Arg Val Val Thr Lys Ser Thr Arg Thr Trp Val Leu Pro 225230 235 240 Ser Tyr Asn Asn His Gln Tyr Arg Glu Ile Lys Ser Gly Ser ValAsp 245 250 255 Gly Ser Asn Ala Asn Ala Tyr Phe Gly Tyr Ser Thr Pro TrpGly Tyr 260 265 270 Phe Asp Phe Asn Arg Phe His Ser His Trp Ser Pro ArgAsp Trp Gln 275 280 285 Arg Leu Ile Asn Asn Tyr Trp Gly Phe Arg Pro ArgSer Leu Arg Val 290 295 300 Lys Ile Phe Asn Ile Gln Val Lys Glu Val ThrVal Gln Asp Ser Thr 305 310 315 320 Thr Thr Ile Ala Asn Asn Leu Thr SerThr Val Gln Val Phe Thr Asp 325 330 335 Asp Asp Tyr Gln Leu Pro Tyr ValVal Gly Asn Gly Thr Glu Gly Cys 340 345 350 Leu Pro Ala Phe Pro Pro GlnVal Phe Thr Leu Pro Gln Tyr Gly Tyr 355 360 365 Ala Thr Leu Asn Arg AspAsn Thr Glu Asn Pro Thr Glu Arg Ser Ser 370 375 380 Phe Phe Cys Leu GluTyr Phe Pro Ser Lys Met Leu Arg Thr Gly Asn 385 390 395 400 Asn Phe GluPhe Thr Tyr Asn Phe Glu Glu Val Pro Phe His Ser Ser 405 410 415 Phe AlaPro Ser Gln Asn Leu Phe Lys Leu Ala Asn Pro Leu Val Asp 420 425 430 GlnTyr Leu Tyr Arg Phe Val Ser Thr Asn Asn Thr Gly Gly Val Gln 435 440 445Phe Asn Lys Asn Leu Ala Gly Arg Tyr Ala Asn Thr Tyr Lys Asn Trp 450 455460 Phe Pro Gly Pro Met Gly Arg Thr Gln Gly Trp Asn Leu Gly Ser Gly 465470 475 480 Val Asn Arg Ala Ser Val Ser Ala Phe Ala Thr Thr Asn Arg MetGlu 485 490 495 Leu Glu Gly Ala Ser Tyr Gln Val Pro Pro Gln Pro Asn GlyMet Thr 500 505 510 Asn Asn Leu Gln Gly Ser Asn Thr Tyr Ala Leu Glu AsnThr Met Ile 515 520 525 Phe Asn Ser Gln Pro Ala Asn Pro Gly Thr Thr AlaThr Tyr Leu Glu 530 535 540 Gly Asn Met Leu Ile Thr Ser Glu Ser Glu ThrGln Pro Val Asn Arg 545 550 555 560 Val Ala Tyr Asn Val Gly Gly Gln MetAla Thr Asn Asn Gln Ser Ser 565 570 575 Thr Thr Ala Pro Ala Thr Gly ThrTyr Asn Leu Gln Glu Ile Val Pro 580 585 590 Gly Ser Val Trp Met Glu ArgAsp Val Tyr Leu Gln Gly Pro Ile Trp 595 600 605 Ala Lys Ile Pro Glu ThrGly Ala His Phe His Pro Ser Pro Ala Met 610 615 620 Gly Gly Phe Gly LeuLys His Pro Pro Pro Met Met Leu Ile Lys Asn 625 630 635 640 Thr Pro ValPro Gly Asn Ile Thr Ser Phe Ser Asp Val Pro Val Ser 645 650 655 Ser PheIle Thr Gln Tyr Ser Thr Gly Gln Val Thr Val Glu Met Glu 660 665 670 TrpGlu Leu Lys Lys Glu Asn Ser Lys Arg Trp Asn Pro Glu Ile Gln 675 680 685Tyr Thr Asn Asn Tyr Asn Asp Pro Gln Phe Val Asp Phe Ala Pro Asp 690 695700 Ser Thr Gly Glu Tyr Arg Thr Thr Arg Pro Ile Gly Thr Arg Tyr Leu 705710 715 720 Thr Arg Pro Leu 115 9 DNA DraIII restriction enzyme site 115caccacgtc 9 116 28 DNA AV2cas 116 cgcagagacc aaagttcaac tgaaacga 28 117255 DNA adeno-associated virus serotype 10 117 ggtaattcct ccggaaattggcattgcgat tccacatggc tgggcgacag agtcatcacc 60 accagcaccc gaacctgggtcctgcccacc tacaacaacc acatctacaa gcaaatctcc 120 agcgagacag gagccaccaacgacaaccac tacttcggct acagcacccc ctgggggtat 180 tttgacttta acagattccactgccacttt tcaccacgtg actggcagcg actcatcaac 240 aacaactggg gattc 255 118258 DNA adeno-associated virus serotype 11 118 ggtaattcct ccggaaattggcattgcgat tccacatggc tgggcgacag agtcatcacc 60 accagcaccc gaacctgggccctgccaacc tacaacaacc acctctacaa acaaatctcc 120 agcgcttcaa cgggggccagcaacgacaac cactactttg gctacagcac cccctggggg 180 tattttgact ttaacagattccactgccac ttctcaccac gtgactggca gcgactcatc 240 aacaacaact ggggattc 258119 255 DNA adeno-associated virus serotype 12 119 ggtaattcct ccggaaattggcattgcgat tccacatggc tgggcgaccg agtcattacc 60 accagcaccc ggacttgggccctgcccacc tacaacaacc acctctacaa gcaaatctcc 120 agccaatcgg gtgccaccaacgacaaccac tacttcggct acagcacccc ttgggggtat 180 tttgatttca acagattccactgccatttc tcaccacgtg actggcagcg actcatcaac 240 aacaactggg gattc 255 1202205 DNA adeno-associated virus serotype, clone A3.1vp1 120 atggctgccgatggttatct tccagattgg ctcgaggaca ctctctctga aggaatcaga 60 cagtggtggaagctcaaacc tggcccacca ccgccgaaac ctaaccaaca acaccgggac 120 gacagtaggggtcttgtgct tcctgggtac aagtacctcg gacccttcaa cggactcgac 180 aaaggagagccggtcaacga ggcagacgcc gcggccctcg agcacgacaa agcctacgac 240 caccagctcaagcaagggga caacccgtac ctcaaataca accacgcgga cgctgaattt 300 caggagcgtcttcaagaaga tacgtctttc gggggcaacc tcgggcgagc agtcttccag 360 gccaaaaagagggtactcga gcctcttggt ctggttgagg aagctgttaa gacggctcct 420 ggaaaaaagagacctataga gcagtctcct gcagaaccgg actcttcctc gggcatcggc 480 aaatcaggccagcagcccgc taagaaaaga ctcaattttg gtcagactgg cgacacagag 540 tcagtcccagaccctcaacc aatcggagaa ccccccgcag ccccctctgg tgtgggatct 600 aatacaatggcttcaggcgg tggggcacca atggcagaca ataacgaagg cgccgacgga 660 gtgggtaattcctcgggaaa ttggcattgc gattccacat ggatgggcga cagagttatc 720 accaccagcacaagaacctg ggccctcccc acctacaata atcacctcta caagcaaatc 780 tccagcgaatcgggagccac caacgacaac cactacttcg gctacagcac cccctggggg 840 tattttgactttaacagatt ccactgtcac ttctcaccac gtgactggca gcgactcatc 900 aacaacaactggggatttag acccaagaaa ctcaatttca agctcttcaa catccaagtc 960 aaggaggtcacgcagaatga tggaaccacg accatcgcca ataaccttac cagcacggtg 1020 caggtcttcacagactctga gtaccagctg ccctacgtcc tcggttcggc tcaccagggc 1080 tgccttccgccgttcccagc agacgtcttc atgattcctc agtacggcta cttgactctg 1140 aacaatggcagccaagcggt aggacgttct tcattctact gtctagagta ttttccctct 1200 cagatgctgaggacgggaaa caacttcacc ttcagctaca cttttgaaga cgtgcctttc 1260 cacagcagctacgcgcacag ccagagtctg gatcggctga tgaatcctct cattgaccag 1320 tacctgtattacctgagcaa aactcagggt acaagtggaa caacgcagca atcgagactg 1380 cagttcagccaagctgggcc tagctccatg gctcagcagg ccaaaaactg gctaccggga 1440 cccagctaccgacagcagcg aatgtctaag acggctaatg acaacaacaa cagtgaattt 1500 gcttggactgcagccaccaa atattacctg aatggaagaa attctctggt caatcccggg 1560 cccccaatggccagtcacaa ggacgatgag gaaaagtatt tccccatgca cggaaatctc 1620 atctttggaaaacaaggcac aggaactacc aatgtggaca ttgaatcagt gcttattaca 1680 gacgaagaagaaatcagaac aactaatcct gtggctacag aacaatacgg acaggttgcc 1740 accaaccatcagagtcagaa caccacagct tcctatggaa gtgtggacag ccagggaatc 1800 ttacctggaatggtgtggca ggaccgcgat gtctatcttc aaggtcccat ttgggccaaa 1860 actcctcacacggacggaca ctttcatcct tctccgctca tgggaggctt tggactgaaa 1920 caccctcctccccagatcct gatcaaaaac acacctgtgc cagcgaatcc cgcgaccact 1980 ttcactcctggaaagtttgc ttcgttcatt acccagtatt ccaccggaca ggtcagcgtg 2040 gaaatagagtgggagctgca gaaagaaaac agcaaacgct ggaacccaga aattcagtac 2100 acctccaactacaacaagtc ggtgaatgtg gagtttaccg tggacgcaaa cggtgtttat 2160 tctgaaccccgccctattgg cactcgttac cttacccgga acttg 2205

What is claimed is:
 1. A method of detecting adeno-associated virus(AAV) sequences in a sample, said method comprising the steps of: (a)subjecting a sample containing DNA to amplification via polymerase chainreaction (PCR) using a first set of primers which specifically amplify afirst region of AAV nucleic acid sequences; (b) optionally subjectingthe DNA to further amplification using a second set of primers whichspecifically amplify a second region which comprises the first region ofAAV sequences and sequences which are 5′ to the first region, such thatAAV 5′ extension sequences which anneal to the 5′ end of the AAVsequences amplified by the primers for the first region are obtained;(c) optionally subjecting the DNA to further amplification using a thirdset of primers which specifically amplify a third region which comprisesthe first region of AAV sequences and sequences which are 3′ to thefirst region, such that AAV 3′ extension sequences which anneal to the3′ end of the AAV sequences amplified by the primers for the firstregion are obtained, wherein each of said regions is predetermined basedupon the alignment of the nucleic acid sequences of at least two AAVserotypes and each of said regions comprises nucleic acid sequenceswhich are highly conserved over at least 18 base pairs at the 5′ end,optionally variable sequences in the middle, and sequences which arehighly conserved over at least 18 base pairs at the 3′ end of thesequences of the region, relative to the sequences of the at least twoaligned AAV serotypes; and wherein each of the sets of primers consistof a 5′ primer and a 3′ primer; wherein the presence of amplifiedsequences indicates the presence of an AAV in the sample.
 2. A methodaccording to claim 1, wherein steps (b) and (c) are performed, andfurther comprising the step of: (d) using the amplified sequences toconstruct a sequence comprising a partial and/or complete AAV gene,thereby isolating an AAV gene sequence from the sample.
 3. The methodaccording to claim 2, wherein the first region is in the AAV capsid, thesecond region extends to the 3′ end of the rep genes, and the thirdregion extends to 5′ of the AAV 3′ ITR, such that step (d) permits theconstruction of AAV gene sequences comprising the complete AAV capsidgene.
 4. The method according to claim 2, further comprising the step ofsubjecting the DNA to amplification with a fourth set of primers whichspecifically amplifies a fourth region which extend 5′ to the thirdregion.
 5. The method according to claim 4, wherein the fourth regionextends to 3′ of the AAV 5′ ITR, such that step (d) permits theconstruction of AAV gene sequences comprising the complete AAV rep andcap genes.
 6. The method according to claim 1, wherein said samplecomprises cellular or genomic DNA.
 7. The method according to claim 1,wherein said DNA has been extracted from the group consisting of cells,cell culture, tissue, tissue culture, and biological fluids.
 8. Themethod according to claim 1, wherein the first region is about 250 basepairs in length.
 9. The method according to claim 1, wherein the firstregion is highly conserved over at least about 25 base pairs at the 5′and/or 3′ end of the region.
 10. The method according to claim 1,wherein the first region is highly conserved over at least about 30 basepairs at the 5′ and/or 3′ end of the region.
 11. The method according toclaim 1, wherein the highly conserved sequences of the first region haveat least 80% identity among the aligned AAV serotypes at the 5′ and/or3′ end of the region.
 12. The method according claim 11, wherein thehighly conserved sequences of the first region have at least 90%identity among the aligned AAV serotypes at the 5′ and/or 3′ end of theregion.
 13. The method according to claim 1, wherein the variablesequences in the middle of the first region have less than 70% identityamong the aligned AAV serotypes.
 14. The method according to claim 1,wherein the first region spans about bp 2800 to about 3200 of AAV 1, SEQID NO:6, and corresponding base pairs in other AAV serotypes.
 15. Themethod according to claim 14, wherein the first region is 257 bpspanning bp 2886 to about 3143 bp of AAV 1, SEQ ID NO:6, andcorresponding base pairs in other AAV serotypes.
 16. The methodaccording to claim 1, wherein the primers are AV1ns and AV2cas.
 17. Amethod of identifying the serotype of adeno-associated virus (AAV)sequences in a sample as known or unknown, said method comprising thesteps of: (a) obtaining an enzymatic digestion analysis of a samplecontaining DNA molecules comprising AAV sequences which span all or aportion of bp 2886 to 3143 of AAV1, SEQ ID NO:1, and correspondingregions of other AAV serotypes; and (b) comparing the enzymaticdigestion analysis from the sample to enzymatic digestion analysis forcorresponding regions of one or more AAV serotypes, thereby identifyingthe AAV sequences in the sample as being from one of the one or more AAVserotypes or from an unknown serotype.
 18. The method according to claim17, wherein the AAV sequences were obtained by a method comprising thesteps of: (a) subjecting a sample containing DNA to amplification viapolymerase chain reaction (PCR) using a first set of primers whichspecifically amplify a first region of AAV nucleic acid sequences; (b)optionally subjecting the DNA to further amplification using a secondset of primers which specifically amplify a second region whichcomprises the first region of AAV sequences and sequences which are 5′to the first region, such that AAV 5′ extension sequences which annealto the 5′ end of the AAV sequences amplified by the primers for thefirst region are obtained; (c) optionally subjecting the DNA to furtheramplification using a third set of primers which specifically amplify athird region which comprises the first region of AAV sequences andsequences which are 3′ to the first region, such that AAV 3′ extensionsequences which anneal to the 3′ end of the AAV sequences amplified bythe primers for the first region are obtained, wherein each of saidregions is predetermined based upon the alignment of the nucleic acidsequences of at least two AAV serotypes and each of said regionscomprises nucleic acid sequences which are highly conserved over atleast 18 base pairs at the 5′ end, optionally variable sequences in themiddle, and sequences which are highly conserved over at least 18 basepairs at the 3′ end of the sequences of the region, relative to thesequences of the at least two aligned AAV serotypes; and wherein each ofthe sets of primers consist of a 5′ primer and a 3′ primer, and whereinthe presence of amplified sequences indicates the presence of an AAV inthe sample.
 19. A diagnostic kit for detecting the presence of anunknown adeno-associated virus (AAV) in a sample, said kit comprising:(a) a first set of primers which specifically amplify a first region ofAAV nucleic acid sequences; (b) optionally a second set of primersspecific for a second region of the AAV nucleic acid sequences whichcomprises the first region of AAV sequences and sequences which are 5′to the first region, such that AAV 5′ extension sequences which annealto the 5′ end of the AAV sequences amplified by the primers for thefirst region are obtained; (c) optionally a third set of primers whichspecifically amplify a third region which comprises the first region ofAAV sequences and sequences which are 3′ to the first region, such thatAAV 3′ extension sequences which anneal to the 3′ end of the AAVsequences amplified by the primers for the first region are obtained,wherein each of said regions is predetermined based upon the alignmentof the nucleic acid sequences of at least two AAV serotypes and each ofsaid regions comprises nucleic acid sequences which are highly conservedover at least 18 base pairs at the 5′ end, optionally variable sequencesin the middle, and sequences which are highly conserved over at least 18base pairs at the 3′ end of the sequences of the region, relative to thesequences of the at least two aligned AAV serotypes wherein each of thesets of primers consist of a 5′ primer and a 3′ primer.
 20. A method forisolating novel adeno-associated viruses (AAV) from a cell, said methodcomprising the steps of: (a) infecting the cell with a virus whichprovides helper functions to said AAV; (b) isolating infectious clonescontaining AAV; (c) sequencing the isolated AAV; and (d) comparing thesequences of the isolated AAV to known AAV serotypes, wherebydifferences in the sequences of the isolated AAV and known AAV serotypesindicates the presence of a novel AAV.
 21. The method according to claim20, wherein said virus is an adenovirus.
 22. The method according toclaim 21, wherein said adenovirus is of human or non-human primateorigin.
 23. A novel adeno-associated virus (AAV) serotype identified bya method according to claim
 2. 24. A novel adeno-associated virus (AAV)serotype identified by a method according to claim
 20. 25. An isolatedadeno-associated virus (AAV) comprising an AAV capsid having an aminoacid sequence selected from the group consisting of: AAV7, amino acids 1to 737 of SEQ ID NO:2; C1, SEQ ID NO:60; C2, SEQ ID NO:61; C5, SEQ IDNO:62; A3-3, SEQ ID NO:66; A3-7, SEQ ID NO:67; A3-4, SEQ ID NO:68; A3-5,SEQ ID NO: 69; 3.3b, SEQ ID NO: 62; 223.4, SEQ ID NO: 73; 223-5, SEQ IDNO:74; 223-10, SEQ ID NO:75; 223-2, SEQ ID NO:76; 223-7, SEQ ID NO: 77;223-6, SEQ ID NO: 78; 44-1, SEQ ID NO: 79; 44-5, SEQ ID NO:80; 44-2, SEQID NO:81; 42-15, SEQ ID NO: 84; 42-8, SEQ ID NO: 85; 42-13, SEQ IDNO:86; 42-3A, SEQ ID NO:87; 42-4, SEQ ID NO:88; 42-5A, SEQ ID NO:89;42-1B, SEQ ID NO:90; 42-5B, SEQ ID NO:91; 43-1, SEQ ID NO: 92; 43-12,SEQ ID NO: 93; 43-5, SEQ ID NO:94; 43-21, SEQ ID NO:96; 43-25, SEQ IDNO: 97; 43-20, SEQ ID NO:99; 24.1, SEQ ID NO: 101; 42.2, SEQ ID NO:102;7.2, SEQ ID NO: 103; 27.3, SEQ ID NO: 104; 16.3, SEQ ID NO: 105; 42.10,SEQ ID NO: 106; 42-3B, SEQ ID NO: 107; 42-11, SEQ ID NO: 108; F1, SEQ IDNO: 109; F5, SEQ ID NO: 110; F3, SEQ ID NO:111; 42-6B, SEQ ID NO: 112;and 42-12, SEQ ID NO:
 113. 26. A host cell transfected with anadeno-associated virus according to claim
 25. 27. A compositioncomprising an AAV according to claim 25 and a physiologically compatiblecarrier.
 28. A method of delivering a transgene to a cell, said methodcomprising the step of contacting the cell with an AAV according toclaim 25, wherein said rAAV comprises the transgene.
 29. A proteincomprising a fragment of an AAV capsid protein, said fragment selectedfrom the group consisting of: vp2 capsid protein, amino acids (aa) 138to 737; vp3 capsid protein, aa 203 to 737; hypervariable region (HVR)1through 12: aa 146 to 152; aa 182 to 187; aa 262 to 264; aa 263 to 266;aa 263 to 266; aa 381 to 383; aa 383 to 385; aa 450 to 474; aa 451 to475; aa 490 to 495; aa 491 to 496; aa500 to 504; aa 501 to 505; aa 514to 522; aa 533 to 554; aa 534 to 555; aa 581 to 594; aa 583 to 596; aa658 to 667; aa 660 to 669; and aa 705 to 719; aa 707 to 772; aa 24-42,aa 25-28; aa 81-85; aa133 to 165; aa 134-165; aa 137 to 143; aa 154 to156; aa 194 to 208; aa 261 to 274; aa 262 to 274; aa 171 to 173; aa 413to 417; aa 449to 478; aa 494to 525; aa 534to 571; aa 581 to 601; aa 660to 671; aa 709 to 723; and aa 1 to 184, aa 199 to 259; aa 274 to 446; aa603 to 659; aa 670 to 706; aa 724 to 736; aa 185 to 198; aa 260 to 273;aa 447 to 477; aa 495 to 602; aa 660; and aa 707 to 723, wherein theamino acid numbers are those of the AAV7 capsid, SEQ ID NO:2, andcorresponding regions in the capsid of C1, SEQ ID NO:60; C2, SEQ IDNO:61; C5, SEQ ID NO:62; A3-3, SEQ ID NO:66; A3-7, SEQ ID NO:67; A3-4,SEQ ID NO:68; A3-5, SEQ ID NO: 69; 3.3b, SEQ ID NO: 62; 223.4, SEQ IDNO: 73; 223-5, SEQ ID NO:74; 223-10, SEQ ID NO:75; 223-2, SEQ ID NO:76;223-7, SEQ ID NO: 77; 223-6, SEQ ID NO: 78; 44-1, SEQ ID NO: 79; 44-5,SEQ ID NO:80; 44-2, SEQ ID NO:81; 42-15, SEQ ID NO: 84; 42-8, SEQ ID NO:85; 42-13, SEQ ID NO:86; 42-3A, SEQ ID NO:87; 42-4, SEQ ID NO:88; 42-5A,SEQ ID NO:89; 42-1B, SEQ ID NO:90; 42-5B, SEQ ID NO:91; 43-1, SEQ ID NO:92; 43-12, SEQ ID NO: 93; 43-5, SEQ ID NO:94; 43-21, SEQ ID NO:96;43-25, SEQ ID NO: 97; 43-20, SEQ ID NO:99; 24.1, SEQ ID NO: 101; 42.2,SEQ ID NO:102; 7.2, SEQ ID NO: 103; 27.3, SEQ ID NO: 104; 16.3, SEQ IDNO: 105; 42.10, SEQ ID NO: 106; 42-3B, SEQ ID NO: 107; 42-11, SEQ ID NO:108; F1, SEQ ID NO: 109; F5, SEQ ID NO: 110; F3, SEQ ID NO:111; 42-6B,SEQ ID NO: 112; and 42-12, SEQ ID NO:
 113. 30. A molecule comprising anucleic acid sequence encoding a protein according to claim
 29. 31. Themolecule according to claim 30, wherein said molecule further comprisesan AAV rep gene.
 32. A host cell transfected with a molecule accordingto claim
 30. 33. A composition comprising a molecule according to claim30 and a physiologically compatible carrier.
 34. A method of generatinga recombinant adeno-associated virus (AAV) comprising an AAV serotypecapsid comprising the steps of culturing a host cell containing: (a) amolecule according to claim 30 which encodes an adeno-associated viruscapsid; (b) a functional rep gene; (c) a minigene comprising AAVinverted terminal repeats (ITRs) and a transgene; and (d) sufficienthelper functions to permit packaging of the minigene into the AAV capsidprotein.
 35. An artificial adeno-associated virus (AAV) capsid proteincomprising one or more of the protein fragments according to claim 29.36. A molecule comprising a nucleic acid sequence encoding a proteinaccording to claim
 29. 37. A recombinant adeno-associated virus (AAV)comprising an artificial capsid according to claim
 29. 38. A host celltransfected with an adeno-associated virus according to claim
 37. 39. Acomposition comprising an AAV according to claim 37 and aphysiologically compatible carrier.
 40. A method of delivering atransgene to a cell, said method comprising the step of contacting thecell with an AAV according to claim 37, wherein said rAAV comprises thetransgene.
 41. The molecule according to claim 36, wherein said moleculeis a plasmid.
 42. The molecule according to claim 36, wherein saidmolecule further comprises an AAV rep gene.
 43. A host cell transfectedwith a molecule according to claim
 36. 44. A composition comprising amolecule according to claim 36 and a physiologically compatible carrier.45. A method of generating a recombinant adeno-associated virus (AAV)comprising an AAV serotype capsid comprising the steps of culturing ahost cell containing: (a) a molecule according to claim 36 which encodesan adeno-associated virus capsid; (b) a functional rep gene; (c) aminigene comprising AAV inverted terminal repeats (ITRs) and atransgene; and (d) sufficient helper functions to permit packaging ofthe minigene into the AAV capsid protein.
 46. A molecule comprising anucleic acid sequence encoding a novel adeno-associated virus (AAV)serotype capsid protein having an amino acid sequence selected from thegroup consisting of: AAV7, amino acids 1 to 737 of SEQ ID NO:2; C1, SEQID NO:60; C2, SEQ ID NO:61; C5, SEQ ID NO:62; A3-3, SEQ ID NO:66; A3-7,SEQ ID NO:67; A3-4, SEQ ID NO:68; A3-5, SEQ ID NO: 69; 3.3b, SEQ ID NO:62; 223.4, SEQ ID NO: 73; 223-5, SEQ ID NO:74; 223-10, SEQ ID NO:75;223-2, SEQ ID NO:76; 223-7, SEQ ID NO: 77; 223-6, SEQ ID NO: 78; 44-1,SEQ ID NO: 79; 44-5, SEQ ID NO:80; 44-2, SEQ ID NO:81; 42-15, SEQ ID NO:84; 42-8, SEQ ID NO: 85; 42-13, SEQ ID NO:86; 42-3A, SEQ ID NO:87; 42-4,SEQ ID NO:88; 42-5A, SEQ ID NO:89; 42-1B, SEQ ID NO:90; 42-5B, SEQ IDNO:91; 43-1, SEQ ID NO: 92; 43-12, SEQ ID NO: 93; 43-5, SEQ ID NO:94;43-21, SEQ ID NO:96; 43-25, SEQ ID NO: 97; 43-20, SEQ ID NO:99; 24.1,SEQ ID NO: 101; 42.2, SEQ ID NO:102; 7.2, SEQ ID NO: 103; 27.3, SEQ IDNO: 104; 16.3, SEQ ID NO: 105; 42.10, SEQ ID NO: 106; 42-3B, SEQ ID NO:107; 42-11, SEQ ID NO: 108; F1, SEQ ID NO: 109; F5, SEQ ID NO: 110; F3,SEQ ID NO:111; 42-6B, SEQ ID NO: 112; and 42-12, SEQ ID NO:
 113. 47. Themolecule according to claim 46, wherein said molecule is a plasmid. 48.The molecule according to claim 46, wherein said molecule furthercomprises an AAV rep gene.
 49. The molecule according to claim 46,wherein said nucleic acid sequence is the AAV7 sequence, SEQ ID NO:1.50. A method of generating a recombinant adeno-associated virus (AAV)comprising an AAV serotype capsid comprising the steps of culturing ahost cell containing: (a) a molecule according to claim 46 which encodesan adeno-associated virus capsid; (b) a functional rep gene; (c) aminigene comprising AAV inverted terminal repeats (ITRs) and atransgene; and (d) sufficient helper functions to permit packaging ofthe minigene into the AAV capsid protein.
 51. A host cell transfectedwith a molecule according to claim
 46. 52. A composition comprising amolecule according to claim 46 and a physiologically compatible carrier.53. A molecule comprising, a nucleic acid sequence encoding a noveladeno-associated virus (AAV) serotype capsid protein, said nucleic acidsequence selected from the group consisting of: AAV5, SEQ ID NO:2; 42-2,SEQ ID NO:9; 42-8 ,SEQ ID NO:27; 42-15, SEQ ID NO:28; 42-5b ,SEQ ID NO:29; 42-1b ,SEQ ID NO:30; 42-13, SEQ ID NO: 31; 42-3a, SEQ ID NO: 32;42-4 ,SEQ ID NO:33; 42-5a, SEQ ID NO: 34; 42-10, SEQ ID NO:35; 42-3b,SEQ ID NO: 36; 42-11, SEQ ID NO: 37; 42-6b, SEQ ID NO:38; 43-1, SEQ IDNO: 39; 43-5, SEQ ID NO: 40; 43-12 ,SEQ ID NO:41; 43-20, SEQ ID NO:42;43-21, SEQ ID NO: 43; 43-23, SEQ ID NO:44; 43-25 ,SEQ ID NO: 45; 44.1,SEQ ID NO:47; 44.5, SEQ ID NO:47; 223.10, SEQ ID NO:48; 223.2, SEQ IDNO:49; 223.4, SEQ ID NO:50; 223.5, SEQ ID NO: 51; 223.6, SEQ ID NO: 52;223.7, SEQ ID NO: 53; A3.4, SEQ ID NO: 54; A3.5, SEQ ID NO:55; A3.7, SEQID NO: 56; A3.3 ,SEQ ID NO:57; 42.12, SEQ ID NO: 58; 44.2, SEQ ID NO:59; AAV10, SEQ ID NO: 117; AAV11, SEQ ID NO: 118; AAV12 ,SEQ ID NO:119;A3.1, SEQ ID NO:120; and H6, SEQ ID NO:
 25. 54. The molecule accordingto claim 53, wherein said molecule is a plasmid.
 55. The moleculeaccording to claim 53, wherein said molecule further comprises an AAVrep gene.
 56. A method of generating a recombinant adeno-associatedvirus (AAV) comprising an AAV serotype capsid comprising the steps ofculturing a host cell containing: (a) a molecule according to claim 53which encodes an adeno-associated virus capsid; (b) a functional repgene; (c) a minigene comprising AAV inverted terminal repeats (ITRs) anda transgene; and (d) sufficient helper functions to permit packaging ofthe minigene into the AAV capsid protein.
 57. A host cell transfectedwith a molecule according to claim
 53. 58. A composition comprising amolecule according to claim 53 and a physiologically compatible carrier.59. A molecule comprising a nucleic acid sequence encoding a fragment ofan adeno-associated virus capsid protein, said nucleic acid sequenceselected from the group consisting of: vp1, nt 825 to 3049; vp2, nt 1234to 3049; vp 3, nt 1434 to 3049; nt 468 to 3090; and nt 725 to 3090,wherein the nucleotides numbers are of AAV7, SEQ ID NO:1 and correspondto sequences in 42-2, SEQ ID NO:9; 42-8 ,SEQ ID NO:27; 42-15 , SEQ IDNO:28; 42-5b ,SEQ ID NO: 29; 42-1b ,SEQ ID NO:30; 42-13, SEQ ID NO: 31;42-3a, SEQ ID NO: 32; 42-4 ,SEQ ID NO:33; 42-5a, SEQ ID NO: 34; 42-10,SEQ ID NO:35; 42-3b, SEQ ID NO: 36; 42-11, SEQ ID NO: 37; 42-6b, SEQ IDNO:38; 43-1, SEQ ID NO: 39; 43-5, SEQ ID NO: 40; 43-12 ,SEQ ID NO:41;43-20, SEQ ID NO:42; 43-21, SEQ ID NO: 43; 43-23, SEQ ID NO:44; 43-25,SEQ ID NO: 45; 44.1, SEQ ID NO:47; 44.5, SEQ ID NO:47; 223.10, SEQ IDNO:48; 223.2, SEQ ID NO:49; 223.4, SEQ ID NO:50; 223.5, SEQ ID NO: 51;223.6, SEQ ID NO: 52; 223.7, SEQ ID NO: 53; A3.4, SEQ ID NO: 54; A3.5,SEQ ID NO:55; A3.7, SEQ ID NO: 56; A3.3 ,SEQ ID NO:57; 42.12, SEQ ID NO:58; 44.2, SEQ ID NO: 59; AAV10, SEQ ID NO: 117; AAV11, SEQ ID NO: 118;AAV12, SEQ ID NO:119; A3.1, SEQ ID NO:120; and H6, SEQ ID NO:
 25. 60.The molecule according to claim 59, wherein said molecule is a plasmid.61. The molecule according to claim 59, wherein said molecule furthercomprises an AAV rep gene.
 62. A method of generating a recombinantadeno-associated virus (AAV) comprising an AAV serotype capsidcomprising the steps of culturing a host cell containing: (a) a moleculeaccording to claim 59; (b) a functional rep gene; (c) a minigenecomprising AAV inverted terminal repeats (ITRs) and a transgene; and (d)sufficient helper functions to permit packaging of the minigene into anAAV capsid protein.
 63. A host cell transfected with a moleculeaccording to claim
 59. 64. A composition comprising a molecule accordingto claim 59 and a physiologically compatible carrier.
 65. A moleculecomprising a heterologous adeno-associated virus (AAV) serotype 7nucleic acid sequence selected from the group consisting of: nucleotides(nt) 1 to 107of SEQ ID NO: 1; nt 107 to 2215 of SEQ ID NO:1; nt334to2215 of SEQ ID NO:1; nt 2222 to 4435 of SEQ ID NO:1; nt 2633 to 4435 ofSEQ ID NO:1; nt 2831 to 4435 of SEQ ID NO:1; and nt 4704 to 4721 of SEQID NO:
 1. 66. A host cell containing a molecule according to claim 65.67. A molecule encoding an adeno-associated virus (AAV) serotype 7 repprotein or a fragment thereof, said protein or fragment selected fromthe group consisting of: amino acid (aa) 1 to 623, aa 1 to 171; aa 172to 372, aa 373 to 444, and aa 445 to 623 of SEQ ID NO:3.
 68. A host cellcontaining a molecule according to claim 67.